<tstset trglang="any" setid="test" srclang="any">
<doc sysid="Edinburgh" docid="doc">
<seg id="1">This document is a summary of the European Public Assessment Report (EPAR) in which the Committee for Medicinal Products (CHMP) has assessed the studies carried out to reach recommendations regarding the use of the medicine.</seg>
<seg id="2">"" "" "" "if you need more information about your illness or treatment, please read the packing instructions (also part of the EPAR) or contact your doctor or pharmacist." "" "" ""</seg>
<seg id="3">"" "" "" "if you would like further information on the basis of CHMP recommendations, please read the scientific discussion (also part of EPAR)." "" "" ""</seg>
<seg id="4">"" "" "" "it is available as 5 mg, 10 mg, 15 mg, and 30 mg tablets, as a solution for intake (1 mg / ml) and as an injection solution (7.5 mg / ml)." "" "" ""</seg>
<seg id="5">"" "" "" "B. wirl thinking and speaking, hallucinations (hearing or vision of things that are not present), distrust and delusions; • Bipolar-I-disorder, a mental disorder where the patients have manic episodes (periods of abnormal mood) alternating with periods of normal mood." "" "" ""</seg>
<seg id="6">"" "" "" "Abilify is used for treatment of moderate to severe manic episodes, and for the prevention of manic episodes in patients receiving the medicine in the past." "" "" ""</seg>
<seg id="7">"" "" "" "the injection solution is used for quick monitoring of increased restlessness or behavioural disorders, if the oral intake of the medicine is not possible." "" "" ""</seg>
<seg id="8">"" "" "" "in both cases, the solution can be used to inhale or melt tablets in patients with difficulty swallowing tablets." "" "" ""</seg>
<seg id="9">"" "" "" "in patients who use other medicines at the same time, the same as Abilify should be reduced, should the dose of Abilify be adjusted." "" "" ""</seg>
<seg id="10">"" "" "" "this impairs the signal transmission between brain cells through" neurotransmitters, "i.e. chemical substances that facilitate the communication of nerve cells." "" "" ""</seg>
<seg id="11">Aripiprazole probably acts above all as a "partial agonist" for receptors for neurotransmitters dopamine and 5-hydroxytryptamin (also called serotonin).</seg>
<seg id="12">"" "" "" "this means that Aripiprazol acts as 5-hydroxytryptamin and dopamine, but at a lesser degree than neurotransmitters to activate the receptors." "" "" ""</seg>
<seg id="13">"" "" "" "since dopamine and 5-hydroxytryptamin plays a role in schizophrenia and bipolar disorder, Aripiprazol contributes to normalize the activity of the brain, reducing psychotic or manic symptoms and preventing her reformation." "" "" ""</seg>
<seg id="14">"" "" "" "the efficacy of Abilify, which prevents the reappearance of symptoms, has been investigated in three studies over up to one year." "" "" ""</seg>
<seg id="15">"" "" "" "in two studies in 805 patients with schizophrenia or similar diseases, the efficacy of the injection solution was compared with placebo over a period of two hours." "" "" ""</seg>
<seg id="16">"" "" "" "in another study, Abilify was compared to 347 patients with haloperidol, in another study the efficacy of Abilify and placebo." "" "" ""</seg>
<seg id="17">The efficacy of Abilify injection solution was compared in a study of 301 patients with bipolar disorder that suffered from increased restlessness with the treatment of Lorazepam (another antipsychotic medication) and placebo over a period of two hours.</seg>
<seg id="18">"" "" "" "in all studies, the changes in the symptoms of patients were examined using a standard dial for bipolar disorder or the number of patients who responded to the treatment." "" "" ""</seg>
<seg id="19">"" "" "" "moreover, the company conducted studies to investigate how the body absorbs the melting tablets and the solution for taking (absorbs)." "" "" ""</seg>
<seg id="20">"" "" "" "in both studies with the injection solution, patients receiving Abilify in doses of 5,25 mg, 9.75 mg or 15 mg received significantly greater anxiety than the patients receiving a placebo." "" "" ""</seg>
<seg id="21">"" "" "" "during the treatment of bipolar disorder, Abilify decreased in four of the five short-term studies of manic symptoms more effectively than placebo." "" "" ""</seg>
<seg id="22">"" "" "" "in addition to 74 weeks, Abilify prevented the reappearance of manic episodes in previously treated patients and if it was administered in addition to an existing treatment." "" "" ""</seg>
<seg id="23">"" "" "" "Abilify injections in 10- or 15 mg doses also decreased more effectively than placebo, and were similarly effective as Lorazepam." "" "" ""</seg>
<seg id="24">"" "" "" "the most common side effects of Abilify (observed in 1 to 10 of 100 patients) are extrapyramidal disorders, nausea, nausea, nausea, nausea, restlessness, restlessness, insomnia (sleep disorders) and anxiety." "" "" ""</seg>
<seg id="25">The Committee for Medicinal Products (CHMP) concluded that the benefits of Abilify in treating schizophrenia and from moderate to severe manic episodes in bipolar-I disorder and in the prevention of a new manic episode in patients with predominantly manic episodes outweigh the risks.</seg>
<seg id="26">"" "" "" "furthermore, the committee came to the conclusion that the benefits of injection solution in quick control of increased anxiety and behavioural disorders in patients with schizophrenia or in patients with manic episodes in bipolar-I disorder, if an oral therapy is not suitable, compared to the risks." "" "" ""</seg>
<seg id="27">"" "" "" "in June 2004, the European Commission granted the company Otsuka Pharmaceutical Europe Ltd. to approve Abilify in the entire European Union." "" "" ""</seg>
<seg id="28">ABILIFY is indicated for the treatment of moderate to severe manic episodes of bipolar disorder and for the prevention of a new manic episode in patients displaying mainly manic episodes and their manic episodes on treatment with Aripiprazol (see section 5.1).</seg>
<seg id="29">The recommended starting dose for ABILIFY is 10 or 15 mg / day at a maintenance dose of 15 mg / day once daily independently of meals.</seg>
<seg id="30">"" "" "" "increased efficacy in dosages over a daily dose of 15 mg has not been proven, although individual patients can benefit from a higher dose." "" "" ""</seg>
<seg id="31">"" "" "" "the recommended starting dose for ABILIFY amounts to 15 mg once daily, regardless of meals as monotherapy or combination therapy (see section 5.1)." "" "" ""</seg>
<seg id="32">The efficacy of ABILIFY in the treatment of schizophrenia and bipolar disorder in patients ≥ 65 years has not been proven.</seg>
<seg id="33">"" "" "" "with regard to the greater sensitivity of these patients, a lower initial dose should be considered when clinical factors justify this (see Section 4.4)." "" "" ""</seg>
<seg id="34">"" "" "" "if the CYP3A4 inductor is removed from combination therapy, the dose should be reduced to the recommended dose (see Section 4.5)." "" "" ""</seg>
<seg id="35">"" "" "" "the incidence of suicidal behavior is related to psychotic disorders and affective disorders and was reported in some cases after the beginning or after menopause of an antipsychotic therapy, also in treatment with Aripiprazol (see Section 4.8)." "" "" ""</seg>
<seg id="36">Results of an epidemiological study showed that in patients with bipolar disorder there was no increased risk of suicide with Aripiprazol compared to other antipsychotics.</seg>
<seg id="37">"" "" "" "Aripiprazl should be applied with caution in patients with known cardiovascular diseases (myocardial infarction, cardiac insufficiency, hypovolemia, treatment with blood pressure lowering drugs) or hypertension (including acute and malignant form)." "" "" ""</seg>
<seg id="38">"" "" "" "3 Spätdyskinesia: in clinical trials, which lasted a year or less, there were occasional reports about dyskinesia occurring during treatment with Aripiprazl." "" "" ""</seg>
<seg id="39">"" "" "" "if patients treated with ABILIFY suffer signs and symptoms of late dynasty, consider taking the dose or breaking the treatment." "" "" ""</seg>
<seg id="40">"" "" "" "if a patient develops signs and symptoms that indicate a mn, or unclear high fever without an additional clinical manifestation of mns, all antipsychotics, including ABILIFY, have to be removed." "" "" ""</seg>
<seg id="41">"" "" "" "therefore, Aripiprazl should be applied with caution in patients with cramp attacks in the anamnesis or in states associated with cramp attacks." "" "" ""</seg>
<seg id="42">"" "" "" "56 - 99 years) with Aripiprazl associated with Alzheimer's disease, patients with Aripiprazol had an increased risk of death compared to placebo." "" "" ""</seg>
<seg id="43">"" "" "" "however, there were in one of these studies, a study with fixed dosage, a significant relationship between the dosage and the response to undesirable zerorovascular events in patients treated with Aripiprazl." "" "" ""</seg>
<seg id="44">"" "" "" "hyperglycemia, in some cases extremely and associated with ketoacidosis or hyperosmolar coma or death, was reported in patients treated with atypical antipsychotic drugs, including ABILIFY." "" "" ""</seg>
<seg id="45">There is no precise risk assessment for hyperglycemia-related adverse events associated with ABILIFY and other atypical antipsychotic drugs that allow direct comparisons.</seg>
<seg id="46">"" "" "" "polymerpsy, polyuria, polyphagia and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be observed regularly regarding deterioration of glucose levels." "" "" ""</seg>
<seg id="47">"" "" "" "weight gain is commonly observed in schizophrenia and in patients with bipolar deficiency, the use of antipsychotics, in which weight gain is known as side effects, or an unhealthy lifestyle and could lead to serious complications." "" "" ""</seg>
<seg id="48">"" "" "" "due to the primary efficacy of Aripiprazol on the central nervous system, caution is advisable if Aripiprazl is used in combination with alcohol or other central potent medicines such as sedation (see Section 4.8)." "" "" ""</seg>
<seg id="49">"" "" "" "the H2 antagonist Famotidin, a gastric acid blocker, reduces the absorption rate of Aripiprazol, but this effect is considered clinically unrelevant." "" "" ""</seg>
<seg id="50">"" "" "" "in a clinical study involving healthy volunteers, a highly effective CYP2D6 inhibitor (chinidine) increased the AUC from Aripiprazl by 107% while the Cmax remained unchanged." "" "" ""</seg>
<seg id="51">"" "" "" "it is expected that other highly effective inhibitors of CYP2D6, such as fluoxetine and paroxetine, have similar effects, and therefore similar doses should be made." "" "" ""</seg>
<seg id="52">CYP2D6 'bad' (= "poor") Metabolism can result in a common application with highly effective inhibitors of CYP3A4 in higher plasma concentrations of Aripiprazl compared to CYP2D6 Extensive Metabolism.</seg>
<seg id="53">"" "" "" "considering the common gift of ketoconazol or other highly effective CYP3A4 inhibitors with ABILIFY, potential benefits should outweigh potential risks for the patient." "" "" ""</seg>
<seg id="54">"" "" "" "other highly effective inhibitors of CYP3A4, such as Iconconazole and HIV-Protease inhibitors, are likely to have similar effects and therefore similar dose reductions should be made." "" "" ""</seg>
<seg id="55">"" "" "" "after replacing the CYP2D6- or 3A4 inhibitors, the dose of ABILIFY should be raised to the dose level before the start of the accompanying therapy." "" "" ""</seg>
<seg id="56">Diltiazem (or escitalopram) or CYP2D6 can be administered together with ABILIFY together with a moderate increase in Aripiprazol- concentrations.</seg>
<seg id="57">In clinical trials doses of 10-30 mg of Aripiprazl showed no significant effect on the metabolism of the substrates of CYP2D6 (Dextromethorphan / 3-methoxymorphine-Ratio) and 2C19 (Omeprazl) and 3A4 (Dextrophy orphan).</seg>
<seg id="58">"" "" "" "patients should be advised to notify your doctor if they are pregnant, or plan a pregnancy during the treatment with Aripiprazol." "" "" ""</seg>
<seg id="59">"" "" "" "due to insufficient data security for humans and because of the concerns raised in the case studies of the animal, this medicine may not be applied during pregnancy, unless the potential benefit justifies the potential risk for the fetus." "" "" ""</seg>
<seg id="60">"" "" "" "however, as with other antipsychotics, patients should be warned of serving dangerous machines, including motor vehicles, until they are sure that Aripiprazl has no negative influence on them." "" "" ""</seg>
<seg id="61">The following adverse events occurred more frequently (≥ 1 / 100) than placebo or were classified as possible medically relevant side effects (*):</seg>
<seg id="62">"" "" "" "the frequency of side effects listed below is defined according to the following criteria: common (&gt; 1 / 100, &lt; 1 / 10); occasionally (&gt; 1 / 1000, &lt; 1 / 100)." "" "" ""</seg>
<seg id="63">"" "" "" "schizophrenia - in a controlled long-term study of 52 weeks, a total of lower incidence (25.8%) of EPS includes parking insonism, acupressure, Dystonia and dyskinesia, compared to patients treated with haloperidol (57.3%)." "" "" ""</seg>
<seg id="64">"" "" "" "in a placebo-controlled long-term study for 26 weeks, the incidence of EPS was 19% in patients with Aripiprazol treatment and 13.1% in patients under placebo." "" "" ""</seg>
<seg id="65">"" "" "" "in another controlled long-term study for 26 weeks, the incidence of EPS was 14.8% in patients treated with Aripiprazol and 15,1% in patients with Oepapin therapy." "" "" ""</seg>
<seg id="66">Manic episodes in bipolar-I disorder - in a controlled study over 12 weeks the incidence of EPS 23.5% in patients under Aripiprazol- treatment and 53.3% in patients with haloperidol treatment amounted to 23.3%.</seg>
<seg id="67">"" "" "" "in another study over 12 weeks, the incidence of EPS was 26.6% in patients under Aripiprazol treatment and 17.6% for those under lithium treatment." "" "" ""</seg>
<seg id="68">Over 26 weeks in a placebo-controlled trial the incidence of EPS was 18.2% for patients under Aripiprazol- treatment and 15.7% for patients treated with placebo.</seg>
<seg id="69">"" "" "" "a comparison between the patient groups under Aripiprazole and placebo, with potentially clinically significant changes in routine controlled laboratory parameters, did not reveal any medically significant differences." "" "" ""</seg>
<seg id="70">"" "" "" "enhancements of CPK (creatine phosphokinase), generally temporary and asymptomatic, were observed at 3.5% of patients treated with Aripiprazl, compared to 2.0% of patients treated with placebo." "" "" ""</seg>
<seg id="71">"" "" "" "among the side effects reported in connection with an antipsychotic therapy include malignant neuroleptic syndrome, late dyspinesia and varicity in older dementia patients, hyperglycemia and diabetes mellitus (see Section 4.4)." "" "" ""</seg>
<seg id="72">"" "" "" "in clinical trials and since the market launch, unintentional or intentional acute overdosages with Aripiprazol alone were observed in adult patients with estimated doses of up to 1260 mg and without death sequence." "" "" ""</seg>
<seg id="73">"" "" "" "it is unlikely that hemodialysis is beneficial in the treatment of overdose, since Aripiprazol has a high plasma protein bond." "" "" ""</seg>
<seg id="74">It is suspected that the efficacy of Aripiprazl in schizophrenia and bipolar-I disorder is mediated on the combination of a partial agonistic effect on dopamine d2 and serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="75">"" "" "" "in vitro, Aripiprazol revealed a high affinity to dopamine D2- and D3 receptor and serotonin 5HT2c- and 5HT7-, alpha-1-adrenergic and the histamine H1receptor." "" "" ""</seg>
<seg id="76">"" "" "" "in a dose-dependent reduction of 11C-Racloprid, a D2 / D3 receptor ligands, at the nucleus caudatus and the putamen." "" "" ""</seg>
<seg id="77">"" "" "" "in three placebo-controlled short-term studies (4 to 6 weeks) to 1,228 schizophrenic patients with positive or negative symptoms, Aripiprazl showed a statistically significant improvement in psychotic symptoms." "" "" ""</seg>
<seg id="78">"" "" "" "in a haloperidol-controlled study, 52% of respondents in response to study medication were similar in both groups (Aripiprazol 77% and haloperidol 73%)." "" "" ""</seg>
<seg id="79">"" "" "" "current values from measuring scales defined as secondary study targets, including PANSS and the Montgomery Asmine Rates scale, showed a significantly stronger improvement than haloperidol." "" "" ""</seg>
<seg id="80">In a placebo-controlled study more than 26 weeks of stabilized patients with chronic schizophrenia showed a significantly higher reduction in the rate of relapse that was 34% in the Aripiprazl group and 57% under placebo.</seg>
<seg id="81">"" "" "" "in an Ourapin-controlled, multinational double blind study involving 314 patients and in which the primary aim 'weight gain' was significantly less patients a weight gain of at least 7% compared to the initial value (i.e. an increase of at least 5.6 kg) with an average weight of ca." "" "" ""</seg>
<seg id="82">"" "" "" "in two placebo-controlled monotherapy studies with flexible dosage over 3 weeks with patients with a manic or mixed episode of bipolar-I disorder, Aripiprazl showed a placebo-superior efficacy in reducing manic symptoms over 3 weeks." "" "" ""</seg>
<seg id="83">"" "" "" "in a placebo-controlled monotherapy study over 3 weeks with fixed dose of patients with a manic or mixed episode of bipolar-I disorder, Aripiprazl showed no superior efficacy compared to placebo." "" "" ""</seg>
<seg id="84">"" "" "" "in two placebo and active-controlled monotherapy studies for 12 weeks in patients with a manic or mixed episode of a bipolar-I disorder, with or without psychotic traits, Aripiprazl showed a cure effect comparable to that of lithium or haloperidol in week 12." "" "" ""</seg>
<seg id="85">"" "" "" "in addition, Aripiprazol showed a comparable percentage of patients with symptomatic remission of mania such as lithium or haloperidol." "" "" ""</seg>
<seg id="86">"" "" "" "in a placebo-controlled study of 6 weeks with patients with a manic or mixed episode of a bipolar-I disorder, with or without psychotic traits, the escort therapy with Aripiprazl revealed a superior efficacy in reducing manic symptoms compared to monotherapy with lithium or valproat." "" "" ""</seg>
<seg id="87">"" "" "" "10 In a placebo-controlled study of 26 weeks followed by a long-term enlargement phase in manic patients with Aripiprazl compared to the prevention of bipolar relapse, mainly in the prevention of a return to mania." "" "" ""</seg>
<seg id="88">"" "" "" "based on in vitro studies, the enzymes CYP3A4 and CYP2D6 are responsible for stretching and hydroxyulation of Aripiprazol, which catalyzes N-dealkylamation by CYP3A4." "" "" ""</seg>
<seg id="89">The average elimination time is approximately 75 hours for Aripiprazl with extensive metabolisation over CYP2D6 and approximately 146 hours in 'bad' (= "poor") Metabolism over CYP2D6.</seg>
<seg id="90">"" "" "" "in Aripiprazol there are no differences in pharmacokinetics between male and female healthy volunteers, as well as in pharmacokinetic examination of schizophrenic patients no gender-dependent effects." "" "" ""</seg>
<seg id="91">A pop-simulation-specific analysis of pharmacokinetics did not reveal any clinically significant differences in ethnic origin or effect of smoking on the pharmacokinetics of Aripiprazl.</seg>
<seg id="92">The pharmacokinetic properties of Aripiprazole and Dehydro-Aripiprazole were similar in patients with severe kidney failure compared to young healthy volunteers.</seg>
<seg id="93">"" "" "" "the study included only 3 patients with liver cirrhosis of the class C, which was not sufficient to draw conclusions on their metabolic capacity." "" "" ""</seg>
<seg id="94">"" "" "" "based on conventional safety resharmacology studies, toxicity in repeated application, reproductive toxicity, genotoxicity, and carcinogenic potential, the preclinical data showed no particular dangers to humans." "" "" ""</seg>
<seg id="95">"" "" "" "toxicologically significant effects were only observed in dosages or exposures, which exceeded the maximum dosage or exposure to humans, so they have limited or no importance for clinical application." "" "" ""</seg>
<seg id="96">The effects covered a dose-dependent secondary-level-toxicity (Lipofuscin accumulation and / or parenchymal loss) in rats after 104 weeks at the recommended maximum dose in humans) and an increase of adrenal-carcinomas / carcinomas in female rats (AUC) at the recommended maximum dose in humans).</seg>
<seg id="97">Cholelithiasis was also detected as a result of the precipitation of the Sulphate conjugates of the hydroxy- metabolites in the bile from 25 to 125 mg / kg / day (1 to 3 times the recommended maximum dose in humans based on mg / m2).</seg>
<seg id="98">"" "" "" "however, the concentrations of the Sulphate conjugate of hydroxy- Aripiprazol found in the human bile at the highest recommended daily dose of 30 mg, and are far below the limit values (6%) of in vitro-solubility." "" "" ""</seg>
<seg id="99">"" "" "" "in rabbits, these effects were observed after dosages, which led to expositions of the 3- and 11fold of the middle Steady State AUC at the recommended clinical maximum dose." "" "" ""</seg>
<seg id="100">"" "" "" "perforated blister packs for the delivery of aluminium cans in folding cartons with 14 x 1, 28 x 1, 49 x 1, 56 x 1, 98 x 1 tablets." "" "" ""</seg>
<seg id="101">"" "" "" "15 late dyskinesia: in clinical trials, which lasted a year or less, there were occasional reports about dyskinesia occurring during treatment with Aripiprazl." "" "" ""</seg>
<seg id="102">It is suspected that the efficacy of Aripiprazl in schizophrenia and bipolar-I disorder is mediated on the combination of a partial agonistic effect on dopamine d2 and serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="103">"" "" "" "22 In a placebo-controlled study of 26 weeks followed by a long-term enlargement phase in manic patients with Aripiprazl compared to the prevention of bipolar relapse, mainly in the prevention of a return to mania." "" "" ""</seg>
<seg id="104">"" "" "" "27 Lessdyskinesia: in clinical trials, which lasted a year or less, there were occasional reports about dyskinesia occurring during treatment with Aripiprazl." "" "" ""</seg>
<seg id="105">It is suspected that the efficacy of Aripiprazl in schizophrenia and bipolar-I disorder is mediated on the combination of a partial agonistic effect on dopamine d2 and serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="106">"" "" "" "34 In a placebo-controlled study of 26 weeks followed by a long-term enlargement phase in manic patients with Aripiprazl compared to the prevention of bipolar relapse, mainly in the prevention of a return to mania." "" "" ""</seg>
<seg id="107">39 Spätdyskinesia: in clinical studies that lasted a year or less there were occasional reports of dyskinesia occurring during treatment with Aripiprazl.</seg>
<seg id="108">It is suspected that the efficacy of Aripiprazl in schizophrenia and bipolar-I disorder is mediated on the combination of a partial agonistic effect on dopamine d2 and serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="109">"" "" "" "46 In a placebo-controlled study over 26 weeks followed by a long-term enlargement phase in manic patients with Aripiprazl compared to the prevention of bipolar relapse, mainly in the prevention of a return to mania." "" "" ""</seg>
<seg id="110">The recommended starting dose for Aripiprazole is 10 or 15 mg / day at a maintenance dose of 15 mg / day once daily independently of meals.</seg>
<seg id="111">Patients who have difficulty swallowing ABILIFY tablets may take the tablets alternatively to ABILIFY tablets (see Section 5.2).</seg>
<seg id="112">"" "" "" "the incidence of suicidal behavior is related to psychotic disorders and affective disorders, in some cases after the beginning or after switching to an antipsychotic therapy, also during treatment with Aripiprazol (see Section 4.8)." "" "" ""</seg>
<seg id="113">"" "" "" "late dyskinesia: in clinical trials, which lasted a year or less, there were occasional reports about dyskinesia occurring during treatment with Aripiprazl." "" "" ""</seg>
<seg id="114">"" "" "" "clinical manifestations of a mns are high fever, rigidity, changing levels of consciousness and signs of autonomous instability (irregular pulse or blood pressure, tachycardia, sweating and cardiac arrhythmia)." "" "" ""</seg>
<seg id="115">"" "" "" "weight gain is commonly observed in schizophrenia and in patients with bipolar deficiency, the use of antipsychotics, in which weight gain is known as side effect or an unhealthy lifestyle and could lead to serious complications." "" "" ""</seg>
<seg id="116">"" "" "" "patients should be advised to notify your doctor if they are pregnant or pregnancy, during treatment with Aripiprazl" "" "" ""</seg>
<seg id="117">The following adverse events occurred more frequently (≥ 1 / 100) than placebo or were classified as possible medically relevant side effects of the medicine (*):</seg>
<seg id="118">"" "" "" "in two placebo-controlled monotherapy studies with flexible dosage over 3 weeks with patients with a manic or mixed episode of bipolar-I disorder, Aripiprazl showed a placebo-superior efficacy in reducing manic symptoms over 3 weeks." "" "" ""</seg>
<seg id="119">"" "" "" "58 In a placebo-controlled study of 6 weeks with patients with a manic or mixed episode of a bipolar-I disorder, with or without psychotic traits, the escort therapy with Aripiprazl revealed a superior efficacy in reducing manic symptoms compared to monotherapy with lithium or valproat." "" "" ""</seg>
<seg id="120">"" "" "" "in a placebo-controlled study of 26 weeks followed by a long-term enlargement phase for patients with Aripiprazl ahead of randomisation, Aripiprazl showed himself superior to the prevention of bipolar relapse." "" "" ""</seg>
<seg id="121">"" "" "" "in rabbits, these effects were dosed according to dosages leading to expositions of the 3- and 11x of the middle Steady State AUC at the recommended clinical" "" "" ""</seg>
<seg id="122">Patients who have difficulty swallowing ABILIFY tablets may take the tablets alternatively to ABILIFY tablets (see Section 5.2).</seg>
<seg id="123">"" "" "" "late dyskinesia: in clinical trials, which lasted a year or less, there were occasional reports about dyskinesia occurring during treatment with Aripiprazl." "" "" ""</seg>
<seg id="124">"" "" "" "71 In a placebo-controlled study of 6 weeks with patients with a manic or mixed episode of a bipolar-I disorder, with or without psychotic traits, the escort therapy with Aripiprazl revealed a superior efficacy in reducing manic symptoms compared to monotherapy with lithium or valproat." "" "" ""</seg>
<seg id="125">Patients who have difficulty swallowing ABILIFY tablets may take the tablets alternatively to ABILIFY tablets (see Section 5.2).</seg>
<seg id="126">"" "" "" "late dyskinesia: in clinical trials, which lasted a year or less, there were occasional reports about dyskinesia occurring during treatment with Aripiprazl." "" "" ""</seg>
<seg id="127">84 In a placebo-controlled study of 6 weeks with patients with a manic or mixed episode of a bipolar-I disorder with or without psychotic traits that sometimes over 2 weeks did not respond to lithium or valproat-monotherapy in therapeutic serum levels compared to monotherapy with lithium or valproat.</seg>
<seg id="128">200 mg of fructose per ml 400 mg Sucrose per ml 1.8 mg of methyl-4 hydroxybenzoate (E218) per ml 0.2 mg propyl-4 hydroxybenzoate (E216) per ml.</seg>
<seg id="129">"" "" "" "the recommended starting dose for ABILIFY amounts to 15 mg once daily, regardless of meals as monotherapy or combination therapy (see section 5.1)." "" "" ""</seg>
<seg id="130">"" "" "" "for the prevention of recurrence of manic episodes in patients who have already received Aripiprazl, therapy should continue with the same dose." "" "" ""</seg>
<seg id="131">"" "" "" "late dyskinesia: in clinical trials, which lasted a year or less, there were occasional reports about dyskinesia occurring during treatment with Aripiprazl." "" "" ""</seg>
<seg id="132">"" "" "" "hyperglycemia, in some cases extremely and associated with ketoacidosis or hyperosmolar coma or death, was reported in patients treated with atypical antipsychotic drugs, including ABILIFY." "" "" ""</seg>
<seg id="133">There is no precise risk assessment for hyperglycemia-related adverse events associated with ABILIFY and other atypical antipsychotic drugs that allow direct comparisons.</seg>
<seg id="134">92 In a clinical study involving healthy volunteers a highly effective CYP2D6 inhibitor (chinidine) increased the AUC from Aripiprazl by 107% while the Cmax remained unchanged.</seg>
<seg id="135">Diltiazem (or escitalopram) or CYP2D6 can be administered together with ABILIFY together with a moderate increase in Aripiprazol- concentrations.</seg>
<seg id="136">"" "" "" "manic episodes in bipolar-I disorder - in a controlled study over 12 weeks, the incidence of EPS 23,5% in patients under Aripiprazol-" "" "" ""</seg>
<seg id="137">It is suspected that the efficacy of Aripiprazl in schizophrenia and bipolar-I disorder is mediated on the combination of a partial agonistic effect on dopamine d2 and serotonin 5HT1a- receptors and an antagonistic effect on serotonin 5HT2a receptors.</seg>
<seg id="138">"" "" "" "in an Ourapin-controlled, multinational double blind study involving 314 patients and in which the primary aim 'weight gain' was significantly less patients a weight gain of at least 7% compared to the initial value (i.e. an increase of at least 5.6 kg) with an average weight of ca." "" "" ""</seg>
<seg id="139">97 In a placebo-controlled monotherapy study over 3 weeks with fixed dose with patients with a manic or mixed episode of bipolar-I disorder Aripiprazl showed no superior efficacy compared to placebo.</seg>
<seg id="140">In a relative bioavailability study in which Pharmacokinetics of 30 mg Aripiprazol were compared with 30 mg Aripiprazol in tablet form in healthy volunteers was the ratio between the geometrical Cmax mean value of the solution and the value of the tablets at 122% (N = 30).</seg>
<seg id="141">99 Furthermore a cholelithiasis was detected as a result of the precipitation of the Sulphate conjugates of the hydroxy- metabolites in the bile from 25 to 125 mg / kg / day (1 to 3 times the recommended maximum dose in humans based on mg / m2).</seg>
<seg id="142">"" "" "" "in rabbits, these effects were observed after dosages, which led to expositions of the 3- and 11fold of the middle Steady State AUC at the recommended clinical maximum dose." "" "" ""</seg>
<seg id="143">ABILIFY injection solution is used for quick control of agility and behavioural disorders in patients with schizophrenia or in patients with manic episodes of bipolar-I disorder if an oral therapy is not appropriate.</seg>
<seg id="144">"" "" "" "as soon as it is clinically appropriate, the treatment with Aripiprazl injection solution should be terminated and started with oral application of Aripiprazl." "" "" ""</seg>
<seg id="145">"" "" "" "to increase the resorption and minimize the variability, an injection into the M. Deltoideus or deep into the gluteus maximus muscle is recommended under the circumvention of obese regions." "" "" ""</seg>
<seg id="146">"" "" "" "a lower dose of 5,25 mg (0,7 ml) may be given depending on the individual clinical status, taking into account the drugs used for preservation or acute therapy (see Section 4.5)." "" "" ""</seg>
<seg id="147">"" "" "" "if a further oral treatment is indicated with Aripiprazol, see the summary of the characteristics of the medicine to ABILIFY tablets, ABILIFY tablets, or ABILIFY solution." "" "" ""</seg>
<seg id="148">There are no investigations to the efficacy of Aripiprazl injections in patients with agility and behavioural disorders which have been caused differently from schizophrenia and manic episodes of the bipolar-I disorder.</seg>
<seg id="149">"" "" "" "in case a parenteral therapy with benzodiazepines is considered necessary in addition to the Aripiprazole injection solution, patients should be observed with regard to extreme sedation or blood pressure drop (see Section 4.5)." "" "" ""</seg>
<seg id="150">Investigations on the safety and efficacy of Aripiprazl injections are not available for patients with alcohol or drug poisoning (by prescribed or illegal drugs).</seg>
<seg id="151">"" "" "" "Aripiprazl should be applied with caution in patients with known cardiovascular diseases (myocardial infarction, cardiac insufficiency, hypovolemia, treatment with blood pressure lowering drugs) or hypertension (including acute and malignant form)." "" "" ""</seg>
<seg id="152">"" "" "" "late dyskinesia: in clinical trials, which lasted a year or less, there were occasional reports about dyskinesia occurring during treatment with Aripiprazl." "" "" ""</seg>
<seg id="153">"" "" "" "clinical manifestations of a mns are high fever, stiffness, changing levels of consciousness and signs of autonomous instability (irregular pulse or blood pressure, tachycardia, sweating and cardiac arrhythmia)." "" "" ""</seg>
<seg id="154">"" "" "" "polymerpsy, polyuria, polyphagia and weakness) are observed and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly regarding the deterioration of glucose levels." "" "" ""</seg>
<seg id="155">"" "" "" "weight gain is commonly observed in schizophrenic patients and patients with bipolar deficiency, the use of antipsychotics, in which weight gain is known as side effects or an unhealthy lifestyle and could lead to serious complications." "" "" ""</seg>
<seg id="156">"" "" "" "nevertheless, the intensity of the Sedation was greater than the intramuscular injection of Aripiprazole (15 mg dosage) in healthy volunteers, and the simultaneous Lorazepam (2 mg dosage) was intramuscular." "" "" ""</seg>
<seg id="157">"" "" "" "105 The H2 antagonist Famotidin, a gastric acid blocker, reduces the absorption rate of Aripiprazol, but this effect is considered clinically unrelevant." "" "" ""</seg>
<seg id="158">CYP2D6 'bad' (= "poor") Metabolism can result in a common application of CYP2D6 Extensive Metabolism in higher plasma concentrations of CYP3A4 in higher plasma concentrations of Aripiprazol.</seg>
<seg id="159">"" "" "" "other highly effective inhibitors of CYP3A4, such as itraconazole and HIV- protease inhibitors, should have similar effects and therefore similar dose reductions should be made." "" "" ""</seg>
<seg id="160">"" "" "" "after replacing the CYP2D6- or 3A4 inhibitors, the dose of ABILIFY should be raised to the dose level before the start of the accompanying therapy." "" "" ""</seg>
<seg id="161">"" "" "" "106 lauazepam (2 mg dosage) was intramuscular, the intensity of the sedation was greater than with the only gift of Aripiprazol." "" "" ""</seg>
<seg id="162">The following adverse events occurred more frequently in clinical trials involving Aripiprazl injections (≥ 1 / 100) than placebo or were classified as possible medically relevant side effects (*) (see section 5.1):</seg>
<seg id="163">"" "" "" "the incidence of side effects listed below is defined according to the following criteria: ≥ 1 / 100, &lt; 1 / 10); occasionally (≥ 1 / 1000, &lt; 1 / 100)." "" "" ""</seg>
<seg id="164">107 The following adverse events occurred more frequently (≥ 1 / 100) than placebo or were classified as possible medically relevant side effects (*) in clinical trials (see section 5.1):</seg>
<seg id="165">"" "" "" "in a placebo-controlled long-term study for 26 weeks, the incidence of EPS was 19% in patients under Aripiprazol- treatment and 13.1% in patients under placebo." "" "" ""</seg>
<seg id="166">"" "" "" "in another study over 12 weeks, the incidence of EPS was 26.6% in patients under Aripiprazol- treatment and 17.6% for those under lithium treatment." "" "" ""</seg>
<seg id="167">"" "" "" "during the long-term recovery period over 26 weeks in a placebo-controlled trial, the incidence of EPS was 18.2% for patients with Aripiprazol treatment and 15.7% for patients treated with placebo." "" "" ""</seg>
<seg id="168">"" "" "" "a comparison between the patient groups under Aripiprazole and placebo, with potentially clinically significant changes in routine controlled laboratory parameters, did not reveal any medically significant differences." "" "" ""</seg>
<seg id="169">"" "" "" "enhancements of CPK (creatinphosphokinase), generally temporary and asymptomatic, were observed at 3.5% of patients treated with Aripiprazl, compared to 2.0% of patients treated with placebo." "" "" ""</seg>
<seg id="170">"" "" "" "among the side effects reported in connection with an antipsychotic therapy include malignant neuroleptic syndrome, late dyspinesia and varicity in older dementia patients, hyperglycemia and diabetes mellitus (see Section 4.4)." "" "" ""</seg>
<seg id="171">"" "" "" "110 and behavioural disorders, the Aripiprazl injection solution was associated with statistically significant improvements of asgibility / behavioural disorders compared to placebo and was similar to haloperidol." "" "" ""</seg>
<seg id="172">In a placebo-controlled short-term study (24 h) with 291 patients with bipolar disorder as well as agility and behavioural disorders the Aripiprazol injection solution was associated with a statistically significant improvement in symptoms regarding asgibility and behavioural disorders compared to placebo and similar to the Lorazepam- reference arm.</seg>
<seg id="173">Observed mean improvement from initial value on the PANSS Excitement Component score with the primary 2-hour limit was 5.8 for placebo and 9.6 for Lorazepam and 8.7 for Aripiprazl.</seg>
<seg id="174">"" "" "" "in analyses of subgroups in patients with mixed episodes or patients with severe agility, a similar effectiveness in relation to the overall population was observed, but a statistical significance could be determined on the basis of a reduced number of patients." "" "" ""</seg>
<seg id="175">"" "" "" "in three placebo-controlled short-term studies (4 to 6 weeks) to 1.228 schizophrenic patients with positive or negative symptoms, Aripiprazol (oral) showed a statistically significant improvement in psychotic symptoms." "" "" ""</seg>
<seg id="176">"" "" "" "in a haloperidol-controlled study, 52% of respondents in response to study medication participated in both groups similar to Aripiprazl 77% (oral) and haloperidol 73%." "" "" ""</seg>
<seg id="177">"" "" "" "current values from measuring scales defined as secondary study targets, including PANSS and the Montgomery Asberg depression rate scale, showed a significantly stronger improvement than haloperidol." "" "" ""</seg>
<seg id="178">In a placebo-controlled study more than 26 weeks of stabilized patients with chronic schizophrenia showed a significantly higher reduction in the rate of relapse that was 34% in the Aripiprazol (oral) group and 57% under placebo.</seg>
<seg id="179">"" "" "" "in an Ourapin-controlled, multinational double blind study involving 314 patients and in which the primary aim 'weight gain' was significantly less patients a weight gain of at least 7% compared to the initial value (i.e. an increase of at least 5.6 kg) with an average weight of ca." "" "" ""</seg>
<seg id="180">"" "" "" "111 in a placebo-controlled study of 6 weeks with patients with a manic or mixed episode of a bipolar-I disorder, with or without psychotic traits that were partially not based on lithium or valproat psychotherapy, compared to monotherapy with lithium or valproat." "" "" ""</seg>
<seg id="181">"" "" "" "in a placebo-controlled study of 26 weeks followed by a 74 week extension in manic patients who had achieved remission with Aripiprazl compared to the prevention of bipolar relapse, mainly in the prevention of a return to mania." "" "" ""</seg>
<seg id="182">"" "" "" "in the first 2 hours after intramuscular injection, the AUC is 90% greater than the same dose as tablet; the systemic exposure was similar between the two formulations." "" "" ""</seg>
<seg id="183">"" "" "" "in 2 studies with healthy volunteers, the mean time to reach the maximum plasma level was 1 to 3 hours after application." "" "" ""</seg>
<seg id="184">The administration of Aripiprazl injections was tolerated by rats and monkeys and resulted in no direct toxicity of a target organ after repeated use in systemic exposure (AUC) which were 15 or 5 times higher than the maximum humanist exposure of 30 mg.</seg>
<seg id="185">"" "" "" "in studies on reproductive toxicity following IV application, no safety-related concerns were found after maternal exposure, the 15- (rats) and 29 times (rabbits) over the maximum humanoid exposure of 30 mg." "" "" ""</seg>
<seg id="186">"" "" "" "based on the conventional studies with Aripiprazol (oral) for safety resharmacology, toxicity in repeated application, reproductive toxicity, genotoxicity, and carcinogenic potential, the preclinical data showed no particular dangers to humans." "" "" ""</seg>
<seg id="187">"" "" "" "toxicologically significant effects were only observed in dosages or exposures, which significantly exceeded the maximum dosage or exposure to humans; therefore they have limited or no importance for clinical application." "" "" ""</seg>
<seg id="188">The effects covered a dose-dependent secondary-level-toxicity (Lipofuscin accumulation and / or parenchymal loss) in rats after 104 weeks at 20 mg / kg / day (equivalent to 3-10 times the mean-state exposure (AUC) at the recommended maximum dose in humans).</seg>
<seg id="189">Cholelithiasis was also detected as a result of the precipitation of the Sulphate conjugates of the hydroxy- metabolites in the bile from 25 to 125 mg / kg / day (1 to 3 times the recommended clinical dose or 16- to 81-times the recommended maximum dose in humans based on mg / m2).</seg>
<seg id="190">"" "" "" "in rabbits, these effects were observed after dosages, which led to expositions of 3- and 11-times the mean-state AUC at the recommended clinical maximum dose." "" "" ""</seg>
<seg id="191">"" "" "" "the authorisation holder must ensure that before and while the product is marketed, the pharmaceutical vigilance system as described in the 1.0 version of Module 1.8.1. of the authorisation application is furnished and functional." "" "" ""</seg>
<seg id="192">"" "" "" "according to the" CHMP Guideline on Risk Management Systems for bottom products for human use, "the updated risk management plan must be submitted simultaneously with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="193">"" "" "" "in addition, an updated risk management plan must be submitted when new information that can affect the current security data, the pharmaceutical vigilance plan or risk minimisation measures, on request of EMEA." "" "" ""</seg>
<seg id="194">"" "" "" "14 x 1 tablets 28 x 1 tablets 49 x 1 tablets 56 x 1 tablets 98 x 1 tablets" "" "" ""</seg>
<seg id="195">EU / 1 / 04 / 276 / 276 / 002 28 x 1 tablets EU / 1 / 276 / 003 49 x 1 tablet EU / 1 / 276 / 005 56 x 1 tablet EU / 1 / 276 / 005 98 x 1 tablets</seg>
<seg id="196">EU / 1 / 04 / 276 / 006 14 x 1 tablet EU / 1 / 276 / 008 49 x 1 tablet EU / 1 / 276 / 009 56 x 1 tablet EU / 1 / 276 / 006 56 x 1 tablets EU / 1 / 276 / 006 56 x 1 tablets</seg>
<seg id="197">EU / 1 / 04 / 276 / 276 28 x 1 tablets EU / 1 / 04 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 014 56 x 1 tablet</seg>
<seg id="198">EU / 1 / 04 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 019 56 x 1 tablet EU / 1 / 276 / 276 / 276 / 276 / 276 / 276 / 276 / 020 98 x 1 tablet</seg>
<seg id="199">"" "" "" "if any of the side effects listed are significantly impaired or you notice side effects that are not indicated in this information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="200">"" "" "" "it is used for treating adults suffering from a disease characterized by symptoms such as hearing, vision or feeling of things that are not present, distrust, delusions, unrelated speech, whirleness behavior and flatter mood." "" "" ""</seg>
<seg id="201">"" "" "" "ABILIFY is used in adults to treat a condition with excessive feeling, feeling excessive energy, much less sleep than usual, very quick speech with fast changing ideas and sometimes strong irritability." "" "" ""</seg>
<seg id="202">"" "" "" "high blood sugar or cases of diabetes (diabetes) in the family seizure disorder or irregular muscle movements, especially in the face of heart or vascular disease in the family, stroke or temporary managulation of the brain (transitory ischemic attack / TIA), abnormal blood pressure." "" "" ""</seg>
<seg id="203">"" "" "" "if you suffer from dementia (loss of memory or other mental abilities), you should tell your doctor whether you have ever had a stroke or a temporary hemorrhage of the brain." "" "" ""</seg>
<seg id="204">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness associated with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="205">"" "" "" "children and adolescents ABILIFY are not to be applied to children and adolescents, as it has not yet been studied in patients under 18 years of age." "" "" ""</seg>
<seg id="206">"" "" "" "if you use ABILIFY with other medicines, please tell your doctor or pharmacist if you use other medicines or use it recently, even if it is not prescription." "" "" ""</seg>
<seg id="207">Medicines used to treat heart rhythm disorders antidepressants or herbal medicines that are used to treat depression and anxiety disorder medicine for treatment of HIV infection antikonvulsiva which are used to treat epilepsy</seg>
<seg id="208">"" "" "" "pregnancy and lactation should not take ABILIFY if you are pregnant, unless you have discussed this with your doctor." "" "" ""</seg>
<seg id="209">Traffic tightness and operation of machines you should not drive and operate no tools or machines until you know how ABILIFY works with you.</seg>
<seg id="210">"" "" "" "please take this medicine after consultation with your doctor, if you know that you suffer from an intolerance to certain sugars." "" "" ""</seg>
<seg id="211">Please talk to your doctor or pharmacist if you have the impression that the effect of ABILIFY is too strong or too weak.</seg>
<seg id="212">"" "" "" "even if you feel better, change or sit down the daily dose of ABILIFY without asking your doctor beforehand." "" "" ""</seg>
<seg id="213">If you have taken a larger amount of ABILIFY as you should notice that you have taken more ABILIFY tablets than recommended by your doctor (or if someone has taken some of your ABILIFY tablets) immediately contact your doctor.</seg>
<seg id="214">"" "" "" "if you have forgotten the intake of ABILIFY If you miss a dose, take the missed dose once you remember, but do not take the double dose on one day." "" "" ""</seg>
<seg id="215">"" "" "" "frequent side effects (with more than 1 of 100, less than 1 of 10 treatment) uncontrollable sugar movements, headache, fatigue, nausea, vomiting, anxiety, anxiety, anxiety, anxiety, trembling and blurred vision." "" "" ""</seg>
<seg id="216">"" "" "" "occasional side effects (with more than 1 of 1,000, less than 1 out of 100 treatment) Some persons may feel dizzy, especially when they arise from a lying or sitting position, or they can establish an accelerated pulse." "" "" ""</seg>
<seg id="217">Please inform your doctor or pharmacist if any of the listed side effects do significantly affect you or notice side effects that are not stated in this information.</seg>
<seg id="218">"" "" "" "like ABILIFY, and content of the pack ABILIFY 5 mg tablets are rectangular and blue, with embossing A-007 and 5 on one side." "" "" ""</seg>
<seg id="219">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness associated with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="220">"" "" "" "even if you feel better, change or sit down the daily dose of ABILIFY without asking your doctor beforehand." "" "" ""</seg>
<seg id="221">"" "" "" "like ABILIFY, and content of the pack ABILIFY 10 mg tablets are rectangular and pink, with embossing A-008 and 10 on one side." "" "" ""</seg>
<seg id="222">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness associated with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="223">"" "" "" "even if you feel better, change or sit down the daily dose of ABILIFY without asking your doctor beforehand." "" "" ""</seg>
<seg id="224">"" "" "" "like ABILIFY, and content of the pack ABILIFY 15 mg tablets are round and yellow, with embossing A-009 and 15 on one side." "" "" ""</seg>
<seg id="225">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness associated with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="226">"" "" "" "even if you feel better, change or sit down the daily dose of ABILIFY without asking your doctor beforehand." "" "" ""</seg>
<seg id="227">"" "" "" "like ABILIFY, and content of the pack ABILIFY 30 mg tablets are round and pink, with embossing A-011 and 30 on one side." "" "" ""</seg>
<seg id="228">"" "" "" "171 If you suffer from dementia (loss of memory or other mental abilities), you should tell your doctor whether you have ever had a stroke or a temporary hemorrhage of the brain." "" "" ""</seg>
<seg id="229">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness associated with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="230">Important information on certain other parts of ABILIFY patients who are not allowed to take phenylalanine should be aware that ABILIFY melt tablets aspartame are contained as a source of phenylalanine.</seg>
<seg id="231">"" "" "" "immediately after opening the blister pack, take the tablet with dry hands and place the tablet in the whole on your tongue." "" "" ""</seg>
<seg id="232">"" "" "" "even if you feel better, change or sit down the daily dose of ABILIFY without asking your doctor beforehand." "" "" ""</seg>
<seg id="233">If you have taken a larger amount of ABILIFY as you should notice that you have taken more ABILIFY melt tablets than recommended by your doctor (or if someone has taken some of your ABILIFY fusion tablets) immediately contact your doctor.</seg>
<seg id="234">"" "" "" "Calcium trimetasilicate, Crop-less sodium, Crop dioxid, silicon dioxide, vanilla aroma artificially (contains vanilla and ethylvanillin), vinylic acid, magnesium stearate, iron (III) - oxide (E172)." "" "" ""</seg>
<seg id="235">"" "" "" "like ABILIFY, and content of the pack The ABILIFY 10 mg of melt tablets are round and pink, with embossing" A "over" 640 "on one side and" 10 "on the other." "" "" ""</seg>
<seg id="236">"" "" "" "177 If you suffer from dementia (loss of memory or other mental abilities), you should tell your doctor whether you have ever had a stroke or a temporary hemorrhage of the brain." "" "" ""</seg>
<seg id="237">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness associated with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="238">"" "" "" "Calcium trimetasilicate, Crop-less sodium, Crop dioxid, silicon dioxide, vanilla aroma artificially (contains vanilla and ethylvanillin), acidity, magnesium stearate, iron (III) - hydroxide oxide x H2O (E172)." "" "" ""</seg>
<seg id="239">"" "" "" "like ABILIFY, and content of the pack The ABILIFY 15 mg of melt tablets are round and yellow, with embossing" A "over" 641 "on one side and" 15 "on the other." "" "" ""</seg>
<seg id="240">"" "" "" "183 If you suffer from dementia (loss of memory or other mental abilities), you should tell your doctor whether you have ever had a stroke or a temporary hemorrhage of the brain." "" "" ""</seg>
<seg id="241">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness associated with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="242">"" "" "" "like ABILIFY, and content of the pack The ABILIFY 30 mg of melt tablets are round and pink, with embossing" A "over" 643 "on one side and" 30 "on the other." "" "" ""</seg>
<seg id="243">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness associated with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="244">Traffic tightness and operation of machines you should not drive and operate no tools or machines until you know how ABILIFY works with you.</seg>
<seg id="245">190 Important information on certain other components of ABILIFY Each ml ABILIFY solution for taking up contains 200 mg of fructose and 400 mg of sucrose.</seg>
<seg id="246">"" "" "" "if your doctor told you that you are suffering from a tolerance of certain sugars, contact your doctor before taking this medicine." "" "" ""</seg>
<seg id="247">The dose of ABILIFY solution to intake must be measured with the calibrated measuring cup or the 2 ml drip pipette that are contained in the package.</seg>
<seg id="248">Please talk to your doctor or pharmacist if you have the impression that the effect of ABILIFY is too strong or too weak.</seg>
<seg id="249">If you have taken a larger amount of ABILIFY as you should notice that you have taken more ABILIFY solution to take intake than recommended by your doctor (or if someone has taken ABILIFY solution for taking) please contact your doctor immediately.</seg>
<seg id="250">"" "" "" "dinatrium edetate, fructose, glycerol, lactic acid, methyl-4 hydroxybenzoate (E216), hydroxide, sucrose, purified water and natural orange-cream aroma with other natural flavours." "" "" ""</seg>
<seg id="251">"" "" "" "like ABILIFY, and content of the pack ABILIFY 1 mg / ml solution for intake is a clear, colourless to light yellow liquid in bottles with a child safe polypropylene cap and 50 ml, 150 ml or 480 ml." "" "" ""</seg>
<seg id="252">"" "" "" "ABILIFY injection solution is used for rapid treatment of increased unrest and desperate behavior that is characterized by symptoms such as: hearing, seeing or feeling things that are not present, distrust, delusions, unrelated speech, whirleness behavior and flatter mood." "" "" ""</seg>
<seg id="253">"" "" "" "people with this disease can also be depressed, feel guilty, anxious or tense. excessive feeling of feeling excessive energy need much less sleep than usual, very fast speech with changing ideas and sometimes strong irritability." "" "" ""</seg>
<seg id="254">"" "" "" "inform your doctor promptly if you suffer from stiffness or stiffness associated with high fever, sweating, altered state of mind or very rapid or irregular heartbeat." "" "" ""</seg>
<seg id="255">"" "" "" "if you use ABILIFY with other medicines, please tell your doctor or pharmacist if you use other medicines or use it recently, even if it is not prescription." "" "" ""</seg>
<seg id="256">"" "" "" "medicines used to treat heart rhythms, antidepressants or herbal medicines used to treat depression and anxiety, are used to treat HIV infection, antikonvulsiva, which are used to treat epilepsy." "" "" ""</seg>
<seg id="257">"" "" "" "196 Pregnancy and lactation should not apply ABILIFY if you are pregnant, unless you have discussed this with your doctor." "" "" ""</seg>
<seg id="258">Traffic tightness and operation of machines you should not drive and operate no tools or machines if you feel using ABILIFY injection solution.</seg>
<seg id="259">"" "" "" "if you have any concerns that you receive more ABILIFY injection solution than you need to, please talk to your doctor or nursing staff about it." "" "" ""</seg>
<seg id="260">"" "" "" "frequent side effects (with more than 1 of 100 patients) of ABILIFY injections are fatigue, dizziness, headache, restlessness, nausea and vomiting." "" "" ""</seg>
<seg id="261">"" "" "" "occasional side effects (with more than 1 of 1,000, less than 1 out of 100 treatment) Some persons may feel dizzy, especially when judging from lying down or sitting, or having a quick pulse, have a dryness feeling or feel downcast." "" "" ""</seg>
<seg id="262">"" "" "" "frequent side effects (with more than 1 of 100, less than 1 of 10 treatment) uncontrollable sugar movements, headache, fatigue, nausea, vomiting, anxiety, anxiety, anxiety, anxiety, trembling and blurred vision." "" "" ""</seg>
<seg id="263">"" "" "" "if you need more information about your illness or treatment, please read the packing instructions (also part of the EPAR), or contact your doctor or pharmacist." "" "" ""</seg>
<seg id="264">"" "" "" "Abraxane should be applied only under the supervision of a qualified oncologist on the application of cytostatika (killing of cells) specialized departments." "" "" ""</seg>
<seg id="265">"" "" "" "in patients with particular side effects on the blood or nervous system, the dose can be reduced or the treatment may be interrupted." "" "" ""</seg>
<seg id="266">(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 e-mail: mail @ emea.eu http: / / www.emea.eu http: / / www.emea.europa.eu</seg>
<seg id="267">"" "" "" "the efficacy of Abraxane was studied in a major study, attended by 460 women with metastatic breast cancer, about three quarters of which had received an anthracycline." "" "" ""</seg>
<seg id="268">The effect of Abraxane (in allsome gift or as monotherapy) was compared with the medication contained in conventional paclitaxel (given in combination with other medicines to reduce side effects).</seg>
<seg id="269">"" "" "" "in total, 72 (31%) of the 229 patients treated with Abraxane responded to the treatment compared to 37 (16%) of the 225 patients with conventional paclitaxel." "" "" ""</seg>
<seg id="270">"" "" "" "considering only the patients who were treated for the first time because of metastatic breast cancer, there was no difference between drugs such as time to deterioration of disease and survival." "" "" ""</seg>
<seg id="271">"" "" "" "on the other hand, patients who had previously received other treatment of their metastatic breast cancer demonstrated that Abraxane was more effective than conventional paclitaxel." "" "" ""</seg>
<seg id="272">"" "" "" "in addition, it may not be used in patients who have low neutrality rates in the blood before the treatment begins." "" "" ""</seg>
<seg id="273">The Medicinal Medicinal Products Committee (CHMP) found that Abraxanes had no more effective treatment than conventional paclitaxel treatment and that unlike other paclitaxel medications did not have to be given with other medicines to reduce side effects.</seg>
<seg id="274">"" "" "" "in January 2008, the European Commission issued a permit for the marketing of Abraxane in the entire European Union." "" "" ""</seg>
<seg id="275">"" "" "" "Abraxane-Monotherapy is indicated for the treatment of metastatic breast cancer in patients with which the first-line treatment for metastatic disease is missing, and for which a standard anthracycline-containing therapy is not shown (see also section 4.4)." "" "" ""</seg>
<seg id="276">In patients with severe neutropenia (neutrophine count &lt; 0.50 x 109 / l over a period of one week or longer) or severe sensory neuropathy the dose should be reduced to 220 mg / m2 during the subsequent series.</seg>
<seg id="277">"" "" "" "in the case of sensory neuropathy grade 3, the treatment must be interrupted until a better dose of 1 or 2 is achieved, and the dose must be reduced in all subsequent cycles." "" "" ""</seg>
<seg id="278">There is currently no adequate data for dosage adjustment in patients with mild to moderate impairment of liver function (see section 4.4. and 5.2).</seg>
<seg id="279">No studies with patients with impaired renal function were performed and there is currently no adequate data on the recommendation of dose adjustments in patients with impaired renal function (see Section 5.2).</seg>
<seg id="280">"" "" "" "Abraxane is not recommended for use in children under 18 years of age, due to insufficient data for unacceptability and efficacy." "" "" ""</seg>
<seg id="281">Abraxane is an albumin-bound nanoparticle formula of paclitaxel which could have significantly other pharmacological features than other formulations of paclitaxel (see section 5.1 and 5.2).</seg>
<seg id="282">"" "" "" "if an allergic reaction occurs, the medicine should be removed immediately and a symptomatic treatment should be initiated and the patient must not be treated with paclitaxel." "" "" ""</seg>
<seg id="283">No further Abraxane treatment cycles should be initiated in patients until the neutrophoses have risen to &gt; 1.5 x 109 / l and the platelet number is increased to &gt; 100 x 109 / l.</seg>
<seg id="284">Patients with severe liver dysfunctions (bilirubin &gt; 5 x ULN or ASL / ALT &gt; 10 x ULN) should not be treated with Abraxane.</seg>
<seg id="285">"" "" "" "while an unequivocally associated cardiotoxicity has not been proven, cardiac arrest in the indicated patient population is not unusual, especially in patients with previous anthracycline treatment or underlying cardiac or lung disease." "" "" ""</seg>
<seg id="286">"" "" "" "if nausea, vomiting and diarrhoea can occur in patients following the application of Abraxane nausea, vomiting and diarrhoea, these can be treated with the usual antiemetika and constipating means." "" "" ""</seg>
<seg id="287">"" "" "" "Abraxane should not be used in pregnant women or in childbearing age that do not practice effective contraception, except treatment of mother with paclitaxel is essential." "" "" ""</seg>
<seg id="288">"" "" "" "during and up to 1 month after treatment with Abraxane, women in childbearing age should apply a reliable contraction method." "" "" ""</seg>
<seg id="289">"" "" "" "male patients treated with Abraxane will be advised, during and up to six months after the treatment, no child testifies." "" "" ""</seg>
<seg id="290">"" "" "" "male patients should be advised before the treatment, because of the treatment with Abraxane the possibility of irreversible infertility." "" "" ""</seg>
<seg id="291">"" "" "" "Abraxane can cause side effects such as tiredness (very common) and dizziness (often), which can affect traffic and ability to operate machines." "" "" ""</seg>
<seg id="292">The following are the most common and most important cases of side effects that occurred in 229 patients with metastatic breast cancer which were treated once every three weeks with 260 mg / m2 of Abraxane in the pivotal phase III study.</seg>
<seg id="293">Neutropenie was the most striking important hematological toxicity (reported in 79% of patients) and was quickly reversible and dose-dependent; leukopenia was reported in 71% of patients.</seg>
<seg id="294">Anemia (Hb &lt; 10 g / dl) was observed in 46% of patients treated with Abraxane and was severe (Hb &lt; 8 g / dl).</seg>
<seg id="295">Table 1 shows the side effects associated with the gift of Abraxane as monotherapy for each dose and indication in studies (N = 789).</seg>
<seg id="296">"" "" "" "very common (≥ 1 / 100, &lt; 1 / 10); occasionally (≥ 1 / 1000, &lt; 1 / 1000); very rare (≥ 1 / 10); very rare (&lt; 1 / 10.000)." "" "" ""</seg>
<seg id="297">"" "" "" "occasional: increased blood pressure, weight gain, increased lactine hydrogenase in the blood, increased blood sugar, elevated blood sugar, increased phosphorus in blood, reduced potassium in the blood heart disease:" "" "" ""</seg>
<seg id="298">"" "" "" "dysphagia, flatulence, tongue burning, dry mouth, painless chair, oesophagitis, pain in the mouth, oral pain, rectal bleeding disorders of the kidneys and urinary tract:" "" "" ""</seg>
<seg id="299">"" "" "" "pain in the chest wall, weakness of muscles, neck pain, pain in skeletal muscles, muscle spasms, discomfort in limbs, muscle weakness, very common:" "" "" ""</seg>
<seg id="300">"" "" "" "restlessness 1 The frequency of hypersensitivity reactions is calculated based on a definite in relation to a population of 789 patients," "" "" ""</seg>
<seg id="301">"" "" "" "since these events were reported on a voluntary basis during clinical practice, no estimates of the actual frequency are possible and no causal relationship with these events was established." "" "" ""</seg>
<seg id="302">Paclitaxel is an anticoagotubules-active substance that promotes the concentration of microtubules from the tubulin indices and stabilizes microtubules by inhibiting their depolymerisation.</seg>
<seg id="303">This stabilisation results in inhibition of the normal dynamic reorganisation of the microtubular network that is essential for the vital interphase and the mitotic cell functions.</seg>
<seg id="304">It is known that albumin mediates the transcytosis of plasma components into endothelial cells and has been demonstrated in vitro studies that the presence of albumin promotes the transport of paclitaxel through endothelial cells.</seg>
<seg id="305">It is assumed that this improved transpondothelial transport is mediated by the gp-60 albuminescent receptor and due to the albumescent protein SPARC (butted protein acidic rich in cysteine) a paclitaxel accumulation occurs in the tumor area.</seg>
<seg id="306">The application of Abraxane for metastatic breast cancer is supported by data from 106 patients in two inhaled unaffiliated studies and 454 patients who were treated in a randomised Phase III comparative study.</seg>
<seg id="307">"" "" "" "in one study, 43 patients with metastatic breast cancer were treated with Abraxane, which in the form of an infusion was given over 30 minutes with a dose of 175 mg. / m2." "" "" ""</seg>
<seg id="308">"" "" "" "in the second study, a dose of 300 mg / m2 was used as infusion about 30 minutes to 63 patients with metastatic breast cancer." "" "" ""</seg>
<seg id="309">This multi-centric study was performed in patients with metastatic breast cancer which received a monotherapy with paclitaxel every 3 weeks in the form of solvent containing paclitaxel (N = 225) or in the form of Abraxane 260 mg / m2 as 30 minutes infusion (N = 229).</seg>
<seg id="310">"" "" "" "in the study, 64% of patients had a impaired general condition (ECOG 1 or 2), 79% had visceral metastases and 76% had more than 3 metastal cells." "" "" ""</seg>
<seg id="311">"" "" "" "14% of patients had previously not received chemotherapy, 27% had only one adjuvant chemotherapy, 40% only due to metastasis and 19% due to metastasis and adjuvant treatment." "" "" ""</seg>
<seg id="312">"" "" "" "9 The results for the overall response rate and time until disease progression as well as progression-free survival and survival for patients receiving &gt; First-line therapy, are shown below." "" "" ""</seg>
<seg id="313">Neurotoxicity compared to paclitaxel was evaluated by the improvement of a degree for patients who experienced a peripheral neuropathy grade 3 at a time during therapy.</seg>
<seg id="314">The natural course of peripheral neuropathy for rejection of baseline based on the cumulative toxicity of Abraxane after &gt; 6 treatment courses has not been evaluated and remains unknown.</seg>
<seg id="315">The pharmacokinetics of the overall paclitaxel after 30- and 180-minute infusion of Abraxane with a dose of 80 to 375 mg / m2 was determined in clinical trials.</seg>
<seg id="316">The active substance exposure (AUC) increased linearly from 2653 to 16736 ng.h / ml as similar to a dose of 80 to 300 mg / m2.</seg>
<seg id="317">10 After IV administration of Abraxane in patients with metastatic breast cancer in the recommended clinical dose of 260 mg / m2 the paclitaxel plasma concentration decreased in multiphase mode.</seg>
<seg id="318">The average distribution volume was 632 l / m2; the high distribution volume indicates a far-reaching extravascular distribution and / or soft binding of paclitaxel.</seg>
<seg id="319">In a study involving patients with advanced solid tumours the pharmacokinetic properties of paclitaxel were compared with intravenous 30 minutes infusion of 260 mg / m2 Abraxane with the values following a 3-hour injection of 175 mg / m2 solvent-containing paclitaxel.</seg>
<seg id="320">The clearing of Paclitaxel was higher after the Abraxane injection (43%) as after a solvent containing paclitaxel injection and also the distribution volume was higher at Abraxane (53%).</seg>
<seg id="321">In published literature on in vitro studies of human liver microsome and tissue layers reported that paclitaxel is primarily metabolized to 6α-hydroxypaclitaxel and to two smaller metabolites (3 "-p-hydroxypaclitaxel and 6α-3" -p-Dihydroxypaclitaxel).</seg>
<seg id="322">After a 30-minute infusion of 260 mg / m2 of Abraxane in patients with metastatic breast cancer the mean value for cumulative urea was 4% of the given total dose with less than 1% of the metabolites 6α-hydroxypaclitaxel and 3 "-p-hydroxypaclitaxel.</seg>
<seg id="323">"" "" "" "however, only a few data is available about patients at the age of more than 75, since only 3 patients of this age group participated in pharmacokinetic analysis." "" "" ""</seg>
<seg id="324">"" "" "" "chemical and physical stability was proven at 2 ° C - 8 ° C in original box, and in light of light over 8 hours." "" "" ""</seg>
<seg id="325">Paclitaxel is a cytotoxic anticarcinogenic medicine and as well as other potentially toxic substances should be taken care of when dealing with Abraxane.</seg>
<seg id="326">Using a sterile syringe is slowly injected over a period of at least 1 minute 20 ml of a 9 mg / ml (0.9%) sodium chloride infusion solution into an abraxane glass bottle.</seg>
<seg id="327">"" "" "" "after complete addition to the solution, the glass bottle should rest at least 5 minutes to ensure a good wetting of the solid." "" "" ""</seg>
<seg id="328">"" "" "" "then the hole should be swivelled slowly and gently for at least 2 minutes, and / or inverted until a complete reset of the powder is done." "" "" ""</seg>
<seg id="329">"" "" "" "if precipitations or sinuses are visible, the glass bottle must be inverted again in order to achieve a complete reset before the application." "" "" ""</seg>
<seg id="330">"" "" "" "the exact total dose volume of the 5 mg / ml suspension is calculated and the corresponding amount of the reconstituted Abraxane is injected into an empty, sterile PVC or non-PVC infusion bag." "" "" ""</seg>
<seg id="331">"" "" "" "pharmaceutical vigilance system The holder of approval for the transport must ensure that the pharmaceutical vigilance system, as described in version 2.0 and presented in module 1.8.1. of the authorisation application, is established and works before and while the medicine is brought into circulation." "" "" ""</seg>
<seg id="332">Risk management plan The holder of approval for the application is obliged to carry out the studies and other pharmaceutical vigilance activities described in the pharmaceutical vigilance plan as described in version 4 of the Risk Management Plan (RMP) and all subsequent updates of the RMP which are agreed with the CHMP.</seg>
<seg id="333">"" "" "" "according to the CHMP directive on risk management systems for drug use, the updated RMP is to be submitted simultaneously with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="334">"" "" "" "in addition, an updated RMP is required • If new information that could affect the current security specification, the pharmaceutical vigilance plan or risk inimitation, • On request of EMEA" "" "" ""</seg>
<seg id="335">"" "" "" "8 hours in the refrigerator in the glass bottle, when stored in the cardboard box to protect the contents from light." "" "" ""</seg>
<seg id="336">"" "" "" "Abraxane is used to treat breast cancer when other therapies have been tried, but not successful, and if you do not question for anthracycline-containing therapies." "" "" ""</seg>
<seg id="337">Abraxane can not be used: • If you are hypersensitive (allergic) to Paclitaxel or any of the other components of Abraxane (initial values for neutrophination of &lt; 1.5 x 109 / l - your doctor will inform you about it)</seg>
<seg id="338">"" "" "" "special caution when using Abraxane is required: if you have a impaired renal function, if you suffer numbness, tingling, tingling sensation, touch sensitivity or muscle weakness, if you suffer from serious liver problems, if you have heart problems" "" "" ""</seg>
<seg id="339">"" "" "" "if you use Abraxane with other medicines, please inform the doctor if you use other medicines or have recently applied, as they might cause an interaction with Abraxane." "" "" ""</seg>
<seg id="340">"" "" "" "during and up to 1 month after treatment with Abraxane, women in childbearing age should apply a reliable contraction method." "" "" ""</seg>
<seg id="341">"" "" "" "in addition, they should be advised before the treatment over a sperm count, as the possibility of permanent infertility through the Abraxane treatment." "" "" ""</seg>
<seg id="342">Traffic tightness and operation of machines Abraxane can cause side effects such as tiredness (very common) and dizziness (often) which can impact on the traffic and the ability to operate machines.</seg>
<seg id="343">"" "" "" "if you are also receiving other medicines during your treatment, you should consult your doctor regarding driving or serving machines." "" "" ""</seg>
<seg id="344">"" "" "" "22 • Effect on peripheral nerves (pain and numbness) • pain in one or more joints • pain in muscles • nausea, diarrhea • vomiting • weakness and tiredness" "" "" ""</seg>
<seg id="345">"" "" "" "severe side effects (reported at least 1 out of 100 patients) include: • rash, itching, dry skin, sore throat, abdominal pain • swelling of the mucous membranes or soft tissue, sore throat, or sore throat, oral soor • sleeping disorders" "" "" ""</seg>
<seg id="346">"" "" "" "the rare side effects (at least 1 of 10,000 patients) are: • lung infection • skin reaction to another substance after irradiation • blood clots" "" "" ""</seg>
<seg id="347">Please inform your doctor or pharmacist if any of the listed side effects do significantly affect you or notice side effects that are not stated in this information.</seg>
<seg id="348">"" "" "" "if it is not used immediately, it can be stored in a glass bottle of up to 8 hours in the fridge (2 ° C - 8 ° C) in order to protect the contents from light." "" "" ""</seg>
<seg id="349">Each drinking bottle contains 100 mg of Paclitaxel. • After the reconstitution each ml of the suspension contains 5 mg of Paclitaxel. • The other component is albuminous solution from the human (contains sodium, sodium caprylate and N acetyltryptophan (Ph.Eur.))</seg>
<seg id="350">Precautions for the preparation and use of Paclitaxel are a cytotoxic anticarcinogenic medicine and as well as other potentially toxic substances should be taken care of when dealing with Abraxane.</seg>
<seg id="351">Using a sterile syringe should be injected slowly over a period of 1 minute 20 ml of a 9 mg / ml (0.9%) sodium chloride infusion solution into an abraxane glass bottle.</seg>
<seg id="352">"" "" "" "after that, the nozzle can be swiveled slowly and gently for at least 2 minutes and / or invert until a complete reset of the powder is made." "" "" ""</seg>
<seg id="353">"" "" "" "calculate the exact total dose volume of the 5 mg / ml suspension and inject the corresponding amount of the reconstituted Abraxane into an empty, sterile PVC infusion bag type IV." "" "" ""</seg>
<seg id="354">Parenteral drugs should be subjected to any particle and discoloration prior to the application of a visual inspection whenever the solution or the container permit this.</seg>
<seg id="355">"" "" "" "stability of unopened bottles with abraxanes are stable up to the date given on the packaging, when the container is stored in the cardboard box to protect the content from light." "" "" ""</seg>
<seg id="356">"" "" "" "after the first reconstitution, the suspension should be filled immediately into an infusion bag." "" "" ""</seg>
<seg id="357">"" "" "" "member states must ensure that the holder of approval for the market launch is provided by medical professionals in dialysis centres, and retail stores with the following information and materials:" "" "" ""</seg>
<seg id="358">"" "" "" "• Training brochure • Summary of the characteristics of the medicine (specialist information), labeling and packaging inserts." "" "" ""</seg>
<seg id="359">This means that Abseamed is similar to a biological medicine approved by the European Union (EU) and contains the same substance (also called "reference drug").</seg>
<seg id="360">"" "" "" "it is used in patients with normal blood-iron values, in which complications may occur in connection with blood transfusion and in which a blood loss of 900 to 1,800 ml is expected." "" "" ""</seg>
<seg id="361">"" "" "" "treatment with Abseamed has to be initiated under the supervision of a doctor, who has experience in treating patients with diseases that the medicine is shown." "" "" ""</seg>
<seg id="362">"" "" "" "in patients with kidney problems and in patients who want to make their own blood donation, Abseamed is injected into a vein." "" "" ""</seg>
<seg id="363">"" "" "" "the injection can also be made by the patient or his supervisor, provided they have received appropriate instructions." "" "" ""</seg>
<seg id="364">Patients with chronic kidney failure or in patients receiving chemotherapy should always lie in the recommended range (between 10 and 12 grams per deciliter in adults and between 9.5 and 11 g / dl in children).</seg>
<seg id="365">"" "" "" "the iron values of all patients are checked before the treatment, to ensure that no iron deficiency exists, and iron supplements should be administered throughout the treatment." "" "" ""</seg>
<seg id="366">"" "" "" "in patients with chemotherapy, or in patients with kidney problems, anaemia can be caused by erythropoietine deficiency or that the body does not respond adequately to the body's own erythropoietin." "" "" ""</seg>
<seg id="367">Erythropoietin is also used before surgery to increase the number of red blood cells and thereby reduce the consequences of blood loss.</seg>
<seg id="368">"" "" "" "it is produced by a cell containing a gene (DNA), which empowers them to the formation of epoetin alfa." "" "" ""</seg>
<seg id="369">"" "" "" "Abseamed was compared to a major study with 479 patients who suffered from kidney problems, compared to the reference drug." "" "" ""</seg>
<seg id="370">All patients participating in this study had been injected Eprex / Erypo at least eight weeks before they either were converted to abseamed or still received Eprex / Erypo.</seg>
<seg id="371">"" "" "" "the main indicator for efficacy was the change in hemoglobin values between the start of the study, and the evaluation period in the weeks 25 to 29." "" "" ""</seg>
<seg id="372">"" "" "" "in addition, the company presented the results of a study in which the effects of injected under the skin were examined with those of Eprex / Erypo at 114 cancer patients receiving chemotherapy." "" "" ""</seg>
<seg id="373">"" "" "" "in the study involving patients suffering from kidney problems, the hemoglobin values were maintained by patients receiving Eprex / Erypo." "" "" ""</seg>
<seg id="374">"" "" "" "in comparison to this, patients who still received Eprex / Erypo showed an increase of 0.063 g / dl of the initial value of 12.0 g / dl." "" "" ""</seg>
<seg id="375">The most common side effect of Abseamed is a rise in blood pressure that can occasionally lead to symptoms of an encephalopathy (brain problems) such as sudden pungent migraine headaches and confusion.</seg>
<seg id="376">"" "" "" "Abseamed may not be used in patients who may be hypersensitive (allergic) to epoetin alfa, or any of the other ingredients." "" "" ""</seg>
<seg id="377">"" "" "" "Abseamed as injections under the skin is not recommended for treating kidney problems, since further studies are required to ensure that there are no allergic reactions." "" "" ""</seg>
<seg id="378">"" "" "" "the Medicinal Products Committee (CHMP) concluded that for Abseamed in accordance with the provisions of the European Union of evidence, the medicine has a comparable quality, safety and efficacy profile such as Eprex / Erypo." "" "" ""</seg>
<seg id="379">"" "" "" "the company that manufactures Abseamed will provide information packages for medical professionals across all Member States, including information on the safety of the medicine." "" "" ""</seg>
<seg id="380">"" "" "" "August 2007, the European Commission granted Medice medicament Pütter GmbH & Co KG a permit for placing Abseamed in the entire European Union." "" "" ""</seg>
<seg id="381">"" "" "" "treatment of anaemia and reduction of transfusion demand in adults with solid tumors, malignant lymphomas or multiplem myeloma (e.g. cardiovascular status, pre-existing anaemia in the onset of chemotherapy)." "" "" ""</seg>
<seg id="382">Treatment should only be carried out in patients with moderate anaemia (hemoglobin [Hb] 10 - 13 g / dl [6.2 - 8.1 mmol / l] if blood-saving measures are not available or insufficient when blood-saving measures require (4 or more units blood in women; 5 or more units blood in men).</seg>
<seg id="383">"" "" "" "to reduce foreign blood, Abseamed can be applied in front of a large elective orthopedic operation in adults with no iron deficiency, in which a high risk of transfusion complications is expected." "" "" ""</seg>
<seg id="384">HB 10-13 g / dl) and an expected blood loss of 900-1800 ml that can not participate in an autologous blood donation program.</seg>
<seg id="385">The hemoglobin target concentration is between 10 and 12 g / dl (6.2 - 7.5 mmol / l) except for pediatric patients in which the hemoglobin concentration should lie between 9.5 and 11 g / dl (5.9 - 6.8 mmol / l).</seg>
<seg id="386">"" "" "" "symptoms and symptoms may vary depending on age, gender and overall illness; therefore, the patient's individual clinical course and disease condition is required by the doctor." "" "" ""</seg>
<seg id="387">An increase in hemoglobin by more than 2 g / dl (1.25 mmol / l) over a period of four weeks should be avoided.</seg>
<seg id="388">"" "" "" "due to the variability between patients, individual hemoglobin values can occasionally be observed in a patient via or under the hemoglobin target concentration." "" "" ""</seg>
<seg id="389">In view of this hemoglobin variability a corresponding dose management should be tried to achieve the hemoglobin target concentration of 10 g / dl (6.2 mmol / l) to 12 g / dl (7.5 mmol / l).</seg>
<seg id="390">If the hemoglobin value increases by more than 2 g / dl (1.25 mmol / l) per month or if the permanent hemoglobin value exceeds 12 g / dl (7.5 mmol / l) the epoetin-alfa dose can be reduced by 25%.</seg>
<seg id="391">"" "" "" "patients should be closely monitored to ensure that epoetin alfa is used in the lowest permitted dose, which is required for controlling anaemia and anaemia." "" "" ""</seg>
<seg id="392">These clinical results indicate that patients with initial low Hb value (&lt; 6 g / dl or &lt; 3,75 mmol / l) may need higher maintenance doses than patients in which initial anaemia is less severe (Hb &gt; 8 g / dl or &gt; 5 mmol / l).</seg>
<seg id="393">These clinical results indicate that patients with initial low Hb value (&lt; 6.8 g / dl or &lt; 4.25 mmol / l) may need higher maintenance doses than patients in which initial anaemia is less severe (Hb &gt; 6.8 g / dl or &gt; 4.25 mmol / l).</seg>
<seg id="394">Starting dose 50 I.U. / kg three times a week by intravenous application if necessary with an increase of 25 I.U. / kg (three times a week) until the desired target value is reached (this should be done in steps of at least 4 weeks).</seg>
<seg id="395">"" "" "" "symptoms of anemia and subsequent symptoms may vary depending on age, gender and overall disease." "" "" ""</seg>
<seg id="396">In view of this hemoglobin variability a corresponding dose management should be tried to achieve the hemoglobin target concentration of 10 g / dl (6.2 mmol / l) to 12 g / dl (7.5 mmol / l).</seg>
<seg id="397">"" "" "" "patients should be closely monitored to ensure that epoetin alfa is used in the lowest permitted dose, which is required for controlling the anaemia symptoms." "" "" ""</seg>
<seg id="398">If after 4 weeks of treatment the hemoglobin value should be increased by at least 1 g / dl (0.62 mmol / l) or the retic number of cells by ≥ 40,000 cells / µl should be maintained three times a week or 450 I.U. / kg once a week.</seg>
<seg id="399">If the hemoglobin increase &lt; 1 g / dl (&lt; 0.62 mmol / l) and the Retidal Range of &lt; 40.000 cells / µl is increased compared to the initial value the dose should be increased to 300 I.U. / kg three times a week.</seg>
<seg id="400">If after another 4 weeks of treatment with 300 I.U. / kg three times per week the hemoglobin value of ≥ 1 g / dl (≥ 0.62 mmol / l) or the Retium rate of ≥ 40,000 cells / µl should be maintained three times a week.</seg>
<seg id="401">On the other hand the hemoglobin value of &lt; 1 g / dl (&lt; 0.62 mmol / l) resp. the retic cell count increased by &lt; 40,000 cells / µl is unlikely and the treatment should be canceled.</seg>
<seg id="402">Patients with mild anemia (hematocrit 33 - 39%) in which the precautionary deposit of ≥ 4 blood konserae is required should receive Abseamed in a dose of 600 I.U. / kg body weight twice a week before surgical procedure.</seg>
<seg id="403">"" "" "" "iron substitution should start as early as possible - e.g. a few weeks before the autologous blood donation program, so that large iron reserves are available before the beginning of the Abseamed therapy." "" "" ""</seg>
<seg id="404">"" "" "" "6 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) before surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="405">"" "" "" "epoetin alfa should present 300 I.U. / kg preoperatively on 10 consecutive days, on the day of surgery and 4 days immediately thereafter." "" "" ""</seg>
<seg id="406">"" "" "" "alternatively, the injection can be given at the end of dialysis via the hose of a fistula, followed by 10 ml isotonic saline solution to rinse the hose and ensure adequate injection of the medicine into circulation." "" "" ""</seg>
<seg id="407">Patients suffering from the treatment with some erythropoetin on an erythropoetin (Pure Red Cell Aplasia, PRCA) should not get Abseamed or another erythropoetin (see Section 4.4 - erythroblastoenie).</seg>
<seg id="408">"" "" "" "heart attack or stroke within one month before the treatment, instable angina pectoris, increased risk of deep venous rombosis (e.g. anamnestically known venous thrombosis)." "" "" ""</seg>
<seg id="409">"" "" "" "the application of epoetin alfa is contraindicated in patients with severe coronary artery disease, peripheral vascular disease, vascular disease, or cerebrovascular disease." "" "" ""</seg>
<seg id="410">Erythroblastoenie (PRCA) Very rare was reported on the occurrence of an antistatic PRCA after months of treatment with subcutaneous erythropoetin.</seg>
<seg id="411">"" "" "" "in patients with sudden loss of loss, defined as reduction of hemoglobin values (1 - 2 g / dl per month) with increased need for transfusions, the Retidal rate or vitamin B12 deficiency, aluminium toxicity, infections, haemolysis) should be examined." "" "" ""</seg>
<seg id="412">"" "" "" "if the Retikulocyte value is reduced, taking into account anaemia (i.e. the" "" "" "" "index" "" "" "" "), thrombocyte and leukocytic numbers should be determined and an examination of the bone marrow for diagnosing a PRCA." "" "" ""</seg>
<seg id="413">The data for immunogenicity in subcutaneous use of Abseamed in patients with a risk for an anti-body induced PRCA (patients with renal anemia) are not sufficient.</seg>
<seg id="414">"" "" "" "8 If patients with chronic renal insufficiency should not be exceeded in maintenance therapy, the upper limit of hemoglobin target concentration should not be exceeded in section 4.2." "" "" ""</seg>
<seg id="415">"" "" "" "in clinical studies, increased mortality risk and risk for serious cardiovascular events were observed if erythropoesis stimulating agents (ESA) were given with a hemoglobin target concentration of more than 12 g / dl (7.5 mmol / l)." "" "" ""</seg>
<seg id="416">Controlled clinical studies have shown no significant benefit if the hemoglobin concentration is due to the concentration of haemoglobin concentrations and the avoidance of blood transfusions.</seg>
<seg id="417">The hemoglobin increase should not exceed 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="418">"" "" "" "in patients with chronic kidney failure and clinically evident coronary heart disease or congestion failure, the upper limit of hemoglobin target concentration should not be exceeded in maintenance therapy." "" "" ""</seg>
<seg id="419">"" "" "" "according to these findings, the treatment of anaemia with epoetin alfa in adults with renal insufficiency, which are still not dialysis, will not accelerate the progression of renal insufficiency." "" "" ""</seg>
<seg id="420">"" "" "" "for tumour patients under chemotherapy, a 2-3-week delay between epoetin-alfa and the erythropoetin response should be taken into account (patients may need to be transacted)." "" "" ""</seg>
<seg id="421">If the Hb increase is exceeded 2 g / dl (1.25 mmol / l) per month or a Hb value of 13 g / dl (8.1 mmol / l) the dose must be adjusted in accordance with Section 4.2 to minimize the risk of possible thrombotic events (see Section 4.2 treatment of patients with chemotherapy-related anemia).</seg>
<seg id="422">The decision to use recombinant erythropoetine should be based on a benefit-risk reduction under the participation of the respective patient that should also take into account the specific clinical context.</seg>
<seg id="423">"" "" "" "in patients who are intended for a greater elective orthopaedic surgery, if possible before the onset of epoetin-alfa-therapy the cause of anaemia is examined and treated accordingly." "" "" ""</seg>
<seg id="424">"" "" "" "patients receiving a greater elective orthopaedic surgery should receive adequate thrombosis prophylaxis, since they have an increased risk of thrombotic and vascular diseases, especially in the underlying cardiovascular disease." "" "" ""</seg>
<seg id="425">"" "" "" "in addition, treatment with epoetin alfa can also be used for patients with an initial initial value of &gt; 13 g / dl to have an increased risk of post-operative thrombotic / vascular events." "" "" ""</seg>
<seg id="426">"" "" "" "in several controlled studies, epoetine has not been proven to improve overall survival in tumour patients with symptomatic anemia or reduce the risk of tumour progression." "" "" ""</seg>
<seg id="427">4 months in patients with metastatic breast cancer which received chemotherapy were returned if a hemoglobin target concentration of 12 to 14 g / dl (7.5 - 8.7 mmol / l) was targeted</seg>
<seg id="428">Epoetin alfa is used together with Ciclosporin should control the blood levels of Ciclosporin and the Ciclosporine dose should be adapted to the growing hematocrit.</seg>
<seg id="429">"" "" "" "in vitro studies on tumor tissues, there are no indications of an interaction between epoetin alfa and G-CSF or GM-CSF concerning haematological differentiation or proliferation." "" "" ""</seg>
<seg id="430">"" "" "" "about thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thromboses, aneurysm, aneurysm, aneurysm, aneurysm, posterior thromboses." "" "" ""</seg>
<seg id="431">The most common side effect during treatment with epoetin alfa is a dose-dependent increase in blood pressure or the worsening of an existing hypertension.</seg>
<seg id="432">Increased incidence of thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="433">"" "" "" "regardless of erythropoetin treatment, surgical patients with cardiovascular disease can lead to thrombotic and vascular complications." "" "" ""</seg>
<seg id="434">The genetically-derived epoetin alfa is glycolic and identical to the endogenous human erythropoetin that was isolated from the urine anemic patient with regard to the amino acids and the carbohydrate content.</seg>
<seg id="435">It could be shown with the help of cultures of human bone marrow cells that epoetin alfa specifically stimulates the erythropoesis and does not affect leukopoesis.</seg>
<seg id="436">"" "" "" "389 patients with hemostomstoses (221 multiple myeloma, 144 non-Hodgkin's lymphomas, 64 gynaecological tumors, 22 prostate cancer, 22 gastrointestinal carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="437">"" "" "" "1895 patients with solid tumors (683 mammary carcinomas, 260 bronchial carcinomas, 174 gynaecological tumors, 300 gastrointestinal tumors and 478 others) and 802 patients with hemoblastoses." "" "" ""</seg>
<seg id="438">"" "" "" "survival and tumour progression was examined in five major controlled trials involving 2833 patients, four of these studies were double-blind placebo-controlled trials and" "" "" ""</seg>
<seg id="439">"" "" "" "in the open study, there was no difference in overall survival between the patients treated with recombinant human erythropoetin and the control patient." "" "" ""</seg>
<seg id="440">"" "" "" "in these studies, patients treated with recombinant human erythropoetics were consistent with an anaemia due to various common malignancies significantly higher mortality than in the controls." "" "" ""</seg>
<seg id="441">Overall survival in the studies could not be explained by differences in the incidence of thrombosis and associated complications with recombinant human erythropoetin patients and in the case of controls.</seg>
<seg id="442">There is an increased risk of thromboembolc events in tumour patients treated with recombinant human erythropoetin and a negative impact on overall survival cannot be excluded.</seg>
<seg id="443">It is not clear how far these results can be transferred to the application of recombinant human erythropoetin in tumour patients receiving chemotherapy with the aim of achieving a hemoglobin value below 13 g / dl as too few patients with these characteristics were included in the verified data.</seg>
<seg id="444">Epoetin-alfa regulations after repeated IV application showed a half-life of about 4 hours in healthy volunteers and a slightly extended half-life of about 5 hours in patients with kidney failure.</seg>
<seg id="445">"" "" "" "after subcutaneous injection, the serum levels of epoetin alfa are much lower than the serum levels that are achieved following intravenous injection." "" "" ""</seg>
<seg id="446">"" "" "" "there is no accumulation: the serum levels remain the same, regardless of whether they are determined 24 hours after the first gift or 24 hours after the last gift." "" "" ""</seg>
<seg id="447">Bone marrow fibrosis is a well-known complication of chronic kidney failure in humans and could be attributed to a secondary hyperparathyreoidism or unknown factors.</seg>
<seg id="448">In a study of hemodialysis patients treated three years with epoetin alfa the incidence of bone marrow fibrosis was not increased compared to the control group with dialysis patients who were not treated with epoetin alfa.</seg>
<seg id="449">"" "" "" "14. in animal experiments with approximately the 20x of the recommended weekly dose, epoetin alfa led to diminished fetal body weight, to a delay of the Ossification and to an increase in fetal mortality." "" "" ""</seg>
<seg id="450">"" "" "" "these reports rely on in vitro studies with cells from human tumor tissue samples, which are of uncertain significance for the clinical situation." "" "" ""</seg>
<seg id="451">"" "" "" "as part of the outpatient application, the patient can store Abseamed once for a maximum of 3 days outside the cooling box and not over 25 ° C." "" "" ""</seg>
<seg id="452">"" "" "" "the syringes are equipped with grading rings and the filling volume is indicated by an attached label, so if necessary, the measurement of partial quantities is possible." "" "" ""</seg>
<seg id="453">Treatment with Abseamed has to be initiated under the supervision of doctors who have experience in treating patients with the above indications.</seg>
<seg id="454">"" "" "" "21 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) before surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="455">"" "" "" "23 In case of chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in patients with chronic kidney failure." "" "" ""</seg>
<seg id="456">The hemoglobin increase should not exceed 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="457">"" "" "" "about thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thromboses, aneurysm, aneurysm, aneurysm, aneurysm, aneurysm, posterior thromboses." "" "" ""</seg>
<seg id="458">Increased incidence of thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="459">"" "" "" "389 patients with hemostomstoses (221 multiple myeloma, 144 non-Hodgkin's lymphomas, 64 gynaecological tumors, 22 prostate cancer, 22 gastrointestinal carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="460">"" "" "" "29 In animal experiments with approximately the 20x of the recommended weekly dose, epoetin alfa led to diminished fetal body weight, to a delay of the Ossification and to an increase in fetal mortality." "" "" ""</seg>
<seg id="461">"" "" "" "as part of the outpatient application, the patient can store Abseamed once for a maximum of 3 days outside the cooling box and not over 25 ° C." "" "" ""</seg>
<seg id="462">"" "" "" "36 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) before surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="463">"" "" "" "38 In case of chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in patients with chronic kidney failure." "" "" ""</seg>
<seg id="464">The hemoglobin increase should not exceed 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="465">"" "" "" "about thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thromboses, aneurysm, aneurysm, aneurysm and 41 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="466">Increased incidence of thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="467">"" "" "" "389 patients with hemostomstoses (221 multiple myeloma, 144 non-Hodgkin's lymphomas, 64 gynaecological tumors, 22 prostate cancer, 22 gastrointestinal carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="468">"" "" "" "44 in animal experimental studies with approximately the 20x of the recommended weekly dose, epoetin alfa led to diminished fetal body weight, to a delay of the Ossification and to an increase in fetal mortality." "" "" ""</seg>
<seg id="469">"" "" "" "as part of the outpatient application, the patient can store Abseamed once for a maximum of 3 days outside the cooling box and not over 25 ° C." "" "" ""</seg>
<seg id="470">"" "" "" "51 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) before surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="471">"" "" "" "53 In case of chronic kidney failure, the recommended upper limit of hemoglobin target concentration should not be exceeded in patients with chronic kidney failure." "" "" ""</seg>
<seg id="472">The hemoglobin increase should not exceed 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="473">"" "" "" "about thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thromboses, aneurysm, aneurysm, aneurysm and 56 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="474">Increased incidence of thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="475">"" "" "" "389 patients with hemostomstoses (221 multiple myeloma, 144 non-Hodgkin's lymphomas, 64 gynaecological tumors, 22 prostate cancer, 22 gastrointestinal carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="476">"" "" "" "59 In animal experiments with approximately the 20x of the recommended weekly dose, epoetin alfa led to diminished fetal body weight, to a delay of the Ossification and to an increase in fetal mortality." "" "" ""</seg>
<seg id="477">"" "" "" "as part of the outpatient application, the patient can store Abseamed once for a maximum of 3 days outside the cooling box and not over 25 ° C." "" "" ""</seg>
<seg id="478">"" "" "" "66 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) before surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="479">"" "" "" "68 In case of chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in patients with chronic kidney failure." "" "" ""</seg>
<seg id="480">The hemoglobin increase should not exceed 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="481">"" "" "" "about thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thromboses, aneurysm, aneurysm, aneurysm, aneurysm, aneurysm, cervical thromboses." "" "" ""</seg>
<seg id="482">Increased incidence of thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="483">"" "" "" "389 patients with hemostomstoses (221 multiple myeloma, 144 non-Hodgkin's lymphomas, 64 gynaecological tumors, 22 prostate cancer, 22 gastrointestinal carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="484">"" "" "" "74 In animal experiments with approximately the 20x of the recommended weekly dose, epoetin alfa led to diminished fetal body weight, to a delay of the Ossification and to an increase in fetal mortality." "" "" ""</seg>
<seg id="485">"" "" "" "as part of the outpatient application, the patient can store Abseamed once for a maximum of 3 days outside the cooling box and not over 25 ° C." "" "" ""</seg>
<seg id="486">"" "" "" "81 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) before surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="487">"" "" "" "83 In case of chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in patients with chronic kidney failure." "" "" ""</seg>
<seg id="488">The hemoglobin increase should not exceed 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="489">"" "" "" "about thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thromboses, aneurysm, aneurysm, aneurysm, aneurysm, aneurysm and 86 blood clots." "" "" ""</seg>
<seg id="490">Increased incidence of thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="491">"" "" "" "389 patients with hemostomstoses (221 multiple myeloma, 144 non-Hodgkin's lymphomas, 64 gynaecological tumors, 22 prostate cancer, 22 gastrointestinal carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="492">"" "" "" "89 In animal experiments with approximately the 20x of the recommended weekly dose, epoetin alfa led to diminished fetal body weight, to a delay of the Ossification and to an increase in fetal mortality." "" "" ""</seg>
<seg id="493">"" "" "" "as part of the outpatient application, the patient can store Abseamed once for a maximum of 3 days outside the cooling box and not over 25 ° C." "" "" ""</seg>
<seg id="494">"" "" "" "96 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) before surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="495">"" "" "" "98 In case of chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in patients with chronic kidney failure." "" "" ""</seg>
<seg id="496">The hemoglobin increase should not exceed 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="497">"" "" "" "about thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thromboses, aneurysm, aneurysm, aneurysm and 101 blood clots in artificial kidneys was reported in patients under epoetin alfa." "" "" ""</seg>
<seg id="498">Increased incidence of thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="499">"" "" "" "389 patients with hemostomstoses (221 multiple myeloma, 144 non-Hodgkin's lymphomas, 64 gynaecological tumors, 22 prostate cancer, 22 gastrointestinal carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="500">"" "" "" "104 In animal experiments with approximately the 20x of the recommended weekly dose, epoetin alfa led to diminished fetal body weight, to a delay of the Ossification and to an increase in fetal mortality." "" "" ""</seg>
<seg id="501">"" "" "" "as part of the outpatient application, the patient can store Abseamed once for a maximum of 3 days outside the cooling box and not over 25 ° C." "" "" ""</seg>
<seg id="502">111. the recommended dosage is 600 I.U. / kg epoetin alfa to be given once a week over three weeks (day 21, 14 and 7) before surgery and on the day of surgery (day 0).</seg>
<seg id="503">"" "" "" "113 In case of chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in patients with chronic kidney failure." "" "" ""</seg>
<seg id="504">The hemoglobin increase should not exceed 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="505">"" "" "" "about thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thromboses, aneurysm, aneurysm, aneurysm, aneurysm, aneurysm, aneurysm." "" "" ""</seg>
<seg id="506">Increased incidence of thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="507">"" "" "" "389 patients with hemostomstoses (221 multiple myeloma, 144 non-Hodgkin's lymphomas, 64 gynaecological tumors, 22 prostate cancer, 22 gastrointestinal carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="508">"" "" "" "119-in-experimental studies with approximately the 20x of the recommended weekly dose, epoetin alfa led to diminished fetal body weight, to a delay of the Ossification and to an increase in fetal mortality." "" "" ""</seg>
<seg id="509">"" "" "" "as part of the outpatient application, the patient can store Abseamed once for a maximum of 3 days outside the cooling box and not over 25 ° C." "" "" ""</seg>
<seg id="510">"" "" "" "126 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) before surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="511">"" "" "" "128 In case of chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in patients with chronic kidney failure." "" "" ""</seg>
<seg id="512">The hemoglobin increase should not exceed 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="513">"" "" "" "about thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thromboses, aneurysm, aneurysm, aneurysm, aneurysm, aneurysm, neurorrhosis." "" "" ""</seg>
<seg id="514">Increased incidence of thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="515">"" "" "" "389 patients with hemostomstoses (221 multiple myeloma, 144 non-Hodgkin's lymphomas, 64 gynaecological tumors, 22 prostate cancer, 22 gastrointestinal carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="516">"" "" "" "134 In animal experiments with approximately the 20x of the recommended weekly dose, epoetin alfa led to diminished fetal body weight, to a delay of the Ossification and to an increase in fetal mortality." "" "" ""</seg>
<seg id="517">"" "" "" "as part of the outpatient application, the patient can store Abseamed once for a maximum of 3 days outside the cooling box and not over 25 ° C." "" "" ""</seg>
<seg id="518">"" "" "" "141 The recommended dosage is 600 I.U. / kg epoetin alfa, which should be given once a week over three weeks (day 21, 14 and 7) before surgery and on the day of surgery (day 0)." "" "" ""</seg>
<seg id="519">"" "" "" "143 In case of chronic kidney failure, the upper limit of hemoglobin target concentration should not be exceeded in patients with chronic kidney failure." "" "" ""</seg>
<seg id="520">The hemoglobin increase should not exceed 1 g / dl (0.62 mmol / l) per month and should not exceed 2 g / dl (1.25 mmol / l) per month to minimize the risk of high blood pressure.</seg>
<seg id="521">"" "" "" "about thrombotic, vascular events such as myocardial infarction, cerebral thrombosis, pulmonary thromboses, aneurysm, aneurysm, aneurysm, aneurysm, posterior thromboses." "" "" ""</seg>
<seg id="522">Increased incidence of thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with erythropoetins.</seg>
<seg id="523">"" "" "" "389 patients with hemostomstoses (221 multiple myeloma, 144 non-Hodgkin's lymphomas, 64 gynaecological tumors, 22 prostate cancer, 22 gastrointestinal carcinomas, 21 gastrointestinal carcinomas and 30 others)." "" "" ""</seg>
<seg id="524">"" "" "" "149 In animal experimental studies with approximately the 20x of the recommended weekly dose, epoetin alfa led to diminished fetal body weight, to a delay of the Ossification and to an increase in fetal mortality." "" "" ""</seg>
<seg id="525">"" "" "" "as part of the outpatient application, the patient can store Abseamed once for a maximum of 3 days outside the cooling box and not over 25 ° C." "" "" ""</seg>
<seg id="526">"" "" "" "prior to the market launch and according to agreement with the relevant authorities of member states, the holder of approval for the transport has to provide medical professionals in dialysis centres and retail stores with the following information and materials." "" "" ""</seg>
<seg id="527">"" "" "" "the holder of approval for the transport has to ensure that the pharmaceutical vigilance system described in version 3.0 and is functioning properly before the medicine is brought into circulation, and as long as the medicine is marketed." "" "" ""</seg>
<seg id="528">"" "" "" "the Risk Management Plan (RMP), listed in Module 1.8.2. of the Risk Management Plan outlined in Module 1.8.2. of the authorisation application, is obliged to carry out the Risk Management Plan listed in Module 1.8.2." "" "" ""</seg>
<seg id="529">An updated RMP should be provided in accordance with the "CHMP Guideline on Risk Management System for" products for human use "at the same time with the next updated report on the harmlessness of the drug (Periodic Safety Update Report.</seg>
<seg id="530">"" "" "" "in addition, an updated RMP should be submitted: • with the receipt of new information, the influence on current safety specifications (Safety Specification), the pharmaceutical vigilance plan or risk reduction measures) milestones following the EMEA" "" "" ""</seg>
<seg id="531">"" "" "" "• For a month before your treatment has suffered a heart attack or stroke, if you suffer from unstable Angina pectoris (for the first time occurring or increased chest pain) - if you have already performed such a blood drop in the veins, for example." "" "" ""</seg>
<seg id="532">"" "" "" "you suffer from severe circulatory disorders of the heart (coronary artery disease), the arteries of the legs or arms (cerebral vascular disease) or brain (cerebrovascular disease), you have recently had a heart attack or stroke." "" "" ""</seg>
<seg id="533">"" "" "" "during treatment with Abseamed, it may occur within the normal range to a slight dose-dependent increase in the number of blood counts, which is back again in the course of further treatment." "" "" ""</seg>
<seg id="534">"" "" "" "your doctor may, if necessary, perform regular blood tests to regularly control the number of platelets during the first 8 weeks of treatment." "" "" ""</seg>
<seg id="535">"" "" "" "lack of iron, disintegration of red blood cells (hemolysis), blood loss, vitamin B12 or folic acid deficiency, should be considered and treated prior to treatment with Abseamed." "" "" ""</seg>
<seg id="536">"" "" "" "very rarely, after months of treatment with subcutaneous (under the skin of speckled) erythropoetin was reported." "" "" ""</seg>
<seg id="537">"" "" "" "if you suffer from erythroblaconia, it will break your therapy with Abseamed and determine how your anaemia is best treated." "" "" ""</seg>
<seg id="538">Therefore Abseamed has to be given by injections into a vein (intravenous) if you are treated because of an anaemia due to kidney disease.</seg>
<seg id="539">"" "" "" "a high hemoglobin is the risk for problems with the heart or blood vessels, and the risk of death could be increased." "" "" ""</seg>
<seg id="540">"" "" "" "in case of elevated or rising potassium levels, your doctor may consider an interruption of treatment with Abseamed until the potassium levels are back in the normal range." "" "" ""</seg>
<seg id="541">"" "" "" "if you suffer from chronic kidney disease and clinically obvious coronary heart disease or congestion signs by insufficient heart performance, your doctor will ensure that your hemoglobin mirror does not exceed certain value." "" "" ""</seg>
<seg id="542">"" "" "" "according to these findings, the treatment of blood armosis with abseamed in adults with chronic kidney failure (kidney failure), which are not dialysis, will not accelerate the progression of renal insufficiency." "" "" ""</seg>
<seg id="543">A 2 - 3-week delay between epoetin-alfa and the desired effect should be considered for assessing the effectiveness of Abseamed.</seg>
<seg id="544">200 your doctor will regularly determine your values of the red blood pigment (hemoglobin) and adjust your Abseamed dose to keep the risk of blood grafting (thrombotic event) as low as possible.</seg>
<seg id="545">"" "" "" "this risk should be carefully weighed against the benefits derived from the treatment with epoetin alfa, especially if you have an increased risk of thrombotic vascular events (e.g. a deep vein thrombosis or lung embolia)." "" "" ""</seg>
<seg id="546">"" "" "" "if you are cancer patients, remember that Abseamed is a growth factor for blood cells and may have a negative effect on the tumour." "" "" ""</seg>
<seg id="547">"" "" "" "if you have a higher orthopedic operation, you should examine the cause of your anaemia before starting treatment with Abseamed." "" "" ""</seg>
<seg id="548">"" "" "" "if your values of the red blood colorant (hemoglobin) are too high, you should not get Abseamed, as there is an increased risk of blood grafting after surgery." "" "" ""</seg>
<seg id="549">"" "" "" "please inform your doctor or pharmacist if you use / apply other medicines, or have recently taken / applied, even if it is not prescription." "" "" ""</seg>
<seg id="550">"" "" "" "if you take Ciclosporin (means to suppress the immune system) during your therapy with Abseamed, your doctor may possibly arrange certain blood tests to measure the blood levels of Ciclosporin." "" "" ""</seg>
<seg id="551">Laboratory tests have no interaction between epoetin alfa and G-CSF or GM-CSF (G-CSF and GM-CSF are means for building the immune system (e.g. for cancer chemotherapy or HIV).</seg>
<seg id="552">"" "" "" "depending on how your wormwood (anemia) speaks to the treatment, the dose can be adjusted every four weeks until your condition is under control." "" "" ""</seg>
<seg id="553">"" "" "" "if necessary, your doctor will arrange regular blood tests to verify the success of the treatment and make sure that the medicine works properly and your hemoglobin value does not exceed certain value." "" "" ""</seg>
<seg id="554">"" "" "" "once you are well tuned, you will receive regular doses of Abseamed between 25 and 50 I.U. / kg twice a week, spread over two equally large injections." "" "" ""</seg>
<seg id="555">"" "" "" "if necessary, your doctor will arrange regular blood tests to verify the success of the treatment and ensure that your hemoglobin value does not exceed certain value." "" "" ""</seg>
<seg id="556">"" "" "" "depending on how the anaemia refers to the treatment, the dose can be adjusted approximately every four weeks until the condition is under control." "" "" ""</seg>
<seg id="557">"" "" "" "to ensure this and ensure that the hemoglobin value does not exceed certain value, the treating physician will perform regular blood tests." "" "" ""</seg>
<seg id="558">"" "" "" "if it is necessary to shorten the treatment time before surgery, a dose of 300 I.U. / kg may be given on 10 consecutive days before surgery, on the day of surgery and another 4 days after surgery." "" "" ""</seg>
<seg id="559">"" "" "" "however, if your doctor holds this for appropriate, you can learn how to squirt Abseamed yourself among the skin." "" "" ""</seg>
<seg id="560">"" "" "" "heart, heart attack, brain hemorrhage, cerebral thrombosis, arterial thromboses, pulmonary thromboses, vascular diseases (aneurysm), thromboses of the retina and blood clots in artificial kidneys were reported in patients under erythropoetin treatment." "" "" ""</seg>
<seg id="561">"" "" "" "eyelids and lips (quinox oil) and shock-like allergic reactions with symptoms such as tingling, redness, itching, heat sensation and accelerated pulse were reported in rare cases." "" "" ""</seg>
<seg id="562">Erythroblaconia means that no more red blood cells can be formed in the bone marrow (see section "Special caution when using Abseamed is required").</seg>
<seg id="563">"" "" "" "after repeated blood donations, it can come - regardless of the treatment with Abseamed - to a blood grafting (thrombotic vascular events)." "" "" ""</seg>
<seg id="564">Treatment with Abseamed can be associated with increased risk of blood prop after surgery (post-operative thrombotic vascular events) when your initial message value is too high</seg>
<seg id="565">Please inform your doctor or pharmacist if any of the listed side effects do significantly affect you or if you notice side effects that are not indicated in this information.</seg>
<seg id="566">"" "" "" "if a syringe is taken out of the fridge and room temperature has reached (up to 25 ° C), it must be used either within 3 days or discarded." "" "" ""</seg>
<seg id="567">"" "" "" "Aclasta is used to treat the following diseases: osteoporosis (a disease that makes the bones brittle), both in women after menopause and in men." "" "" ""</seg>
<seg id="568">"" "" "" "it is used in patients with a high fracture risk (fractures), including in patients who have recently suffered a low traumatic hip fracture like with the Hinfallen; • Morbus Paget of the bone, a disease that changes the normal course of bone growth." "" "" ""</seg>
<seg id="569">"" "" "" "additionally, patients with Morbus Paget should take at least 500 mg of calcium twice daily for at least 10 days after the treatment; patients with hip fracture should receive a large dose of vitamin D (50 000 to 125 000 IE) before the first infusion." "" "" ""</seg>
<seg id="570">"" "" "" "the administration of paracetamol or ibuprofen (remedy against inflammation) shortly after the application of acetamol can reduce the symptoms occurring in the three days following the infusion, such as fever, muscle pain, influenza-like symptoms, joint pain and headache." "" "" ""</seg>
<seg id="571">"" "" "" "for the treatment of the Morbus Paget, Aclasta may only be prescribed by doctors who have experience in treating this disease." "" "" ""</seg>
<seg id="572">"" "" "" "as the active ingredient in Aclasta is the same as in Zometa, a portion of the data material for Zometa was used to evaluate Aclasta." "" "" ""</seg>
<seg id="573">"" "" "" "in the first study, almost 8 000 elderly women were involved with osteoporosis, and the number of spine and hip fractures was examined over a period of three years." "" "" ""</seg>
<seg id="574">"" "" "" "the second study included 2 127 men and women with osteoporosis more than 50 years, who recently had suffered a hip fracture; the number of fractures was examined over a period of up to five years." "" "" ""</seg>
<seg id="575">"" "" "" "at Morbus Paget, Aclasta was tested in two studies to a total of 357 patients and compared with Risedronat (another bisphosphonate) for six months." "" "" ""</seg>
<seg id="576">The main indicator for the effectiveness was whether the content of alkaline phosphatase in serum (an enzyme that decreases bone substance) in the blood again normalized or decreased at least 75% compared to the initial value.</seg>
<seg id="577">"" "" "" "in the study involving elderly women, the risk of cycled fractures in patients under Aclasta (without any other osteoporosis) was reduced by 70% over a period of three years." "" "" ""</seg>
<seg id="578">"" "" "" "compared to all patients under Aclasta (with or without other osteoporosis treatments) with those under placebo, the risk of hip fractures decreased by 41%." "" "" ""</seg>
<seg id="579">In the study involving men and women with hip fracture 9% of patients under Aclasta had a fracture (92 of 1 065) compared to 13% of patients under placebo (139 of 1 062).</seg>
<seg id="580">"" "" "" "most of the side effects of Aclasta occur within the first three days after the infusion, and are less frequent in repeated infusions." "" "" ""</seg>
<seg id="581">Aclasta may not be used in patients who may be hypersensitive (allergic) to zoledron juice or other bisphosphonates or any of the other ingredients.</seg>
<seg id="582">"" "" "" "as with all bisphosphonates, patients in Aclasta are subject to the risk of kidney problems, reactions at the infusion point and osteoarthritis (dying of bone tissue) in the jaw." "" "" ""</seg>
<seg id="583">The manufacturer of Aclasta provides clarification material for doctors who prescribe Aclasta for the treatment of osteoporosis as well as similar material for patients in which the side effects of the medicine are explained and pointed out when they should contact the doctor.</seg>
<seg id="584">"" "" "" "April 2005, the European Commission issued a permit for the transport of Aclasta in the entire European Union to Novartis Europharm Limited." "" "" ""</seg>
<seg id="585">Conditions OR constraints regarding THE SICHERE AND effective ANWENDING OF DISCOUNCTION to implement THE DURCH THE member states OR constraints regarding THE SICHERE AND effective ANWENDING OF DISCOUNT TO THE member states ZU implement SIND</seg>
<seg id="586">"" "" "" "osteoporosis treatment in postmenopausal women and men with increased risk of fractures, including patients with a recent low-traumatic hip fracture." "" "" ""</seg>
<seg id="587">"" "" "" "the patient information package should be provided and the following core messages include: • The provision of treatment in pregnancy and in nursing women, appropriate physical activity, non-smoking and a healthy diet • Important signs and symptoms for serious side effects • When to access medical or nursing assistance" "" "" ""</seg>
<seg id="588">"" "" "" "osteoporosis treatment • in postmenopausal women • in men with increased risk of fractures, including patients with a recent low-traumatic hip fracture." "" "" ""</seg>
<seg id="589">"" "" "" "for the treatment of postmenopausal osteoporosis and osteoporosis in men, an intravenous infusion of 5 mg Aclasta is recommended once a year." "" "" ""</seg>
<seg id="590">"" "" "" "in patients with low-traumatic hip fracture, the administration of the infusion of Aclasta is recommended two or more weeks after the surgical care of the hip fracture (see section 5.1)." "" "" ""</seg>
<seg id="591">"" "" "" "for the treatment of the Morbus Paget, Aclasta should only be prescribed by doctors who have experience in treating the Morbus Paget." "" "" ""</seg>
<seg id="592">"" "" "" "after a treatment by the Morbus Paget with Aclasta, a long remission rate was observed in patients who responded to the therapy (see section 5.1)." "" "" ""</seg>
<seg id="593">"" "" "" "in addition, it is highly advisable in patients with Morbus Paget an adequate intake of calcium, twice daily at least 500 mg. of elementary calcium, for at least 10 days after the administration of Aclasta (see Section 4.4)." "" "" ""</seg>
<seg id="594">"" "" "" "in patients with a recent low-traumatic hip fracture, a initial dose of 50,000 to 125,000 I.E. oralem or intramuscular Vitamin D is recommended before the first Aclasta infusion." "" "" ""</seg>
<seg id="595">The frequency of symptoms occurring within the first three days after the administration of acetamol or ibuprofen may be reduced shortly after the application of acetamol.</seg>
<seg id="596">Patients with kidney dysfunction (see Section 4.4) in Patients with a Creatinin Clearance &lt; 35 ml / min are not recommended for a limited clinical experience for this group of patients.</seg>
<seg id="597">"" "" "" "older patients (≥ 65 years) A dose adjustment is not necessary, since bioavailability, distribution and elimination in older patients is similar to younger ones." "" "" ""</seg>
<seg id="598">"" "" "" "" "" "" "" "children and adolescents Aclasta is not recommended for use in children and adolescents under 18 years of age as data are missing for lack of safety and efficacy." "" "" ""</seg>
<seg id="599">"" "" "" "Aclasta is not recommended in patients with severe kidney failure (Creatinin-Clearance, &lt; 35 ml / min), as there are only limited clinical experience for this patient population." "" "" ""</seg>
<seg id="600">"" "" "" "before starting treatment with Aclasta, a pre-existing hypokalemia will be treated with an adequate intake of calcium and vitamin D (see Section 4.3)." "" "" ""</seg>
<seg id="601">"" "" "" "due to the rapid implementation of the effect of zoledron acid on bone reconstruction, a temporary, sometimes symptomatic hypokalemia can develop whose maximum occurs within the first 10 days after the infusion of Aclasta (see Section 4.8)." "" "" ""</seg>
<seg id="602">"" "" "" "in addition, it is highly advisable in patients with Morbus Paget an adequate intake of calcium, twice daily at least 500 mg. of elementary calcium, for at least 10 days after the administration of Aclasta (see Section 4.2)." "" "" ""</seg>
<seg id="603">"" "" "" "cancer, chemotherapy, treatment with corticosteroids, bad oral hygiene should be considered before an application of bisphosphonates with proper preventive dental treatment." "" "" ""</seg>
<seg id="604">"" "" "" "for patients requiring dental interventions, no data is available to reduce the risk of osteoporosis in the jaw area." "" "" ""</seg>
<seg id="605">The clinical evaluation by the treating physician should be the basis for the treatment plan of each patient and based on an individual benefit risk assessment.</seg>
<seg id="606">The frequency of symptoms occurring within the first three days after administration of acetamol or ibuprofen may be reduced shortly after the application of acetamol (see Section 4.2).</seg>
<seg id="607">The incidence of serious adverse events reported cases of atrial fibrillation was increased in patients with Aclasta (1.3%) (51 of 3.862) compared to patients receiving placebo (0.6%) (22 of 3.852).</seg>
<seg id="608">"" "" "" "in osteoporosis studies (PFT, HORIZON - Recurrent Fracture Trial [RFT]), the overall frequency of atrial fibrillation between Aclasta (2.6%) and placebo (2.1%) was comparable." "" "" ""</seg>
<seg id="609">"" "" "" "very common (≥ 1 / 100, &lt; 1 / 10), occasional (≥ 1 / 1000, &lt; 1 / 1000), rare (≥ 1 / 1000, &lt; 1 / 1000)." "" "" ""</seg>
<seg id="610">Kidney dysfunction Zoledron folic was associated with kidney function disorders that expressed itself as a decrease in the kidney function (i.e. an increase of serum-creatinins) and in rare cases as acute kidney failure.</seg>
<seg id="611">The change in the creatinin-Clearance (measured annually before administration) and the occurrence of kidney failure as well as a restricted kidney function were comparable to a clinical study in osteoporosis over three years compared to the Aclasta- and the placebo group.</seg>
<seg id="612">A temporary increase of serum-creatine in 10 days after administration was observed in 1.8% of patients treated with Aclasta compared to 0.8% of patients treated with placebo.</seg>
<seg id="613">Based on the evaluation of the laboratory findings the transient asymptomatic calcium values which were below the normal fluctuation range (less than 2.10 mmol / l) were observed in 2.3% of patients treated with Aclasta in a large clinical trial in the patients treated with Aclasta.</seg>
<seg id="614">"" "" "" "all patients received sufficient amounts of vitamin D and calcium in the study for postmenopausal osteoporosis, in the study to avoid clinical fractures after hip fracture and in the Morbus Paget studies (see Section 4.2)." "" "" ""</seg>
<seg id="615">"" "" "" "in the study to avoid clinical fractures after a recent hip fracture, the vitamin D levels were not routinely measured, but the majority of patients received an initial dose of vitamin D prior to the administration of Aclasta (see Section 4.2)." "" "" ""</seg>
<seg id="616">"" "" "" "local reactions after administration of zoledronate in a large clinical study was reported on local reactions at the infusion site, such as redness, swelling and / or pain, reported (0.7%)." "" "" ""</seg>
<seg id="617">"" "" "" "osteonecrosis in the jaw area has been treated especially in cancer patients, about osteochekroses (primarily in the jaw area), which were treated with bisphosphonates, including zoledron juice." "" "" ""</seg>
<seg id="618">"" "" "" "many of these patients had signs of local infections including osteomyelitis, and most of the reports refer to cancer patients after tooth extraction or other dental interventions." "" "" ""</seg>
<seg id="619">"" "" "" "7 patients with 7,736 patients showed osteoarthritis in the jaw area at an Aclasta and a patient treated with placebo." "" "" ""</seg>
<seg id="620">"" "" "" "in case of overdose, which leads to clinically relevant hypokalzemia, the administration of calcium and / or an intravenous infusion of calcium gluconate can be achieved." "" "" ""</seg>
<seg id="621">Clinical efficacy in the treatment of postmenopausal osteoporosis (PFT) The efficacy and safety of Aclasta 5 mg once a year for 3 consecutive years was shown with either one bone density value of ≤ -1.5 and at least two light or a medium-heavy existing vertebral body fracture ≤ -2.5 with or without signs of an existing vertebral body fracture.</seg>
<seg id="622">Effects on morphometric spine fractures Aclasta lowered significantly over a period of three years and already after one year the incidence of one or more new vertebral fractures (see table 2).</seg>
<seg id="623">Aclasta treated patients from 75 years and older had a 60% reduced risk of vertebral fractures compared to placebo patients (p &lt; 0.0001).</seg>
<seg id="624">Effects on hip fractures Aclasta showed a constant effect over three years which resulted in a reduced risk of hip fractures in an increase of 41% (95% CI (17% to 58%).</seg>
<seg id="625">"" "" "" "effect on bone density (BMD) Aclasta increased bone density on the lumbar vertebraic acid, hip and distal radius compared to placebo treatment at all times (6, 12, 24 and 36 months)." "" "" ""</seg>
<seg id="626">"" "" "" "9 Increase of the bone density of the lumbar spine by 6.7%, the total hip around 6.0%, the cervical diameter by 5.2% and the distal radius by 3.2%." "" "" ""</seg>
<seg id="627">"" "" "" "in the case of 152 postmenopausal osteoporosis patients treated with Aclasta (N = 82) or placebo (N = 70), bone biopsies were taken from the pool." "" "" ""</seg>
<seg id="628">"" "" "" "in comparison with placebo, a microcomputer tomography (µCT) analysis showed an increase in the trabecular bone volume and the preservation of trabecular bone architecture." "" "" ""</seg>
<seg id="629">Bone replacement markers The bone-specific alkaline phosphatase (BSAP) in serum and beta-C-telopeptide (b-CTX) in serum and beta-C-telopeptide (b-CTX) in serum was determined in intervals of 517 to 1.246 patients.</seg>
<seg id="630">"" "" "" "after 12 months, the treatment with an annual 5 mg dose decreased by 30% compared to the initial value and was kept at 28% below the initial value up to 36 months." "" "" ""</seg>
<seg id="631">P1NP was significantly reduced by 61% below the initial value after 12 months and was kept at 52% below the initial value up to 36 months.</seg>
<seg id="632">B-CTX was significantly reduced by 61% below the initial value after 12 months and was kept at 55% below the initial value up to 36 months.</seg>
<seg id="633">"" "" "" "the vitamin D levels were not routinely measured, but the majority of patients received a starting dose of vitamin D (50,000 to 125,000 I.U. oral or intramuscular) 2 weeks before infusion." "" "" ""</seg>
<seg id="634">"" "" "" "overall survival was 10% (101 patients) in the group treated with Aclasta, compared to 13% (141 patients) in the placebo group." "" "" ""</seg>
<seg id="635">Effect on bone mineral density (BMD) in the HORIZON RFT study increased the BMD in comparison to placebo treatment at all times.</seg>
<seg id="636">"" "" "" "for more than 24 months, the Aclasta treatment led to a 5.4% increase in BMD by 5.4% compared to placebo." "" "" ""</seg>
<seg id="637">"" "" "" "clinical efficacy in men In the HORIZON RFT study were randomised to 508 men, and in 185 patients the BMD was evaluated after 24 months." "" "" ""</seg>
<seg id="638">"" "" "" "the study was not designed to show a reduction in clinical fractures in men; the incidence of clinical fractures was 7.5%, compared to 8.7% in placebo." "" "" ""</seg>
<seg id="639">In another study in men (study CZOL446M2308) the once annual administration of Aclasta was not inferior to the once weekly gift of Alendronat based on the percentage change in the lumbar vertebrae BMD after 24 months compared to the initial value.</seg>
<seg id="640">Clinical efficacy of the treatment at Morbus Paget of the bone Aclasta was investigated in patients and patients aged over 30 years with radiologically confirmed disease (mean serum levels of alkaline phosphatase corresponding to the 2.6 times up to 3 times the upper normal average when recording in the study).</seg>
<seg id="641">11 The effectiveness of an infusion of 5 mg of zoledron juice compared to taking 30 mg of risedronate once a day during 2 months was demonstrated in two six month comparative studies.</seg>
<seg id="642">"" "" "" "after 6 months, a similar decrease in pain and pain influence was observed in the combined results compared to the initial value for Aclasta and Risedronat." "" "" ""</seg>
<seg id="643">"" "" "" "patients, which were classified as respondents at the end of the six-month main study (had responded to the therapy), could be included in a follow-up phase." "" "" ""</seg>
<seg id="644">"" "" "" "from the 143 patients treated with Aclasta and the 107 patients who participated in the follow-up study, the therapeutic approach to 141 of patients treated with Risedronate was maintained during an average duration of 18 months following the application." "" "" ""</seg>
<seg id="645">"" "" "" "infusions of 2, 4, 8 and 16 mg of colic acid in 64 patients showed the following pharmacokinetic data which proved to be dosisindependent." "" "" ""</seg>
<seg id="646">"" "" "" "after this, the plasma level rapidly decreased to &lt; 10% of the maximum value after 4 h and &lt; 1% after 24 h, followed by a long period of very low concentration, no more than 0.1% of the maximum value." "" "" ""</seg>
<seg id="647">Rapid biphasic vanishing from the large cycle with half-life t ½ α 0.24 and t ½ β 1.87 hours followed by a long elimination period with a terminal elimination period t ½ g 146 hours.</seg>
<seg id="648">"" "" "" "the early work phases (α and β, with the above -½ -values) presumably represent the fast resorption in the bones and excretion over the kidneys." "" "" ""</seg>
<seg id="649">"" "" "" "in the first 24 hours 39 ± 16% of the administered dose is found in the urine, while the rest is mainly bound to bone tissue." "" "" ""</seg>
<seg id="650">"" "" "" "the total body-Clearance is independent of the dose 5.04 ± 2.5 l / h and remains unaffected by sex, age, race or body weight." "" "" ""</seg>
<seg id="651">"" "" "" "an extension of the infusion time from 5 to 15 minutes led to the decrease in the acid concentration by 30% at the end of the infusion, but had no effect on the surface under the curve (plasma concentration against time)." "" "" ""</seg>
<seg id="652">A decreased clearing of metrochrom P450 enzyme systems metabolized substances is unlikely because Zoledron's acid is not metabolized in humans and because it is a weak or no direct and / or irreversible agent inhibitor of the P450-</seg>
<seg id="653">Specific patient groups (see Section 4.2) correlated with the Creatinin-Clearance - 75 ± 33% of the creatinin-Clearance and was 84 ± 29 ml / min (range 22 to 143 ml / min) in 64 patients.</seg>
<seg id="654">This results in an easy (clcr = 50- 80 ml / min) and moderate renal dysfunction down to a creatinin-Clearance up to 35 ml / min no dose adjustment of the cioledron juice.</seg>
<seg id="655">"" "" "" "because for severe kidney dysfunction (Creatinin- Clearance, &lt; 30 ml / min) only restricted data are available, no statements are possible for this population." "" "" ""</seg>
<seg id="656">Acute toxicity The highest non-letally active intravenous single dose was 10 mg / kg body weight in mice and at rats 0.6 mg / kg body weight.</seg>
<seg id="657">"" "" "" "in dogs studies, single doses of 1.0 mg / kg (based on the AUC the 6 times the recommended human-therapeutic exposure), administered over a period of 15 minutes, well and without a renal influence." "" "" ""</seg>
<seg id="658">"" "" "" "chronic and chronic toxicity in studies with intravenous use was determined in intervals of 0.2 mg / kg (a cumulative dose corresponding to the 6-minute infusion in 3-day intervals (a cumulative dose corresponding to the 7x of human-therapeutic exposure, related to AUC)." "" "" ""</seg>
<seg id="659">"" "" "" "in long-term studies with repeated use in accumulated exposures, which exceeded the maximum of the intended human exposure, toxicological effects occurred in other organs including the gastrointestinal tract and the liver and the intravenous injection point." "" "" ""</seg>
<seg id="660">"" "" "" "the most frequent occurrence in studies with repeated use was an increased primary spontaneous tumor in the metaphysis of the long bones of animals in the growth phase with almost all dosages, an infection that reflects the pharmacological, anti-absorptive effect of the substance." "" "" ""</seg>
<seg id="661">"" "" "" "in rats, one observed teratogeneity in dosages from 0.2 mg / kg as external and internal (visceral) abnormalities and such of the skeleton." "" "" ""</seg>
<seg id="662">"" "" "" "no teratogenic effects or embryo-fetal effects were observed in rabbits, although maternal toxicity was pronounced at 0.1 mg / kg as a result of decreased serum calcium levels." "" "" ""</seg>
<seg id="663">"" "" "" "if the medicine is not directly used, the user is responsible for the storage period following preparation and conditions before the application; normally 24 h should not be exceeded at 2 ° C to 8 ° C." "" "" ""</seg>
<seg id="664">Aclasta is delivered as a package with a bottle as a packing unit or as a bundling package consisting of 5 packs each containing one bottle.</seg>
<seg id="665">"" "" "" "osteoporosis treatment in postmenopausal women and men with increased risk of fractures, including patients with a recent low-traumatic hip fracture." "" "" ""</seg>
<seg id="666">"" "" "" "the patient information package should be provided and the following core messages include: • The provision of treatment in pregnancy and in nursing women, appropriate physical activity, non-smoking and healthy eating 17 • Important signs and symptoms for serious side effects • When to access medical or nursing assistance" "" "" ""</seg>
<seg id="667">"" "" "" "July 2007, completed on 29 September 2006, in module 1.8.1 of the application for the application of pharmaceutical covigilance system in force and works before and while the product is marketed." "" "" ""</seg>
<seg id="668">"" "" "" "the risk management plan approved by the Risk Management Plan (RMP) in Module 1.8.2 of the Risk Management Plan (RMP) in Module 1.8.2 of the Risk Management Plan (RMP) in Module 1.8.2 of the Risk Management Plan (RMP), approved by the RMP." "" "" ""</seg>
<seg id="669">"" "" "" "according to the CHMP directive on risk management systems for human medicines, the revised RMP should be submitted together with the next" Periodic Safety Update Report "(PSUR)." "" "" ""</seg>
<seg id="670">"" "" "" "a revised RMP should be submitted • If new information is known, the current statements on security, the pharmaceutical vigilance plan or activities might affect minimization of risk. • On request of EMEA." "" "" ""</seg>
<seg id="671">"" "" "" "Zoledron's acid is a representative of a substance class called bisphosphonate, and is used to treat osteoporosis in postmenopausal women, osteoporosis in men and the murder of the bone." "" "" ""</seg>
<seg id="672">"" "" "" "decreasing blood levels of sex hormones, especially estrogens that are made of androgens, play a role in the rather gradual loss of bone mass that is observed in men." "" "" ""</seg>
<seg id="673">"" "" "" "with the Morbus Paget, bone reconstruction takes place too fast, and new bone material is structured unordered, which makes the bone material weaker than normal." "" "" ""</seg>
<seg id="674">"" "" "" "Aclasta works by normalizing the bone reconstruction, ensuring a normal bone formation and gives the bone more strength again." "" "" ""</seg>
<seg id="675">"" "" "" "if you are in dental treatment or undergo a dental surgery, tell your doctor that you are treated with Aclasta." "" "" ""</seg>
<seg id="676">"" "" "" "if you use Aclasta with other medicines Please tell your doctor, pharmacist or nursing staff if you use other medicines / use / apply recently / applied, even if it is not prescription." "" "" ""</seg>
<seg id="677">"" "" "" "for your doctor, it is particularly important to know if you take medicine, known by those who are known to damage the kidneys." "" "" ""</seg>
<seg id="678">"" "" "" "when using Aclasta along with food and drinks, you are concerned that you take enough fluids according to your doctor's instructions before and after treatment with Aclasta." "" "" ""</seg>
<seg id="679">"" "" "" "osteoporosis The usual dose is 5 mg once a year, which is administered to you by your doctor or nursing staff as infusion in a vein." "" "" ""</seg>
<seg id="680">"" "" "" "if you have recently broken the hip, it is recommended to make the administration of Aclasta two or more weeks after operating the hip fracture." "" "" ""</seg>
<seg id="681">"" "" "" "the usual dose is 5 mg, which is administered to you by your doctor or nursing staff as an infusion in a vein." "" "" ""</seg>
<seg id="682">"" "" "" "since Aclasta acts for a long time, you may need to take another dose only after one year or longer." "" "" ""</seg>
<seg id="683">"" "" "" "it is important to follow these instructions carefully, so that the calcium level in your blood is not too low during the infusion." "" "" ""</seg>
<seg id="684">"" "" "" "at Morbus Paget, Aclasta can work longer than a year and your doctor will inform you if you need a renewed treatment." "" "" ""</seg>
<seg id="685">"" "" "" "if the administration of Aclasta has been missed, please contact your doctor or hospital immediately to arrange a new appointment." "" "" ""</seg>
<seg id="686">"" "" "" "before termination of treatment with Aclasta If you are considering the termination of the treatment with Aclasta, please take your next doctor's appointment and discuss it with your doctor." "" "" ""</seg>
<seg id="687">"" "" "" "side effects associated with the first infusion occur very often (with more than 30% of patients), but are less frequent after the infusion." "" "" ""</seg>
<seg id="688">"" "" "" "fever and chills, muscle or joint pain and headache arise within the first three days after the administration of Aclasta." "" "" ""</seg>
<seg id="689">"" "" "" "currently it is unclear whether Aclasta causes this irregular heartbeat, but you should tell your doctor if you notice such symptoms after you have received Aclasta." "" "" ""</seg>
<seg id="690">"" "" "" "physical signs because of too low calcium concentration in the blood, such as muscle cramps or numbbing or numbbing feeling, especially in the area around the mouth." "" "" ""</seg>
<seg id="691">"" "" "" "pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain, pain." "" "" ""</seg>
<seg id="692">Persistent pain and / or non-healing wounds in the mouth or jaw were reported especially in patients treated with bisphosphonates because of other diseases.</seg>
<seg id="693">"" "" "" "an allergic reaction, including rare cases of respiratory problems, hives and angioedema (such as swelling in the face, tongue or throat), was reported." "" "" ""</seg>
<seg id="694">"" "" "" "please inform your doctor, pharmacist or nursing staff, if one of the side effects listed you significantly affects or you notice side effects that are not listed in this information." "" "" ""</seg>
<seg id="695">"" "" "" "if the medicine is not directly used, the user is responsible for storage time and conditions up to the application; normally 24 h should not be exceeded at 2 ° C to 8 ° C." "" "" ""</seg>
<seg id="696">"" "" "" "in patients with a recent low-traumatic hip fracture, it is recommended to perform the infusion of Aclasta two or more weeks after the surgical care of the hip fracture." "" "" ""</seg>
<seg id="697">"" "" "" "before and after the administration of Aclasta, patients need to be sufficiently supplied with liquid; this is particularly important for patients receiving a diuretic therapy." "" "" ""</seg>
<seg id="698">"" "" "" "due to the rapid implementation of the effect of zoledron acid on bone reconstruction, a temporary, sometimes symptomatic, can develop, whose maximum occurs within the first 10 days after the infusion of Aclasta." "" "" ""</seg>
<seg id="699">"" "" "" "in addition, it is highly advisable in patients with Morbus Paget an adequate intake of calcium, according to at least twice daily 500 mg. of elementary calcium, for at least 10 days after the administration of Aclasta." "" "" ""</seg>
<seg id="700">"" "" "" "in patients with a recent low-traumatic hip fracture, an initial dose of 50,000 to 125,000 I.E. oralem or intramuscular Vitamin D is recommended before the infusion of Aclasta." "" "" ""</seg>
<seg id="701">"" "" "" "if you need more information about your illness or treatment, please read the packing instructions (also part of the EPAR) or contact your doctor or pharmacist." "" "" ""</seg>
<seg id="702">ACOMPLIA is additionally applied to a diet and exercise for the treatment of adult patients with a body mass index (BMI) of 30 kg / m ² or above respectively • which are overweight (BMI of 27 kg / m ² or above) and beyond one or more I</seg>
<seg id="703">"" "" "" "in addition, four studies were carried out on more than 7 000 patients in which ACOMPLIA was used in comparison to a placebo as a supportive agent for setting up smoking." "" "" ""</seg>
<seg id="704">"" "" "" "in contrast to the studies on the setting of smoking, however, no uniform results showed that the effect of ACOMPLIA was difficult to assess in this application area." "" "" ""</seg>
<seg id="705">What risk is associated with ACOMPLIA? he The most common side effects of ACOMPLIA observed during the trials (observed in more than 1 of 10 patients) were Nausea (nausea) and upper respiratory tract infection.</seg>
<seg id="706">"" "" "" "it may not be used in patients suffering from an existing severe depression or with antidepressants, as it can increase the risk of depression and can cause suicidal thoughts among others." "" "" ""</seg>
<seg id="707">"" "" "" "caution is required at the same time using ACOMPLIA with medicines such as ketoconazole or itraconazole (medication against fungal infections), ythromycin or Clarithromycin (antibiotics)." "" "" ""</seg>
<seg id="708">The Committee for Medicinal Products (CHMP) concluded that the efficacy of ACOMPLIA in relation to weight reduction in patients with obesity or overweight people</seg>
<seg id="709">"" "" "" "medicines used in patients who need it for health and not for cosmetic reasons (by providing information packages for patients and physicians), and around the arz" "" "" ""</seg>
<seg id="710">It also increases diet and exercise for the treatment of obesity (BMI ≥ 30 kg / m ²) or overweight patients (BMI &gt; 27 kg / m ²) that have one or more risk factors such as type 2 diabetes or dyslipidemia (see section 5.1).</seg>
<seg id="711">"" "" "" "ACOMPLIA is not recommended for use in children and adolescents under the age of 18, due to the lack of data on efficacy and harmlessness." "" "" ""</seg>
<seg id="712">"" "" "" "La depressive diseases or mood changes with depressive symptoms were reported at up to 10%, suicidal thoughts with up to 1% of patients receiving Rimonabant (see Section 4.8)." "" "" ""</seg>
<seg id="713">"" "" "" "if the benefits of treatment in an individual case exceed the risk (see Section 4.3 and 4.8)." "" "" ""</seg>
<seg id="714">"" "" "" "in addition to obesity, it also occurs in patients with no recognisable risks." "" "" ""</seg>
<seg id="715">"" "" "" "relatives or other close relatives are to point out that it is necessary to monitor the new occurrence of such symptoms, and immediately get medical advice if these symptoms occur." "" "" ""</seg>
<seg id="716">• Elderly patients The effectiveness and harmlessness of Rimonabant during the treatment of patients over 75 years have not been adequately shown.</seg>
<seg id="717">Patients with a cardiovascular event (myocardial infarction or stroke etc.) before less than 6 months were excluded from studies with Rimonabant. ln</seg>
<seg id="718">"" "" "" "Rifampicin, phenytoin, phenobarbital, carbamazepine, carbamazepine, carbamazepine, carbamazepine, carbamazepine, carbamazepine, carbamazepin, carbamazepine, carbamazepin, carbamazepine, carbamazepin, carbamazepine, carbamazepin, carbamazepine, carbamazepin, carbamazepine, carbamazepin, carbamazepin, carbamazepine, carbamazepin, carbamazepin, carbamazepine, carbamazepin, carbamazepin, carbamazepin, carbamazepine, carbamazepin</seg>
<seg id="719">"" "" "" "overweight patients and patients with obesity have been examined, and in addition to 3800 patients in further indications." "" "" ""</seg>
<seg id="720">"" "" "" "the following table shows the undesirable effects of placebo-controlled trials in patients who have been treated for weight reduction, and metabolic diseases." "" "" ""</seg>
<seg id="721">It was statistically significant higher than the corresponding placebo (for undesirable effects ≥ 1%) or if they were clinically relevant (for unwanted effects &lt; 1%).</seg>
<seg id="722">Very common (≥ 10%); frequently (≥ 1; &lt; 10%); occasionally (≥ 0.1% &lt; 1%); rare (≥ 0.01; &lt; 0.1%); very t lä</seg>
<seg id="723">"" "" "" "in a tolerability study, in which a limited number of persons were administered up to 300 mg, only slight symptoms were observed." "" "" ""</seg>
<seg id="724">Patients had a BMI ≥ 30 kg / m ² or BMI &gt; 27 kg / m ² and a hypertonia and / or dyslipidemia.</seg>
<seg id="725">N weight reduction after a year was 20 mg 6.5 kg in relation to the initial value compared to 1.6 kg for the placebo group (difference -4.9 kg CI95% -5.3) p &lt; 0.001).</seg>
<seg id="726">The patients treated with ACOMPLIA 20 mg and 1.2 kg in the placebo group (difference -3.8 kg; CI95% -4.3; p &lt; 0.001).</seg>
<seg id="727">"" "" "" "after 2 years, the difference in total weight reduction was between ACOMPLIA and placebo -4.2 kg (CI95% -5.0%; -3.4, p &lt; 0.001)." "" "" ""</seg>
<seg id="728">"" "" "" "9 weight reduction and further risk factors In studies in patients with no diabetes, in which a mixed population of patients with" "" "" ""</seg>
<seg id="729">Under Rimonabant 20 mg an average decrease of triglyceride was seen from 6.9% (initial triglyceride 1.62 mmol / l) compared to an increase of 5.8%</seg>
<seg id="730">In a second study in patients with obesity and with previously untreated type 2 diabetes (Serenade) the absolute change of HbA1c value (with an initial value of 7.9% for both groups) after 6 months -0.8 for Rimonabant 20 mg and -0.3 among placebo I</seg>
<seg id="731">The percentage of patients who reached a HbA1c- value of &lt; 7% was 51% in the Rimonabant group and 35% in the placebo group.</seg>
<seg id="732">The difference in the mean weight change between the 20 mg- and the placebo group was 3.8 kg (CI95% -5.0) -2.6 p &lt; 0.001). LN</seg>
<seg id="733">Improvement of the HbA1c value in patients who had taken the Rimonabant 20 mg were about 50% due to the direct effects of Rimonabant and about 50% explained by weight reduction. n eim arz</seg>
<seg id="734">Reached after 13 days (Cmax = 196 ± 28,1 ng / ml; Ctrough = 91,6 ± 14.1 ng / ml; AUC0-24 = 2960 ± 268 ng.h / ml).</seg>
<seg id="735">"" "" "" "in the case of food intake, a 67% increased Cmax or 48% increased ng AUC in the case of food intake." "" "" ""</seg>
<seg id="736">Patients with black skin color can have a reduction of up to 31% and a 43% lower AUC than patients of other ethnic populations.</seg>
<seg id="737">N populationspharmacokinetic analyses (age range 18- 81 years) is estimated that a 75-year-old patient has a 21% higher Cmax and a 27% higher AUC than a 40-year-old</seg>
<seg id="738">"" "" "" "5.3 Clinical clinical data, which were not observed in clinical trials, but which occurred in animals after exposure to the human therapeutic area, were considered to be potentially relevant for clinical application:" "" "" ""</seg>
<seg id="739">"" "" "" "in some, however, not in all cases, the beginning of convulsions seems to be associated with a process-related stress such as dealing with the animals." "" "" ""</seg>
<seg id="740">"" "" "" "on a longer period before the mating (9 weeks), Rimonabant was given a recovery from the initials effects of Rimonabant, so no adverse effects were observed on fertility or cycle disorders." "" "" ""</seg>
<seg id="741">The influence of Rimonabant on pre- and postnatal development was studied at the rat in dosages of up to 10 mg / kg / day.</seg>
<seg id="742">"" "" "" "in a study of rats for pre- and postnatal development, an exposition with Rimonabant in utero caused no changes in learning behaviour or memory." "" "" ""</seg>
<seg id="743">Detailed information on this medicine can be found on the website of the European Medicines Agency (EMEA) http: / / www.emea.europa.eu / availab. itte n eim Arz</seg>
<seg id="744">"" "" "" "La On the prescription label of the medicine, name and address of the manufacturer must be specified for the release of the respective charge." "" "" ""</seg>
<seg id="745">"" "" "" "26 Several psychiatric events such as depression or mood changes were reported in patients receiving ACOMPLIA (see paragraph," "" "" ""</seg>
<seg id="746">"" "" "" "if symptoms of depression (see below) occur during treatment with ACOMPLIA, contact your doctor and break the treatment." "" "" ""</seg>
<seg id="747">"" "" "" "dizziness, diarrhoea, anxiety, itching, excessive sensitivity (reduced sensation or unusual burning or tingling) on hands and feet, heat flushes, fall, gripping infections, joint pain." "" "" ""</seg>
<seg id="748">"" "" "" "please inform your doctor or pharmacist, if one of the side effects listed you significantly affects or you notice side effects that are not stated in this information." "" "" ""</seg>
<seg id="749">Summary of EPAR for the public The present document is a summary of the European Public Beurination Report (EPAR) in which the Committee for Human Use (CHMP) has assessed the trials conducted to reach recommendations regarding the use of the medicine.</seg>
<seg id="750">Actos is used to treat type 2 diabetes (also known as non-insulin-dependent diabetes). it can be used alone (monotherapy) in patients (especially obese patients).</seg>
<seg id="751">"" "" "" "it can also be applied to metformin in patients (especially obese patients), which can not be satisfactory with metformin alone in the highest tolerable dose." "" "" ""</seg>
<seg id="752">"" "" "" "in combination with a sulfonyotropic substance or insulin, the previous dose of the sulfonyotropic substance or insulin can be maintained except in patients with hypoglycemia (low blood sugar)." "" "" ""</seg>
<seg id="753">"" "" "" "this means that the body's insulin can be better utilized and the blood sugar level sinks, making type 2 diabetes better." "" "" ""</seg>
<seg id="754">"" "" "" "in more than 1,400 patients the efficacy of acetone was evaluated in tripletion; in addition, patients received a combination of metformin with a sulfonyl resin, in addition they received either Actos or placebo for up to 3.5 years." "" "" ""</seg>
<seg id="755">"" "" "" "in the studies the concentration of a substance in the blood (glycosylated hemoglobin, HbA1c) was measured, indicating how well the blood sugar is set." "" "" ""</seg>
<seg id="756">"" "" "" "Actos led to lowering the HbA1c value, suggesting that blood sugar levels were reduced from 15 mg, 30 mg and 45 mg." "" "" ""</seg>
<seg id="757">"" "" "" "at the end of the tripletion study, the effect of the additional administration of acetin and a sulfonyotropic substance in lowering the HbA1c value was 0.94% while the additional administration of placebo had led to a reduction of 0.35%." "" "" ""</seg>
<seg id="758">"" "" "" "in a small study in which the combination of Actos and insulin was examined in 289 patients, the patients, the Actos in addition to insulin, showed a decrease in the HbA1c values of 0.69% after 6 months, compared to placebo." "" "" ""</seg>
<seg id="759">"" "" "" "the most common side effects associated with Actos were visual disturbances, upper respiratory tract infections (colds), weight gain and hypoaesthesia (reduced sensitivity to stimuli)." "" "" ""</seg>
<seg id="760">"" "" "" "Actos may not be used in patients who may be hypersensitive (allergic) to pioglitazone or one of the other components, nor in patients with liver problems, heart failure or diabetic ketoacidosis (high level of blood - in the blood)." "" "" ""</seg>
<seg id="761">"" "" "" "it has been decided that acetin should serve as an alternative to the standard treatment with metformin in patients, where metformin is not indicated." "" "" ""</seg>
<seg id="762">"" "" "" "in October 2000, the European Commission granted Takeda Europe R & D Centre Limited a permit for the transport of Actos in the entire European Union." "" "" ""</seg>
<seg id="763">"" "" "" "the tablets are white to whitish, round, arched and carry on one side the marking" 15 "and on the other side the inscription" Actos. "" "" "" ""</seg>
<seg id="764">"" "" "" "Pioglitazone is also indicated for the combination with insulin in patients with type 2 diabetes mellitus, whose blood sugar is insufficient with insulin, which is inappropriate for metformin due to contraindications or intolerance (see Section 4.4)." "" "" ""</seg>
<seg id="765">"" "" "" "for the use of pioglitazon in patients under 18 years of age, no data is available, so the application in this age group is not recommended." "" "" ""</seg>
<seg id="766">"" "" "" "in patients suffering from the presence of at least one risk factor (e.g. previous heart attack or symptomatic coronary heart disease), the physician should start treatment with the lowest available dose and increase the dose gradually." "" "" ""</seg>
<seg id="767">"" "" "" "patients should be observed at signs and symptoms of heart failure, weight gain or oedema, especially those with reduced cardiac reserve." "" "" ""</seg>
<seg id="768">"" "" "" "patients should be observed at signs and symptoms of heart failure, weight gain and oedema if Pioglitazone is used in combination with insulin." "" "" ""</seg>
<seg id="769">A cardiovascular outcome study with pioglitazon in patients under 75 years with type 2 diabetes mellitus and pre-existing advanced macrovascular disease was performed.</seg>
<seg id="770">"" "" "" "this study showed an increase in heart failure reports, which however did not lead to an increase in mortality in the study." "" "" ""</seg>
<seg id="771">"" "" "" "in patients with increased output liver enzymes (ALT &gt; 2.5 x upper limit of the normal range), or with other signs of liver disease, Pioglitazon may not be used." "" "" ""</seg>
<seg id="772">"" "" "" "when the ALT levels are increased to 3 times the upper limit of the normal range, the liver enzymes are to be checked again as soon as possible." "" "" ""</seg>
<seg id="773">"" "" "" "if a patient develops symptoms that indicate a hepatic dysfunction like unexplained nausea, vomiting, upper abdomen, fatigue, loss of appetite and / or dark harn, the liver enzymes must be checked." "" "" ""</seg>
<seg id="774">"" "" "" "the decision whether the treatment of the patient with pioglitazone continues, should be led until the laboratory parameters are prescribed by the clinical evaluation." "" "" ""</seg>
<seg id="775">"" "" "" "in clinical trials with pioglitazone a dose-dependent weight gain has been proven, which can be absorbed by fat deposits and in some cases associated with fluid retention." "" "" ""</seg>
<seg id="776">A slight reduction of middle hemoglobin (relative reduction by 4%) and hematokrits (relative reduction by 4.1%) occurred as a result of hemodilution under therapy with pioglitazone.</seg>
<seg id="777">Similar changes were observed in comparing controlled trials with pioglitazone in patients under metformin (relative reduction of hemoglobin by 3.1% and insulin (relative reduction of hemoglobin by 1-2% and hematokrits by 1-3.2%).</seg>
<seg id="778">"" "" "" "as a result of increased insulin sensitivity, patients who receive Pioglitazone as oral dual or triple combination therapy with a sulfonyotropic substance or two-fold combination therapy with insulin are the risk of dose-dependent hypoglycemia." "" "" ""</seg>
<seg id="779">"" "" "" "after the market launch, treatment with thiazolidindions, including pioglitazone, was reported on a occurrence or deterioration of a diabetic macular edema with a reduction in visual acuity." "" "" ""</seg>
<seg id="780">It is unclear whether there is a direct connection between taking Pioglitazone and the occurrence of macular edema; however prescription doctors should be aware of the possibility of macular edema; a suitable ophthalmological examination should be considered.</seg>
<seg id="781">"" "" "" "in a summarizing analysis of messages undesirable events regarding bone fractures from randomised, controlled, double-blind clinical studies over a period of up to 3.5 years with more than 8,100 patients treated with pioglitazone" "" "" ""</seg>
<seg id="782">The calculated fracture incidence was 1.9 fractures per 100 years of patients with pioglitazone treated women and 1.1 fractures per 100 patient years in women treated with a comparison medication.</seg>
<seg id="783">"" "" "" "in the ProActive study, a study of 3.5 years for the investigation of cardiovascular events, fractures appeared in patients treated with pioglitazone (2.5%; 0.5 fractures per 100 patient years) in patients treated with a comparison medication." "" "" ""</seg>
<seg id="784">"" "" "" "patients should be aware of the possibility of pregnancy, and if a patient wants a pregnancy or this occurs, the treatment is to be removed (see section 4.6)." "" "" ""</seg>
<seg id="785">Studies on the investigation of the interactions have shown that pioglitazon has no relevant effects on the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin.</seg>
<seg id="786">"" "" "" "drug interactions that are metabolized by these enzymes, e.g. oral contraceptives, cyclosporine, calcium channel blocker and HMGCoA Reductase inhibitors are not expected." "" "" ""</seg>
<seg id="787">The simultaneous use of pioglitazone with gemfibrozil (a cytochrom P450 2C8- inhibitor) resulted in an increase in AUC from Pioglitazone by 3 times.</seg>
<seg id="788">The simultaneous application of Pioglitazone with Rifampicin (a Cytochrom P450 2C8 Inductor) resulted in lowering the AUC from Pioglitazon by 54%.</seg>
<seg id="789">"" "" "" "this is due to the fact that treatment with pioglitazone reduces the hyperinsulin resistance of the mother animal in pregnancy, thereby reducing the availability of the metabolic substrates for the fetal growth." "" "" ""</seg>
<seg id="790">"" "" "" "very common &gt; 1 / 10; frequently &gt; 1 / 1000, &lt; 1 / 10000, &lt; 1 / 10000; rare &lt; 1 / 10000, individual cases: unknown (not estimated from available data)." "" "" ""</seg>
<seg id="791">"" "" "" "these lead to a temporary modification of the tower and refracting index of the lens, as it can also be observed in other hypoglycemic agents." "" "" ""</seg>
<seg id="792">"" "" "" "in clinical trials with pioglitazone ALT ascents went beyond three times the upper limit of the normal range, however more rarely than in comparison groups under metformin or sulfonyamin resin." "" "" ""</seg>
<seg id="793">In an Outcome study in patients with pre-existing advanced macrovascular disease the incidence of severe heart failure under pioglitazone was 1.6% higher than under placebo if Pioglitazon bzw.</seg>
<seg id="794">"" "" "" "since the market launch it has rarely been reported on heart failure under pioglitazone, more frequently if Pioglitazone was used in combination with insulin or in patients with heart failure in anamnesis." "" "" ""</seg>
<seg id="795">"" "" "" "a summary analysis of messages undesirable events regarding bone fractures from randomised, controlled, double-blind clinical studies over a period of up to 3.5 years with more than 8.100 patients in the groups treated with pioglitazone and over 7,400 patients." "" "" ""</seg>
<seg id="796">"" "" "" "in the ProActive study period over a period of 3.5 years, fractures of 44 / 870 (5.1%) of patients treated with pioglitazone were compared with 23 / 905 (2.5%) in patients treated with a comparison medication." "" "" ""</seg>
<seg id="797">"" "" "" "when taking the reported maximum dose of 120 mg / day over four days, then 180 mg / day after seven days, no symptoms appeared." "" "" ""</seg>
<seg id="798">"" "" "" "pioglitazone appears to have an activation of specific nuclear receptors (PPAR-γ) which leads to increased insulin sensitivity of liver, fat and skeletal muscle cells." "" "" ""</seg>
<seg id="799">It could be shown that Pioglitazone reduces the glucose production in the liver and increases the peripheral glucose level in the case of insulin resistance.</seg>
<seg id="800">A clinical study with pioglitazone versus Glicladal as monotherapy was carried out over two years to investigate the time until after the therapeutic effect (defined as HbA1c ≥ 8.0% after the first 6 months of treatment).</seg>
<seg id="801">At the time after two years after the beginning of the therapy a blood sugar control (defined as HbA1c &lt; 8.0%) was maintained by pioglitazon in 69% of the treated patients (compared to 50% of the patients under Gliclacide).</seg>
<seg id="802">"" "" "" "in a placebo-controlled study for 12 months, patients whose blood sugar was insufficient despite three months of optimization with insulin, were randomised to Pioglitazone or placebo." "" "" ""</seg>
<seg id="803">In patients under pioglitazone the mean HbA1c - value reduced by 0.45% compared to the patients who continued only insulin; a reduction in insulin dosage in the group treated with pioglitazone was observed.</seg>
<seg id="804">"" "" "" "in clinical trials over a year, a statistically significant decrease in the albumin / creatinin ratio showed a statistically significant decrease in the initial values." "" "" ""</seg>
<seg id="805">"" "" "" "the effect of Pioglitazon (monotherapy with 45 mg versus placebo) was tested in a small, 18-week study of type 2 diabetes." "" "" ""</seg>
<seg id="806">"" "" "" "in most clinical studies, compared to placebo a reduction in total plasma triglycerides and free fatty acids and an increase in HDL- cholesterol levels were observed, but clinically not significantly increased LDL cholesterol levels." "" "" ""</seg>
<seg id="807">"" "" "" "in clinical trials over a period of up to two years, pioglitazone compared to placebo, metformin or Glicladal decreased overall plasma levels and free fatty acids and increased HDL cholesterol." "" "" ""</seg>
<seg id="808">"" "" "" "compared to placebo, no statistically significant increase in LDL cholesterol was found under Pioglitazon, while metformin and Glicladal decreased levels." "" "" ""</seg>
<seg id="809">"" "" "" "in a study more than 20 weeks, Pioglitazon did not only reduce the triglyceride levels, but also enhanced triglyceride levels by means of an effect on triglyceride absorption as well as hepatic triglyceride synthesis." "" "" ""</seg>
<seg id="810">"" "" "" "in the ProActive study, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and pre-existing advanced macrovascular disease were randomised in groups that received either pioglitazone or placebo over a period of up to 3.5 years." "" "" ""</seg>
<seg id="811">"" "" "" "after oral application, Pioglitazon is absorbed quickly, with the peak concentrations of unmodified pioglitazon generally 2 hours after application." "" "" ""</seg>
<seg id="812">"" "" "" "on this basis, the contribution of M-IV is equivalent to the triple of the efficacy of Pioglitazon, whereas the relative effectiveness of M-II is minimally pronounced." "" "" ""</seg>
<seg id="813">In interaction studies it has been proven that Pioglitazon has no relevant effect on the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin.</seg>
<seg id="814">Simultaneous use of pioglitazone with gemfibrozil (a Cytochrom P450 2C8 Inhibitor) or with Rifampicin (a Cytochrom P450 2C8-Inductor) or decreases the plasma concentration of Pioglitazon (see Section 4.5).</seg>
<seg id="815">"" "" "" "after oral use of radioactively marked pioglitazon in humans, the marker was found mainly in the Fäces (55%), and to a lesser extent in the urine (45%)." "" "" ""</seg>
<seg id="816">The mean plasma-elimination time of unmodified pioglitazon amounts to 5-6 hours in humans and the total active metabolites is 16 - 23 hours.</seg>
<seg id="817">"" "" "" "the plasma concentrations of Pioglitazone and its metabolites are lower than in healthy subjects in patients with reduced kidney function, but the rates of oral traction of the parent substance are similar." "" "" ""</seg>
<seg id="818">"" "" "" "in toxicological studies, rats, rats, dogs and monkeys coincided after repeated administration of plasma volume enlargement with hemodilution, anemia and reversible eccentric heart hypertrophy." "" "" ""</seg>
<seg id="819">"" "" "" "this is due to the fact that in treatment with pioglitazone the hyperinsulinemia and increased insulin resistance of the mother animal decreases, thereby reducing the availability of the metabolic substrates for the fetal growth." "" "" ""</seg>
<seg id="820">In long-term studies (up to 2 years) increased incidence of hyperplasia (in male and female rats) and tumors (in male rats) and tumors (in male rats) of the bladder epithelium were induced.</seg>
<seg id="821">"" "" "" "in an animal model of the family adenomatous polyposis (FAP), treatment with two other thiazolidindian led to an increased frequency of colonic tumors." "" "" ""</seg>
<seg id="822">"" "" "" "the tablets are white to whitish, round, flat and carry on one side the marking" 30 "and on the other side the inscription" Actos. "" "" "" ""</seg>
<seg id="823">The calculated fracture incidence was 1.9 fractures per 100 years of patients with pioglitazone treated women and 1.1 fractures per 100 patient years in women treated with a comparison medication.</seg>
<seg id="824">"" "" "" "in the ProActive study, a study of 3.5 years for the investigation of cardiovascular events, fractures appeared in patients treated with pioglitazone (2.5%; 0.5 fractures per 100 patient years) in patients treated with a comparison medication." "" "" ""</seg>
<seg id="825">"" "" "" "in another study over two years, the effects of a combination therapy of metformin with pioglitazone or Glicladal have been investigated." "" "" ""</seg>
<seg id="826">"" "" "" "in clinical trials over 1 year, a statistically significant decrease in the albumin / creatinin ratio showed a statistically significant decrease in the initial values." "" "" ""</seg>
<seg id="827">"" "" "" "in a study more than 20 weeks, Pioglitazon did not only reduce the triglyceride levels, but also enhanced the postdendrodial elevated triglyceride levels as well as an effect on tryglyceride absorption as well as hepatic tryglizeride synthesis." "" "" ""</seg>
<seg id="828">"" "" "" "although the study was lacking in terms of its primary endpoint, which represented a combination of total ringing, non-fatal myocardial infarction, stroke, acute coronary syndrome, coronary revascularisation and revascularisation of the leg arteries, the results suggest that no cardiovascular long-term risks are associated with taking Pioglitazon." "" "" ""</seg>
<seg id="829">"" "" "" "the tablets are white to whitish, round, flat and carry on one side the marking" 45 "and on the other side the inscription" Actos. "" "" "" ""</seg>
<seg id="830">"" "" "" "in a summary analysis of adverse events concerning fractures from randomised, controlled, double-blind clinical studies over a period of up to 3.5 years with more than 8.100 patients receiving comparative medication, increased incidence of fractures in women." "" "" ""</seg>
<seg id="831">"" "" "" "in the ProActive study, a study of 3.5 years for the investigation of cardiovascular events, fractures appeared in patients treated with pioglitazone (2.5%; 0.5 fractures per 100 patient years) in patients treated with a comparison medication." "" "" ""</seg>
<seg id="832">"" "" "" "in a study more than 20 weeks, Pioglitazon did not only reduce the triglyceride levels, but also enhanced triglyceride levels by means of an effect on triglyceride absorption as well as hepatic triglyceride synthesis." "" "" ""</seg>
<seg id="833">"" "" "" "on the prescription label of the medicine, the name and address of the manufacturer must be specified for the release of the respective charge." "" "" ""</seg>
<seg id="834">"" "" "" "in September 2005, the pharmaceutical entrepreneur will submit an additional 6 month Periodic Safety Update Report (PSUR) and then submit an annual PSURs until a different CHMP decision." "" "" ""</seg>
<seg id="835">An updated risk management plan must be submitted in accordance with the CHMP Guideline on Risk Management System for Medicinal Products for Human Use.</seg>
<seg id="836">"" "" "" "if you are infected with type 2 diabetes, Actos 15 mg tablets support the control of your blood sugar levels by causing a better recovery of the body's insulin." "" "" ""</seg>
<seg id="837">"" "" "" "if you know that you suffer from a sugar intolerance, please contact your doctor before taking Actos 15mg tablets." "" "" ""</seg>
<seg id="838">"" "" "" "please inform your doctor or pharmacist if you take further medicine or have until recently taken, even if it is not prescription medicine." "" "" ""</seg>
<seg id="839">"" "" "" "if you use Actos 15 mg tablets in combination with other medicines to treat diabetes (such as insulin, chloroplaamide, glide-amide), your doctor will tell you if you need to reduce the dose of your medicines." "" "" ""</seg>
<seg id="840">"" "" "" "in some patients with long-term type 2 diabetes mellitus and heart disease or previous stroke, which were treated with Actos and insulin, a heart failure developed." "" "" ""</seg>
<seg id="841">"" "" "" "in clinical trials comparing pioglitazone with other oral antidiabetic or placebo (drug-free tablets), there was a higher number of fractures in women (but not in men)." "" "" ""</seg>
<seg id="842">"" "" "" "if you have inadvertently taken too many tablets, or if another or one child has taken your medicine, you must contact a doctor or pharmacist immediately." "" "" ""</seg>
<seg id="843">"" "" "" "like Actos, and contents of the pack Actos 15 mg tablets are white to whitish, round, curved tablets with marking" 15 "on one side and the inscription" Actos "on the other side." "" "" ""</seg>
<seg id="844">"" "" "" "if you are infected with type 2 diabetes, Actos 30 mg tablets support the control of your blood sugar levels by causing a better recovery of the body's insulin." "" "" ""</seg>
<seg id="845">"" "" "" "if you know that you suffer from a sugar incompatibility, please contact your doctor before taking Actos 30mg tablets." "" "" ""</seg>
<seg id="846">"" "" "" "if you use Actos 30 mg tablets in combination with other medicines to treat diabetes (such as insulin, chloroplaamide, glide-amide), your doctor will tell you if you need to reduce the dose of your medicines." "" "" ""</seg>
<seg id="847">61 Inform your doctor as soon as possible if you notice signs of heart failure with you such as unusual short-breath or rapid weight gain or local swelling (edema).</seg>
<seg id="848">"" "" "" "in clinical trials comparing pioglitazone with other oral antidiabetic or placebo (drug-free tablets), there was a higher number of fractures in women (but not in men)." "" "" ""</seg>
<seg id="849">"" "" "" "like Actos, and contents of the pack Actos 30 mg tablets are white to whitish, round, flat tablets with marking" 30 "on one side and the inscription" Actos "on the other side." "" "" ""</seg>
<seg id="850">"" "" "" "if you are infected with type 2 diabetes, Actos 45 mg tablets support the control of your blood sugar levels by causing a better recovery of the body's insulin." "" "" ""</seg>
<seg id="851">"" "" "" "if you know that you suffer from a sugar incompatibility, please contact your doctor before taking Actos 45mg tablets." "" "" ""</seg>
<seg id="852">"" "" "" "if you use Actos 45 mg tablets in combination with other medicines to treat diabetes (such as insulin, chloroplaamide, glide-amide), your doctor will tell you if you need to reduce the dose of your medicines." "" "" ""</seg>
<seg id="853">"" "" "" "66 In some patients with long-term type 2 diabetes mellitus and heart disease or previous stroke, which were treated with Actos and insulin, a heart failure developed." "" "" ""</seg>
<seg id="854">"" "" "" "as soon as possible, inform your doctor if you notice signs of heart failure, such as unusual shortness or rapid weight gain or local swelling (edema)." "" "" ""</seg>
<seg id="855">"" "" "" "in clinical trials comparing pioglitazone with other oral antidiabetic or placebo (drug-free tablets), there was a higher number of fractures in women (but not in men)." "" "" ""</seg>
<seg id="856">"" "" "" "67 If any of the side effects listed are significantly impaired or you notice side effects that are not indicated in this information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="857">"" "" "" "like Actos, and contents of the pack Actos 45 mg tablets are white to whitish, round, flat tablets with marking" 45 "on one side and the inscription" Actos "on the other side." "" "" ""</seg>
<seg id="858">This document is a summary of the European Public Assessment Report (EPAR) in which the Committee for Human Use (CHMP) investigates the trials conducted to reach recommendations regarding the use of the medicine.</seg>
<seg id="859">"" "" "" "if you need more information about your medical condition or treatment of your illness, please read the packing instructions (which is also part of the EPAR) or contact a doctor or pharmacist." "" "" ""</seg>
<seg id="860">"" "" "" "if you would like further information on the basis of CHMP recommendations, please read the scientific discussion (which is also part of the EPAR)." "" "" ""</seg>
<seg id="861">Actraphane 10: soluble Insulin 10% and Isopan Insulin 80% Actraphane 30: soluble Insulin 30% and Isopan Insulin 60% Actraphane 50: soluble Insulin 50% and Isopan Insulin 50%</seg>
<seg id="862">"" "" "" "Actraphane is usually applied once or twice daily, if a rapid initial effect along with a longer lasting effect is desired." "" "" ""</seg>
<seg id="863">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.eu.int © EMEA 2006 Reproduction and / or distribution of this document is Authorised for non commercial purposes (rDNA).</seg>
<seg id="864">"" "" "" "Actraphane was tested to 294 patients with type 1 diabetes in which the pancreas does not produce insulin, and type 2 diabetes in which the body is unable to use insulin effectively." "" "" ""</seg>
<seg id="865">"" "" "" "in the study, after 12 weeks the concentration of a substance (glycosylated hemoglobin (HbA1c) was measured, indicating how well the blood sugar is set." "" "" ""</seg>
<seg id="866">"" "" "" "Actraphane has led to a decrease in the HbA1c mirror, indicating that blood sugar levels have been lowered similar to another human insulin." "" "" ""</seg>
<seg id="867">"" "" "" "Actraphane should not be used in patients who may be hypersensitive (allergic) to human insulin (rDNA), or any of the other components." "" "" ""</seg>
<seg id="868">"" "" "" "in addition, the doses of acetphane may be adjusted if it is administered together with a number of other medicines that can affect blood sugar (the complete list is to be found in the package)." "" "" ""</seg>
<seg id="869">"" "" "" "the Committee for Medicinal Products (CHMP) concluded that, in the treatment of diabetes, the benefits of acetphane outweigh the risks." "" "" ""</seg>
<seg id="870">"" "" "" "in October 2002, the European Commission issued a permit to the company Novo Nordisk A / S for the transport of Actraphane across the European Union." "" "" ""</seg>
<seg id="871">Pre-mixed insulin products are normally applied once or twice a day if a rapid initial effect along with a longer lasting effect is desired.</seg>
<seg id="872">"" "" "" "the injection needle must be left under the skin for at least 6 seconds, to ensure that the entire dose was injected." "" "" ""</seg>
<seg id="873">"" "" "" "patients whose blood sugar level has improved significantly, for example, by intensified insulin therapy, can detect the hypoglycemia warning symptoms and should be advised accordingly." "" "" ""</seg>
<seg id="874">"" "" "" "any change regarding strength, brand (manufacturer), insulin type (fast acting, biphasic, long-acting insulin, human insulin or insulin analogue) and / or production method (due to recombinant DNA to insulin-animal origin) may cause a change in dosage." "" "" ""</seg>
<seg id="875">"" "" "" "if a dose adjustment is required when changing to Actraphane in the patient, it may be necessary during the first dose or during the first weeks or months after the conversion." "" "" ""</seg>
<seg id="876">Some patients with hypoglycemic responses after a change from animal to human insulin reported that the early warning symptoms of hypoglycaemia were less pronounced or different from their previous insulin.</seg>
<seg id="877">"" "" "" "before travelling, which go over several time zones, the patient should be advised to take the advice of his doctor as such journeys may lead to insulin and meals to be applied or taken at other times." "" "" ""</seg>
<seg id="878">"" "" "" "therefore, the doctor must consider possible interactions during therapy and ask his patients always after other medicines taken by them." "" "" ""</seg>
<seg id="879">4 Free hypoglycemia as well as hyperglycemia which may occur in a non-controlled diabetes treatment increase the risk of abnormalities and fruit tod in utero.</seg>
<seg id="880">"" "" "" "severe hypoglycemia can lead to unconsciousness and / or cramps, and with temporary or persistent disruption of brain function and even death." "" "" ""</seg>
<seg id="881">Diseases of the nervous system gels - peripheral neuropathy A rapid improvement of blood sugar control can be associated with discomfort associated with acute painful neuropathy and usually reversible.</seg>
<seg id="882">"" "" "" "5 A intensification of insulin therapy with abrupt improvement of blood sugar level, however, may be associated with a temporary degradation of diabetic retinopathy." "" "" ""</seg>
<seg id="883">Diseases of the skin and the skin tissue - Lipodystrophy At the injection point a lipodystrophy can occur if missed to change the insertion points within the injection area.</seg>
<seg id="884">"" "" "" "general illnesses and complaints at the site of gelding - Local hypersensitivity reactions at the injection point During the insulin therapy, local hypersensitivity reactions (redness, swelling, itching, pain and haematoma at the injection site) occur." "" "" ""</seg>
<seg id="885">"" "" "" "diseases of the immune system Jelly - Urticaria, Exanthem Very rare - anaphylactic reactions Symptoms of generalized hypersensitivity, including general rash, breathing difficulties, heart palpitations, low blood pressure, and impotence." "" "" ""</seg>
<seg id="886">"" "" "" "however, hypoglycaemia can develop gradually: • Easy hypoglycemia can be treated by the oral supply of glucose and sugary foods." "" "" ""</seg>
<seg id="887">"" "" "" "• Severe hypoglycemia is treated with an intramuscular or subcutaneous injection of Glucagon (0.5 to 1.0 mg), or by glucose that is administered intravenously by the doctor." "" "" ""</seg>
<seg id="888">"" "" "" "the effect begins within half an hour, the active maximum is reached within 2 to 8 hours and the total duration of the operation is up to 24 hours." "" "" ""</seg>
<seg id="889">Resorption The resorption profile is based on the fact that the product is a mixture of insulin products with faster or delayed resorption.</seg>
<seg id="890">"" "" "" "a number of fissile (hydrolysis) places on the human insulin molecule were considered, and none of the metabolites formed by the split is active." "" "" ""</seg>
<seg id="891">"" "" "" "based on conventional safety resharmacology studies, toxicity in repeated application, genotoxicity, carcinogenic potential and reproductive toxicity, preclinical data do not reveal any particular danger to humans." "" "" ""</seg>
<seg id="892">It is recommended - after the acetphane water bottle is taken out of the refrigerator - increase the temperature of the insulin at room temperature (not above 25 ° C) before it is resuscitated according to the manual for the first use.</seg>
<seg id="893">Some patients with hypoglycemic responses after a change from animal to human insulin reported that the early warning symptoms of hypoglycaemia were less pronounced or different from their previous insulin.</seg>
<seg id="894">"" "" "" "therefore, the doctor must consider possible interactions during therapy and ask his patients always after other medicines taken by them." "" "" ""</seg>
<seg id="895">12 Both hypoglycemia as well as hyperglycemia which may occur in a non-controlled diabetes treatment increase the risk of abnormalities and fruit tod in utero.</seg>
<seg id="896">"" "" "" "13 A intensification of insulin therapy with abrupt improvement of blood sugar level, however, may be associated with a temporary degradation of diabetic retinopathy." "" "" ""</seg>
<seg id="897">The terminale half-life time (t ½) is therefore more a measure of resorption as a measure of the elimination per se of the insulin from the plasma (insulin has a t ½ of just a few minutes).</seg>
<seg id="898">It is recommended - after the acetphane water bottle is taken out of the refrigerator - increase the temperature of the insulin at room temperature (not above 25 ° C) before it is resuscitated according to the manual for the first use.</seg>
<seg id="899">Some patients with hypoglycemic responses after a change from animal to human insulin reported that the early warning symptoms of hypoglycaemia were less pronounced or different from their previous insulin.</seg>
<seg id="900">20 Free hypoglycemia as well as hyperglycemia which may occur in a non-controlled diabetes treatment increase the risk of abnormalities and fruit tod in utero.</seg>
<seg id="901">"" "" "" "21 A intensification of insulin therapy with abrupt improvement of blood sugar level, however, may be associated with a temporary degradation of diabetic retinopathy." "" "" ""</seg>
<seg id="902">"" "" "" "diseases of the immune system Jelly - Urticaria, Exanthem Very rare - anaphylactic reactions Symptoms of generalized hypersensitivity, including general rash, breathing difficulties, heart palpitations, low blood pressure, and impotence." "" "" ""</seg>
<seg id="903">Cartridges may only be used together with products that are compatible with them and ensure a safe and effective function of the cartridge.</seg>
<seg id="904">It is recommended - after acetphane penetration is taken out of the refrigerator - increase the temperature of the insulin at room temperature (not above 25 ° C) before it is resuscitated according to the manual for the first use.</seg>
<seg id="905">Some patients with hypoglycemic responses after a change from animal to human insulin reported that the early warning symptoms of hypoglycaemia were less pronounced or different from their previous insulin.</seg>
<seg id="906">28 Free hypoglycemia as well as hyperglycemia which may occur in a non-controlled diabetes treatment increase the risk of abnormalities and fruit tod in utero.</seg>
<seg id="907">"" "" "" "29 A intensification of insulin therapy with abrupt improvement of blood sugar level, however, may be associated with a temporary degradation of diabetic retinopathy." "" "" ""</seg>
<seg id="908">Some patients with hypoglycemic responses after a change from animal to human insulin reported that the early warning symptoms of hypoglycaemia were less pronounced or different from their previous insulin.</seg>
<seg id="909">"" "" "" "36 Both hypoglycemia as well as hyperglycemia, which may occur in a non-controlled diabetes treatment, increase the risk of abnormalities and fruiting in utero." "" "" ""</seg>
<seg id="910">"" "" "" "37 A intensification of insulin therapy with abrupt improvement of blood sugar level, however, may be associated with a temporary degradation of diabetic retinopathy." "" "" ""</seg>
<seg id="911">44 Free hypoglycemia as well as hyperglycemia which may occur in a non-controlled diabetes treatment increase the risk of abnormalities and fruit tod in utero.</seg>
<seg id="912">"" "" "" "45 A intensification of insulin therapy with abrupt improvement of blood sugar level, however, may be associated with a temporary degradation of diabetic retinopathy." "" "" ""</seg>
<seg id="913">Some patients with hypoglycemic responses after a change from animal to human insulin reported that the early warning symptoms of hypoglycaemia were less pronounced or different from their previous insulin.</seg>
<seg id="914">52 Both hypoglycemia as well as hyperglycemia which may occur in a non-controlled diabetes treatment increase the risk of abnormalities and fruit tod in utero.</seg>
<seg id="915">"" "" "" "53 A intensification of insulin therapy with abrupt improvement of blood sugar level, however, may be associated with a temporary degradation of diabetic retinopathy." "" "" ""</seg>
<seg id="916">"" "" "" "the injection devices must be prepared in front of the injection so that the dose control goes back to zero, and a insulin-drop at the tip of the injection needle appears." "" "" ""</seg>
<seg id="917">"" "" "" "59 patients whose blood sugar level has improved significantly, for example, by intensified insulin therapy, can detect hypoglycemia warning symptoms and should be advised accordingly." "" "" ""</seg>
<seg id="918">"" "" "" "hypoglycemia as well as hyperglycemia, which can occur in a non-controlled diabetes treatment, increase the risk of abnormalities and fruiting in utero." "" "" ""</seg>
<seg id="919">"" "" "" "however, an intensification of insulin therapy with an abrupt improvement of blood sugar adjustment may be associated with a temporary worsening of diabetic retinopathy." "" "" ""</seg>
<seg id="920">"" "" "" "diseases of the immune system Jelly - Urticaria, Exanthem Very rare - anaphylactic reactions Symptoms of generalized hypersensitivity, including general rash, breathing difficulties, heart palpitations, low blood pressure, and impotence." "" "" ""</seg>
<seg id="921">"" "" "" "these ready-made pens may only be used together with products that are compatible with them, ensuring a safe and effective function of the production pens." "" "" ""</seg>
<seg id="922">It is recommended - after Actraphane NovoLet is taken out of the fridge - increase the temperature of the insulin at room temperature (not above 25 ° C) before it is resuscitated according to the manual for the first use.</seg>
<seg id="923">"" "" "" "67 patients whose blood sugar level has improved significantly, for example, by intensified insulin therapy, can detect hypoglycemia warning symptoms and should be advised accordingly." "" "" ""</seg>
<seg id="924">"" "" "" "75 patients whose blood sugar level has improved significantly, for example, by intensified insulin therapy, can detect hypoglycemia warning symptoms and should be advised accordingly." "" "" ""</seg>
<seg id="925">"" "" "" "83 patients whose blood sugar level has improved significantly, for example, by intensified insulin therapy, can detect the hypoglycemia warning symptoms and should be advised accordingly." "" "" ""</seg>
<seg id="926">"" "" "" "91 patients whose blood sugar level has improved significantly, for example, by intensified insulin therapy, can detect hypoglycemia warning symptoms and should be advised accordingly." "" "" ""</seg>
<seg id="927">"" "" "" "99 patients whose blood sugar level has improved significantly, for example, by intensified insulin therapy, can detect hypoglycemia warning symptoms and should be advised accordingly." "" "" ""</seg>
<seg id="928">"" "" "" "any change regarding strength, brand (manufacturer), insulin type (fast acting, biphasic, long-acting insulin, human insulin or insulin analogue) and / or production method (due to recombinant DNA to insulin-animal origin) may cause a change in dosage." "" "" ""</seg>
<seg id="929">It is recommended - after acetphane InnoLet is taken out of the refrigerator - increase the temperature of the insulin at room temperature (not above 25 ° C) before it is resuscitated according to the manual for the first use.</seg>
<seg id="930">It is recommended - after acetphane FlexPen was taken out of the refrigerator - increase the temperature of the insulin at room temperature (not above 25 ° C) before it is resuscitated according to the manual for the first use.</seg>
<seg id="931">"" "" "" "on the prescription label of the medicine, the name and address of the manufacturer must be specified for the release of the respective charge." "" "" ""</seg>
<seg id="932">Store in the fridge (2 ˚ C - 8 ˚ C) Don't freeze the water bottle in the cardboard box to protect the contents from light after quarry: do not store in the fridge or over 25 ° C</seg>
<seg id="933">Subcutaneous application Penfill cartridges are intended for application with insulin injectors from Novo Nordisk provided mixture of the instructions resuspends prescription supplements should only be used by one person</seg>
<seg id="934">Store in the fridge (2 ˚ C - 8 ˚ C) Don't freeze the cartridge in the cardboard box to protect the contents from light after quarry: do not store in the fridge or over 30 ° C</seg>
<seg id="935">Subcutaneous application Penfill cartridges are intended for application with insulin injectors from Novo Nordisk provided mixture of instructions resuspends prescription supplements should only be used by one person</seg>
<seg id="936">Subcutaneous application Penfill cartridges are intended for application with insulin injector devices from Novo Nordisk provided to adhere to the instructions in the instructions on the prescription supplement Actraphane 30 Penfill must be used only by one person</seg>
<seg id="937">Subcutaneous application Penfill cartridges are intended for application with insulin injector devices from Novo Nordisk provided to adhere to the instructions of the instructions in case of acetphane 40 Penfill must be used only by one person</seg>
<seg id="938">Subcutaneous application Penfill cartridges are intended for application with insulin injectors from Novo Nordisk provided to adhere to the instructions in the instructions on the prescription supplement Actraphane 50 Penfill must be used only by one person</seg>
<seg id="939">Subcutaneous application For use with Actraphane 10 NovoLet NovoFine injection needles are provided to adhere to the instructions resuspening package inserts. Actraphane 10 NovoLet can only be used by one person</seg>
<seg id="940">Store in the fridge (2 ˚ C - 8 ˚ C) Don't freeze for light After breaking: do not store in the fridge or over 30 ° C</seg>
<seg id="941">Subcutaneous application For use with Actraphane 20 NovoLet NovoFine injection needles are provided to adhere to the instructions resuspening package inserts. Actraphane 20 NovoLet can only be used by one person</seg>
<seg id="942">Subcutaneous application For use with Actraphane 30 NovoLet NovoFine injection needles are provided to adhere to the instructions resuspening package inserts. Actraphane 30 NovoLet can only be used by one person</seg>
<seg id="943">Subcutaneous application For use with Actraphane 40 NovoLet NovoFine injection needles are provided to adhere to the instructions resuspening package inserts. Actraphane 40 NovoLet can only be used by one person</seg>
<seg id="944">Subcutaneous application For use with Actraphane 50 NovoLet NovoFine injection needles are provided to adhere to the instructions resuspening package inserts. Actraphane 50 NovoLet may only be used by one person</seg>
<seg id="945">Subcutaneous application For use with Actraphane 30 InnoLet NovoFine S injection needles are provided to adhere to the instructions resuspening package inserts. Actraphane 30 InnoLet can only be used by one person</seg>
<seg id="946">"" "" "" "this means that after half an hour after you have applied it, your blood sugar begins to sink and that the effect will last approximately 24 hours." "" "" ""</seg>
<seg id="947">"" "" "" "► If you are allergic to this insulin product, Metacresol or any of the other components (see Section 7 for more information)." "" "" ""</seg>
<seg id="948">"" "" "" "consider the symptoms of an allergy ► described symptoms of an allergy ► If you feel first signs of hypoglycaemia (symptoms of underwear)," "" "" ""</seg>
<seg id="949">"" "" "" "if your doctor has caused a change from an insulin type or brand to another, you may need to adjust the dose by your doctor." "" "" ""</seg>
<seg id="950">"" "" "" "► Check the label, whether it is the correct insulin type ► Dessert the rubber membrane with a medical tampon." "" "" ""</seg>
<seg id="951">"" "" "" "if it is not completely undamaged when you get the glass bottle, enter the glass bottle to your pharmacy if it was not stored correctly or frozen (see 6 How is acetphane stored?) ► If it is not evenly white and cloudy." "" "" ""</seg>
<seg id="952">Use the injection technique recommended to your doctor or your diabetic consultant ► Let the injection needle be under your skin for at least 6 seconds in order to make sure the full dose is injected.</seg>
<seg id="953">"" "" "" "the warning signs of an underplucking can occur suddenly and can be: cold sweat, cold pale skin, headache, heart rasen, nausea, severe fatigue, nervousness, anxiety, anxiety, confusion, concentration difficulties." "" "" ""</seg>
<seg id="954">"" "" "" "tell your relatives, friends and close colleagues that they will bring you into the stable side position in the event of an unconsciousness and immediately notify a doctor." "" "" ""</seg>
<seg id="955">"" "" "" "► If a severe underwear is not treated, this may lead to (temporary or permanent) brain damage or even death." "" "" ""</seg>
<seg id="956">"" "" "" "you can regain consciousness quicker, if the hormone glucagon is injected by a person familiar with the gift." "" "" ""</seg>
<seg id="957">"" "" "" "this can happen: if you injure too much insulin, if you eat too little or leave a meal, if you strain yourself more then physically." "" "" ""</seg>
<seg id="958">"" "" "" "increased urination, thirst, loss of appetite, nausea or vomiting, dizziness or fatigue, cured dry skin, dry mouth and fruity (after acetone) irritating breath." "" "" ""</seg>
<seg id="959">• You have forgotten an insulin injector • repeated injecting less insulin as you need • an infection or fever • more food than usual • less physical exercise than usual.</seg>
<seg id="960">"" "" "" "if you often give an injection to the same spot, the subcutaneous fat tissue can shrink (Lipatrophies) or increase (Lipohypertrophy)." "" "" ""</seg>
<seg id="961">"" "" "" "if you notice deepenings or thickening of your skin at the injection point, tell your doctor or your diabetcounsellor, because these reactions can worsen or affect your insulin if you are injected into such a place." "" "" ""</seg>
<seg id="962">"" "" "" "immediately seek a doctor if the symptoms of an allergy spread to other parts of the body, or if you suddenly feel uncomfortable and you are feeling faint or you have the impression to become unconscious." "" "" ""</seg>
<seg id="963">You may have a very rare severe allergic reaction to acetphane or one of its constituents (a systemic allergic reaction).</seg>
<seg id="964">"" "" "" "if any of the side effects listed below are significantly impaired or you notice side effects that are not stated in this manual information, please inform your doctor, your diabetcounsellor or your pharmacist." "" "" ""</seg>
<seg id="965">"" "" "" "what Actraphane 30 contains - The active ingredient is insulin produced by recombinant DNA technology (30% as a soluble insulin and 70%, as an isophan insulin)." "" "" ""</seg>
<seg id="966">"" "" "" "like acetphane and contents of the package The injection suspension is supplied as a cloudy, white, aqueous suspension in packs of 1 or 5 packs of 10 ml or bundling bottles for 10 ml each." "" "" ""</seg>
<seg id="967">Use the injection technique recommended to your doctor or your diabetic consultant ► Let the injection needle be under your skin for at least 6 seconds in order to make sure the full dose is injected.</seg>
<seg id="968">"" "" "" "it is recommended - after removing it from the refrigerator - increase the temperature of the glass bottle at room temperature, before the insulin is resuscitated according to the manual for the first use." "" "" ""</seg>
<seg id="969">"" "" "" "like acetphane and contents of the package The injection suspension is supplied as a cloudy, white, aqueous suspension in packs of 1 or 5 packs of 10 ml or bundling bottles for 10 ml each." "" "" ""</seg>
<seg id="970">"" "" "" "► Check the label, whether it is the correct insulin type ► Check the penfill cartridge including rubber piston (plugs)." "" "" ""</seg>
<seg id="971">Do not use it when any damage is visible or a gap between the rubber piston and the white belt of the label is visible.</seg>
<seg id="972">"" "" "" "for further information, please refer to the manual of your insulin injector system. ► Desinfect the rubber membrane with a medical tampon." "" "" ""</seg>
<seg id="973">"" "" "" "► in insulin infusion pumps ► If the penfill or the device that contains the penfill is damaged or broken, there is a risk of running insulin." "" "" ""</seg>
<seg id="974">"" "" "" "if you are treated with Actraphane 10 Penfill and another insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="975">"" "" "" "before inserting the cartridge into the insulin injector system, move them at least 20 times between positions a and b (see picture), so that the glass ball moves from one end of the cartridge to the other." "" "" ""</seg>
<seg id="976">Use the injection technique that your doctor or your diabeterer has recommended and which is described in the manual of your injection system ► Let the injection needle be removed for at least 6 seconds under your skin to ensure that the full dose is injected.</seg>
<seg id="977">"" "" "" "183 Say to your relatives, friends and close colleagues, that they will bring you into the stable side position in the event of an unconsciousness and immediately notify a doctor." "" "" ""</seg>
<seg id="978">• You have forgotten an insulin injector • repeated injecting less insulin as you need • an infection or fever • more food than usual • less physical exercise than usual.</seg>
<seg id="979">"" "" "" "if any of the side effects listed below are significantly impaired or you notice side effects that are not stated in this manual information, please inform your doctor, your diabetcounsellor or your pharmacist." "" "" ""</seg>
<seg id="980">"" "" "" "it is recommended - after removing it from the refrigerator - increase the temperature of the penfill cartridge at room temperature, before the insulin is resuscitated in accordance with the manual for the first use." "" "" ""</seg>
<seg id="981">185 Remove the cartridges always in carton if you do not use them to protect them from light.</seg>
<seg id="982">What Actraphane 10 contains - The active ingredient is insulin produced by recombinant DNA technology (10% as a soluble insulin and 90% as an isophan insulin).</seg>
<seg id="983">"" "" "" "like acetphane and contents of the package The injection suspension is delivered as a cloudy, white, aqueous suspension in packs of 1, 5 or 10 cartridges per 3 ml each." "" "" ""</seg>
<seg id="984">"" "" "" "for further information, please refer to the manual of your insulin injector system. ► Desinfect the rubber membrane with a medical tampon." "" "" ""</seg>
<seg id="985">"" "" "" "if you are treated with Actraphane 20 Penfill and another insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="986">"" "" "" "189 Say to your relatives, friends and close colleagues, that they will bring you into the stable side position in the event of an unconsciousness and immediately notify a doctor." "" "" ""</seg>
<seg id="987">"" "" "" "if any of the side effects listed below are significantly impaired or you notice side effects that are not stated in this manual information, please inform your doctor, your diabetcounsellor or your pharmacist." "" "" ""</seg>
<seg id="988">"" "" "" "191 Keep the cartridges always in carton, if you do not use them to protect them from light." "" "" ""</seg>
<seg id="989">"" "" "" "what Actraphane 20 contains - The active ingredient is insulin produced by recombinant DNA technology (20% as a soluble insulin, and 80% as an isophan insulin)." "" "" ""</seg>
<seg id="990">"" "" "" "like acetphane and contents of the package The injection suspension is delivered as a cloudy, white, aqueous suspension in packs of 1, 5 or 10 cartridges per 3 ml each." "" "" ""</seg>
<seg id="991">"" "" "" "for further information, please refer to the manual of your insulin injector system. ► Desinfect the rubber membrane with a medical tampon." "" "" ""</seg>
<seg id="992">"" "" "" "if you are treated with Actraphane 30 Penfill and another insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="993">"" "" "" "195 Say to your relatives, friends and close colleagues, that they will bring you into the stable side position in the event of an unconsciousness and immediately notify a doctor." "" "" ""</seg>
<seg id="994">"" "" "" "if any of the side effects listed below are significantly impaired or you notice side effects that are not stated in this manual information, please inform your doctor, your diabetcounsellor or your pharmacist." "" "" ""</seg>
<seg id="995">"" "" "" "197 Keep the cartridges always in carton, if you do not use them to protect them from light." "" "" ""</seg>
<seg id="996">"" "" "" "the manufacturer can be identified based on the batch designation, which is printed on the carton of the carton and on the label:" "" "" ""</seg>
<seg id="997">"" "" "" "if on the second and third position of the Chargen term the character combination W5, S6, P5, K7 or ZF is published, the manufacturer Novo Nordisk A / S, Novo allé, DK- 2880 Bagsvaerd, Denmark" "" "" ""</seg>
<seg id="998">"" "" "" "the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F-28002 Chartres, France." "" "" ""</seg>
<seg id="999">"" "" "" "for further information, please refer to the manual of your Inconjection System. ► Dessert the rubber membrane with a medical tampon." "" "" ""</seg>
<seg id="1000">"" "" "" "if you are treated with Actraphane 40 Penfill and another insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="1001">"" "" "" "201 Say to your relatives, friends and close colleagues, that they will bring you into the stable side position in the event of an unconsciousness and immediately notify a doctor." "" "" ""</seg>
<seg id="1002">"" "" "" "if any of the side effects listed below are significantly impaired or you notice side effects that are not stated in this manual information, please inform your doctor, your diabetcounsellor or your pharmacist." "" "" ""</seg>
<seg id="1003">203 Keep the cartridges always in the cardboard box if you do not use them to protect them from light.</seg>
<seg id="1004">"" "" "" "what Actraphane 40 contains - the active ingredient is insulin produced by recombinant DNA technology (40% as a soluble insulin and 60%, as an isophan insulin)." "" "" ""</seg>
<seg id="1005">"" "" "" "for further information, please refer to the manual of your Inconjection System. ► Dessert the rubber membrane with a medical tampon." "" "" ""</seg>
<seg id="1006">"" "" "" "if you are treated with Actraphane 50 Penfill and another insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="1007">"" "" "" "before inserting the penfill cartridge into the insulin injector system, move them at least 20 times between positions a and b (see picture), so that the glass ball moves from one end of the cartridge to the other." "" "" ""</seg>
<seg id="1008">"" "" "" "207 Say to your relatives, friends and close colleagues, that they will bring you into the stable side position in the event of an unconsciousness and immediately notify a doctor." "" "" ""</seg>
<seg id="1009">"" "" "" "if any of the side effects listed below are significantly impaired or you notice side effects that are not stated in this manual information, please inform your doctor, your diabetcounsellor or your pharmacist." "" "" ""</seg>
<seg id="1010">"" "" "" "209 Keep the cartridges always in carton, if you do not use them to protect them from light." "" "" ""</seg>
<seg id="1011">What Actraphane 50 contains - The active ingredient is insulin produced by recombinant DNA technology (50% as a soluble insulin and 50% as Isopan insulin).</seg>
<seg id="1012">"" "" "" "oral antidiabetic (for taking), monoamine oxidase inhibitors, angiotensin-inhibitors, acetylsalicylic acid, anabolic steroids, beta-athomimetika, growth hormone, Danazol, Octopotid or Lanreotid." "" "" ""</seg>
<seg id="1013">"" "" "" "► Check on the label, whether it is the right Inconsul." "" "" ""</seg>
<seg id="1014">"" "" "" "► in insulin infusion pumps ► If the NovoLet is dropped, damaged or broken, there is a risk of running insulin." "" "" ""</seg>
<seg id="1015">"" "" "" "the warning signs of an underplucking can occur suddenly and can be: cold sweat, cold pale skin, headache, heart rasen, nausea, severe fatigue, nervousness, anxiety, anxiety, confusion, concentration difficulties." "" "" ""</seg>
<seg id="1016">"" "" "" "214 If any of the side effects listed are significantly impaired or you notice side effects that are not stated in this manual information, please inform your doctor, your diabetcounsellor or your pharmacist." "" "" ""</seg>
<seg id="1017">"" "" "" "in use NovoLet's ready-ready pens and those that will be used shortly or as a replacement, are not stored in the refrigerator." "" "" ""</seg>
<seg id="1018">It is recommended - after being taken out of the refrigerator - increase the temperature of the NovoLet ready-to-room pens at room temperature before the insulin is resuscitated in accordance with the manual for the first use.</seg>
<seg id="1019">"" "" "" "if Novofold is not in use to protect the insulin from light, leave the closing lid of your NovoLet ready-ready pens." "" "" ""</seg>
<seg id="1020">"" "" "" "like acetphane and contents of the package The injection suspension is delivered as a cloudy, white, aqueous suspension in packs of 5 or 10 finished pens per 3 ml." "" "" ""</seg>
<seg id="1021">"" "" "" "before each injection, check if there are at least 12 units remaining in the cartridge so that a uniform mixture is ensured." "" "" ""</seg>
<seg id="1022">"" "" "" "follow these steps to avoid the injection of air, and ensure correct dosage: • Keep Actraphane 10 NovoLet with the injection needle upside • knock a few times with your finger gently against the cartridge." "" "" ""</seg>
<seg id="1023">"" "" "" "if bubbles are present, they will keep them up in the cartridge - While you keep the injection needle upward, press the button in the direction of the arrow (Figure D) • Now a drop of insulin must be extracted from the tip of the injection needle." "" "" ""</seg>
<seg id="1024">"" "" "" "• Replace the closing cap onto the finished pen again, that the digit 0 is in front of the metering brand (Figure E)" "" "" ""</seg>
<seg id="1025">"" "" "" "if not, turn the closing cap until the push button is pressed completely down • Keep your Actraphane 10 NovoLet horizontally." "" "" ""</seg>
<seg id="1026">"" "" "" "if the push button cannot move freely outside, insulin is pressed from the injection needle • The scale on the closing cap shows 0, 2, 4, 6, 8, 10, 12, 14, 16 and 18 units." "" "" ""</seg>
<seg id="1027">"" "" "" "the push button moves outward, while you rotate the cap • The scale under the push button shows 20, 40 and 60 units." "" "" ""</seg>
<seg id="1028">"" "" "" "check the number on the closing cap next to the dosing token • add the highest number you can see on the push button • If you have set a wrong dose, turn the cap down or backwards until you set the correct number of units." "" "" ""</seg>
<seg id="1029">"" "" "" "otherwise, insulin can be extracted from the injection needle and the suggested dose will not be correct • If you have tried to adjust a dose of more than 78 units, follow these steps:" "" "" ""</seg>
<seg id="1030">"" "" "" "then remove the closing cap and set it up again, so that the 0 of the metering brand is opposite." "" "" ""</seg>
<seg id="1031">"" "" "" "make sure to press the button only during the injection. • Keep the button down after the injection, until the injection needle is pulled out of the skin." "" "" ""</seg>
<seg id="1032">"" "" "" "if not, turn the closing cap until the push button is fully pressed and then proceed as described before use • Can you hear a clickering noise when pressing the button." "" "" ""</seg>
<seg id="1033">It may be inaccurate • You can not adjust a dose which is higher than the number of units remaining in the cartridge • You can use the residual amounts scale to estimate how much insulin is still left.</seg>
<seg id="1034">"" "" "" "oral antidiabetic (for taking), monoamine oxidase inhibitors, angiotensin-inhibitors, acetylsalicylic acid, anabolic steroids, beta-athomimetika, growth hormone, Danazol, Octopotid or Lanreotid." "" "" ""</seg>
<seg id="1035">"" "" "" "224 If any of the side effects listed are significantly impaired or you notice side effects that are not stated in this manual information, please inform your doctor, your diabetcounsellor or your pharmacist." "" "" ""</seg>
<seg id="1036">"" "" "" "226 Before each injection, check if there are at least 12 units remaining insulin in the cartridge so that an even mix is ensured." "" "" ""</seg>
<seg id="1037">"" "" "" "follow these steps to avoid the injection of air, and ensure correct dosage: • Keep Actraphane 20 NovoLet with the injection needle upside • knock a few times with your finger gently against the cartridge." "" "" ""</seg>
<seg id="1038">"" "" "" "if bubbles are present, they will keep them up in the cartridge - While you keep the injection needle upward, press the button in the direction of the arrow (Figure D) • Now a drop of insulin must be extracted from the tip of the injection needle." "" "" ""</seg>
<seg id="1039">"" "" "" "if not, turn the closing cap until the push button is pressed completely down • Keep your Actraphane 20 NovoLet horizontally." "" "" ""</seg>
<seg id="1040">"" "" "" "oral antidiabetic (for taking), monoamine oxidase inhibitors, angiotensin-inhibitors, acetylsalicylic acid, anabolic steroids, beta-athomimetika, growth hormone, Danazol, Octopotid or Lanreotid." "" "" ""</seg>
<seg id="1041">"" "" "" "234 If any of the side effects listed are significantly impaired or you notice side effects that are not stated in this manual information, please inform your doctor, your diabetcounsellor or your pharmacist." "" "" ""</seg>
<seg id="1042">"" "" "" "236 Before each injection, check if there are at least 12 units remaining insulin in the cartridge so that an even mix is ensured." "" "" ""</seg>
<seg id="1043">"" "" "" "follow these steps to avoid the injection of air, and ensure correct dosage: • Keep Actraphane 30 NovoLet with the injection needle upside • knock a few times with your finger gently against the cartridge." "" "" ""</seg>
<seg id="1044">"" "" "" "if bubbles are present, they will keep them up in the cartridge - While you keep the injection needle upward, press the button in the direction of the arrow (Figure D) • Now a drop of insulin must be extracted from the tip of the injection needle." "" "" ""</seg>
<seg id="1045">"" "" "" "if not, turn the closing cap until the push button is fully pressed • Keep your Actraphane 30 NovoLet horizontally." "" "" ""</seg>
<seg id="1046">"" "" "" "oral antidiabetic (for taking), monoamine oxidase inhibitors, angiotensin-inhibitors, acetylsalicylic acid, anabolic steroids, beta-athomimetika, growth hormone, Danazol, Octopotid or Lanreotid." "" "" ""</seg>
<seg id="1047">"" "" "" "244 If any of the side effects listed are significantly impaired or you notice side effects that are not stated in this manual information, please inform your doctor, your diabetcounsellor or your pharmacist." "" "" ""</seg>
<seg id="1048">"" "" "" "246 Before each injection, check if there are at least 12 units remaining insulin in the cartridge so that an even mix is ensured." "" "" ""</seg>
<seg id="1049">"" "" "" "follow these steps to avoid the injection of air, and ensure correct dosage: • Keep Actraphane 40 NovoLet with the injection needle upside • knock a few times with your finger gently against the cartridge." "" "" ""</seg>
<seg id="1050">"" "" "" "if bubbles are present, they will keep them up in the cartridge - While you keep the injection needle upward, press the button in the direction of the arrow (Figure D) • Now a drop of insulin must be extracted from the tip of the injection needle." "" "" ""</seg>
<seg id="1051">"" "" "" "if not, turn the closing cap until the push button is pressed completely down • Keep your Actraphane 40 NovoLet horizontally." "" "" ""</seg>
<seg id="1052">"" "" "" "oral antidiabetic (for taking), monoamine oxidase inhibitors, angiotensin-inhibitors, acetylsalicylic acid, anabolic steroids, beta-athomimetika, growth hormone, Danazol, Octopotid or Lanreotid." "" "" ""</seg>
<seg id="1053">"" "" "" "254 If any of the side effects listed are significantly impaired or you notice side effects that are not stated in this manual information, please inform your doctor, your diabetcounsellor or your pharmacist." "" "" ""</seg>
<seg id="1054">It is recommended - after being taken out of the refrigerator - increase the temperature of the NovoLet ready-to-room pens at room temperature before the insulin is resuscitated in accordance with the manual for the first use.</seg>
<seg id="1055">"" "" "" "256 Before each injection, check if there are at least 12 units remaining in the cartridge so that a uniform mixture is ensured." "" "" ""</seg>
<seg id="1056">"" "" "" "follow these steps to avoid the injection of air, and ensure correct dosage: • Keep Actraphane 50 NovoLet with the injection needle downwards • knock a few times with your finger gently against the cartridge." "" "" ""</seg>
<seg id="1057">"" "" "" "if bubbles are present, they will keep them up in the cartridge - While you keep the injection needle upward, press the button in the direction of the arrow (Figure D) • Now a drop of insulin must be extracted from the tip of the injection needle." "" "" ""</seg>
<seg id="1058">"" "" "" "if not, turn the closing cap until the push button is pressed completely down • Keep your Actraphane 50 NovoLet horizontally." "" "" ""</seg>
<seg id="1059">"" "" "" "oral antidiabetic (for taking), monoamine oxidase inhibitors, angiotensin-inhibitors, acetylsalicylic acid, anabolic steroids, beta-athomimetika, growth hormone, Danazol, Octopotid or Lanreotid." "" "" ""</seg>
<seg id="1060">"" "" "" "► in insulin infusion pumps ► If the InnoLet has been dropped, damaged or broken, there is a risk of running insulin." "" "" ""</seg>
<seg id="1061">"" "" "" "the warning signs of an underplucking can occur suddenly and can be: cold sweat, cold pale skin, headache, heart rasen, nausea, severe fatigue, nervousness, anxiety, anxiety, confusion, concentration difficulties." "" "" ""</seg>
<seg id="1062">"" "" "" "264 If any of the side effects listed are significantly impaired or you notice side effects that are not stated in this manual information, please inform your doctor, your diabetcounsellor or your pharmacist." "" "" ""</seg>
<seg id="1063">"" "" "" "in use, InnoLet's ready-ready pens and those that will be used shortly or as a substitute must not be kept in the refrigerator." "" "" ""</seg>
<seg id="1064">It is recommended - after being taken out of the refrigerator - increase the temperature of the InnoLet's pens at room temperature before the insulin is resuscitated in accordance with the manual for the first use.</seg>
<seg id="1065">"" "" "" "if Innovice is not in use to protect the insulin from light, leave the closure of your InnoLet ready-ready pens." "" "" ""</seg>
<seg id="1066">"" "" "" "like acetphane and contents of the package The injection suspension is delivered as a cloudy, white, aqueous suspension in packs of 1, 5 or 10 finished pens per 3 ml." "" "" ""</seg>
<seg id="1067">"" "" "" "the movement must be repeated until the liquid looks equally white and cloudy. after the resusendium, you perform all the following steps of the injection without delay." "" "" ""</seg>
<seg id="1068">• Desect the rubber membrane with a medical tampon • always use a new injection needle to avoid contamination • Remove the injection needle straight and firmly on Actraphane 30 InnoLet (Figure 1B) • Drag the large outer injection needle and remove the inner injection needle.</seg>
<seg id="1069">"" "" "" "• always control whether the push button is fully pressed and the dose control is zero, set the number of units you need to inject by turning the dose control clockwise (Figure 2)." "" "" ""</seg>
<seg id="1070">Do not use the restriction scale to measure your insulin dose • You will hear a click-on noise for each unit set individually.</seg>
<seg id="1071">"" "" "" "perform the injection technique, which your doctor has shown to you • Enter the dose by simply pressing the button (Figure 3)." "" "" ""</seg>
<seg id="1072">The dose control adjusts to zero and you hear clipping noises • The injection needle must remain under the skin after injection to ensure that the full insulin dose has to be injected for at least 6 seconds after injection.</seg>
<seg id="1073">"" "" "" "medical personnel, family members and other caregivers must observe general precautions to remove and dispose of the injection needles to avoid accidental stitches with the injection needle." "" "" ""</seg>
<seg id="1074">"" "" "" "oral antidiabetic (for taking), monoamine oxidase inhibitors, angiotensin-inhibitors, acetylsalicylic acid, anabolic steroids, beta-athomimetika, growth hormone, Danazol, Octopotid or Lanreotid." "" "" ""</seg>
<seg id="1075">"" "" "" "► in insulin infusion pumps ► If the flexPen was dropped, damaged or broken, there is a risk of running insulin." "" "" ""</seg>
<seg id="1076">"" "" "" "if you notice deepenings or thickening of your skin at the injection point, tell your doctor or your diabetcounsellor, because these reactions can worsen or affect your insulin if you are injected into such a place." "" "" ""</seg>
<seg id="1077">"" "" "" "274 If any of the side effects listed are significantly impaired or you notice side effects that are not stated in this manual information, please inform your doctor, your diabetcounsellor or your pharmacist." "" "" ""</seg>
<seg id="1078">"" "" "" "in use, FlexPen finished pens and those that are used shortly or used as a replacement are not stored in the refrigerator." "" "" ""</seg>
<seg id="1079">It is recommended - after being taken out of the fridge - increase the temperature of the FlexPen case at room temperature before the insulin is resuscitated in accordance with the manual for the first use.</seg>
<seg id="1080">"" "" "" "if FlexPen is not in use to protect the insulin from light, leave the closing lid of your FlexPen case." "" "" ""</seg>
<seg id="1081">"" "" "" "like acetphane and contents of the package The injection suspension is delivered as a cloudy, white, aqueous suspension in packs of 1, 5 or 10 finished pens per 3 ml." "" "" ""</seg>
<seg id="1082">"" "" "" "the manufacturer can be identified based on the batch designation, which is printed on the carton of the carton and on the label:" "" "" ""</seg>
<seg id="1083">"" "" "" "the manufacturer Novo Nordisk A / S, Novo allé, DK-2880 Bagsvaerd, Denmark • In the second and third place of the batch name the character combination H7 or T6 appears, is the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F- 28002 Chartres, France." "" "" ""</seg>
<seg id="1084">"" "" "" "B Move the finished pen between positions 1 and 2 times, so that the glass ball moves from one end of the cartridge to the other." "" "" ""</seg>
<seg id="1085">"" "" "" "move the finished pen at least 10 times between positions 1 and 2, until liquid appears uniformly white and cloudy." "" "" ""</seg>
<seg id="1086">"" "" "" "• To reduce the risk of unintentional needlepunch, never put the inner shell back on the injection needle once you have lost it once." "" "" ""</seg>
<seg id="1087">"" "" "" "279 G Keep the flexure up with the injection needle and knock a few times with the finger, so that existing air bubbles will accumulate in the cartridge." "" "" ""</seg>
<seg id="1088">"" "" "" "the dose can be corrected either upward or downwards, by turning the dosed dial button in the appropriate direction until the correct dose is placed opposite the marking of the ad." "" "" ""</seg>
<seg id="1089">This document is a summary of the European Public Assessment Report (EPAR) in which the Committee for Medicinal Products (CHMP) has assessed the studies carried out to reach recommendations regarding the use of the medicine.</seg>
<seg id="1090">"" "" "" "the most effective ingredient in Actrapid, insulin in human (rDNA) is produced using the process of so-called" recombinant technology. "" "" "" ""</seg>
<seg id="1091">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.eu http: / / www.emea.europa.eu ww.EMEA 2007 Reproduction and / or distribution of this document is Authorised for non commercial purposes How was Actrapid examined?</seg>
<seg id="1092">Actrapid should not be used in patients who may be hypersensitive to insulin in human (rDNA) or any of the other components.</seg>
<seg id="1093">"" "" "" "in addition, the doses of Actrapid may be adjusted if it is administered together with a number of other medicines that can affect blood sugar." "" "" ""</seg>
<seg id="1094">"" "" "" "in October 2002, the European Commission issued a permit for the implementation of Actrapid in the entire European Union by Novo Nordisk A / S." "" "" ""</seg>
<seg id="1095">"" "" "" "when two types of insulin are mixed, the amount of the fast acting insulin must first be raised, followed by the amount of insulin." "" "" ""</seg>
<seg id="1096">"" "" "" "3 If a dose adjustment is required when changing to Actrapid in the patient, it may be necessary during the first dose or during the first weeks or months after the conversion." "" "" ""</seg>
<seg id="1097">"" "" "" "before travelling, which go over several time zones, the patient should be advised to take the advice of his doctor as such journeys may lead to insulin and meals to be applied or taken at other times." "" "" ""</seg>
<seg id="1098">"" "" "" "5 General conditions and complaints at the site of gelding - Local hypersensitivity reactions to the injection point During insulin therapy, local hypersensitivity reactions (redness, swelling, itching, pain and haematoma at the injection site) occur." "" "" ""</seg>
<seg id="1099">"" "" "" "• Severe hypoglycemia is treated with an intramuscular or subcutaneous injection of Glucagon (0.5 to 1.0 mg), or by glucose that is administered intravenously by the doctor." "" "" ""</seg>
<seg id="1100">A clinical trial in an intensive care unit for the treatment of hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients undergoing major surgical procedures has shown that a 42% reduction in blood sugar was reduced by 42% (8% vs 4.6%).</seg>
<seg id="1101">"" "" "" "the effect begins within half an hour, the active maximum is reached within 1.5 to 3,5 hours and the total duration of the operation is approximately 7 to 8 hours." "" "" ""</seg>
<seg id="1102">The pharmacokinetic profile of Actrapid was studied at a smaller number (n = 18) of diabetic children (aged between 6 and 12) and adolescent (aged between 13 and 17 years old).</seg>
<seg id="1103">"" "" "" "the data are limited, but suggest that pharmacokinetic profile in children and adolescents is similar to adults." "" "" ""</seg>
<seg id="1104">Infusion systems with Actrapid in concentrations 0.05 I.U. / ml - 1.0 I.U. / ml insulin in the infusion fluids of 0.9% sodium chloride; 5% D-glucose and 10% D- Glucose with 40 mmol / l potassium chloride are stable at room temperature for 24 hours.</seg>
<seg id="1105">"" "" "" "11 If a dose adjustment is required when changing to Actrapid in the patient, it may be necessary during the first dose or during the first weeks or months after the changeover." "" "" ""</seg>
<seg id="1106">"" "" "" "before travelling, which go over several time zones, the patient should be advised to take the advice of his doctor as such journeys may lead to insulin and meals to be applied or taken at other times." "" "" ""</seg>
<seg id="1107">"" "" "" "13 General conditions and complaints at the site of gelding - Local hypersensitivity reactions to the injection point During insulin therapy, local hypersensitivity reactions (redness, swelling, itching, pain and haematoma at the injection site) occur." "" "" ""</seg>
<seg id="1108">"" "" "" "• Severe hypoglycemia is treated with an intramuscular or subcutaneous injection of Glucagon (0.5 to 1.0 mg), or by glucose that is administered intravenously by the doctor." "" "" ""</seg>
<seg id="1109">The pharmacokinetic profile of Actrapid was studied at a smaller number (n = 18) of diabetic children (aged between 6 and 12) and adolescent (aged between 13 and 17 years old).</seg>
<seg id="1110">"" "" "" "the intravenous use of actrapid from prepens or cartridges should be an exception, and can only occur in situations where there are no leakage bottles available." "" "" ""</seg>
<seg id="1111">"" "" "" "if a dose adjustment is required when changing to Actrapid in the patient, it may be necessary during the first dose or during the first weeks or months after the changeover." "" "" ""</seg>
<seg id="1112">21 diseases of the skin and the skin tissue - Lipodystrophy At the injection point a lipodystrophy can occur if missed to change the insertion points within the injection area.</seg>
<seg id="1113">The pharmacokinetic profile of Actrapid was studied at a smaller number (n = 18) of diabetic children (aged between 6 and 12) and adolescent (aged between 13 and 17 years old).</seg>
<seg id="1114">29 disorders of the skin and the skin tissue gel - Lipodystrophy At the injection point a lipodystrophy can occur if missed to change the insertion points within the injection area.</seg>
<seg id="1115">"" "" "" "diseases of the immune system Jelly - Urticaria, Exanthem Very rare - anaphylactic reactions Symptoms of generalized hypersensitivity, including general rash, breathing difficulties, heart palpitations, low blood pressure, and impotence." "" "" ""</seg>
<seg id="1116">The pharmacokinetic profile of Actrapid was studied at a smaller number (n = 18) of diabetic children (aged between 6 and 12) and adolescent (aged between 13 and 17 years old).</seg>
<seg id="1117">"" "" "" "diseases of the immune system Jelly - Urticaria, Exanthem Very rare - anaphylactic reactions Symptoms of generalized hypersensitivity, including general rash, breathing difficulties, heart palpitations, low blood pressure, and impotence." "" "" ""</seg>
<seg id="1118">38 A clinical trial in an intensive care unit for the treatment of hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients undergoing major surgical procedures have shown that a 42% reduction in blood sugar was reduced by 42% (8% vs 4.6%).</seg>
<seg id="1119">"" "" "" "diseases of the immune system Jelly - Urticaria, Exanthem Very rare - anaphylactic reactions Symptoms of generalized hypersensitivity, including general rash, breathing difficulties, heart palpitations, low blood pressure, and impotence." "" "" ""</seg>
<seg id="1120">46 A clinical trial in an intensive care unit for the treatment of hyperglycemia (blood sugar over 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients undergoing major surgical procedures has shown that a 42% reduction in blood sugar was reduced by 42% (8% vs 4.6%).</seg>
<seg id="1121">Store in the fridge (2 ° C - 8 ° C) Do not freeze the container in the cardboard box to protect the contents from light after quarry: do not store in the fridge or over 25 ° C</seg>
<seg id="1122">Subcutaneous application Penfill cartridges are intended for use with Novo Nordisk insulin injections intended to comply with Actrapid Penfill must be used only by one person</seg>
<seg id="1123">Store in the fridge (2 ° C - 8 ° C) Don't freeze the cartridge in the cardboard box to protect the contents from light after quarry: do not store in the fridge or over 30 ° C</seg>
<seg id="1124">"" "" "" "subcutaneous application For use with Actrapid NovoLet, NovoFine injection needles are intended to adhere to Actrapid NovoLet only be used by one person." "" "" ""</seg>
<seg id="1125">Store in the fridge (2 ° C - 8 ° C) Don't freeze in the fridge. do not store in the fridge or over 30 ° C</seg>
<seg id="1126">"" "" "" "subcutaneous application For use with Actrapid InnoLet, NovoFine S injection needles are intended to adhere to Actrapid InnoLet only be used by one person." "" "" ""</seg>
<seg id="1127">"" "" "" "this means that approximately half an hour after you have applied it, your blood sugar begins to sink and that the effect will stop around 8 hours." "" "" ""</seg>
<seg id="1128">"" "" "" "► Check the label, whether it is the correct insulin type. ► Dessert the rubber membrane with a medical tampon." "" "" ""</seg>
<seg id="1129">"" "" "" "if it is not completely undamaged when you get the glass bottle, enter the glass bottle to your pharmacy if it was not correctly stored or frozen (see 6 How to keep Actrapid?) ► if it doesn't look like water and colorless." "" "" ""</seg>
<seg id="1130">Use the injection technique recommended to your doctor or your diabetic consultant ► Let the injection needle be under your skin for at least 6 seconds in order to make sure the full dose is injected.</seg>
<seg id="1131">"" "" "" "83 Say to your relatives, friends and close colleagues, that they will bring you into the stable side position in the event of an unconsciousness and immediately notify a doctor." "" "" ""</seg>
<seg id="1132">You may have a very rare severe allergic reaction to Actrapid or any of its constituents (a systemic allergic reaction).</seg>
<seg id="1133">"" "" "" "the injection solution is supplied as a clear, colorless, aqueous solution in packs of 1 or 5 packs of 10 ml or bundling bottles with 5 glass bottles for each 10 ml." "" "" ""</seg>
<seg id="1134">"" "" "" "89 Say to your relatives, friends and close colleagues, that they will bring you into the stable side position in the event of an unconsciousness and immediately notify a doctor." "" "" ""</seg>
<seg id="1135">"" "" "" "► Check the label, whether it is the correct insulin type ► Check always the cartridge including rubber piston (plugs)." "" "" ""</seg>
<seg id="1136">"" "" "" "► in insulin infusion pumps ► If the fill fill or the device that contains the penfill has been dropped or broken, there is the risk of running insulin." "" "" ""</seg>
<seg id="1137">"" "" "" "if you are treated with Actrapid Penfill and another insulin in Penfill cartridges, you should use two insulin injections, one for each insulin type." "" "" ""</seg>
<seg id="1138">Use the injection technique that your doctor or your diabeterer has recommended and which is described in the manual of your injection system ► Let the injection needle be removed for at least 6 seconds under your skin to ensure that the full dose is injected.</seg>
<seg id="1139">"" "" "" "• If the character combination W5, S6, P5, K7 or ZF is published, the manufacturer Novo Nordisk A / S, Novo allé, DK-2880 Bagsvaerd, Denmark" "" "" ""</seg>
<seg id="1140">"" "" "" "• If the character combination H7 or T6 appears in the second and third position, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F- 28002 Chartres, France." "" "" ""</seg>
<seg id="1141">"" "" "" "oral antidiabetic (for taking), monoamine oxidase inhibitors, angiotensin-inhibitors, acetylsalicylic acid, anabolic steroids, beta-athomimetika, growth hormone, Danazol, Octopotid or Lanreotid." "" "" ""</seg>
<seg id="1142">"" "" "" "► Check the label, whether it is the correct insulin type." "" "" ""</seg>
<seg id="1143">"" "" "" "► in insulin infusion pumps ► If the NovoLet drop is dropped, damaged or broken, there is the risk of running insulin." "" "" ""</seg>
<seg id="1144">"" "" "" "this can happen: if you injure too much insulin, if you eat too little or leave a meal, if you strain yourself more than otherwise physically." "" "" ""</seg>
<seg id="1145">"" "" "" "if it is not in use to protect it from light, leave the cap of your NovoLet ready-ready pens." "" "" ""</seg>
<seg id="1146">"" "" "" "• Remove the rubber membrane with a medical tampon, always use a new injection needle to avoid contamination. • Remove the injection needle straight and firmly on Actrapid NovoLet (Figure A) • Drag the large outer cap of the injection needle and the inner cap of the injection needle." "" "" ""</seg>
<seg id="1147">"" "" "" "follow these steps to avoid the injection of air, and ensure correct dosage: • Keep Actrapid NovoLet with the injection needle upside • knock a few times with your finger gently against the cartridge." "" "" ""</seg>
<seg id="1148">"" "" "" "while the injection needle continues upward, press the button in the direction of the arrow (Figure B) • While the injection needle continues pointing upwards, push the button in it (Figure C) • Now a drop of insulin must be extracted from the tip of the injection needle." "" "" ""</seg>
<seg id="1149">"" "" "" "• Replace the closing cap onto the finished pen again, that the digit 0 is in front of the metering brand (Figure D)." "" "" ""</seg>
<seg id="1150">"" "" "" "if the push button cannot move freely, insulin is pressed from the injection needle • The scale on the closing cap shows 0, 2, 4, 6, 8, 10, 12, 14, 16 and 18 units." "" "" ""</seg>
<seg id="1151">"" "" "" "the push button moves outward, while you rotate the cap • The scale under the push button (button scale) shows 20, 40 and 60 units." "" "" ""</seg>
<seg id="1152">"" "" "" "107 • Record the highest number you can see on the button scale • Adding the two numbers to get the suggested dose • If you have set a wrong dose, turn the cap forward or backwards until you set the correct number of units." "" "" ""</seg>
<seg id="1153">"" "" "" "rotate it until the push button is at the bottom and you sense a resistance, then remove the cap and put it back on that the 0 of the metering brand is opposite." "" "" ""</seg>
<seg id="1154">"" "" "" "make sure to press the push button only during the injection, when the injection needle is pulled out of the skin until the injection needle was pulled out of the skin." "" "" ""</seg>
<seg id="1155">It may be inaccurate • You can not adjust a dose which is higher than the number of units remaining in the cartridge • You can use the remaining scale scale to estimate how much insulin is still left but you can not use it to stop or select your dose.</seg>
<seg id="1156">"" "" "" "oral antidiabetic (for taking), monoamine oxidase inhibitors, angiotensin-inhibitors, acetylsalicylic acid, anabolic steroids, beta-athomimetika, growth hormone, Danazol, Octopotid or Lanreotid." "" "" ""</seg>
<seg id="1157">"" "" "" "► in insulin infusion pumps ► If the InnoLet has been dropped, damaged or broken, there is the risk of running insulin." "" "" ""</seg>
<seg id="1158">"" "" "" "let the end cap of your InnoLet's pens always be set up, if it is not in use to protect it from light." "" "" ""</seg>
<seg id="1159">• disinfect the rubber membrane with a medical tampon • always use a new injection needle for each injection to avoid contamination. • Remove the injection needle straight and firmly on Actrapid InnoLet (Figure 1A) • Drag the large outer cap of the injection needle and the inner cap of the injection needle.</seg>
<seg id="1160">"" "" "" "after injection, the dose regulator must remain under the skin for at least 6 seconds after injection." "" "" ""</seg>
<seg id="1161">"" "" "" "oral antidiabetic (for taking), monoamine oxidase inhibitors, angiotensin-inhibitors, acetylsalicylic acid, anabolic steroids, beta-athomimetika, growth hormone, Danazol, Octopotid or Lanreotid." "" "" ""</seg>
<seg id="1162">"" "" "" "if it was not stored correctly or frozen (see 6), how to store Actrapid?) ► if it doesn't look like water and colourless." "" "" ""</seg>
<seg id="1163">"" "" "" "if any of the side effects listed below are significantly impaired or you notice side effects that are not stated in this manual information, please inform your doctor, your diabetcounsellor or your pharmacist." "" "" ""</seg>
<seg id="1164">"" "" "" "always set up the closing lid of your FlexPen case, if it is not in use to protect it from light." "" "" ""</seg>
<seg id="1165">F Keep the flexure with the injection needle up and knock a few times with the finger gently against the cartridge so that existing air bubbles will accumulate in the cartridge.</seg>
<seg id="1166">"" "" "" "the dose can be corrected either upward or downwards, by turning the dosed dial button in the appropriate direction until the correct dose is placed opposite the dosage of the dose display." "" "" ""</seg>
<seg id="1167">"" "" "" "Adenuric is used in patients with signs of crystallization, including arthritis (pain and inflammation in joints) or plaster nodes (" stones "that can lead to joint and bone damage)." "" "" ""</seg>
<seg id="1168">"" "" "" "if the uric acid level is still over 6 mg per deciliter for two to four weeks, the dose can be increased to 120 mg once a day." "" "" ""</seg>
<seg id="1169">"" "" "" "during the first treatment months, even plaster attacks can occur; therefore, it is recommended that patients continue to take medicines at least during the first six months of treatment with Adenuric." "" "" ""</seg>
<seg id="1170">"" "" "" "the medicine is not recommended in children and in patients who had an organ transplant, since it was not examined for these groups." "" "" ""</seg>
<seg id="1171">"" "" "" "in the first study, participated in 1 072 patients, the efficacy of three different choroic dosages (once daily 80, 120 and 240 mg) was compared to a placebo (placebo) and of Allopurinol (another medicine for the treatment of hyperuricanemia)." "" "" ""</seg>
<seg id="1172">"" "" "" "in the second study, two doses of Adenuric (once daily 80 and 120 mg) were compared to 762 patients with Allopurinol." "" "" ""</seg>
<seg id="1173">"" "" "" "in both studies, Allopurinol was used in a dose of once daily 300 mg; patients with kidney problems received only 100 mg per day." "" "" ""</seg>
<seg id="1174">"" "" "" "the main indicator for efficacy was the number of patients, whose uric acid levels were below 6 mg / dl in the last three measurements." "" "" ""</seg>
<seg id="1175">In the first study 48% (126 of 262) of patients who took Adenuric in a dose of once daily 80 mg and 65% (175 of 269) of the patients who once daily received 120 mg of urine during the last three measurements obtained a uric acid level in the blood of less than 6 mg / dl.</seg>
<seg id="1176">"" "" "" "in comparison to this, this was 22% (60 of 268) of patients with Allopurinol and none of the 134 patients under placebo." "" "" ""</seg>
<seg id="1177">"" "" "" "the most common side effects of Adenuric (observed in 1 to 10 of 100 patients) are headache, diarrhea, nausea (nausea), rash and abnormal liver values." "" "" ""</seg>
<seg id="1178">"" "" "" "especially in patients with heart problems in prehistory, there may also be an increased risk of certain side effects that affect the heart and blood vessels." "" "" ""</seg>
<seg id="1179">"" "" "" "the Committee for Medicinal Products (CHMP) concluded that Adenuric was more effective in lowering the uric acid levels in the blood, but also a higher risk of side effects related to the heart and blood vessels." "" "" ""</seg>
<seg id="1180">Treatment of chronic hyperuricanemia in diseases that have already led to uratdeposits (including a current node known or present in the case of illness and / or arthritis).</seg>
<seg id="1181">A dose increase on ADENURIC 120 mg 1 x can be taken into consideration daily after 2 - 4 weeks still &gt; 6 mg / dl (357 µmol / l).</seg>
<seg id="1182">"" "" "" "in patients with severe kidney function restrictions, efficacy and safety have not been fully investigated until now (Creatinin Clearance &lt; 30 ml / min, see Section 5.2)." "" "" ""</seg>
<seg id="1183">"" "" "" "since there are no experiences in children and adolescents, the application of Febuxostat is not recommended in this group of patients." "" "" ""</seg>
<seg id="1184">"" "" "" "since there are no experiences in organ transplant receivers, the application of Febuxostat is not recommended in this group of patients (see section 5.1)." "" "" ""</seg>
<seg id="1185">"" "" "" "cardiovascular disease in patients with ischemic heart disease or decompensated heart failure, treatment with Febuxostat is not recommended (see Section 4.8)." "" "" ""</seg>
<seg id="1186">"" "" "" "as with other diuretic medicines, acute gout attack can occur during the treatment, because uric acid deposits can initially be mobilized in the tissue by lowering serum levels." "" "" ""</seg>
<seg id="1187">"" "" "" "B. in malignant diseases and their treatment, Lesch- Nyhan's syndrome) the absolute concentration of Xanthin increases in the urine in rare cases so far that it comes to a storage in the urinary tract." "" "" ""</seg>
<seg id="1188">"" "" "" "during Phase 3 clinical trials, minor abnormalities of liver function were observed in patients treated with Febuxostat (3.5%)." "" "" ""</seg>
<seg id="1189">"" "" "" "therefore, it is recommended to perform a liver function test before the start of the febuxostats (see section 5.1)." "" "" ""</seg>
<seg id="1190">"" "" "" "Theophyllin Zwas no interaction studies carried out to Febuxostat, but it is known that the XO inhibition can lead to an increase in theophylline level (an inhibition of theophylline metabolism was also reported for other XO inhibitors)." "" "" ""</seg>
<seg id="1191">"" "" "" "in subjects, the simultaneous administration of Febuxostat and naproxen was associated with an increase in Febuxostature (Cmax 28%, AUC 41% and t1 / 2 26%)." "" "" ""</seg>
<seg id="1192">"" "" "" "in clinical trials, the use of naproxen or other NSAR / Cox-2 inhibitors was not associated with a clinically significant increase of adverse events." "" "" ""</seg>
<seg id="1193">Colchicin / Indometacin / hydrochlorthiazide / Warfarin Febuxostat can be applied together with Colchicin or Indometacin without requiring a dose adjustment for Febuxostat or the other active agent.</seg>
<seg id="1194">"" "" "" "in a study involving subjects, 120 mg of ADENURIC 1 x showed a medium 22% increase in the AUC of Desipramine, a CYP2D6 substrate, indicating a possible weak inhibitory effect of Febuxostat on the CYP2D6 enzyme in vivo." "" "" ""</seg>
<seg id="1195">"" "" "" "Antazida It could be shown that the simultaneous intake of an antacid, magnesium hydroxide and aluminium hydroxide, slowed down the intake of Febuxostat (about 1 hour) and a reduction of the Cmax by 32%, but no significant change in the AUC." "" "" ""</seg>
<seg id="1196">Pregnancy data on a very limited number of exposed pregnancy can not be close to side effects of Febuxostat on pregnancy or the health of the fetus / newborn.</seg>
<seg id="1197">"" "" "" "animal experimental studies do not allow direct or indirect harmful effects on pregnancy, embryonic / fetal development or birth (see Section 5.3)." "" "" ""</seg>
<seg id="1198">"" "" "" "patients should be careful when controlling a vehicle, operating machinery or the exercise of dangerous activities until they can be reasonably certain that ADENURIC does not affect their performance." "" "" ""</seg>
<seg id="1199">A numerically higher incidence of cardiovascular events observed in the overall febuxostats was observed in the overall febuxostats in the pivotal study of phase 3 (1.3 versus 0.7 events per 100 patient years) although no statistically significant differences were found and no causal connection could be detected with Febuxostat.</seg>
<seg id="1200">The risk factors identified in these patients were arteriosclerosis and / or a myocardial infarction or a decompensated heart failure in the medical history.</seg>
<seg id="1201">"" "" "" "frequent (≥ 1 / 100 to &lt; 1 / 100), occasional (≥ 1 / 1000 to &lt; 1 / 100) and rare (≥ 1 / 1000 mg of Febuxostat) and a total of more than once reported in all Febuxostat treatment groups are listed below." "" "" ""</seg>
<seg id="1202">Diarrhoea and vomiting are more common in patients treated at the same time with Colchicin. * * In the clinical trials no severe skin rash or severe hypersensitivity reactions were observed.</seg>
<seg id="1203">"" "" "" "7 Open long-term extension studies In the open long-term extension studies, 906 patients were treated with Febuxostat 80 mg / 120 mg for up to 3 years and 53 patients up to 3 years." "" "" ""</seg>
<seg id="1204">The events related to the long-term extension studies were similar to those reported in Phase 3 studies (see table 1).</seg>
<seg id="1205">The following treatment-related events were reported in all cases of the Febuxostat 80 mg / 120 mg in patients who received Febuxostat 80 mg / 120 mg in long-term extension studies (up to 4 years with an exposure time of &gt; 1.900 patient years).</seg>
<seg id="1206">"" "" "" "the following treatment-related events were either not reported at the pivotal studies of phase 3, or with a lower frequency:" "" "" ""</seg>
<seg id="1207">"" "" "" "diabetes, hyperlipidemia, sleeplessness, hypesthesia, skin lesions, skin lesions, skin lesions, kidney insufficiency, decrease of lymphocytes, decrease in the number of white blood cells." "" "" ""</seg>
<seg id="1208">The effect mechanism of uric acid is the end product of the purinmetabolism in humans and occurs in the context of the reaction skate Hypoxanthin → Xanthin → uric acid.</seg>
<seg id="1209">Febuxostat is a potent non-purine-selective inhibitor of the XO (NP-SIxO) with a Ki value for the in vitro-inhibitory lies below the nanomolar range.</seg>
<seg id="1210">"" "" "" "clinical trial results The effectiveness of ADENURIC was shown in two pivotal studies of phase 3 (APEX study and FACT study, as described below), which were conducted with 1.832 patients with hyperuricanemia and gout." "" "" ""</seg>
<seg id="1211">"" "" "" "in each study, the primary efficacy endpoint was the proportion of patients in which the last three month-monthly serum levels were &lt; 6.0 mg / dl (357 µmol / l)." "" "" ""</seg>
<seg id="1212">Placebo (n = 134), ADENURIC 80 mg 1 x daily (n = 269) and ADENURIC 300 mg 1 x daily (n = 269) for patients with a serum incremental value to study beginning of &gt; 1.5 mg / dl and ≤ 2,0 mg / dl.</seg>
<seg id="1213">The APEX study showed the statistically significant superiority of the treatment with ADENURIC 80 mg 1 x daily as well as with ADENURIC 120 mg 1 x daily compared to the treatment with conventionally used doses Allopurinol 300 mg (n = 258) / 100 mg (n = 10).</seg>
<seg id="1214">The FACT study showed the statistically significant superiority of the treatment with ADENURIC 80 mg 1 x daily as well as with ADENURIC 120 mg 1 x daily compared to the conventional dose Allopurinol 300 mg.</seg>
<seg id="1215">Patients with serum increments &gt; 1.5 and ≤ 2,0 mg / dl) or 300 mg 1 x daily (n = 509) were summarised for analysis. * p &lt; 0.001 versus Allopurinol; p &lt; 0.001 versus 80 mg</seg>
<seg id="1216">The lowering of serum levels at &lt; 6.0 mg / dl (357 µmol / l) was observed during the visit to the doctor in week 2 and maintained permanently over the entire treatment.</seg>
<seg id="1217">509 patients received Allopurinol 300 mg 1 x daily; 10 patients with serum increments &gt; 1.5 and &lt; 2,0 mg / dl were given 100 mg 1 x daily.</seg>
<seg id="1218">Primary endpoint in the subgroup of patients with kidney function restriction The APEX study evaluated the efficacy in 40 patients with kidney function restriction (d. h.</seg>
<seg id="1219">"" "" "" "with ADENURIC, the primary efficacy endpoint was 44% (80 mg 1 x daily), 45% (120 mg 1 x daily) and 60% (240 mg 1 x daily) of patients." "" "" ""</seg>
<seg id="1220">There were no clinical significant differences in the percentage decline of serum concentration in subjects regardless of their kidney function (58% in group with normal kidney function and 55% in group with severe kidney function disorders).</seg>
<seg id="1221">Primary endpoint in the group of patients with serum concentration of serum concentration ≥ 10 mg / dl of Etwa 40% of patients (APEX- and FACT study) had a serum concentration of ≥ 10 mg / dl.</seg>
<seg id="1222">The data from the open extension study of Phase 3 showed that the sustained reduction of serum levels of serum was reduced to &lt; 6 mg / dl (&lt; 357 µmol / l) so that less than 3% of patients in the months 16-24 needed treatment against a watering rate (i.e. more than 97% of patients did not require treatment against a cast).</seg>
<seg id="1223">"" "" "" "this was associated with a reduction in the size of the gypsum node, which resulted in 54% of the total disappearance of the plaster nodes by month 24." "" "" ""</seg>
<seg id="1224">Increased TSH- values (&gt; 5.5 µie / ml) were observed in patients who received long-term treatment with Febuxostat (5.0%) and received allopurinol (5.8%) in the open long-term extension studies (see Section 4.4).</seg>
<seg id="1225">In healthy volunteers the maximum plasma concentrations (Cmax) and the surface under the plasma concentration time curve (AUC) of Febuxostat increased from 10 mg to 120 mg dosisproportional.</seg>
<seg id="1226">"" "" "" "for doses between 120 mg and 300 mg, an increase in AUC is observed for Febuxostat, which is greater than the dose-proportional rise." "" "" ""</seg>
<seg id="1227">"" "" "" "after intake of simple or multipler doses of 80 and 120 mg 1 x daily, the Cmax is approximately 2.8-3,2 µg / ml and 5,0-5,3 µg / ml." "" "" ""</seg>
<seg id="1228">"" "" "" "however, no clinically significant change was observed in the percentage decrease in serum concentration concentration provided this was tested (multiple doses of 80 mg)." "" "" ""</seg>
<seg id="1229">Distribution The apparent steady state distribution volume (Vss / F) of Febuxostat is in the range from 29 to 75 l after taking doses of 10-300 mg.</seg>
<seg id="1230">The plasma protein binding of Febuxostat is approximately 99.2% (primary binding on albumin) and is constant over the concentration width that is reached with doses of 80 and 120 mg.</seg>
<seg id="1231">"" "" "" "in vitro studies in human liver microsomes, these oxidative metabolites are mainly formed by CYP1A1, CYP1A2, CYP2C8 or CYP2C9." "" "" ""</seg>
<seg id="1232">After taking an 80 mg dose of 14C-markedly Febuxostat approximately 49% of the dose in the urine was found as unmodified Febuxostat (30%) and its well-known oxidative metabolites and their conjugate (13%) as well as other unknown metabolites (3%).</seg>
<seg id="1233">"" "" "" "besides the excretion of the urine, approximately 45% of the dose in the chair found itself as unmodified Febuxostat (12%), the known oxidative metabolites and their conjugate (25%) as well as other unknown metabolites (7%)." "" "" ""</seg>
<seg id="1234">"" "" "" "after taking multiple doses of 80 mg of ADENURIC in patients with mild, moderate or severe kidney failure, the Cmax of Febuxostat did not change in relation to subjects with normal renal function." "" "" ""</seg>
<seg id="1235">The medium total AUC of Febuxostat increased about 1.8-times of 7.5 g / ml in the group with normal renal function to 13.2 μ and / ml in the group with severe kidney function.</seg>
<seg id="1236">12 Liver function After taking multiple doses of 80 mg of ADENURIC in patients with mild (Child- Pugh classification A) or moderate (child-Pugh-classification B) Liver function changes the Cmax and AUC of Febuxostat and its metabolites significantly compared to normal liver function.</seg>
<seg id="1237">No significant changes were observed with regard to the AUC of Febuxostat or its metabolites following the intake of multiple orally doses of ADENURIC in elderly patients compared to younger subjects.</seg>
<seg id="1238">"" "" "" "carcinogenesis, mutagenesis, impairment of fertility In male rats was found only in connection with xanthin stones in the highly dosed group, with approximately 11 times the exposure to humans." "" "" ""</seg>
<seg id="1239">"" "" "" "these findings are seen as a result of a specific purinmetabolisation and urine composition, and are considered not relevant for clinical use." "" "" ""</seg>
<seg id="1240">It has been noted that Febuxostat has no effect on fertility and reproductive performance of male and female rats in oral doses of up to 48 mg / kg / day.</seg>
<seg id="1241">"" "" "" "in high doses, which were about 3 times the human therapeutic exposure, maternal toxicity occurred, which was accompanied by a decrease in the performance and a developmental delay in the offspring of rats." "" "" ""</seg>
<seg id="1242">"" "" "" "teratological studies in supporting rats with exposures, such as 4,3 times and in supporting rabbits with exposures, which are approximately 13 times the human therapeutic exposure, have no teratogenic effects." "" "" ""</seg>
<seg id="1243">Colchicin / Indometacin / hydrochlorthiazide / Warfarin Febuxostat can be applied together with Colchicin or Indometacin without requiring a dose adjustment for Febuxostat or the other active agent.</seg>
<seg id="1244">Diarrhoea and vomiting are more common in patients treated at the same time with Colchicin. * * In the clinical trials no severe skin rash or severe hypersensitivity reactions were observed.</seg>
<seg id="1245">"" "" "" "21 Open long-term extension studies In the open long-term extension studies, 906 patients were treated with Febuxostat 80 mg / 120 mg for up to 3 years and 53 patients up to 3 years." "" "" ""</seg>
<seg id="1246">"" "" "" "in each study, the primary efficacy endpoint was the proportion of patients in which the last three month-monthly serum levels were &lt; 6.0 mg / dl (357 µmol / l)." "" "" ""</seg>
<seg id="1247">The data from the open extension study of Phase 3 showed that the sustained reduction of serum levels of serum was reduced to &lt; 6 mg / dl (&lt; 357 µmol / l) so that less than 3% of patients in the months 16-24 needed treatment against a watering rate (i.e. more than 97% of patients did not require treatment against a cast).</seg>
<seg id="1248">26 as unmodified Febuxostat (3%) and AcylGlucuronid of the active substance (30%) and its well-known oxidative metabolites and their conjugate (13%) as well as other unknown metabolites (3%).</seg>
<seg id="1249">"" "" "" "after taking multiple doses of 80 mg of ADENURIC in patients with mild (Child- Pugh classification A) or moderate (child-Pugh classification B), the Cmax and AUC of Febuxostat and its metabolites were not significantly compared with normal liver function." "" "" ""</seg>
<seg id="1250">"" "" "" "carcinogenesis, mutagenesis, impairment of fertility In male rats was found only in connection with xanthin stones in the highly dosed group, with approximately 11 times the exposure to humans." "" "" ""</seg>
<seg id="1251">"" "" "" "the holder of approval for the transport has to ensure that a pharmaceutical vigilance system as described in version 2.0 module 1.8.1 of the authorisation application is ready before the medicine is brought into circulation, and as long as the medicine is brought into circulation." "" "" ""</seg>
<seg id="1252">"" "" "" "according to the CHMP Guideline, an updated RMP can be submitted to risk management systems for human medicines with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="1253">"" "" "" "in addition, an update of the RMP is required • when new information is available, which have an impact on the safety data, the pharmaceutical vigilance plan or risk management activities • within 60 days of reaching important milestones (pharma vigilance or risk minimisation)" "" "" ""</seg>
<seg id="1254">"" "" "" "in some cases, uric acid accumulates in the blood and can reach concentrations that are so high that uric acid is insoluble." "" "" ""</seg>
<seg id="1255">"" "" "" "if you hold the uric acid concentration through the 1 x daily intake of ADENURIC, the crystal formation is prevented and in this way a reduction of the discomfort is achieved." "" "" ""</seg>
<seg id="1256">ADENURIC may not be taken if you are hypersensitive (allergic) to the active ingredient Febuxostat or any of the other components of ADENURIC.</seg>
<seg id="1257">Tell your doctor before you start taking this medicine if you have a heart failure or suffer from any other heart problem. • If you suffer from a high uric acid concentration in a result of cancer or the Lesch-Nyhan-syndrome (a rare congenital disease in which too much uric acid in the blood) is treated.</seg>
<seg id="1258">"" "" "" "if you have a gout attack at the moment (sudden occurrence of severe pain, pressure sensitivity, redness, heat and joint swelling), wait until the gout attack is off before you begin with the treatment with ADENURIC." "" "" ""</seg>
<seg id="1259">"" "" "" "this does not have to be with everyone, but may also occur with you, especially during the first weeks of treatment or - months, if you take ADENURIC." "" "" ""</seg>
<seg id="1260">"" "" "" "your doctor will prescribe other medicines, if necessary, to prevent diarrhoea or to treat the associated symptoms (such as pain and joint swelling)." "" "" ""</seg>
<seg id="1261">"" "" "" "please inform your doctor or pharmacist if you use / apply other medicines, or have recently taken / applied, even if it is not prescription." "" "" ""</seg>
<seg id="1262">It is particularly important for you to inform your doctor or pharmacist if you take medicine using ADENURIC and your doctor may consider necessary measures. • Merctopurine (for treatment of cancer) • Theophylline (for treating asthma) • Warfarin (for treating asthma) • Warfarin (for blood thinning in heart disease)</seg>
<seg id="1263">There have been no studies on the effects of ADENURIC on traffic and the ability to operate machines.</seg>
<seg id="1264">"" "" "" "therefore, please take ADENURIC after consultation with your doctor if you know that you suffer from an intolerance to certain sugars." "" "" ""</seg>
<seg id="1265">"" "" "" "on the back of the blister packs the individual weekdays are printed, so you can check if you have taken a tablet every day. • The tablets must be swallowed and can be taken with or without food." "" "" ""</seg>
<seg id="1266">"" "" "" "if you have unintentionally taken an overdose, please contact your doctor or emergency room at the nearest hospital." "" "" ""</seg>
<seg id="1267">"" "" "" "if you have forgotten the intake of ADENURIC, get it as soon as possible unless the next dose is shortly before." "" "" ""</seg>
<seg id="1268">"" "" "" "if you stop taking ADENURIC, your uric acid concentration can increase again, and your complaints can worsen as new urine crystals can form in your joints and kidneys as well as their surroundings." "" "" ""</seg>
<seg id="1269">"" "" "" "common side effects (more than 1 out of 100 treatment, but less than 1 out of 10 treatment): • Precious liver tests • diarrhea • headache • rash" "" "" ""</seg>
<seg id="1270">"" "" "" "rare side effects (more than 1 of 10,000 people, but less than 1 out of 1,000 patients): • weakness • nervousness • During feeling • palpitations" "" "" ""</seg>
<seg id="1271">Please inform your doctor or pharmacist if any of the listed side effects do significantly affect you or notice side effects that are not stated in this information.</seg>
<seg id="1272">ADENURIC is available in 2 blister packs each with 14 tablets (pack of 28 tablets) or in 6 blister packs with 14 tablets (pack of 84 tablets).</seg>
<seg id="1273">10 rue Erlanger F-75781 Paris Cedex 16 France Tél: + 33 - 44 96 13 13</seg>
<seg id="1274">Danmark, Norge, Suomi / Finland, Sverige, Ísland Institut Produits synthèse (IPSEN) AB Kista Science Tower heigatan 33 SE - 164 51 Kista Sverige / Ruotsi / Puh / Sími: + 46 8 588 370 70</seg>
<seg id="1275">"" "" "" "ADROVANCE is used for treating osteoporosis (a disorder where the bones are brittle) in women after menopause, where there is a risk of low vitamin D levels." "" "" ""</seg>
<seg id="1276">"" "" "" "the patient must take the tablet with a full glass of water (no mineral water) at least 30 minutes before eating, drinking or taking other medicines (including antacids, calcium and vitamin supplements)." "" "" ""</seg>
<seg id="1277">"" "" "" "in order to avoid irritation of the esophagus, the patient must not lay down until after the first food intake of the day, which should take place at the earliest 30 minutes after taking the tablet." "" "" ""</seg>
<seg id="1278">"" "" "" "since Alendronat and vitamin D3 are already used separately in pharmaceuticals that are approved in the European Union, the company submitted data from previous studies and published literature." "" "" ""</seg>
<seg id="1279">The company also conducted a study involving 35 men and 682 postmenopausal women with osteoporosis in order to demonstrate the efficacy of ADROVANCE in relation to the increase in vitamin D levels.</seg>
<seg id="1280">After a 15-week treatment the proportion of patients with low vitamin D levels was lower in patients treated with ADROVANCE (11%) compared to those who were solely responsible for alendronate (32%).</seg>
<seg id="1281">"" "" "" "the company also presented data that present the alendronate dose included in ADROVANCE, which is required to prevent bone loss." "" "" ""</seg>
<seg id="1282">"" "" "" "the most common side effects (observed in 1 to 10 of 100 patients) are headache, pain of the musculoskeletal system such as abdominal pain, dyspepsy (diarrhea), ulcer (swallowing), battered abdomen (bloated stomach) as well as sour retraction." "" "" ""</seg>
<seg id="1283">"" "" "" "in patients with any hypersensitivity to alendronate, vitamin D3 or any of the other ingredients, ADROVANCE cannot be applied." "" "" ""</seg>
<seg id="1284">"" "" "" "it may not be used in cases of oesophagus, in patients with hypocalcemia (low calcium levels) or in patients who cannot stand or sit for at least 30 minutes." "" "" ""</seg>
<seg id="1285">"" "" "" "in January 2007, the European Commission issued the merger of Merck Sharp & Dohme Ltd. to transport ADROVANCE to the European Union." "" "" ""</seg>
<seg id="1286">"" "" "" "capsular, white to broken white tablets, marked with the outline of a bone on one side and" 710 "on the other." "" "" ""</seg>
<seg id="1287">"" "" "" "ADROVANCE is only available with water (not with mineral water) at least 30 minutes before the first meal, drink or intake of medicines (including antacids, calcium and vitamin supplements) for the day." "" "" ""</seg>
<seg id="1288">"" "" "" "follow these instructions carefully to reduce the risk of esophageal irritation and associated side effects (see Section 4.4), as follows:" "" "" ""</seg>
<seg id="1289">• ADROVANCE should be swallowed only with a full glass of water (at least 200 ml). • Patients should not chew the tablet or leave the tablet in the mouth as there is a risk for oropharyngeal ulcera.</seg>
<seg id="1290">"" "" "" "B. peptic ulcer, active gastrointestinal bleedings or surgical procedures in the upper gastrointestinal tract except pyloroplasty, can be given only with special caution (see Section 4.3)." "" "" ""</seg>
<seg id="1291">"" "" "" "esophageal reactions, such as oesophagitis, esophageal erosions, rarely followed by esophageal strokes, were reported in patients taking Alendronat (some were severe and required hospitalisation)." "" "" ""</seg>
<seg id="1292">"" "" "" "therefore, the doctor should point attention to all signs and symptoms that indicate possible esophageal reactions such as dysphagia, pain in swallowing or retrostar pain or new or worsening heartburn." "" "" ""</seg>
<seg id="1293">3 The risk of serious esophageal side effects seems to be increased in patients who do not take the medicine correctly and / or after the occurrence of symptoms that indicate an esophageal irritation.</seg>
<seg id="1294">It is very important that all dispensing instructions are passed on to the patient and be understood by the patient (see Section 4.2).</seg>
<seg id="1295">"" "" "" "while in large-scale clinical studies with Alendronat no increased risk was detected, stomach and duodenal ulcera were rare (after market introduction) stomach and duodenal ulcera, including some severe and with complications (see Section 4.8)." "" "" ""</seg>
<seg id="1296">Osteoarthritis of the jaw commonly associated with a tooth extraction and / or a local infection (including osteomyelitis) was reported in cancer patients whose therapy regimen predominantly administered intravenously administered bisphosphonates.</seg>
<seg id="1297">"" "" "" "there are no data available that give clues, whether the removal of bisphosphonate therapy in patients requiring a surgical procedure reduces the risk of osteoarthritis of the jaw." "" "" ""</seg>
<seg id="1298">"" "" "" "the clinical evaluation by the attending physician is authoritative for therapy planning, for each patient based on an individual benefit risk assessment." "" "" ""</seg>
<seg id="1299">"" "" "" "patients should be instructed to take a dose of ADROVANCE when taking a dose of ADROVANCE, after they have noticed their failure." "" "" ""</seg>
<seg id="1300">"" "" "" "they should not take two tablets the same day, but should continue taking one tablet per week as originally scheduled on the scheduled day of the week." "" "" ""</seg>
<seg id="1301">Other diseases affecting the metabolism (such as vitamin D deficiency and hypoparathyreoidism) should also be treated adequately before beginning treatment with ADROVANCE.</seg>
<seg id="1302">"" "" "" "Alendronate foods and beverages (including mineral water), calcium supplements, antacids and some oral medicines may affect the resorption of alendronate if they are taken at the same time." "" "" ""</seg>
<seg id="1303">"" "" "" "therefore, patients must wait for at least 30 minutes after taking Alendronat before taking other medicines (see Sections 4.2 and 5.2)." "" "" ""</seg>
<seg id="1304">"" "" "" "although specific interaction studies were not carried out, Alendronat was taken together with a variety of commonly prescribed medicines without clinically relevant interactions." "" "" ""</seg>
<seg id="1305">"" "" "" "ADROVANCE is intended only for postmenopausal women, and is therefore not to be applied during pregnancy or lactating women." "" "" ""</seg>
<seg id="1306">Animal studies with Alendronat leave no indication of direct damaging effects with regard to pregnancy that detect embryonic / fetal or postnatal development.</seg>
<seg id="1307">Osteoarthritis of the jaw was reported in patients with bisphosphonates; most reports stem from cancer patients but was also reported in osteoporosis patients.</seg>
<seg id="1308">"" "" "" "however, the serum levels decreased to &lt; 8.0 mg / dl (2.0 mmol / l) and serum phosphats up to ≤ 2,0 mg / dl (0,65 mmol / l) in both treatment groups with similar frequency." "" "" ""</seg>
<seg id="1309">"" "" "" "alendronate insequence of an oral overdose can occur hypocalcemia, hypophosphatemia and side effects in the upper gastrointestinal tract such as stomach upset, heartburn, oesophagitis, gastritis or ulcera." "" "" ""</seg>
<seg id="1310">"" "" "" "colecalciferol (vitamin D3) Vitamin D3 is produced in the skin by UV light, over the transformation of 7-Dehydroves to vitamin D3." "" "" ""</seg>
<seg id="1311">"" "" "" "the main effect of vitamin D3 is the increase in the intestinal absorption of calcium and phosphate, as well as the regulation of serum calcium, calcium and phosphate, bone formation and bone resorption." "" "" ""</seg>
<seg id="1312">"" "" "" "in severe cases, a deficiency can lead to secondary hyperparathyreoidism, hypophosphatemia, weakness of proximal musculature and osteomalazie and thus to a further increased risk for falls and fractures in osteoporosis." "" "" ""</seg>
<seg id="1313">"" "" "" "bone mineral density in spine or hip, which is 2.5 standard deviations below the average for a normal, young population, or irrespective of bone density as a present pathological fracture." "" "" ""</seg>
<seg id="1314">Patients received ADROVANCE in the lower thickness (70 mg / 2.800 I.U.) (n = 350) or Fosamax (Alendronat) 70 mg once a week (n = 332); other vitamin D supplements were forbidden.</seg>
<seg id="1315">After a 15-week treatment the mean serum levels of 25 hydroxylic D were significantly higher (26%) in the group under ADROVANCE (70 mg / 2.800 I.U.) than in the group under Alendronat alone (46 nmol / l [18.2 ng / ml]).</seg>
<seg id="1316">ADROVANCE (70 mg / 2.800 I.U.) decreased significantly after 15 weeks of patients with vitamin D insufficiency (serum value of 25 hydroxylic D &lt; 37.5 nmol / l [&lt; 15 ng / ml]) by 62.5% compared to alendronate alone (12% vs).</seg>
<seg id="1317">Studies with Alendronat once weekly 70 mg (n = 519) and Alendronate 10 mg daily (n = 370) was demonstrated in a one-year multi-center study of postmenopausal women with osteoporosis.</seg>
<seg id="1318">The effects of Alendronate on bone mass and fracture incidence in postmenopausal women were examined in two phase III studies of identical design (n = 944) as well as in fracture intervention study (FIT: n = 6.459).</seg>
<seg id="1319">"" "" "" "in phase III studies, the average stimulation of the BMD with Alendronat 10 mg / day in relation to placebo after 3 years amounted to 8.8% on the spinal column, 5.9% on the femur and 7.8% on the Trochanter." "" "" ""</seg>
<seg id="1320">"" "" "" "in the group treated with Alendronate, a 48% reduction in the placebo group was reached by 48% (Alendronat 3.2%) in the proportion of patients suffering one or more vertebrates." "" "" ""</seg>
<seg id="1321">"" "" "" "in the two-year extension of these studies, the ascents of the BMD of the spine and trough continued; the BMD of the femur and the entire body was also maintained." "" "" ""</seg>
<seg id="1322">"" "" "" "fit consisted of two plazeboat studies, in which Alendronate was taken daily (5 mg daily for 2 years and then 10 mg daily either over 1 or 2 years):" "" "" ""</seg>
<seg id="1323">"" "" "" "in this study, the daily dose of Alendronat reduced the occurrence of at least a new fluid fracture by 47% (Alendronat 7.9% versus placebo 15.0%)." "" "" ""</seg>
<seg id="1324">Resorption Beackled on an intravenous reference dose was the mean oral bioavailability of Alendronat in women 0.64% for doses between 5 and 70 mg following night fasting and two hours before taking a standardized breakfast.</seg>
<seg id="1325">Bioavailability increased to about 0.46% and 0.39% when Alendronate was taken one or half an hour before a standardized breakfast.</seg>
<seg id="1326">"" "" "" "in osteoporosis studies, Alendronat was effective if it was taken at least 30 minutes before the first meal or drinking of the day." "" "" ""</seg>
<seg id="1327">In healthy volunteers the administration of oralem Prednison (20 mg three times a day over five days) led to no clinically significant change in oral bioavailability of alendronate (increase in average in the range from 20% to 44%).</seg>
<seg id="1328">"" "" "" "9 distribution studies of rats have shown that alendronate is temporarily distributed according to IV administration of 1 mg / kg, but then quickly circulated into the bones or excreted with urine." "" "" ""</seg>
<seg id="1329">"" "" "" "after intravenous administration of a single dose of 14C-Alendronate, about 50% of the radioactivity was excreted within 72 hours with the urine and little or no radioactivity was found in the fences." "" "" ""</seg>
<seg id="1330">After intravenous dosage of a single dose of 10 mg the renal Clearance of Alendronat was 71 ml / min and the systemic clearing passed not 200 ml / min.</seg>
<seg id="1331">"" "" "" "in rats, Alendronat is not excreted by the acid or alkaline transport system of the kidneys and therefore it is not assumed that the excretion of other drugs is affected by these transport systems." "" "" ""</seg>
<seg id="1332">Resorption Of healthy adult subjects (women and men) was after the administration of ADROVANCE after nightly fasting and two hours before taking a meal the middle area under the serum concentration time curve (AUC0-120 h) for vitamin D3 296.4 ng • h / ml (without taking into account endogenous vitamin D3 mirror).</seg>
<seg id="1333">The mean maximum concentration in serum (Cmax) of vitamin D3 was 5.9 ng / ml and the median time up to the maximum serum concentration (Tmax) 12 hours.</seg>
<seg id="1334">"" "" "" "in the liver, vitamin D3 is quickly hydroxylic and then metabolized in the kidney to 1.25-Dihydroxylic D3, the bioactive form, metabolized." "" "" ""</seg>
<seg id="1335">"" "" "" "the mean excretion of radioactivity in the urine after 48 hours was 2.4%, in the Fäces after 4 days 4.9%." "" "" ""</seg>
<seg id="1336">"" "" "" "characteristics in patients preclinical studies have shown that the share of Alendronat, which is not deposited in the bone, is quickly excreted via urine." "" "" ""</seg>
<seg id="1337">"" "" "" "although no clinical data is available, it is nevertheless expected that the renal elimination of alendronate as in animal tests is also reduced in patients with reduced kidney function." "" "" ""</seg>
<seg id="1338">"" "" "" "therefore, a slightly increased accumulation of alendronate is expected in patients with reduced kidney function (see Section 4.2)." "" "" ""</seg>
<seg id="1339">"" "" "" "non-clinical data on the basis of conventional safety harmacology, chronic toxicity, genotoxicity and carcinogenic potential leave no particular danger to humans." "" "" ""</seg>
<seg id="1340">Studies on rats showed that the gift of Alendronat was associated with pregnant rats with the occurrence of dystoia in the mother animals that was attributable to a hypocemia.</seg>
<seg id="1341">Microcrystalline cellulose (E 460) lactless middle-chain triglycerides Gelatin Croscarid-sodium Sucrose High disperses silicon dioxide (Ph.Eur.) (E 572) starch, modified (corn) Aluminum natriumsilicate (E 554)</seg>
<seg id="1342">"" "" "" "Etui with sealed aluminium / aluminum blister packs in cartons to 2 (1 case with 4 tablets), 6 (3 cases with 4 tablets), 12 (3 cases with 4 tablets) or 40 (10 cases with 4 tablets) tablets." "" "" ""</seg>
<seg id="1343">EU / 1 / 06 / 364 / 002 - 6 tablets EU / 1 / 06 / 364 / 003 - 6 tablets EU / 1 / 06 / 364 / 005 - 40 tablets EU / 1 / 364 / 005 - 40 tablets</seg>
<seg id="1344">"" "" "" "rectangle, white to broken white tablets, marked with the outline of a bone on one side and" 270 "on the other." "" "" ""</seg>
<seg id="1345">13 • Patients should not lie down after taking ADROVANCE for at least 30 minutes. • ADROVANCE should not be taken before bedtime or before the first appearance of the day.</seg>
<seg id="1346">The risk of serious esophageal side effects seems to be increased in patients who do not take the medicine correctly and / or after the occurrence of symptoms that indicate an esophageal irritation.</seg>
<seg id="1347">"" "" "" "while in large-scale clinical studies with Alendronat no increased risk was detected, stomach and duodenal ulcera were rare (after market introduction) stomach and duodenal ulcera, including some severe and with complications (see Section 4.8)." "" "" ""</seg>
<seg id="1348">18 Colecalciferol (vitamin D3) Vitamin D3 is produced in the skin by UV light over the transformation of 7-Dehydroves to vitamin D3.</seg>
<seg id="1349">Patients received ADROVANCE in the lower thickness (70 mg / 2.800 I.U.) (n = 350) or Fosamax (Alendronat) 70 mg once a week (n = 332); other vitamin D supplements were forbidden.</seg>
<seg id="1350">Vitamin D3 (the amount of vitamin D3 in the higher dose of ADROVANCE) once weekly was shown in a 24 week extension study with 619 postmenopausal women with osteoporosis.</seg>
<seg id="1351">After 24 weeks of treatment the mean serum levels of 25 hydroxylic D were significantly higher in the 5.600-I.D. vitamin D3 group (69 nmol / l [27.6 ng / ml]) than in the 2,800-I.D. vitamin D3 group (64 nmol / l [25.5 ng / ml]).</seg>
<seg id="1352">There was no statistically significant difference between treatment groups in the proportion of patients with hypercalciurie at the end of the 24-week extension.</seg>
<seg id="1353">"" "" "" "3.1% of the total hip in the group with 70 mg once a week, or in the 10 mg daily." "" "" ""</seg>
<seg id="1354">"" "" "" "in this study, the daily dose of Alendronat reduced the occurrence of at least a new fluid fracture by 47% (Alendronat 7.9% versus placebo 15.0%)." "" "" ""</seg>
<seg id="1355">Bioavailability increased to about 0.46% and 0.39% when Alendronate lasted one or half an hour before a standardized breakfast.</seg>
<seg id="1356">"" "" "" "distribution studies of rats have shown that alendronate is temporarily distributed in tissue tissue following IV administration of 1 mg / kg, but then quickly circulated into the bones or excreted with urine." "" "" ""</seg>
<seg id="1357">Resorption in healthy adult subjects (women and men) was according to the application of ADROVANCE (70 mg / 5.600 I.U.) after night fasting and two hours before taking a meal the middle area under the serum concentration time curve (AUC0-80 h) for vitamin D3 490.2 ng • h / ml (without taking into account endogenous vitamin D3 mirrors).</seg>
<seg id="1358">The mean maximum concentration in serum (Cmax) of vitamin D3 was 12.2 ng / ml and the median time up to the maximum serum concentration (Tmax) 10.6 hours.</seg>
<seg id="1359">"" "" "" "smaller amounts are divided into fat and muscle tissue and are stored there as vitamin D3, to be released later in the circulatory system." "" "" ""</seg>
<seg id="1360">"" "" "" "21 vitamin D3 is quickly hydroxylic in the liver and then hydroxylic to 1.25-Dihydroxylic D3, the bioactive form, metabolized." "" "" ""</seg>
<seg id="1361">There were no indications of saturation of the bone's receptivity after long-term dosing of cumulative intravenous doses of up to 35 mg / kg in animals.</seg>
<seg id="1362">"" "" "" "Etui with sealed aluminium / aluminum blister packs in cartons with 2 tablets), 4 (1 case with 4 tablets), 12 (3 cases with 4 tablets) or 40 (10 cases with 4 tablets) tablets." "" "" ""</seg>
<seg id="1363">"" "" "" "Pharmacovigilance System The holder of approval for the transport has to ensure that a pharmaceutical vigilance system is available as described in version 2 module 1.8.1 of the approval documents, and so long is available as the medicine is marketed in circulation." "" "" ""</seg>
<seg id="1364">"" "" "" "risk management plan The holder of approval for the transfer is committed to carrying out studies and further pharmacological activities of the pharmaceutical vigilance plan, which are described in detail in the Risk Management Plan (RMP) and its corresponding updates in accordance with version 1 module 1.8.2 of the approval documents." "" "" ""</seg>
<seg id="1365">"" "" "" "according to the CHMP Guideline, an updated RMP is to be submitted to risk management systems for human medicines with the next periodicc Saftey Update Report (PSUR)." "" "" ""</seg>
<seg id="1366">"" "" "" "in addition, an update of the RMP is required − if new information is available that have an impact on the safety data, pharmatvigilance plan or risk minimisation - upon request of EMEA" "" "" ""</seg>
<seg id="1367">Take an ADROVANCE tablet on your chosen day of the week as well as before the first meal and drink and before taking any other medicine by swallowing the tablet with a full glass of water (not chewing and not chewing).</seg>
<seg id="1368">"" "" "" "if you have any further questions, please contact your doctor or pharmacist." "" "" ""</seg>
<seg id="1369">"" "" "" "in the menopause, the ovaries produce no female hormones, estrogen, more that help to preserve the skeleton of women." "" "" ""</seg>
<seg id="1370">"" "" "" "the fractures usually occur on hip, spine or wrist, and may not only cause pain, but also considerable problems such as bent posture (" wihbacks ") and a loss of flexibility." "" "" ""</seg>
<seg id="1371">"" "" "" "ADROVANCE not only prevents loss of bone mass, but also helps to balance bone loss and reduce the risk of vertebral and hip fractures." "" "" ""</seg>
<seg id="1372">Narrowing of esophagus or swallowing problems (3) if it is not possible for you to sit or stand for at least 30 minutes (4) if your doctor has found that your calcium level is lower in the blood.</seg>
<seg id="1373">"" "" "" "40 • If you have problems with swallowing or digestion, if you have cancer, if you have cancer, if you are taking cancer or radiotherapy, if you do not routinely go to your dental care." "" "" ""</seg>
<seg id="1374">"" "" "" "these complaints can occur in particular if patients do not take the ADROVANCE tablet with a full glass of water, and / or sit down before intake 30 minutes after intake." "" "" ""</seg>
<seg id="1375">"" "" "" "taking ADROVANCE with other medicines Calcium supplement, Antazida and some other medicines can hinder the effectiveness of ADROVANCE while taking ingesting." "" "" ""</seg>
<seg id="1376">"" "" "" "certain medicines or food additives can hinder the absorption of vitamin D contained in ADROVANCE including artificial adipose, mineral oils, orlistat and cholesterol lowering drugs cholestyramin and colestipol." "" "" ""</seg>
<seg id="1377">"" "" "" "please inform your doctor or pharmacist if you use / apply other medicines, or have recently taken / applied, even if it is not prescription medicaments." "" "" ""</seg>
<seg id="1378">"" "" "" "please take this medicine after consultation with your doctor, if you know that you suffer from an intolerance to certain sugars." "" "" ""</seg>
<seg id="1379">Please follow the clues 2) (3) (3) and 5) to facilitate the transport of the ADROVANCE tablet into the stomach and to reduce possible irritation of the esophagus (esophagus - the tube that connects your mouth with the stomach).</seg>
<seg id="1380">(2) Take the ADROVANCE tablet after the first appearance and before taking any other medication only with a full glass (at least 200 ml) of water (not with mineral water). • Do not use with mineral water (with or without carbonic acid). • Do not use with coffee or milk. • Do not use with juice or milk.</seg>
<seg id="1381">"" "" "" "(3) Do not lie down - stay completely erect (sitting, standing or walking) - at least 30 minutes after taking the tablet." "" "" ""</seg>
<seg id="1382">"" "" "" "(5) If you have difficulty or pain when swallowing, pain behind the sternum, re-use or worsening heartburn, put ADROVANCE and search your doctor." "" "" ""</seg>
<seg id="1383">"" "" "" "(6) Wait after swallowing your ADROVANCE tablet at least 30 minutes before you take your first food, beverages or other medicines such as antacids (acid-binding medicines), calcium or vitamin preparations this day." "" "" ""</seg>
<seg id="1384">"" "" "" "if you accidentally took too many tablets at one time, drink a full glass of milk and contact your doctor immediately." "" "" ""</seg>
<seg id="1385">"" "" "" "if you missed the intake of a tablet, take only one tablet the next morning after you have noticed your failure." "" "" ""</seg>
<seg id="1386">"" "" "" "pain when swallowing, pain in chest, heartburn, pain or discomfort when swallowing, pain in chest, heartburn, pain or discomfort. diarrhoea, diarrhea, headaches." "" "" ""</seg>
<seg id="1387">"" "" "" "occasionally: • nausea; vomiting, • irritation and inflammation of the esophagus (oesophagus - the tube that connects your mouth with your stomach) or the stomach mucosa, • skin rash; itching; irritated skin." "" "" ""</seg>
<seg id="1388">"" "" "" "after market launch the following side effects reported (frequency not known): • (rotary) dizziness, • fatigue, • hair loss, • jaw problems (osteoarthritis) in conjunction with delayed wound healing and infections, often after pulling teeth, • swelling at hands or legs." "" "" ""</seg>
<seg id="1389">"" "" "" "43 Dabei, it is helpful if you note which complaints you had when they started and how long they stopped." "" "" ""</seg>
<seg id="1390">"" "" "" "the other components are microcrystalline cellulose (E 460), lactose, medium chain triglycerides, gelatine, high dispersed silicon dioxide (E 572), starch, modified (corn), and aluminium natriumsilicate (E 554)." "" "" ""</seg>
<seg id="1391">The tablets are available in Etuis with sealed aluminium / aluminum blister packs in cartons in the following packaging sizes: • 2 tablets (1 case with 2 tablets in aluminum blister packs) • 12 tablets (3 cases with 4 tablets in aluminum blister packs) • 40 tablets (10 capsules with 4 tablets in aluminum blister packs).</seg>
<seg id="1392">"" "" "" "in the menopause, the ovaries produce no female hormones, estrogen, more that help to preserve the skeleton of women." "" "" ""</seg>
<seg id="1393">"" "" "" "48 • If you have allergies, if you have problems with swallowing or digestion, if you have cancer, if you have cancer, if you are taking steroids (cortisonant), if you do not routinely go to your dental care." "" "" ""</seg>
<seg id="1394">"" "" "" "taking ADROVANCE with other medicines Calcium supplement, Antazida and some other medicines can hinder the effectiveness of ADROVANCE while taking ingesting." "" "" ""</seg>
<seg id="1395">2) Take the ADROVANCE tablet after the first appearance and before taking any other medication only with a full glass (at least 200 ml) of water (not with mineral water). • Do not use with mineral water (with or without carbonic acid). • Do not use with coffee or milk. • Do not use with juice or milk.</seg>
<seg id="1396">"" "" "" "3) Do not leave - stay completely erect (sitting, standing or walking) - at least 30 minutes after taking the tablet." "" "" ""</seg>
<seg id="1397">"" "" "" "5) If you have difficulty or pain when swallowing, pain behind the sternum, re-use or worsening heartburn, put ADROVANCE and search your doctor." "" "" ""</seg>
<seg id="1398">"" "" "" "6) Wait after swallowing your ADROVANCE tablet at least 30 minutes before you take your first food, beverages or other medicines such as antacids (acid-binding medicines), calcium or vitamin preparations this day." "" "" ""</seg>
<seg id="1399">"" "" "" "• (turning) dizziness, • joint swelling, • fatigue, • hair loss, • jaw problems (osteoarthritis) in conjunction with delayed wound healing and infections, often after pulling teeth, • swelling at hands or legs." "" "" ""</seg>
<seg id="1400">"" "" "" "tablets are available as rectangular, white to broken white tablets, marked with the outline of a bone on one side and" 270 "on the other." "" "" ""</seg>
<seg id="1401">"" "" "" "advagraf is given to adult patients, who have been transplanted kidney or liver to prevent transplanting of the transplanted organ by the immune system." "" "" ""</seg>
<seg id="1402">"" "" "" "as Tacrolimus and Prograf / Prograft are already used in the EU, the company has presented the results from previously carried out studies with Prograf / Prograft as well as data from published literature." "" "" ""</seg>
<seg id="1403">"" "" "" "furthermore, the results of a clinical study of 668 patients with kidney transplant were presented, whereby the application of Advagraf with Prograf / Prograft or Ciclosporin was compared." "" "" ""</seg>
<seg id="1404">"" "" "" "the main indicator of the efficacy was the number of patients with which the graft was rejected after a treatment duration of one year (for example, for example, how often a renewed organ transplant or resumption of dialysis was required)." "" "" ""</seg>
<seg id="1405">"" "" "" "in addition, more studies on 119 patients with kidney transplant and 129 patients with liver transplant were conducted and examined, as advagraf is absorbed by the body in comparison to Prograf / Prograft." "" "" ""</seg>
<seg id="1406">"" "" "" "tremor (tremor), headache, nausea / vomiting, diarrhea, diabetes, increased potassium content (hypertension), hypertension and insomnia (Insomnia)." "" "" ""</seg>
<seg id="1407">"" "" "" "in patients with any hypersensitivity to Tacrolimus, macrolide antibiotics (such as erythromycin) or any of the other components, advagraf may not be applied." "" "" ""</seg>
<seg id="1408">Patients and physicians must be cautious when others (in particular some herbal) drugs should be taken at the same time with advagraf as the advagraf dose or the dose of the medication that is taken at the same time must be adjusted accordingly.</seg>
<seg id="1409">"" "" "" "hard capsules, retarded yellow-orange gelatine capsules, printed in red ink on the light yellow cap top with" "" "" "" "647" "" "" "" "; they contain white powder." "" "" ""</seg>
<seg id="1410">"" "" "" "only physicians, who are familiar with immunosuppressive therapy and treatment of transplant patients, should prescribe this medicine or make changes in immunosuppressive therapy." "" "" ""</seg>
<seg id="1411">"" "" "" "due to clinically relevant differences in the systemic exposure of tacrolimus, this may lead to graft rejection or increased incidence of side effects, including sub- or immunosuppression." "" "" ""</seg>
<seg id="1412">Patients should always maintain the same tacrolimus formulation and the appropriate daily dosage; changes of the formulation or the regime should only be carried out under close-meshed control of an experienced physician (see Sections 4.4 and 4.8).</seg>
<seg id="1413">"" "" "" "as a result of a transition to an alternative formulation, a therapeutic drug monitoring and appropriate dose adaptations must be carried out to ensure that the systemic exposure of tacrolimus remains intact." "" "" ""</seg>
<seg id="1414">The dosage of Advagraf should primarily be based on the clinical evaluation of rejection and tolerability in individual cases and on blood-level provisions (see below "Recommendations</seg>
<seg id="1415">"" "" "" "after switching from Prograf to advagraf, the tacrolimus level mirrors should be controlled before switching and over two weeks after switching." "" "" ""</seg>
<seg id="1416">"" "" "" "on day 4, systemic exposure, measured as a valley mirror, was comparable with both formulations in both niery- and liver transplants." "" "" ""</seg>
<seg id="1417">Careful and repeated checks of the tacrolimus level are recommended during the first two weeks after transplantation under advagraf to ensure proper substance exposure in the immediate aftercare phase.</seg>
<seg id="1418">"" "" "" "since tacrolimus is a substance with low Clearance, an adjustment of the advagraf dose can take several days until the Steady State is reached." "" "" ""</seg>
<seg id="1419">"" "" "" "if the condition of the patient does not allow oral treatment in the first postoperative period, the Tacrolimus treatment can be administered intravenously (Prograf 5 mg / ml concentrate) with a dose of ca." "" "" ""</seg>
<seg id="1420">"" "" "" "duration of the application To suppress the graft rejection, immunosuppression must be maintained; consequently, a maximum duration of oral therapy cannot be indicated." "" "" ""</seg>
<seg id="1421">Dosage recommendations - kidney transplant prophylaxis of transplantation The oral advagraf therapy should start at 0.20 - 0.30 mg / kg / day as daily dosage in the morning.</seg>
<seg id="1422">"" "" "" "further dosage adjustments can be required later, as the pharmacokinetics of tacrolimus can change after transplantation." "" "" ""</seg>
<seg id="1423">Dosage recommendations - liver transplant prophylaxis of transplantation The oral advagraf therapy should start at 0.10 - 0.20 mg / kg / day as daily dosage in the morning.</seg>
<seg id="1424">Dosage recommendation - conversion from prograf to advagraf must be converted by a transplant recipient of twice daily dose of prograf capsules to a once daily intake of advagraf. this changeover in relation to 1: 1 (mg: mg) has to take place in relation to the entire daily dose.</seg>
<seg id="1425">Kidney and liver transplantation After a changeover from other immunosuppressants to advagraf once daily the treatment with the oral initial dose recommended in kidney and liver transplant must begin with the prophylaxis of graft rejection.</seg>
<seg id="1426">"" "" "" "heart transplant in adult patients, which are converted to advagraf, is an oral initial dose of 0.15 mg / kg / day to be taken once daily in the morning." "" "" ""</seg>
<seg id="1427">Other transplant recipients showed no clinical experience with advagraf in lung and pancreatic and colon cancer patients in an oral initial dose of 0.2 mg / kg / day and in an oral initial dose of 0.3 mg / kg / day.</seg>
<seg id="1428">Dosage adjustments in special patient groups patients with reduced liver function to maintain blood flow in the targeted area may be required in patients with severe liver dysfunctions a reduction of the dose.</seg>
<seg id="1429">"" "" "" "patients with reduced kidney function, as the renal function does not affect the pharmacokinetics of tacrolimus, can be assumed that a dose adjustment is not necessary." "" "" ""</seg>
<seg id="1430">"" "" "" "however, due to the nephrotoxic potential of tacrolimus, careful monitoring of the renal function (including regular determination of serum levels), a calculation of the inininaris and a monitoring of the urinary volume is recommended." "" "" ""</seg>
<seg id="1431">Changeover from Ciclosporin to Advagraf When switching from a Ciclosporto to a tacrolimus-based therapy caution is advisable (see Sections 4.4 and 4.5).</seg>
<seg id="1432">"" "" "" "in the first instance, the dose should be based on the clinical evaluation of rejection and tolerability in individual cases under the help of thoroughbred tacrolimus level controls." "" "" ""</seg>
<seg id="1433">"" "" "" "it is recommended to perform common checks of tacrolimus level levels during the first two weeks after transplantation, followed by periodic inspections during maintenance therapy." "" "" ""</seg>
<seg id="1434">"" "" "" "blood-sebum of tacrolimus should also be controlled after switching from prograf to advagraf, dose adaptation, changes in immunosuppressive therapy or while using substances that could change the tacrolimus whole blood concentration (see Section 4.5)." "" "" ""</seg>
<seg id="1435">"" "" "" "as advagraf is a medicine with a low Clearance, adjustments to the dose may require several days until the Steady State has entered." "" "" ""</seg>
<seg id="1436">"" "" "" "the data in clinical trials suggest that successful treatment is possible in most cases, if the level of the level in the blood is 20 ng / ml." "" "" ""</seg>
<seg id="1437">"" "" "" "in clinical practice, the level of tacrolimus in full blood in the first time after liver transplantation is usually in the range of 5 - 20 ng / ml and in transplanted and heart transplanted patients at 10 - 20 ng / ml." "" "" ""</seg>
<seg id="1438">"" "" "" "during the subsequent maintenance therapy of liver, kidney and heart transplants, blood concentrations in the range of 5 - 15 ng / ml were generally used." "" "" ""</seg>
<seg id="1439">"" "" "" "this has led to serious adverse events including graft rejection or other side effects, which can occur in a sequence of tacrolimus under- or overexposure." "" "" ""</seg>
<seg id="1440">Patients should always maintain the same tacrolimus formulation and the appropriate daily dosage; changes of the formulation or the regime should only be carried out under close-meshed control of an experienced physician (see Sections 4.2 and 4.8).</seg>
<seg id="1441">"" "" "" "5 For the treatment of adult patients with graft rejection, which proved to be more effective against other immunosuppressants, no clinical data is available for the retarded formulation advagraf." "" "" ""</seg>
<seg id="1442">"" "" "" "for prophylaxis of graft rejection in adult cardiac transplant receivers and transplant receivers in childhood, no clinical data is available for the retarded formulation advagraf." "" "" ""</seg>
<seg id="1443">"" "" "" "because of possible interactions that may lead to a reduction of the tacrolimus level in the blood and a weakening of the clinical effect of tacrolimus, taking herbal supplements (Hypericum perforatum) is to avoid other plant remedies during treatment with advagraf (see Section 4.5)." "" "" ""</seg>
<seg id="1444">"" "" "" "in patients with diarrhoea, a particularly careful observation of the Tacrolimus concentration in the blood is required, since the Tacrolimus blood mirrors can be subject to considerable fluctuations in such circumstances." "" "" ""</seg>
<seg id="1445">"" "" "" "in rare cases, a detectable chamber or septum hypertrophy was observed under Prograf, which can therefore also occur under advagraf." "" "" ""</seg>
<seg id="1446">"" "" "" "other factors that increase the risk of such clinical disorders include an already existing heart disease, a treatment with corticosteroids, high blood pressure, kidney or liver dysfunctions, infections, fluid overload and oil." "" "" ""</seg>
<seg id="1447">"" "" "" "as with other immunosuppressants, exposure to sunlight or UV light should be limited due to the potential risk of malignant skin lesions due to suitable clothing or use of sun protection using a high protection factor." "" "" ""</seg>
<seg id="1448">"" "" "" "if patients who take tacrolimus, symptoms for PRES like headaches, altered states of consciousness, convulsions and vision disturbances should show a radiological examination (e.g.." "" "" ""</seg>
<seg id="1449">"" "" "" "da advagraf hard capsules, retarded, lactose-free, is especially recommended in patients with rare hereditary galactose intolerance, lactase deficiency or glucose levels." "" "" ""</seg>
<seg id="1450">"" "" "" "the simultaneous use of medicines or herbal medicines known as inhibitors or inductors of CYP3A4 can influence the metabolism of tacrolimus, and thus increase or decrease the blood values of tacrolimus." "" "" ""</seg>
<seg id="1451">"" "" "" "therefore, it is recommended to monitor the Tacrolimus blood level at the same time offering substances that can change the CYP3A's metabolism and adjust the Tacrolimus dose to maintain uniform concentrations (see Sections 4.2 and 4.4)." "" "" ""</seg>
<seg id="1452">"" "" "" "a strongly pronounced interaction has been achieved with antimycotics like ketconazole, fluid conazole, itraconazole and Voriconazole as well as with the Macroeyelid antibiotic erythromycin and HIV-Protease Inhibitors (z)." "" "" ""</seg>
<seg id="1453">"" "" "" "pharmacokinetic studies revealed that the rise in blood levels was mainly due to the increased oral bioavailability of tacrolimus, due to the inhibition of gastrointestinal contamination." "" "" ""</seg>
<seg id="1454">"" "" "" "highly dosed prednisolone or methylprednisolone, as it is used in acute rejection reactions, can increase or decrease the concentration of tacrolimus in the blood." "" "" ""</seg>
<seg id="1455">The effect of tacrolimus on the metabolism of other drugs tacrolimus is known as CYP3A4 inhibitor; therefore the simultaneous application of tacrolimus with medicines that are metabolized by CYP3A4 can affect their metabolism.</seg>
<seg id="1456">"" "" "" "since tacrolimus slows down the clearing of steroid contraceptives, so that hormonal exposure can increase particularly cautiously in decisions about contractive measures." "" "" ""</seg>
<seg id="1457">The results of animal experiments have shown that tacrolimus potentially reduce the clearing of pentobarbital and phenazone and their half-life can prolong.</seg>
<seg id="1458">The results of a low number of examinations in transplant patients provide no indication that in comparison to other immunosuppressants an increased risk of undesirable events with regard to the course and outcome of the pregnancy is made.</seg>
<seg id="1459">"" "" "" "in utero exposure, it is advisable to monitor the newborn on any harmful effects of tacrolimus (especially regarding its effect on the kidneys)." "" "" ""</seg>
<seg id="1460">"" "" "" "there is the risk of premature birth (&lt; week 37) and hyperinflation of the newborn (incidence 8 of 111 newborns, i.e.:" "" "" ""</seg>
<seg id="1461">The side effect profile of immunosuppressants is often not determined precisely because of the patient's disease and simultaneous treatment with a multitude of other medicines.</seg>
<seg id="1462">"" "" "" "(≥ 1 / 10, ≤ 1 / 10), rare (≥ 1 / 1000, ≤ 1 / 10), very rare (≥ 1 / 10, ≤ 1 / 10), very rare (≥ 1 / 10), not known (frequency based on available data is not estimated)." "" "" ""</seg>
<seg id="1463">"" "" "" "ischemic interference of the heart cranial vessels, tachycardia's chamber arrhythmia, heart failure, heart disease, supraventricular arrhythmias, palpitatio, anomalies in ECG, abnormal heart and pulse frequency" "" "" ""</seg>
<seg id="1464">"" "" "" "diarrhea, nausea, gastrointestinal inflammation, gastrointestinal ulcer and perforation, bleeding, pain in the gastrointestinal area and abdomen, dyspeptic signs and symptoms, obstipation, flatulence, signs and symptoms in the gastrointestinal area" "" "" ""</seg>
<seg id="1465">"" "" "" "infections and parasitic diseases as well as other highly effective immunosuppressants are often elevated in patients with tacrolimus, the susceptibility to infections (viral, bacterial, mycotic, protozoa)." "" "" ""</seg>
<seg id="1466">Cases of Nephropathy and JC-Virus-associated progressive multifocal Leukoencephalopathy (PML) were reported in patients with immunosuppression therapy including therapy with advagraf.</seg>
<seg id="1467">Benign or malignant neoplasms including EBV- associated lymphoproliferative diseases and skin tumours in conjunction with tacrolimus were reported.</seg>
<seg id="1468">"" "" "" "due to its high molecular weight, its low water solubility and the high binding of erythrocytes and plasma proteins, Tacrolimus is not dialysifiable." "" "" ""</seg>
<seg id="1469">Action mechanisms and pharmacoco-dynamic effects on the molecular level are likely to mediate the effects of tacrolimus by its binding to a cytosolean protein (FKBP12) which is responsible for the enrichment of the connection in the cellular nucleus.</seg>
<seg id="1470">"" "" "" "this leads to calciumdependent inhibiting of signal transductions in the T cell, thereby preventing transcription of a certain number of lymphokin genes." "" "" ""</seg>
<seg id="1471">"" "" "" "tacrolimus inhibits the activation of the T cells and the proliferation of the T cells, the formation of lymphokines (like interleukin-2, interleukin-3 and g-interferon) and the expression of the interleukin 2 receptor." "" "" ""</seg>
<seg id="1472">12 confirmed acute impact was 32.6% within the first 24 weeks in the Advagraf Group (N = 237) and in the Prograf Group (N = 234) 29.3%.</seg>
<seg id="1473">Patients "survival rates after 12 months were 89.2% for advagraf and 90.8% for Prograf; 25 (14 women and 11 men) and in Prograf arm 24 (5 women and 19 men) deaths.</seg>
<seg id="1474">"" "" "" "kidney transplantation The efficacy and safety of advagraf and prograf was compared in combination with mycophenolatmofetil (MMF) and corticosteroids, in 667 de novo kidney transplant receivers." "" "" ""</seg>
<seg id="1475">"" "" "" "patients survival rates after 12 months were 96.9% for advagraf and 97.5% for Prograf; in the Advagraf arm, 10 (3 women, 7 men) and in Prograf arm 8 (3 women, 5 men) deaths." "" "" ""</seg>
<seg id="1476">"" "" "" "the efficacy and safety of Prograf, Ciclosporin and Advagraf was compared in combination with Basiliximab antibody production, MMF and corticosteroids, in 638 de novo kidney transplant receivers." "" "" ""</seg>
<seg id="1477">Incidence of treatment failure after 12 months (defined as death, loss of transplantion or missing follow-up data) was 14.0% in the Advagraf Group (N = 212) and 17.0% in the group (N = 212).</seg>
<seg id="1478">The treatment difference was -3.0% (Advagraph Ciclosporin) (95.2%) for advagraf vs Ciclosporin and -1.9% (Prograf Ciclosporin) (95.2%) for Prograf vs Ciclosporin.</seg>
<seg id="1479">"" "" "" "in the Advagraf arm 3 (men), in Prograf arm 10 (3 women, 7 men) and in the Ciclosporin arm 6 (3 women, 3 men) deaths." "" "" ""</seg>
<seg id="1480">Published results of primary immunosuppression with tacrolimus in the form of twice daily applied Prograf capsules after other primary organ transplants Prograf has developed into a recognised primary immunosuppressor to pancreas, lung and intestinal transplants.</seg>
<seg id="1481">"" "" "" "175 treatment-transplanted patients, with 475 patients undergoing pancreatic transplantation and in 630 cases after an intestinal transplant, were used as primary immunosuppressive." "" "" ""</seg>
<seg id="1482">"" "" "" "overall, the safety profile of oral Prograf was consistent in these published studies in the large studies in which Prograf was used for primary immunosuppression in liver, kidney and heart transplant." "" "" ""</seg>
<seg id="1483">"" "" "" "lung transplantation In an interim analysis over a recently conducted, multi-center study with oral Prograf was reported over 110 patients receiving either tacrolimus or Ciclosporin within 1: 1 randomisation." "" "" ""</seg>
<seg id="1484">"" "" "" "chronic graft rejection, bronchiolitis obliteral syndrome, was observed in the first year after transplantation (2.86% versus 8.57%)." "" "" ""</seg>
<seg id="1485">"" "" "" "the survival rate after one year was 80,8% in the Tacroldrone and 83% in the Ciclosporin group (Treaties et al., 3rd ICI San Diego, USA, 2004; abstract 22)." "" "" ""</seg>
<seg id="1486">"" "" "" "in patients treated with tacrolimus, the incidence of bronchiolitis increased in 21.7% compared to 38.0% under Ciclosporin (p = 0,025)." "" "" ""</seg>
<seg id="1487">The number of cases in which Ciclosporin had to be converted to tacrolimus (n = 0.02) was significantly larger (p = 0.02) than the number of patients who were converted from tacrolimus to Ciclosporin (n = 2) (Keenan et al.; Ann Thoracic Surg 1995; 60: 580).</seg>
<seg id="1488">The number of cases in which there was no acute transplant rejection was higher after 6 months (57.7% versus 45.8%) and after 1 year (50% versus 33.3%) in the treatment-transplanted patients of the Tacrolimus group (Trethy et al.; J Heart Lung Transplant 2001; 20: 511).</seg>
<seg id="1489">"" "" "" "in one study, the incidence of bronchiolitis was significantly lower in patients treated with tacrolimus." "" "" ""</seg>
<seg id="1490">"" "" "" "pancreatic transplantation A multi-center study conducted with oral Prograf has been conducted to 205 patients who simultaneously received pancreatic and kidney transplant, following a randomised tacrolimus (n = 103) or Ciclosporin (n = 102)." "" "" ""</seg>
<seg id="1491">The oral initial dose (per minutes) of tacrolimus was 0.2 mg / kg / day and was then used to achieve the desired level of sebum from 8 to 15 ng / ml on 5.</seg>
<seg id="1492">"" "" "" "in 155 patients (65 only intestine, 75 liver and intestines and 25 multivisceral transplantations), a current survival rate of 75% after 1 year, 5% after 5 years and 42% after 10 years." "" "" ""</seg>
<seg id="1493">"" "" "" "methods for early detection of Epstein-Barr (EBV) - and CMV infections, bone marlargement, additional administration of interleukin 2 antagonists Daclizumab, late graft radiation (Abu-Elmagd et al., Ann Surg 2001; 234: 404)." "" "" ""</seg>
<seg id="1494">Factors such as low haematocrit and low protein concentrations that lead to an increase in the unbound group of Tacrolimus or a strengthening of the metabolism caused by treatment with corticosteroids should be responsible for the higher clearing rates observed after transplantation.</seg>
<seg id="1495">"" "" "" "this suggests that tacrolimus is almost completely metabolized before excretion, whereby the excretion mainly occurs via bile." "" "" ""</seg>
<seg id="1496">The systemic exposure of Tacrolimus (AUC0-24) at Advagraf was approximately 10% lower than under Prograf.</seg>
<seg id="1497">"" "" "" "it is recommended to perform common checks of tacrolimus level levels during the first two weeks after transplantation, followed by periodic inspections during maintenance therapy." "" "" ""</seg>
<seg id="1498">"" "" "" "21 To treat adult patients with graft rejection, which proved to be more effective against other immunosuppressants, no clinical data is available for the retarded formulation advagraf." "" "" ""</seg>
<seg id="1499">"" "" "" "other factors that increase the risk of such clinical disorders include an already existing heart disease, a treatment with corticosteroids, high blood pressure, kidney or liver dysfunctions, infections, fluid overload and oil." "" "" ""</seg>
<seg id="1500">28 confirmed acute cancellations occurred within the first 24 weeks in the Advagraf Group (N = 237) 32.6% and in the Prograf Group (N = 234) 29.3%.</seg>
<seg id="1501">"" "" "" "the efficacy and safety of Prograf, Ciclosporin and Advagraf was compared in combination with Basiliximab antibody production, MMF and corticosteroids, in 638 de novo kidney transplant receivers." "" "" ""</seg>
<seg id="1502">"" "" "" "hard capsules, retarded greyish red-orange gelatine capsules, printed in red ink on the bright red capsule top with" "" "" "" "687" "" "" "", "they contain white powder." "" "" ""</seg>
<seg id="1503">"" "" "" "it is recommended to perform common checks of tacrolimus level levels during the first two weeks after transplantation, followed by periodic inspections during maintenance therapy." "" "" ""</seg>
<seg id="1504">"" "" "" "37 For the treatment of adult patients with graft rejection, which proved to be more effective against other immunosuppressants, no clinical data is available for the retarded formulation advagraf." "" "" ""</seg>
<seg id="1505">"" "" "" "other factors that increase the risk of such clinical disorders include an already existing heart disease, a treatment with corticosteroids, high blood pressure, kidney or liver dysfunctions, infections, fluid overload and oil." "" "" ""</seg>
<seg id="1506">44 confirmed acute cancellations occurred within the first 24 weeks in the Advagraf Group (N = 237) 32.6% and in the Prograf Group (N = 234) 29.3%.</seg>
<seg id="1507">"" "" "" "the efficacy and safety of Prograf, Ciclosporin and Advagraf was compared in combination with Basiliximab antibody production, MMF and corticosteroids, in 638 de novo kidney transplant receivers." "" "" ""</seg>
<seg id="1508">"" "" "" "in total 34 patients of Ciclosporin were converted to Tacrolimus, while only 6 Tacrolimus patients required a different therapy (Bechstein et al., Transplantation 2004; 77: 1221)." "" "" ""</seg>
<seg id="1509">"" "" "" "in 155 patients (65 only intestine, 75 liver and intestines and 25 multivisceral transplantations), a current survival rate of 75% after 1 year, 5% after 5 years and 42% after 10 years." "" "" ""</seg>
<seg id="1510">"" "" "" "this suggests that tacrolimus is almost completely metabolized before excretion, whereby the excretion mainly occurs via bile." "" "" ""</seg>
<seg id="1511">"" "" "" "risk management Plan The holder of approval for the application is obliged to carry out the studies and additional pharmaceutical vigilance activities described in version 3.2 of the Risk Management Plan (RMP), as well as all other updates of the RMP which are approved by the CHMP." "" "" ""</seg>
<seg id="1512">"" "" "" "according to the CHMP guideline on the risk management systems for drug use, the updated RMP must be submitted simultaneously with the next periodic safety report (Periodic Safety Update Report, PSUR)." "" "" ""</seg>
<seg id="1513">"" "" "" "you might also get advagraf to treat your liver, kidney or heart transplants or other transplanted organ or because the immune response of your body could not be ruled by a preceding treatment." "" "" ""</seg>
<seg id="1514">"" "" "" "when taking Advagraf with other medicines, please tell your doctor or pharmacist if you take other medicines or have recently taken, even if it is not prescription medicine or remedy of herbal origin." "" "" ""</seg>
<seg id="1515">"" "" "" "Amiloride, Triamteren or Spironolacton), certain pain killers (so-called non steroidal anti-phlogistica such as ibuprofen), anticoagulants or medicines used to treat diabetes mellitus." "" "" ""</seg>
<seg id="1516">"" "" "" "pregnancy and breastfeeding If a pregnancy is planned or already exists, consult your doctor or pharmacist before taking any medicines." "" "" ""</seg>
<seg id="1517">Traffic tightness and operation of machines you may not sit on the wheel of a vehicle or use tools or machines if you feel dizzy or drowsy after taking Advagraf or blurry.</seg>
<seg id="1518">"" "" "" "important information on certain other constituent parts of Advagraf Please contact your doctor only after consultation with your doctor, if you know that you suffer from an intolerance to certain sugars." "" "" ""</seg>
<seg id="1519">"" "" "" "make sure you get the same tacrolimus medication if you redeem your prescription, unless your specialist has expressly agreed to change the Tacrolimus remedy." "" "" ""</seg>
<seg id="1520">"" "" "" "if you receive a medicine whose appearance is altered from the usual deviance or the dosage instructions, please contact your doctor or pharmacist as soon as possible." "" "" ""</seg>
<seg id="1521">"" "" "" "so that your doctor can determine the correct dose and adjust time to time, he has to perform regular blood tests." "" "" ""</seg>
<seg id="1522">"" "" "" "if you have taken a larger quantity of advagraf as you should have accidentally taken a larger amount of advagraf, seek immediately your doctor or the emergency department of the nearest hospital." "" "" ""</seg>
<seg id="1523">"" "" "" "if you have forgotten the intake of Advagraf, if you forgot to take the capsules, please get it the same day at the earliest possible time." "" "" ""</seg>
<seg id="1524">"" "" "" "if you stop taking Advagraf at the end of the treatment with advagraf, the risk of rejection of your transplant can increase." "" "" ""</seg>
<seg id="1525">"" "" "" "advagraf 0,5 mg of hard capsules, retarded, are hard gelatine capsules whose pale yellow top is printed with" "" "" "" "647" "" "" "" "and whose orange bottom is filled with white powder." "" "" ""</seg>
<seg id="1526">"" "" "" "advagraf 1 mg of hard capsules, retarded, are hard gelatine capsules, whose white top is printed with" "" "" "" "677" "" "" "" "with white powder." "" "" ""</seg>
<seg id="1527">"" "" "" "advagraf 5 mg of hard capsules, retarded, are hard gelatine capsules, whose grunchy upper part is printed with" "" "" "" "687" "" "" "". "" "" "" ""</seg>
<seg id="1528">România Astellas Pharma Internahn ional Detalii de contact pentru România Schooleaua Bucureş ti-Ploieş ti-Ploieş ti Tel: + 40 (0) 21 361 0495</seg>
<seg id="1529">Slovenská republika Astellas Pharma s.r.o. and organizač ná zložka Galvániho 15 / C SK- 821 04 Bratislava 2 Tel: + 421 2 4444 2157</seg>
<seg id="1530">"" "" "" "advance is used to treat and prevent hemorrhages in patients with hemophilia A (a congenital blood coagulation disorder caused by the lack of factor VIII)." "" "" ""</seg>
<seg id="1531">"" "" "" "the dosage and frequency of the application will depend on whether lawyers are used to treat bleeding, or to prevent bleeding during surgical procedures." "" "" ""</seg>
<seg id="1532">"" "" "" "patients with hemophilia A suffer from a factor VIII deficiency, resulting in bleeding problems such as bleeding in joints, muscles, or internal organs." "" "" ""</seg>
<seg id="1533">"" "" "" "Octocog alfa is not extracted from human plasma, but produced according to a method known as" recombinant DNA technology ":" "" "" ""</seg>
<seg id="1534">"" "" "" "it is produced by a cell in which a gene (DNA) is brought into, which empowers it to the formation of the human coagulation factor VIII." "" "" ""</seg>
<seg id="1535">"" "" "" "advance is similar to another in the European Union called Recombinate, but is made differently, so that the medicine does not contain any proteins or animal origin." "" "" ""</seg>
<seg id="1536">"" "" "" "in three additional studies of patients with severe to moderate hemophilia A, including a study of 53 children under six years, the use of the medicine for the prevention of bleeding and surgical procedures has been investigated." "" "" ""</seg>
<seg id="1537">"" "" "" "in the main study, the efficacy of advant in the prevention of bleeding in 86% of 510 new blood sepals was evaluated with" excellent "resp." good. "" "" "" ""</seg>
<seg id="1538">"" "" "" "the most common side effects of advance (observed in 1 to 10 of 100 patients) are dizziness, headache, pyrexia (fever) and the formation of antibodies against factor VIII." "" "" ""</seg>
<seg id="1539">"" "" "" "advance may not be used in patients who may be hypersensitive (allergic) to human coagulation factor VIII, mouse or hamster protein or one of the other ingredients." "" "" ""</seg>
<seg id="1540">"" "" "" "in March 2004, the European Commission granted the company Baxter AG a permit for the placing of lawyers throughout the European Union." "" "" ""</seg>
<seg id="1541">"" "" "" "dosage The dosage and duration of the substitution therapy depend on the severity of the factor VIII deficiency, according to the location and the extent of the bleeding and the clinical condition of the patient." "" "" ""</seg>
<seg id="1542">"" "" "" "in the following hemorrhagic events, the factor VIII activity should not fall below the specified plasma level (in% of the standard or I.U. / dl)." "" "" ""</seg>
<seg id="1543">"" "" "" "injection every 12-24 hours (8-24 hours in patients under 6 years) for 3-4 days or longer, until the pain and acute impairment are removed." "" "" ""</seg>
<seg id="1544">"" "" "" "repeat injections every 8-24 hours (6-12 hours in patients under 6 years), until the risk is over for the patient." "" "" ""</seg>
<seg id="1545">"" "" "" "during the treatment course, adequate provision of the factor VIII plasma is recommended for controlling the dose to be administered and the frequency of injections." "" "" ""</seg>
<seg id="1546">"" "" "" "individual patients may differ in their response to factor VIII, various in vivo recovery and exhibit different half-value times." "" "" ""</seg>
<seg id="1547">"" "" "" "3 prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A, doses between 20 and 40 I.U. of factor VIII per kg body weight should be given in the distance of 2-3 days." "" "" ""</seg>
<seg id="1548">"" "" "" "if the expected factor VIII plasma activity is not reached or if the bleeding is not ruled by adequate dose, a test must be performed to prove an inhibitor if necessary." "" "" ""</seg>
<seg id="1549">"" "" "" "in patients with high inhibitors, it is possible that the factor VIII therapy is not effective so that other therapeutic measures must be considered." "" "" ""</seg>
<seg id="1550">"" "" "" "the dosage speed should be directed after finding the patient, whereby a maximum injection rate of 10 ml / min should not be exceeded." "" "" ""</seg>
<seg id="1551">The formation of neutralizing antibodies (inhibitors) against factor VIII is a well-known complication in the treatment of patients with hemophilia A.</seg>
<seg id="1552">These inhibitors are always against the prooagulatory activity of factor VIII-orientated IgG immunoglobulins that are quantified in Bethesda units (B.E.) per ml plasma by means of modified Bethesda Assay.</seg>
<seg id="1553">"" "" "" "the risk of developing inhibitors correlates with the extent of exposure to factor VIII, whereby the risk depends on the first 20 exposures and depends on genetic and other factors." "" "" ""</seg>
<seg id="1554">"" "" "" "in pre-treated patients (PTPs) with more than 100 position days and anamnesian well-known inhibitors, VIII-product was observed after switching from a recombinant factor VIII to inhibitors." "" "" ""</seg>
<seg id="1555">"" "" "" "due to the rare occurrence of hemophilia A in women, there is no experience regarding the application of factor VIII during pregnancy and lactation." "" "" ""</seg>
<seg id="1556">"" "" "" "the ADRs occurring in the largest number of patients were inhibitors against factor VIII (5 patients), which exhibit a higher risk for the formation of inhibitors (5 patients), fever and dizziness (3 patients)." "" "" ""</seg>
<seg id="1557">"" "" "" "≥ 1 / 100 to &lt; 1 / 10), rare (≥ 1 / 1000 to &lt; 1 / 1000), rare (≥ 1 / 1000 to &lt; 1 / 1000), rarely known (frequency based on available data is not estimated)." "" "" ""</seg>
<seg id="1558">A) The percentage of patients was calculated according to the sum of the individual patients (234). the unexpected decline of the blood coagulation factor VIII-Spike was observed in a patient using continuous ADVATE infusion (10 - 14 postoperative day).</seg>
<seg id="1559">"" "" "" "blood clotting was maintained throughout the time, and both the factor VIII- levels in the plasma and the Clearance rate showed sufficient values again on the 15th postoperative day." "" "" ""</seg>
<seg id="1560">In clinical trials involving ADVATE to 145 children and adults 2 with severe severe hemophilia A (FVIII ≤ 2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitortiter (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1561">"" "" "" "in addition, in none of 53 pediatric patients with an age of under 6 years and diagnosed severe to moderate haemophilia A (FVIII ≤ 2%), a FVIII inhibitor was detected after prior exposure to factor VIII- concentrates (≥ 50 days)." "" "" ""</seg>
<seg id="1562">"" "" "" "in previously untreated patients, 5 out of 25 (20%) treated with ADVATE treated inhibitors against factor VIII." "" "" ""</seg>
<seg id="1563">"" "" "" "the patient's immune response to the traces of contaminated proteins was analysed by investigating the antibody titers against these proteins, laboratory parameters and reported side effects." "" "" ""</seg>
<seg id="1564">"" "" "" "a patient showed both a statistically significant upward trend as well as a persistent peak of the antibody level against anti-CHO cell protein, but otherwise no signs or symptoms appeared that showed an allergic reaction or hypersensitivity." "" "" ""</seg>
<seg id="1565">"" "" "" "in four patients the incidence of urticaria, pruritus, skin rash and increased number of eosinophiles granulocytes was reported in several repeated product expositions within the study." "" "" ""</seg>
<seg id="1566">"" "" "" "7 As in other intravenous products, ADVATE was reported on hypersensitivity reactions of the allergic type, including anaphylactic / anaphylactic reactions (frequency not known)." "" "" ""</seg>
<seg id="1567">"" "" "" "the activated factor VIII acts as a co-factor for the activated factor IX, accelerating the formation of activated factor X by factor X." "" "" ""</seg>
<seg id="1568">All pharmacokinetic studies with ADVATE were performed in pre-treated patients with severe or moderate haemophilia A (base value of factor VIII-activity ≤ 2%).</seg>
<seg id="1569">The pharmacokinetic parameters come from a cross-over study with ADVATE in 100 previously treated patients alike or &gt; 10 years and are listed in Table 3 below.</seg>
<seg id="1570">Table 3 Summary of the pharmacokinetic parameters of ADVATE in 100 patients with severe to moderate haemophilia A (factor VIII &lt; 2%) PK parameters (Pharmacokinetics)</seg>
<seg id="1571">"" "" "" "non-clinical data, based on the studies on safety resharmacology, acute, repeatable and local toxicity, and genotoxicity, show no special risk for humans." "" "" ""</seg>
<seg id="1572">"" "" "" "each pack consists of a glass bottle containing powder, a glass bottle containing 5 ml solvents (both glass type I with chlorobutyl rubber stoppers) and a device for reconstitution (BAXJECT II)." "" "" ""</seg>
<seg id="1573">"" "" "" "if the product is still stored in the fridge, remove both conductive bottles with ADVATE powder and solvents from the fridge at room temperature (between 15 and 25 ° C)." "" "" ""</seg>
<seg id="1574">"" "" "" "a significant increase in pulse frequency can be decreased immediately by slow or temporary injunction of the injection (see Sections 4.4, 4.8)." "" "" ""</seg>
<seg id="1575">14 prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A doses between 20 and 40 I.U. of factor VIII per kg body weight should be given in the distance of 2-3 days.</seg>
<seg id="1576">"" "" "" "due to the rare occurrence of hemophilia A in women, there is no experience regarding the application of factor VIII during pregnancy and lactation." "" "" ""</seg>
<seg id="1577">"" "" "" "3 newborns (aged 0-1 month), infants (aged 1 month - 2 years), children (aged 2-12), adolescents (aged 12-16), adults (over 16 years old)" "" "" ""</seg>
<seg id="1578">In clinical trials involving ADVATE to 145 children and adults 4 with severe severe hemophilia A (FVIII ≤ 2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitortiter (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1579">"" "" "" "18 As in other intravenous products, ADVATE was reported on hypersensitivity reactions of the allergic type, including anaphylactic / anaphylactic reactions (frequency not known)." "" "" ""</seg>
<seg id="1580">Table 3 Summary of the pharmacokinetic parameters of ADVATE in 100 patients with severe to moderate haemophilia A (factor VIII &lt; 2%) PK parameters (Pharmacokinetics)</seg>
<seg id="1581">"" "" "" "non-clinical data, based on the studies on safety resharmacology, acute, repeatable and local toxicity, and genotoxicity, show no special risk for humans." "" "" ""</seg>
<seg id="1582">25 prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A doses between 20 and 40 I.U. of factor VIII per kg body weight should be given in the distance of 2-3 days.</seg>
<seg id="1583">"" "" "" "5 newborns (aged 0-1 month), infants (aged 1 month - 2 years), children (aged 2-12), adolescents (aged 12-16), adults (over 16 years old)" "" "" ""</seg>
<seg id="1584">In clinical trials involving ADVATE to 145 children and adults 6 with severe severe hemophilia A (FVIII ≤ 2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitortiter (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1585">"" "" "" "29 As in other intravenous products, ADVATE was reported on hypersensitivity reactions of the allergic type, including anaphylactic / anaphylactic reactions (frequency not known)." "" "" ""</seg>
<seg id="1586">"" "" "" "non-clinical data, based on the studies on safety resharmacology, acute, repeatable and local toxicity, and genotoxicity, show no special risk for humans." "" "" ""</seg>
<seg id="1587">36 prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A doses between 20 and 40 I.U. of factor VIII per kg body weight should be given in the distance of 2-3 days.</seg>
<seg id="1588">"" "" "" "7 newborns (aged 0-1 month), infants (aged 1 month - 2 years), children (aged 2-12), adolescents (aged 12-16), adults (over 16 years old)" "" "" ""</seg>
<seg id="1589">In clinical trials involving ADVATE to 145 children and adults 8 with severe severe hemophilia A (FVIII ≤ 2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitortiter (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1590">"" "" "" "40 As in other intravenous products, ADVATE was reported on hypersensitivity reactions from the allergic type, including anaphylactic / anaphylactic reactions (frequency not known)." "" "" ""</seg>
<seg id="1591">"" "" "" "non-clinical data, based on the studies on safety resharmacology, acute, repeatable and local toxicity, and genotoxicity, show no special risk for humans." "" "" ""</seg>
<seg id="1592">47 Prophylaxis for long-term prophylaxis of bleeding in patients with severe hemophilia A should be given doses between 20 and 40 I.U. of factor VIII per kg body weight at intervals of 2-3 days.</seg>
<seg id="1593">"" "" "" "9 newborns (aged 0-1 month), infants (aged 1 month - 2 years), children (aged 2-12), adolescents (aged 12-16), adults (over 16 years old)" "" "" ""</seg>
<seg id="1594">In clinical trials involving ADVATE to 145 children and adults 10 with severe severe hemophilia A (FVIII ≤ 2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitortiter (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1595">"" "" "" "51 As in other intravenous products, ADVATE was reported on hypersensitivity reactions from the allergic type, including anaphylactic / anaphylactic reactions (frequency not known)." "" "" ""</seg>
<seg id="1596">"" "" "" "non-clinical data, based on the studies on safety resharmacology, acute, repeatable and local toxicity, and genotoxicity, show no special risk for humans." "" "" ""</seg>
<seg id="1597">"" "" "" "58 prophylaxis For long-term prophylaxis of bleeding in patients with severe hemophilia A, doses between 20 and 40 I.U. of factor VIII per kg body weight should be given in the distance of 2-3 days." "" "" ""</seg>
<seg id="1598">"" "" "" "11 newborns (aged 0-1 month), infants (aged 1 month - 2 years), children (aged 2-12), adolescents (aged 12-16), adults (over 16 years old)" "" "" ""</seg>
<seg id="1599">In clinical trials involving ADVATE to 145 children and adults 12 with severe severe hemophilia A (FVIII ≤ 2%) and previous exposure to factor VIII- concentrates (≥ 150 days) only one patient showed a low inhibitortiter (2.4 B.E. in the modified Bethesda approach).</seg>
<seg id="1600">"" "" "" "62 As in other intravenous products, ADVATE was reported on hypersensitivity reactions of the allergic type, including anaphylactic / anaphylactic reactions (frequency not known)." "" "" ""</seg>
<seg id="1601">"" "" "" "non-clinical data, based on the studies on safety resharmacology, acute, repeatable and local toxicity, and genotoxicity, show no special risk for humans." "" "" ""</seg>
<seg id="1602">"" "" "" "the authorisation holder has to ensure that a pharmaceutical vigilance system, as described in section 1.1 of the chapter 1.8.1 of the drug approval, has been established and that this system remains in force throughout the period in which the product is located on the market." "" "" ""</seg>
<seg id="1603">"" "" "" "as defined in the CHMP directive on the risk management plan for human medicines, these updates are to be submitted simultaneously with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="1604">"" "" "" "• If new information is available, the influence on the valid safety instructions, the pharmaceutical vigilance plan or the risk-minimization measures could have occurred within 60 days of an important event (regarding pharma vigilance or with regard to risk minimization)" "" "" ""</seg>
<seg id="1605">"" "" "" "1 glass bottle with ADVATE 500 I.e Octocog alfa, 1 glass bottle with 5 ml sterilized water for injection purposes, 1 BAXJECT II medical device." "" "" ""</seg>
<seg id="1606">"" "" "" "1 glass bottle with ADVATE 1000 i.e Octocog alfa, 1 glass bottle with 5 ml sterilized water for injection purposes, 1 BAXJECT II medical device" "" "" ""</seg>
<seg id="1607">"" "" "" "special caution when using ADVATE is necessary to inform your doctor if you have recently been treated with factor VIII products, especially if you have developed inhibitors." "" "" ""</seg>
<seg id="1608">"" "" "" "these symptoms can represent early signs of an anaphylactic shock, which can include the following symptoms: extreme dizziness, loss of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1609">"" "" "" "if you use other medicines, please tell your doctor if you take other medicines or have recently taken, even if it is not prescription." "" "" ""</seg>
<seg id="1610">Your doctor will calculate your dose ADVATE (in international units or I.U.) depending on your physical condition and your body weight and whether it is used to prevent or treat bleeding.</seg>
<seg id="1611">"" "" "" "patients who develop factor VIII inhibitors If the expected factor VIII mirrors cannot be achieved in your plasma with ADVATE or the bleeding cannot be controlled, this could occur in the development of factor VIII-" "" "" ""</seg>
<seg id="1612">"" "" "" "in conjunction with surgery catheter infections, lower number of red blood cells, swelling of limbs and joints, prolonged bleeding after removal of drainage, decreased factor VIII mirror and postoperative hematoma." "" "" ""</seg>
<seg id="1613">"" "" "" "rare adverse effects due to the introduction of the drug on the market were isolated, reported by serious and potentially life-threatening reactions (anaphylactic) and other allergic reactions (see above)." "" "" ""</seg>
<seg id="1614">"" "" "" "tell your doctor if any of the side effects listed are significantly impaired or if you notice side effects, which are not listed in this package." "" "" ""</seg>
<seg id="1615">Portugal Baxter Médico Farmacêutica Lda Sintra Business Park Zona Industrial da Abrunheira; Edifício 10 P-2710-089 Sintra Tel: + 351 21 925 25 00</seg>
<seg id="1616">"" "" "" "use BAXJECT II if its sterile barrier is broken, its packaging is damaged or signs of manipulation, as shown in the symbol" "" "" ""</seg>
<seg id="1617">Important note: • Do not administer yourself before receiving the special training from your doctor or nurse. • Check the product on suspended particles or discoloration.</seg>
<seg id="1618">"" "" "" "the solution should slowly be administered with an infusion speed, which is available to the patient and does not exceed 10 ml per minute." "" "" ""</seg>
<seg id="1619">"" "" "" "106 In case of bleeding, the factor VIII-level should not fall under the given plasma activity level (in% or I.U. / ml) within the corresponding period." "" "" ""</seg>
<seg id="1620">"" "" "" "these symptoms can represent early signs of an anaphylactic shock, which can include the following symptoms: extreme dizziness, loss of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1621">"" "" "" "patients who develop factor VIII inhibitors If the expected factor VIII mirrors cannot be achieved in your plasma with ADVATE or the bleeding cannot be controlled, this could occur in the development of factor VIII-" "" "" ""</seg>
<seg id="1622">"" "" "" "occasional side effects itching, increased sweating, unusual taste sensation, heat flushes, diarrhea, diarrhea, diarrhoea, diarrhoea, inflammations, skin rashes, extreme sweating," "" "" ""</seg>
<seg id="1623">"" "" "" "116 In case of bleeding, the factor VIII-level should not fall under the given plasma activity level (in% or I.U. / ml) within the corresponding period." "" "" ""</seg>
<seg id="1624">"" "" "" "these symptoms can represent early signs of an anaphylactic shock, which can include the following symptoms: extreme dizziness, loss of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1625">"" "" "" "patients who develop factor VIII inhibitors If the expected factor VIII mirrors cannot be achieved in your plasma with ADVATE or the bleeding cannot be controlled, this could occur in the development of factor VIII-" "" "" ""</seg>
<seg id="1626">"" "" "" "126 In case of bleeding, the factor VIII-level should not fall under the given plasma activity level (in% or I.U. / ml) within the corresponding period." "" "" ""</seg>
<seg id="1627">"" "" "" "these symptoms can represent early signs of an anaphylactic shock, which can include the following symptoms: extreme dizziness, loss of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1628">"" "" "" "patients who develop factor VIII inhibitors If the expected factor VIII mirrors cannot be achieved in your plasma with ADVATE or the bleeding cannot be controlled, this could occur in the development of factor VIII-" "" "" ""</seg>
<seg id="1629">"" "" "" "136 In case of bleeding, the factor VIII-level should not fall under the given plasma activity level (in% or I.U. / ml) within the corresponding period." "" "" ""</seg>
<seg id="1630">"" "" "" "these symptoms can represent early signs of an anaphylactic shock, which can include the following symptoms: extreme dizziness, loss of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1631">"" "" "" "patients who develop factor VIII inhibitors If the expected factor VIII mirrors cannot be achieved in your plasma with ADVATE or the bleeding cannot be controlled, this could occur in the development of factor VIII-" "" "" ""</seg>
<seg id="1632">"" "" "" "146 In case of bleeding, the factor VIII-mirror should not fall under the given plasma activity level (in% or I.U. / ml) within the corresponding period." "" "" ""</seg>
<seg id="1633">"" "" "" "these symptoms can represent early signs of an anaphylactic shock, which can include the following symptoms: extreme dizziness, loss of consciousness and extreme breathing difficulties." "" "" ""</seg>
<seg id="1634">"" "" "" "patients who develop factor VIII inhibitors If the expected factor VIII mirrors cannot be achieved in your plasma with ADVATE or the bleeding cannot be controlled, this could occur in the development of factor VIII-" "" "" ""</seg>
<seg id="1635">"" "" "" "occasional side effects itching, increased sweating, unusual taste sensation, heat flushes, diarrhea, diarrhea, diarrhoea, diarrhoea, inflammations, skin rashes, extreme sweating," "" "" ""</seg>
<seg id="1636">"" "" "" "rare adverse effects due to the introduction of the drug on the market were isolated, reported by serious and potentially life-threatening reactions (anaphylactic) and other allergic reactions (see above)." "" "" ""</seg>
<seg id="1637">"" "" "" "156 In case of bleeding, the factor VIII-level should not fall under the given plasma activity level (in% or I.U. / ml) within the corresponding period." "" "" ""</seg>
<seg id="1638">"" "" "" "based on the data available since initial approval, CHMP has further evaluated the benefits risk weighing as positive, but considering that the safety profile must be closely monitored for the following reasons:" "" "" ""</seg>
<seg id="1639">"" "" "" "therefore CHMP has decided on the ADVATE security profile, which necessitates filing of PSURs every 6 months, and decided that the registrant will apply for another extension procedure in 5 years." "" "" ""</seg>
<seg id="1640">"" "" "" "in December 2008, Gendux Molecular Limited granted the Medicinal Medicinal Products Committee (CHMP) to withdraw its application for approval of Advance for the treatment of Li-Fraumeni cancer." "" "" ""</seg>
<seg id="1641">"" "" "" "normally, however, the breast, the brain, the bones or the soft tissue (tissue that connects other structures in the body, surrounds and supports) is affected." "" "" ""</seg>
<seg id="1642">"" "" "" "this is a kind of virus that has been genetically modified, that it can carry a gene into the cells of the body." "" "" ""</seg>
<seg id="1643">"" "" "" "the virus in Advance is a" adenovirus, "which has been modified so that there are no copies of itself and thus no infection can be triggered in humans." "" "" ""</seg>
<seg id="1644">"" "" "" "advexin should have been injected directly into the tumors, thus enabling the cancer cells to re-form the normal p53 protein." "" "" ""</seg>
<seg id="1645">"" "" "" "the p53 protein formed by the p53 gene which is not defective in the human body, normally contributes to the restoration of damaged DNA and to kill the cells if the DNA cannot be recovered." "" "" ""</seg>
<seg id="1646">"" "" "" "with Li-Fraumeni cancer, where the p53 gene is defective, the p53 protein is not working properly, and the cancer cells can grow further and divide." "" "" ""</seg>
<seg id="1647">"" "" "" "the company presented data from a study with a patient, with Li-Fraumeni cancer in the area of the sub-building, in the bones and in the brain." "" "" ""</seg>
<seg id="1648">"" "" "" "after the CHMP tested the company's answers to the questions asked, some questions were still unclear." "" "" ""</seg>
<seg id="1649">"" "" "" "based on the examination of the documents submitted, the CHMP will create a list of questions sent to the company by day 120." "" "" ""</seg>
<seg id="1650">"" "" "" "according to the CHMP opinion, the injections of Advexin in Li-Fraumeni tumours have demonstrated benefits for patients." "" "" ""</seg>
<seg id="1651">"" "" "" "the committee also had concerns about the treatment of the medicine in the body, the type of administration and the safety of the medicine." "" "" ""</seg>
<seg id="1652">"" "" "" "furthermore, the company had not sufficiently demonstrated that advexin can be produced in a reliable manner and that it is neither harmful to the environment nor for people who come in close contact with the patient." "" "" ""</seg>
<seg id="1653">"" "" "" "the company did not know whether the withdrawal will have consequences for patients, who are currently participating in clinical trials or" Compassionate Use "programmes." "" "" ""</seg>
<seg id="1654">"" "" "" "" "" "" "" "changed drug release" means that the tablets are so compound that one of the effective components is released immediately and the other is released slowly over a few hours. "" "" "" "</seg>
<seg id="1655">Aerinaze is used to treat symptoms of the seasonal allergic rhinitis (hay fever caused by an allergy to pollen caused inflammation of the nasal channels) in patients with nasal mucous membrane (clogged nose).</seg>
<seg id="1656">"" "" "" "in adults and adolescents from 12 years onwards, the recommended dose of Aerinaze is twice daily a tablet, which should be taken with a glass of water with or without food." "" "" ""</seg>
<seg id="1657">"" "" "" "the duration of the treatment should be as short as possible and end as soon as the symptoms, especially the swelling of the nasal mucosa (clogged nose), are cluttered." "" "" ""</seg>
<seg id="1658">"" "" "" "a treatment duration of more than 10 days is not recommended, because the effects of the medicine can be reduced to constipation of the nose." "" "" ""</seg>
<seg id="1659">"" "" "" "the main efficacy was the changes in the severity of the hay fever symptoms, which were reported by the patients prior to the treatment and during the 15-day treatment." "" "" ""</seg>
<seg id="1660">"" "" "" "during the study, patients carried out their symptoms every 12 hours in a diary and assessed with a standard scale, how difficult the symptoms were in the last 12 hours." "" "" ""</seg>
<seg id="1661">"" "" "" "in view of all hay fever symptoms except the constipation of the nose, the patients who took Aerinaze reported a decrease in symptoms by 46.0%, compared with 35.9% in patients receiving pseudoephedrine alone." "" "" ""</seg>
<seg id="1662">"" "" "" "if only the swelling of the nasal mucosa was observed, patients under Aerinaze showed a reduction of symptoms by 37.4% to 26,7% in patients receiving desloratadine alone." "" "" ""</seg>
<seg id="1663">"" "" "" "the most common side effects of aerinaze (observed in 1 to 10 of 100 patients) are tachycardia, mouth dryness, headache, fatigue, insomnia (sleeplessness), sleep disorders and nervousness." "" "" ""</seg>
<seg id="1664">"" "" "" "aerinaze may not be used in patients who may be hypersensitive (allergic) to desloratadine, pseudoephedrine or any of the other ingredients, against noradrenergic substances or Loratadine (another medicine for treating allergies)." "" "" ""</seg>
<seg id="1665">"" "" "" "aerinaze should not be used in patients who suffer from conjunctival glaucoma, hypertension (hypertension), hyperthyrosis, hyperthyrosis, or a hemorrhagic stroke." "" "" ""</seg>
<seg id="1666">"" "" "" "on 30 July 2007, the European Commission issued an approval for the transport of Aerinaze across the European Union to the SP Europe." "" "" ""</seg>
<seg id="1667">"" "" "" "the tablet can be taken with a glass of water, but can be swallowed whole (i.e. without breaking, breaking or chewing)." "" "" ""</seg>
<seg id="1668">"" "" "" "aerinaze should not be applied to children under 12 years due to the lack of data for unacceptability and efficacy, (see Section 5.1)." "" "" ""</seg>
<seg id="1669">"" "" "" "the duration of the application is as short as possible, and should not be continued after sounding the symptoms." "" "" ""</seg>
<seg id="1670">"" "" "" "it is recommended to limit the duration of application to 10 days, as long-term use of pseudoephedrine can decrease with time." "" "" ""</seg>
<seg id="1671">"" "" "" "after decreasing the swelling of the mucous membranes in the upper respiratory tract, treatment can be continued with desloratadin as a monotherapy." "" "" ""</seg>
<seg id="1672">"" "" "" "since Aerinaze contains pseudoephedrine, the medicine is also contraindicated in patients treated with monoamine oxidase (MAO) inhibitors or within 2 weeks of termination of such therapy." "" "" ""</seg>
<seg id="1673">"" "" "" "this is due to alphamimetic activity in combined use of pseudoephedrine, Pergolid, Lisurid, Cabergoline, ergylephrine, ephedrine, oxymetazoline, Napoli, etc.)." "" "" ""</seg>
<seg id="1674">"" "" "" "the safety and efficacy of this combination therapy were not checked for this patient collective, and the data do not suffice to give appropriate dosage recommendations." "" "" ""</seg>
<seg id="1675">"" "" "" "the safety and efficacy of aerinaze were not examined in patients with kidney or liver dysfunction, and the data do not suffice to give appropriate dosage recommendations." "" "" ""</seg>
<seg id="1676">"" "" "" "patients need to be informed that treatment with hypertension or tachycardia or palpitations, heart rhythm disorders, nausea or any other neurological symptoms (such as headache or strengthening of headache) must be stopped." "" "" ""</seg>
<seg id="1677">"" "" "" "caution: • Patients suffering from a myocardial infarction • Patients with hypertension • Patients with hypertension • Patients with a myocardial infarction in the anamnesis, diabetes mellitus, bladder surgery or bronchospasm in the anamnesis." "" "" ""</seg>
<seg id="1678">"" "" "" "aerinaze is at least 48 hours prior to the implementation of dermatological tests, since antihistaminicians can otherwise prevent positive reactions to indicators for skin reactions or reduce them to their extent." "" "" ""</seg>
<seg id="1679">"" "" "" "however, no clinically relevant interactions or changes in the plasma concentration of desloratadin were observed in the course of clinical trials with desloratadin, in which erythromycin or ketoconazole was administered." "" "" ""</seg>
<seg id="1680">"" "" "" "with the results of the psychomotorical test, no significant differences could be found between the patients treated with either desloratadin and placebo-treated patients." "" "" ""</seg>
<seg id="1681">"" "" "" "the enzyme responsible for the metabolism of loratadin has not yet been identified, so that drug interactions can not be completely ruled out." "" "" ""</seg>
<seg id="1682">"" "" "" "desloratadin does not inhibit CYP3A4, and in vitro studies have shown that the drug CYP2D6 is not inhibiting and neither a substrate nor an inhibitor of the P-glycoproteins." "" "" ""</seg>
<seg id="1683">The harmlessness of the application of aerinaze during pregnancy is not secured. experience from a large number of affected pregnancies however did not increase the frequency of abnormalities compared to the frequency of the normal population.</seg>
<seg id="1684">"" "" "" "since reproduction studies on animals are not always transmitted to humans and due to the vasoconstrictor properties of pseudoephedrine, aerinaze should not be applied during pregnancy." "" "" ""</seg>
<seg id="1685">"" "" "" "however, patients should be informed that in very rare cases it may lead to a dizziness that can lead to impairment of traffic and ability to operate machines." "" "" ""</seg>
<seg id="1686">"" "" "" "symptoms can vary between a CNS-depression (sedation, apnea, decreased mental alertness, cyanosis, coma, cardiovascular collapse) and a CNS stimulation (insomnia, hallucinations, tremor, convulsions)." "" "" ""</seg>
<seg id="1687">"" "" "" "headache, anxiety, frightened miction, muscle weakness, and increased muscle tension, euphoria, arousal, vomiting, precordial pain, dizziness, tinnitus, ataxia, eyesight, hypertension, or hypotony." "" "" ""</seg>
<seg id="1688">"" "" "" "CNS stimulation is particularly likely in children, as well as atropin-typical symptoms (mouth dry, pupillary dire and - dilatation, skin redness, hyperthermia, and gastrointestinal symptoms)." "" "" ""</seg>
<seg id="1689">These include both the inhibition of the release of proinflammatory cytokines such as IL-4, IL-8 and IL-13 from human mast cells / basophiles as well as the inhibition of the expression of the adhesion of the P-selectin on endothelial cells.</seg>
<seg id="1690">"" "" "" "in a single dose study involving adults, desloratadin 5 mg showed no influence on standard measurement values of the flight performance including amplification of subjective mackness or the tasks associated with flying." "" "" ""</seg>
<seg id="1691">"" "" "" "in controlled clinical trials, at the recommended dosage of 5 mg daily no increased frequency of drowsiness was detected in comparison to placebo." "" "" ""</seg>
<seg id="1692">"" "" "" "the oral application of pseudoephedrine in the recommended dosage can cause other symptomatic effects, such as an increase in blood pressure, a tachycardia or manifestation of a CNS-arousal." "" "" ""</seg>
<seg id="1693">"" "" "" "1,248 patients were treated with seasonal allergic rhinitis between 12 and 78 years, with 414 patients receiving Aerinaze tablets." "" "" ""</seg>
<seg id="1694">"" "" "" "in both studies, the immunodeficiency efficacy of aerinaze tablets was significantly higher than in a monotherapy with pseudoephedrine over the 2-week treatment period." "" "" ""</seg>
<seg id="1695">"" "" "" "the efficacy of aerinaze tablets with regard to the swelling effect, determined by the nasal mucous membrane, was significantly higher than with a monotherapy with desloratadin over the 2-week treatment period." "" "" ""</seg>
<seg id="1696">"" "" "" "the efficacy of aerinaze tablets did not show any significant differences regarding sex, age or ethnicity." "" "" ""</seg>
<seg id="1697">"" "" "" "as part of a single dose study for Pharmacokinetics of Aerinaze, loratadine is detected within 30 minutes after administration in the plasma." "" "" ""</seg>
<seg id="1698">"" "" "" "after the peroral application of aerinaze in healthy volunteers for more than 14 days, the floating equilibrium of desloratadin, 3-hydroxydesloratad and pseudoephedrine was achieved on day 10." "" "" ""</seg>
<seg id="1699">"" "" "" "as part of a pharmacokinetic multi-dose study, which was carried out with the formulation as a tablet in healthy adult subjects, four subjects of loratadin were badly confused." "" "" ""</seg>
<seg id="1700">A component interaction study shows that the exposure (Cmax and AUC) of pseudoephedrine after the sole application of pseudoephedrine bioequivalent was to exposure to the gift of an aerinaze tablet.</seg>
<seg id="1701">"" "" "" "based on conventional safety resharmacology studies, toxicity in repeated application, genotoxicity and reproductive toxicity, the preclinical data with disloratadin does not reveal any particular danger to humans." "" "" ""</seg>
<seg id="1702">"" "" "" "the combination had no greater toxicity than its individual components, and the observed effects were generally related to the ingredient pseudoephedrine." "" "" ""</seg>
<seg id="1703">In reproductive toxicological studies the combination of Loratadin / pseudoephedrine was not teratogenic in a dose of up to 150 mg / kg / day and in rabbits in a dosage of up to 120 mg / kg / day.</seg>
<seg id="1704">"" "" "" "in March 2007 and in Module 1.8.1 of the application, the pharmaceutical vigilance system described and works before and while the product is on the market." "" "" ""</seg>
<seg id="1705">"" "" "" "antihistamines contribute to the relief of the allergic symptoms, preventing histamine, a body's own substance, its effect." "" "" ""</seg>
<seg id="1706">"" "" "" "aerinaze tablets relieve symptoms that occur in connection with seasonal allergic rhinitis (hay fever), such as sneezing, running or itching nose and tearing eyes while constipating the nose." "" "" ""</seg>
<seg id="1707">"" "" "" "20 Under certain circumstances, you may be particularly sensitive to pseudoephedrine mucous membrane, which is contained in this medicine." "" "" ""</seg>
<seg id="1708">"" "" "" "(diabetes), a stenozing stomach ulcer (ulcer, which leads to a narrowing of the stomach or the duodenum), a closure of the stomach or the duodenum (respiratory), a prostate enlargement or problems with the liver, kidneys or bladder." "" "" ""</seg>
<seg id="1709">"" "" "" "tell your doctor if you are diagnosed or diagnosed with aerinaze following symptoms or diseases: • High blood pressure • Cardiac disease, heart rhythm disorders, nausea and headache, or strengthening existing headaches." "" "" ""</seg>
<seg id="1710">"" "" "" "if you use Aerinaze with other medicines, please tell your doctor or pharmacist if you take other medicines or have recently taken, even if it is not prescription." "" "" ""</seg>
<seg id="1711">"" "" "" "traffic tightness and operation of machines In case of use at the recommended dosage, it is not expected that aerinaze leads to dizziness or decreases attention." "" "" ""</seg>
<seg id="1712">If you have taken a larger amount of aerinaze than you ought to inform immediately your doctor or pharmacist if you have taken a larger amount of aerinaze than you should.</seg>
<seg id="1713">"" "" "" "if you have forgotten the intake of Aerinaze If you have forgotten to take a dose in time, take the application as soon as possible and use the next dose at the scheduled time." "" "" ""</seg>
<seg id="1714">Please inform your doctor or pharmacist if any of the listed side effects do significantly affect you or notice side effects that are not stated in this information.</seg>
<seg id="1715">"" "" "" "heart hunting, restlessness with increased physical activity, mouth dryness, dizziness, sore throat, loss of appetite, thirst, fatigue, headache, sleep disorders, nervousness and dizziness." "" "" ""</seg>
<seg id="1716">"" "" "" "heart palpitations, heart rhythm disorders, increased physical activity, redness, headache, stomach upset, pain or difficulty passing urine, anxiety, anxiety, anxiety, anxiety and irritability." "" "" ""</seg>
<seg id="1717">"" "" "" "after the market launch of desloratadin very rarely was reported about cases of severe allergic reactions (breath, whistling breathing, itching, hives, swelling) or skin rash." "" "" ""</seg>
<seg id="1718">"" "" "" "about cases of heart palpitations, heart hunting, stomach pain, nausea, vomiting, stomach pain, diarrhoea, headache, headache, headache, headache, diarrhoea, diarrhoea, diarrhoea, diarrhoea, loss of liver disease." "" "" ""</seg>
<seg id="1719">"" "" "" "it is available as 5 mg tablet, 5 mg- lyophilizer for intake (soluble tablet), 2.5 mg- and 5 mg tablets (tablets that dissolve in the mouth), 0.5 mg / ml syrup and as 0.5 mg / ml solution." "" "" ""</seg>
<seg id="1720">"" "" "" "for children aged one to five years, the dose is 1.25 mg once daily, in the form of 2.5 ml syrup resp." "" "" ""</seg>
<seg id="1721">"" "" "" "for children aged six to eleven, the dose is 2.5 mg once daily, either in the form of 5 ml syrup resp." "" "" ""</seg>
<seg id="1722">"" "" "" "Aerius was studied in eight studies with about 4,800 adults and adolescents with rhinitis (including four studies of seasonal allergic rhinitis and two studies to patients who also had asthma)." "" "" ""</seg>
<seg id="1723">"" "" "" "the efficacy was measured by changing the symptoms (itching, number and size of paddling, sleep and performance in the day) before and after six weeks of treatment." "" "" ""</seg>
<seg id="1724">"" "" "" "further studies have been submitted to prove that the body uses the syrup, the solution to intake and melt tablets in the same way as the tablets and the application in children is harmless." "" "" ""</seg>
<seg id="1725">"" "" "" "in case of allergic rhinitis, if the results of all studies were summarized, the two-week treatment with 5 mg Aerius increased by 25 to 32% compared to a decrease of 12 to 26% in patients receiving a placebo." "" "" ""</seg>
<seg id="1726">"" "" "" "after six weeks of treatment with Aerius 58 and 67%, the two studies with Aerius were 58 and 33% compared to patients treated with placebo." "" "" ""</seg>
<seg id="1727">"" "" "" "Aerius may not be used in patients who may be hypersensitive (allergic) to desloratadine, lauatadin or any of the other ingredients." "" "" ""</seg>
<seg id="1728">"" "" "" "January 2001, the European Commission issued an approval to the Company SP Europe for the transport of Aerius throughout the European Union." "" "" ""</seg>
<seg id="1729">"" "" "" "one tablet once a day, with or without a meal, to relieve the symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria (see section 5.1)." "" "" ""</seg>
<seg id="1730">"" "" "" "there is limited experience from clinical trials for efficacy in the use of diloratas in adolescents from 12 to 17 years (see Sections 4.8 and 5.1)." "" "" ""</seg>
<seg id="1731">The treatment of the intermittent allergic rhinitis (occurrence of symptoms for less than 4 days a week or less than 4 weeks) should be carried out according to previous disease progression and can be resumed after the symptoms of the symptoms and may be resumed.</seg>
<seg id="1732">"" "" "" "in case of persistent allergic rhinitis (symptoms of 4 or more days a week and more than 4 weeks), the patient can be recommended during the allergy period." "" "" ""</seg>
<seg id="1733">Clinically relevant interactions were not found in clinical trials with desloratadin tablets where erythromycin or ketoconazole were administered in addition (see section 5.1).</seg>
<seg id="1734">"" "" "" "in a clinical pharmacological study, the performance of alcohol was not increased while taking Aerius and alcohol (see section 5.1)." "" "" ""</seg>
<seg id="1735">"" "" "" "however, patients should be informed that in very rare cases it may result in a decrease in traffic and ability to operate machines." "" "" ""</seg>
<seg id="1736">"" "" "" "in clinical trials in various indications including allergic rhinitis and chronic idiopathic urticaria, 3% more side effects were reported in patients with Aerius, than in patients treated with placebo." "" "" ""</seg>
<seg id="1737">"" "" "" "the most frequently encountered side effects, reported more frequently than in placebo, were tiredness (1.2%), mouth dry (0,8%) and headache (0.6%)." "" "" ""</seg>
<seg id="1738">"" "" "" "in a clinical study involving 578 adolescent patients from 12 to 17 years the most common side effect was headaches, which was treated with 5.9% of patients treated with desloratamn and 6.9% of patients treated with placebo." "" "" ""</seg>
<seg id="1739">"" "" "" "in a multiple dose study, which was administered up to 45 mg of loratine (nine times a clinical dose), no clinically relevant effects were observed." "" "" ""</seg>
<seg id="1740">"" "" "" "this includes both the inhibition of the release of proinflammatory cytokines such as IL-4, IL-6, IL-8 and IL-13 from human mast cells / basophiles as well as inhibiting the expression of the adhesion of the P-selectin to endothelial cells." "" "" ""</seg>
<seg id="1741">"" "" "" "as part of a clinical study with multiple doses, in which desloratamn was administered over 14 days in a dose of up to 20 mg, no statistically significant or clinically relevant cardiovascular effect was described." "" "" ""</seg>
<seg id="1742">"" "" "" "in a clinical pharmacological study, in which desloratamn was administered in a dose of 45 mg daily (the nine times the clinical dose) was administered over ten days, there was no extension of the Qtc interval." "" "" ""</seg>
<seg id="1743">"" "" "" "in a single dose study involving adults, desloratadin 5 mg showed no influence on standard measurement values of the flight performance including amplification of subjective mackness or the tasks associated with flying." "" "" ""</seg>
<seg id="1744">"" "" "" "in patients with allergic rhinitis, Aerius was effective in alleviating symptoms such as sneezing, nasal secretion and itching of the nose, itching, lacrimal flow and redness of the eyes and itching on the palate." "" "" ""</seg>
<seg id="1745">"" "" "" "in addition to the established classification in seasonal and perennial, allergic rhinitis may also be divided into intermittent allergic rhinitis and persistent allergic rhinitis." "" "" ""</seg>
<seg id="1746">"" "" "" "intermittent allergic rhinitis is defined as the occurrence of symptoms for less than 4 days a week, or less than 4 weeks." "" "" ""</seg>
<seg id="1747">"" "" "" "persisting allergic rhinitis is defined as the occurrence of symptoms on 4 or more days a week, and more than 4 weeks." "" "" ""</seg>
<seg id="1748">"" "" "" "as shown on the overall score of the questionnaire for quality of life in Rhino-conjunctivitis, Aerius effectively reduces the burden caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1749">"" "" "" "the chronic idiopathic urticaria was examined for further forms of urticaria, as the underlying pathophysiology irrespective of the etiology of the different forms is similar and chronic patients can be recited prospectively." "" "" ""</seg>
<seg id="1750">"" "" "" "since histamine is a causal factor in all urinary diseases, Desloratadin is also expected to improve the symptoms in other forms of urticaria; this is confirmed by the recommendations of the clinical guidelines." "" "" ""</seg>
<seg id="1751">In two placebo-controlled trials over 6 weeks in patients with Chronic idiopathic Urticaria Aerius was effective in improving Pruritus and the reduction of size and number of paddles at the end of the first dose interval.</seg>
<seg id="1752">"" "" "" "as in other studies with antihistamines in chronic idiopathic urticaria, the majority of patients who did not respond to antihistamines were excluded from the study." "" "" ""</seg>
<seg id="1753">Improvement of the itching stimulus by more than 50% was observed in 55% of patients treated with desloratamn compared to 19% of patients treated with placebo.</seg>
<seg id="1754">"" "" "" "the treatment with Aerius significantly reduced sleep and waking, as measured by a 4-point scale to evaluate these variables." "" "" ""</seg>
<seg id="1755">"" "" "" "in a Pharmacokinetic trial, which were comparable to the general seasonal allergic rhinitis population, 4% of patients have reached a higher concentration of desloratadin." "" "" ""</seg>
<seg id="1756">"" "" "" "there are no clues for clinically relevant cumulation, after once daily application of desloratadin (5- 20 mg) over 14 days." "" "" ""</seg>
<seg id="1757">"" "" "" "however, the enzyme responsible for the metabolism of loratadin has not yet been identified so that interactions with other medicines are not completely ruled out." "" "" ""</seg>
<seg id="1758">"" "" "" "in vivo, desloratadin does not inhibit CYP3A4 and in-vitro studies that the drug CYP2D6 is not inhibiting and neither a substrate nor an inhibitor of the P-glycoproteins." "" "" ""</seg>
<seg id="1759">"" "" "" "in a single dose study with desloratadin at a dose of 7.5 mg, meals (fatty, calorie rich breakfast) did not affect the availability of desloratadin." "" "" ""</seg>
<seg id="1760">"" "" "" "the preclinical studies carried out by Desloratadin and Loratadin showed no qualitative or quantitative differences in the toxicity profile of Desloratadin, and Loratadin." "" "" ""</seg>
<seg id="1761">"" "" "" "based on conventional safety resharmacology studies, toxicity in repeated application, genotoxicity and reproductive toxicity, the preclinical data with desloratadin can not detect any particular danger for humans." "" "" ""</seg>
<seg id="1762">"" "" "" "colourless film (contains lactose-monohydrate, Hypromless, Titanium dioxide 400, Indigo carmin (E 132)), colourless film (includes Hypromless, Macrogol 400), carnauba wax, slight wax." "" "" ""</seg>
<seg id="1763">"" "" "" "Aerius can be taken apart from meals, to relieve the symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria (see section 5.1)." "" "" ""</seg>
<seg id="1764">The prescribing physician should be aware that most cases of rhinitis in children under 2 years are caused by an infection (see section 4.4) and that no data is available which support a treatment of a infectious rhinitis with Aerius.</seg>
<seg id="1765">"" "" "" "besides the exclusion of upper respiratory infections or anatomical anomalies, anamnesis, physical examination and corresponding laboratory and skin tests should play a role." "" "" ""</seg>
<seg id="1766">"" "" "" "approximately 6% of adults and children between 2 and 11 years of age metabolize desloratadin, and experience higher substance exposure (see section 5.2)." "" "" ""</seg>
<seg id="1767">"" "" "" "the safety of Aerius syrup in children between 2 and 11 years, which metabolizes, is identical to that of children that are normally metabolized." "" "" ""</seg>
<seg id="1768">"" "" "" "this medicine contains sucrose and sorbitol; therefore, patients with hereditary problems of fructose intolerance, glucose galactose absorption or a sucroase isomaltas- insufficiency should not take this medicine." "" "" ""</seg>
<seg id="1769">Clinically relevant interactions were not found in clinical studies with Aerius tablets where erythromycin or ketoconazole were administered in addition (see section 5.1).</seg>
<seg id="1770">"" "" "" "in a clinical pharmacological study, taking Aerius tablets and alcohol was not enhanced the performance-reducing effect of alcohol (see section 5.1)." "" "" ""</seg>
<seg id="1771">"" "" "" "the overall incidence of side effects in children between 2 and 11 years was similar to the Aerius Sirup group, similar to the placebo group." "" "" ""</seg>
<seg id="1772">"" "" "" "in clinical trials involving adults and adolescents in various indications including allergic rhinitis and chronic idiopathic urticaria, 3% more side effects were reported in patients with Aerius than in patients treated with placebo." "" "" ""</seg>
<seg id="1773">"" "" "" "in a multiple dose study of adults and adolescents, with up to 45 mg of desloratadine (nine times clinical dose), no clinically relevant effects were observed." "" "" ""</seg>
<seg id="1774">Children aged between 1 and 11 years old for antihistamine therapy were diagnosed with a dose of 1.25 mg. (aged between 1 and 5 years) or 2.5 mg (between the ages of 6 and 11).</seg>
<seg id="1775">"" "" "" "because the progression of hypogetis / chronic idiopathic urticaria and the profile of desloratadin in adults and children, the efficacy data of desloratadin in adults can be extrapolated to the children's population." "" "" ""</seg>
<seg id="1776">"" "" "" "as part of a clinical study with multiple doses of adults and adolescents, in a dose of up to 20 mg daily for over 14 days, no statistically significant or clinically relevant cardiovascular effect has been described." "" "" ""</seg>
<seg id="1777">"" "" "" "in a clinical pharmacological study of adults and adolescents, in a dose of 45 mg daily (the nine times the clinical dose) was applied for ten days in adults, no prolongation of the Qtc interval was observed." "" "" ""</seg>
<seg id="1778">"" "" "" "in controlled clinical trials, at the recommended dosage of 5 mg daily for adults and adolescents no increased frequency of drowsiness compared to placebo." "" "" ""</seg>
<seg id="1779">"" "" "" "at an individual daily dose of 7.5 mg, Aerius tablets in adults and adolescents in clinical trials led to no impairment of psychomotism." "" "" ""</seg>
<seg id="1780">"" "" "" "in clinical pharmacological studies in adults, the simultaneous consumption of alcohol was neither a strengthening of alcohol induced performance impairment nor increase of drowsiness." "" "" ""</seg>
<seg id="1781">"" "" "" "in adult and adolescent patients with allergic rhinitis, Aerius tablets were effective in alleviating symptoms such as sneezing, nasal secretion, and itching of eyes and itching on the palate." "" "" ""</seg>
<seg id="1782">"" "" "" "as shown on the overall score of the questionnaire for quality of life in Rhino-conjunctivitis, Aerius tablets reduce the effect caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1783">In two placebo-controlled trials over 6 weeks in patients with Chronic idiopathic Urticaria Aerius was effective in improving Pruritus and the reduction of size and number of paddles at the end of the first dose interval.</seg>
<seg id="1784">The spread of this limited metabolic phenotype was comparable to adults (6%) and children between 2 and 11 years (6%) and in both populations larger in black (18% adults and 16% children) than in Caucasus (2% adults, 3% children).</seg>
<seg id="1785">"" "" "" "similar pharmacokinetic parameters were observed in a pharmacokinetic multi-dose study, with the syrup formulation of children between 2 and 11 years with allergic rhinitis, which are severely metabolized." "" "" ""</seg>
<seg id="1786">"" "" "" "after 3 to 6 hours, the load (AUC) was about 6 times higher and the Cmax approximately 3 to 4 times higher with a terminal half-life of about 120 hours." "" "" ""</seg>
<seg id="1787">"" "" "" "there are no clues for a clinically relevant drug accumulation after once daily application of desloratadin (5- 20 mg) over 14 days in adults and adolescents." "" "" ""</seg>
<seg id="1788">12 In various single dose studies AUC- and Cmax levels of diloratadin in pediatric patients were comparable to those of adults who received the desloratamn syrup in a dose of 5 mg.</seg>
<seg id="1789">"" "" "" "however, the enzyme responsible for the metabolism of loratadin has not yet been identified so that drug interactions can not be completely ruled out." "" "" ""</seg>
<seg id="1790">"" "" "" "Aerius syrup is offered in type III braunglass tanks with a child safe polypropylene junction with 30, 50, 60, 100, 120, 150, 225 and 300 ml." "" "" ""</seg>
<seg id="1791">"" "" "" "equipped with a rigid, transparent polystyrene measuring spoon, calibrated with 2.5 ml and 5 ml or with an application syringe for preparations to take with scaling of 2.5 ml and 5 ml (only for the 150 ml bottle)." "" "" ""</seg>
<seg id="1792">"" "" "" "take a dose of Aerius Lyophilisat once daily, to relieve the symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria (see section 5.1)." "" "" ""</seg>
<seg id="1793">"" "" "" "immediately before the application, the blister must be carefully opened and the dose of the lyophilisate must be removed without damaging them." "" "" ""</seg>
<seg id="1794">Clinically relevant interactions were not found in clinical studies with Aerius tablets where erythromycin or ketoconazole were additionally applied (see section 5.1).</seg>
<seg id="1795">"" "" "" "in clinical trials in various indications including allergic rhinitis and chronic idiopathic urticaria, 3% more side effects were reported in patients with Aerius tablets, than in patients treated with placebo." "" "" ""</seg>
<seg id="1796">"" "" "" "no clinically relevant effects were observed in a multiple dose trial, which was up to 45 mg of desloratadine (nine times a clinical dose)." "" "" ""</seg>
<seg id="1797">"" "" "" "in two single dose studies, Aerius Lyophilisat was well tolerated; this was documented by clinical laboratory results, medical examinations, vital signs and ECG interval data." "" "" ""</seg>
<seg id="1798">"" "" "" "as part of a clinical study with multiple doses, in the desloratad in a dose of up to 20 mg daily for over 14 days, no statistically significant or clinically relevant cardiovascular effect has been described." "" "" ""</seg>
<seg id="1799">"" "" "" "in a clinical pharmacological study, in the diloratadine in a dose of 45 mg daily (the nine times the clinical dose) was applied for over ten days, no prolongation of the Qtc interval was observed." "" "" ""</seg>
<seg id="1800">"" "" "" "in controlled clinical trials, at the recommended dosage of 5 mg daily no increased frequency of drowsiness was detected in comparison to placebo." "" "" ""</seg>
<seg id="1801">"" "" "" "in a 17 single dose study with adults, Desloratadin 5 mg showed no influence on standard measurement ranges of flight performance, including reinforcement of subjective mackness or the tasks associated with flying." "" "" ""</seg>
<seg id="1802">"" "" "" "in patients with allergic rhinitis, Aerius tablets were effective in alleviating symptoms such as sneezing, nasal secretion and itching of the nose, itching, lacrimal flow and redness of the eyes, as well as itching on the palate." "" "" ""</seg>
<seg id="1803">"" "" "" "as shown on the overall score of the questionnaire for quality of life in Rhino-conjunctivitis, Aerius effectively reduces the burden caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1804">"" "" "" "18 In a pharmacokinetic trial, which were comparable to the general seasonal allergic rhinitis population, 4% of patients have reached a higher concentration of desloratadin." "" "" ""</seg>
<seg id="1805">Food has no significant influence on AUC and Cmax by Aerius Lyophilisat for taking while Food Tmax by Desloratadin is extended from 2.5 to 4 hours and Tmax of 3-OH-desloratadin from 4 to 6 hours.</seg>
<seg id="1806">Gelatine Mannitol Aspartame (E 951) Polacrilin Potassium int Red (containing iron (III) -oxide (E 172) and Hypromless (E 464)) aroma Tutti-Frutti water-free citric acid</seg>
<seg id="1807">"" "" "" "put an Aerius 2.5 mg melting tablet once daily, to relieve the symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria (see section 5.1)." "" "" ""</seg>
<seg id="1808">Two Aerius 2.5 mg tablets apply once daily in the mouth to relieve symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria (see section 5.1).</seg>
<seg id="1809">"" "" "" "there is limited experience from clinical trials for efficacy in the use of diloratas in adolescents from 12 to 17 years (see Sections 4.8 and 5.1)," "" "" ""</seg>
<seg id="1810">"" "" "" "immediately before the application, the blister must be carefully opened and the dose of the enamel tablet removed without damaging it." "" "" ""</seg>
<seg id="1811">"" "" "" "until now, the efficacy and harmlessness of Aerius 2.5 mg weld tablets during the treatment of children under 6 years have not been proven." "" "" ""</seg>
<seg id="1812">The overall frequency of the side effects between the disloratadine syrup and the placebo group was the same and did not differ significantly from the safety profile identified in adult patients.</seg>
<seg id="1813">"" "" "" "at the recommended dose, Aerius melt tablet proved to be a bioequivalent to the Aerius 5 mg conventional tablet formulation and the Aerius 5 mg lyophilisate for detecting desloratadin." "" "" ""</seg>
<seg id="1814">"" "" "" "as part of a clinical study with multiple doses, in the desloratad in a dose of up to 20 mg daily for over 14 days, no statistically significant or clinically significant" "" "" ""</seg>
<seg id="1815">"" "" "" "in a single dose study involving adults, desloratadin 5 mg showed no influence on standard measurement ranges of flight performance, including amplification of subjective mackness or the tasks associated with flying." "" "" ""</seg>
<seg id="1816">"" "" "" "the spread of this poorly metabolising phenotype was comparable to adult (6%) and pediatric patients between 2 and 11 years (adults 18%, children 3%), but the safety profile of these patients was not different from that of the general population." "" "" ""</seg>
<seg id="1817">"" "" "" "in single dose crossover studies of Aerius melt tablets with Aerius 5 mg of conventional tablets or Aerius 5 mg Lyophilisat, the formulations were bioequivalent." "" "" ""</seg>
<seg id="1818">"" "" "" "Aerius 2.5 mg tablets were not examined for pediatric patients, but the pharmacokinetic data for Aerius melt tablets support the use of the 2.5 mg dose in children aged 6 to 11." "" "" ""</seg>
<seg id="1819">Food has no significant influence on AUC and Cmax by Aerius Aerius Lyophilisat for taking while Food Tmax by Desloratadin is extended from 2.5 to 4 hours and Tmax of 3-OH- desloratadin from 4 to 6 hours.</seg>
<seg id="1820">The overall analysis of preclinical and clinical trials for the melting tablet revealed that this formulation is an improbable risk for local irritation in clinical application.</seg>
<seg id="1821">Microcrystalline cellulose Premised starch Carboxymethylmethacrylate sodium hydrogenate sodium hydrogenate sodium hydrogenate high dispersion silicon dioxide Mannitol Aspartame (E951) Aroma Tutti Frutti</seg>
<seg id="1822">The cold forming film is made of polyvinyl chloride (PVC) laminated onto a covered polyamid (OPA) film. laminated lamatin on an aluminum foil adhesive laminated to a polyvinyl chloride (PVC) film.</seg>
<seg id="1823">"" "" "" "put an Aerius 5 mg melting tablet once daily, to relieve the symptoms of allergic rhinitis (including intermittent and persistent allergic rhinitis) and urticaria (see section 5.1)." "" "" ""</seg>
<seg id="1824">"" "" "" "at the recommended dose, Aerius 5 mg melts tablet proved to be a bioequivalent to the Aerius 5 mg conventional tablet formulation and the 5 mg lyophilisate for detecting desloratadin." "" "" ""</seg>
<seg id="1825">"" "" "" "as part of a clinical study with multiple doses, in the desloratad in a dose of up to 20 mg daily for over 14 days, no statistically significant or clinically relevant cardiovascular effect has been described." "" "" ""</seg>
<seg id="1826">"" "" "" "in a 30 single dose study with adults, Desloratadin 5 mg showed no influence on standard measurement ranges of flight performance, including amplification of subjective mackness or the tasks associated with flying." "" "" ""</seg>
<seg id="1827">"" "" "" "in patients with allergic rhinitis, Aerius tablets were effective in alleviating symptoms such as sneezing, nasal secretion and itching of the nose, itching, lacrimal flow and redness of the eyes, as well as itching on the palate." "" "" ""</seg>
<seg id="1828">"" "" "" "in single dose crossover studies of Aerius 5 mg tablets with Aerius 5 mg of conventional tablets or Aerius 5 mg Lyophilisat, the formulations were bioequivalent." "" "" ""</seg>
<seg id="1829">The overall analysis of preclinical and clinical trials for the melting tablet revealed that this formulation is an improbable risk for local irritation in clinical application.</seg>
<seg id="1830">"" "" "" "the safety of loratadine children between the ages of 2 and 11, which metabolizes limited metabolized, is identical to that of children that are normally metabolized." "" "" ""</seg>
<seg id="1831">"" "" "" "this medicine contains sorbitol; therefore, patients with hereditary problems of a fructose intolerance, glucose galactose absorption or a sucroase isomaltase insufficiency should not take this medicine." "" "" ""</seg>
<seg id="1832">"" "" "" "the overall frequency of adverse events in children between 2 and 11 years was similar to the placebo group, similar to the placebo group." "" "" ""</seg>
<seg id="1833">"" "" "" "in infants between 6 and 23 months, the most common side-effects reported was diarrhoea (3.7%), fever (2.3%) and sleeplessness (2.3%)." "" "" ""</seg>
<seg id="1834">"" "" "" "in an additional study, at a single dose of 2.5 mg Desloratadin solution, no side effects were observed in patients aged between 6 and 11 years." "" "" ""</seg>
<seg id="1835">"" "" "" "in the recommended doses, the plasma concentrations of desloratadin (see section 5.2) were comparable in the children's and adult population." "" "" ""</seg>
<seg id="1836">"" "" "" "in controlled clinical trials, at the recommended dosage of 5 mg daily for adults and adolescents no increased frequency of drowsiness compared to placebo." "" "" ""</seg>
<seg id="1837">"" "" "" "in addition to the established classification in seasonal and perennial, allergic rhinitis may alternatively also interact with allergic rhinitis in intermittent allergic rhinitis." "" "" ""</seg>
<seg id="1838">"" "" "" "as shown on the overall score of the questionnaire for quality of life in Rhino-conjunctivitis, Aerius tablets reduce the burden caused by seasonal allergic rhinitis." "" "" ""</seg>
<seg id="1839">The spread of this limited metabolic phenotype was comparable to adults (6%) and children between 2 and 11 years (6%) and in both populations larger in black (18% adults and 16% children) than in Caucasus (2% adults, 3% children).</seg>
<seg id="1840">"" "" "" "since Aerius contains solution for taking the same concentration on desloratadin, no Bioequivalence study was necessary and it is expected that it complies with the syrup and the tablets." "" "" ""</seg>
<seg id="1841">In various single dose studies AUC- and Cmax levels of diloratadin in pediatric patients were comparable to those of adults who received the desloratamn syrup in a dose of 5 mg.</seg>
<seg id="1842">"" "" "" "sorbitol, propylene glycol, sucralosis E 955, sodium citrate 2 H2O, natural and artificial aromas (bubble-gum), water-free citric acid, sodium edetate (Ph.Eur.), purified water." "" "" ""</seg>
<seg id="1843">"" "" "" "Aerius solution for intake is offered with 30, 50, 60, 100, 120, 150, 225 and 300 ml in type III brake bottles with a multi-layer polyethylene coating." "" "" ""</seg>
<seg id="1844">"" "" "" "all packaging sizes except the 150 ml packer size are offered with a measuring spoon, with markers for dosages of 2.5 ml and 5 ml." "" "" ""</seg>
<seg id="1845">"" "" "" "the 150 ml packer size is a measuring spoon, or an application spray for preparations to take with scaling of 2.5 ml and 5 ml." "" "" ""</seg>
<seg id="1846">"" "" "" "subsequently, the authorisation holder will submit the regularly updated reports about the harmlessness of a drug every two years unless something else is decided from CHMP." "" "" ""</seg>
<seg id="1847">"" "" "" "1 film tablet 2 film tablets, 5 film tablets, 5 film tablets, 15 film tablets, 20 film tablets, 50 film tablets, 50 film tablets, 100 film tablets" "" "" ""</seg>
<seg id="1848">"" "" "" "1 film tablet 2 film tablets, 5 film tablets, 5 film tablets, 15 film tablets, 20 film tablets, 50 film tablets, 50 film tablets, 100 film tablets" "" "" ""</seg>
<seg id="1849">Syrup 30 ml with 1 measuring spoon 100 ml with 1 measuring spoon 100 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 100 ml with 1 measuring spoon 100 ml</seg>
<seg id="1850">30 ml with 1 measuring spoon 100 ml with 1 measuring spoon 100 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 100 ml with 1 measuring spoon 100 ml</seg>
<seg id="1851">1 dosage lyophilisate for taking 2 doses of Lyophilisat for taking in 5 doses of Lyophilisat for taking in 15 doses Lyophilisat for taking in 15 doses Lyophilisat for taking in 15 doses Lyophilisat for taking over 50 doses Lyophilisat for taking over 100 doses Lyophilisat for taking over 100 doses Lyophilisat for taking 100 doses Lyophilisat for taking 100 doses Lyophilisat for taking 100 doses Lyophilisat for taking 100 doses Lyophilisat for taking 100 doses of Lyophilisat to take in 100 doses Lyophilisat</seg>
<seg id="1852">5 melt tablets 10 melt tablets 12 melt tablets 15 melt tablets 15 melt tablets 20 melt tablets 30 melt tablets 90 melt tablets 90 melt tablets 100 melt tablets</seg>
<seg id="1853">1 measuring spoon 100 ml with 1 measuring spoon 100 ml with 1 measuring spoon 100 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 100 ml with 1 measuring spoon 100 ml</seg>
<seg id="1854">"" "" "" "during pregnancy and lactation, ask your doctor or pharmacist for advice during pregnancy and lactation before taking any medication." "" "" ""</seg>
<seg id="1855">"" "" "" "traffic tightness and operation of machines In case of use at the recommended dosage, it is not expected that Aerius conducts or decreases attention." "" "" ""</seg>
<seg id="1856">"" "" "" "if you have been told by your doctor that you have an intolerance against certain sugars, consult your doctor before taking this medicine." "" "" ""</seg>
<seg id="1857">"" "" "" "regarding treatment duration, your doctor will notice the type of allergic rhinitis under which you suffer and will determine how long you should take Aerius." "" "" ""</seg>
<seg id="1858">If your allergic rhinitis are intermittent (the symptoms less than 4 days a week or less than 4 weeks) your doctor will recommend you a treatment scheme that is dependent on your previous disease progression.</seg>
<seg id="1859">"" "" "" "if your allergic rhinitis persists (symptoms on 4 or more days a week or more than 4 weeks), your doctor may recommend you a lasting treatment." "" "" ""</seg>
<seg id="1860">"" "" "" "if you forgot to take Aerius if you forgot to take your dose in time, take it as soon as possible and then follow the normal treatment plan again." "" "" ""</seg>
<seg id="1861">"" "" "" "71 Since the market launch of Aerius very rarely was reported about cases of severe allergic reactions (difficulty breathing, whistling breathing, itching, hives, swelling) and rash." "" "" ""</seg>
<seg id="1862">"" "" "" "about cases of heart palpitations, heart hunting, stomach pain, nausea, vomiting, stomach upset, stroke, restlessness with increased physical activity, liver inflammation and unusual liver function values has also been reported very rarely." "" "" ""</seg>
<seg id="1863">"" "" "" "tablet coating consists of coloured film (includes lactose monohydrate, hypromless, titanium dioxide, Macrogol 400), colourless film (including Hypromless, Macrogol 400), carnauba wax, lighter wax." "" "" ""</seg>
<seg id="1864">"" "" "" "Aerius 5 mg tablet tablets are individually packaged in blister packs of 1, 2, 3, 5, 10, 14, 20, 21, 30, 50, 90 or 100 tablets." "" "" ""</seg>
<seg id="1865">"" "" "" "Aerius syrup is indicated for children between 1 and 11 years, young people (12 years and older) and adults, older people included." "" "" ""</seg>
<seg id="1866">"" "" "" "important information about certain other ingredients of Aerius you should not take Aerius Sirup, if you are allergic to the dye E 110." "" "" ""</seg>
<seg id="1867">"" "" "" "if your doctor told you that you have an intolerance to some sugars, please contact your doctor before taking this medicine." "" "" ""</seg>
<seg id="1868">"" "" "" "when applying a syrup for use with scaling with scaling, you can use it alternatively to take the appropriate amount of syrup." "" "" ""</seg>
<seg id="1869">"" "" "" "regarding treatment duration, your doctor will notice the type of allergic rhinitis under which you suffer and will determine how long you should take Aerius syrup." "" "" ""</seg>
<seg id="1870">"" "" "" "however, in children under 2 years diarrhea, fever and insomnia, frequent side effects, while in adults, fatigue, dry mouth and headache have been reported more often than with placebo." "" "" ""</seg>
<seg id="1871">"" "" "" "after launching Aerius very rarely was reported about cases of severe allergic reactions (difficulty breathing, whistling breathing, itching, hives, swelling) and rash." "" "" ""</seg>
<seg id="1872">"" "" "" "77 Aerius syrup is available in bottles with a child-safe closing cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml." "" "" ""</seg>
<seg id="1873">"" "" "" "Aerius Lyophilisat improves the symptoms of allergic rhinitis (caused by allergy causes inflammation of the nasal passages, for example hay fever or household dust allergy)." "" "" ""</seg>
<seg id="1874">"" "" "" "when taking Aerius Lyophilisat together with food and drinks, Aerius Lyophilisat does not need to be taken with water or another liquid." "" "" ""</seg>
<seg id="1875">"" "" "" "regarding treatment duration, your doctor will notice the type of allergic rhinitis under which you suffer and will determine how long you should take Aerius Lyophilisat." "" "" ""</seg>
<seg id="1876">"" "" "" "81 If you forgot to take Aerius Lyophilisat, if you forgot to take your dose in time, take it as soon as possible and then follow the normal treatment plan again." "" "" ""</seg>
<seg id="1877">"" "" "" "after launching Aerius very rarely was reported about cases of severe allergic reactions (difficulty breathing, whistling breathing, itching, hives, swelling) and rash." "" "" ""</seg>
<seg id="1878">"" "" "" "Aerius Lyophilisat can be packed individually in blister packs of 1, 2, 3, 5, 10, 15, 20, 21, 30, 50 or 100 doses of the lyophilisate." "" "" ""</seg>
<seg id="1879">"" "" "" "Aerius melt tray improves symptoms of allergic rhinitis (caused by allergy causes inflammation of the nasal passages, for example hay fever or household dust mites allergy)." "" "" ""</seg>
<seg id="1880">"" "" "" "when taking Aerius melt tablets, together with food and drinks, Aerius melt tablet does not need to be taken with water or any other liquid." "" "" ""</seg>
<seg id="1881">"" "" "" "regarding treatment duration, your doctor will notice the type of allergic rhinitis under which you suffer and will determine how long you should take Aerius melt tablets." "" "" ""</seg>
<seg id="1882">"" "" "" "86 If you forgot to take Aerius melt tablets if you forgot to take your dose in time, take it as soon as possible and then follow the normal treatment plan again." "" "" ""</seg>
<seg id="1883">"" "" "" "Aerius melt tray is packed individually in blister packs of 5, 6, 10, 12, 15, 20, 30, 50, 60, 90 and 100 cans of the melt tray." "" "" ""</seg>
<seg id="1884">"" "" "" "when taking Aerius melt tablets, together with food and drinks, Aerius melt tablet does not need to be taken with water or any other liquid." "" "" ""</seg>
<seg id="1885">"" "" "" "if you forgot to take Aerius melt tablets if you forgot to take your dose in time, take it as soon as possible and then follow the normal treatment plan again." "" "" ""</seg>
<seg id="1886">"" "" "" "after launching Aerius very rarely was reported about cases of severe allergic reactions (difficulty breathing, whistling breathing, itching, hives, swelling) and rash." "" "" ""</seg>
<seg id="1887">"" "" "" "Aerius solution for boarding is indicated for children between 1 and 11 years, young people (12 years and older) and adults, older people included." "" "" ""</seg>
<seg id="1888">"" "" "" "if the solution for inserting a application syringe for preparations to include with scaling is included, you can use it alternatively to take the appropriate amount of solution for taking." "" "" ""</seg>
<seg id="1889">"" "" "" "regarding treatment duration, your doctor will notice the type of allergic rhinitis under which you suffer and will determine how long you should take Aerius solution for taking." "" "" ""</seg>
<seg id="1890">"" "" "" "however, in children under 2 years diarrhea, fever and insomnia, frequent side effects during adults have been reported more often than placebo." "" "" ""</seg>
<seg id="1891">"" "" "" "97 Aerius solution for intake is available in bottles with a child-safe closing cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml." "" "" ""</seg>
<seg id="1892">"" "" "" "the 150 ml packer size is a measuring spoon, or an application syringe fûr preparations for insertion with scaling of 2.5 ml- and 5 ml cans." "" "" ""</seg>
<seg id="1893">June 2008 Novartis Vaccines and Diagnostics S.r.l. was officially announced to the Committee for Medicinal Products for Medicinal Products (CHMP) that the Company accepts his application for the transfer of Aflunov to prevent the aviary H5N1 influenza in adults and elderly people.</seg>
<seg id="1894">Aflunov should be used in adults and elderly people to protect against influenza caused by the strain (type) H5N1 of the influenza A virus.</seg>
<seg id="1895">"" "" "" "this is a special type of vaccine that could protect against a strain of the flu virus, which could cause a future pandemic." "" "" ""</seg>
<seg id="1896">"" "" "" "a influenza pandemic breaks out when a new strain of the flu virus appears, which can easily spread from man to man, because people still have no immunity." "" "" ""</seg>
<seg id="1897">"" "" "" "after administration of the vaccine, the immune system recognizes the parts of the influenza virus as" foreign body "and forms antibodies against it." "" "" ""</seg>
<seg id="1898">"" "" "" "in this way, the immune system will later be able to make contact with a influenza virus of this common molecule." "" "" ""</seg>
<seg id="1899">"" "" "" "subsequently, the membrane cover of the virus with the" surface antigens "(proteins on the membrane surface, which recognizes the human body as a foreign body), was purified and used as a component of the vaccine." "" "" ""</seg>
<seg id="1900">A survey of some of the study sites showed that the study was not carried out in accordance with the "Good Clinical Practice" (GCP).</seg>
<seg id="1901">"" "" "" "as a result, the extent of the clinical data basis for evaluating the safety of the vaccine was insufficient to meet the requirements of the EMEA guidelines for pre-pandemic vaccines." "" "" ""</seg>
<seg id="1902">"" "" "" "should you take part in a clinical trial and need more information about your treatment, please contact your doctor." "" "" ""</seg>
<seg id="1903">"" "" "" "if you would like further information on the basis of CHMP recommendations, please read the scientific discussion (also part of the EPAR)." "" "" ""</seg>
<seg id="1904">It is used in combination with other antiviral medicines for treating adults and children over four years which are infected with the human immunodeficiency virus type 1 (HIV-1) that causes the acquired immunodeficiency syndrome (AIDS).</seg>
<seg id="1905">"" "" "" "for patients who cannot swallow the capsules, asgenerase is available as a solution to intake, but this cannot be taken together with Ritonavir since the safety of this combination has not been studied." "" "" ""</seg>
<seg id="1906">"" "" "" "Agenerase should only be prescribed when the doctor has checked which antiviral medication the patient has previously taken, and the likelihood that the virus will respond to the medicine." "" "" ""</seg>
<seg id="1907">"" "" "" "the recommended dose for patients over twelve years is 600 mg twice daily, which together with twice daily 100 mg of pinion and other antiviral medicines are taken." "" "" ""</seg>
<seg id="1908">"" "" "" "in children between four and twelve years and in patients with a body weight of less than 50 kg, the recommended dose of asgenerase depends on body weight." "" "" ""</seg>
<seg id="1909">"" "" "" "in combination with other antiviral medicines, Agenerase lowers the HIV-quantity in the blood and keeps them at a low level." "" "" ""</seg>
<seg id="1910">"" "" "" "aids not to cure, however, can delay the damage of the immune system and thus also the development of associated infections and diseases." "" "" ""</seg>
<seg id="1911">"" "" "" "Agenerase was examined in combination with other antiviral medicines, but without knight studies, in two main studies with 736 HIV-infected adults who had previously not been treated with Protease inhibitors." "" "" ""</seg>
<seg id="1912">"" "" "" "the drug Agenerase, with low dose levels, was compared with other Protease inhibitors in 206 adults who had previously taken Protease inhibitors." "" "" ""</seg>
<seg id="1913">"" "" "" "the main indicator for efficacy was the proportion of patients with non-detectable concentrations of HIV in the blood (viral load), or the change in viral load after treatment." "" "" ""</seg>
<seg id="1914">"" "" "" "after 48 weeks under Agenerase more patients had a viral load of 400 copies / ml than placebo, but Agenerase was less effective than indinavir." "" "" ""</seg>
<seg id="1915">"" "" "" "in children, Agenerase also reduced the viral load, but with the children who had previously been treated with protease inhibitors, very few responded to the treatment." "" "" ""</seg>
<seg id="1916">"" "" "" "in the study with adults, who had previously been treated with Protease Inhibitors, the medication used to increase viral load after 16-week treatment was as effective as other Protease inhibitors:" "" "" ""</seg>
<seg id="1917">"" "" "" "in the patients with HIV, which was resistant to four other protease inhibitors, it came under Agenerase to a stronger viral load after four weeks than in patients receiving their previous protease inhibitors:" "" "" ""</seg>
<seg id="1918">"" "" "" "the most common side effects of asgenerase (observed in more than 1 of 10 patients) are headaches, diarrhoea, flatulence (nausea), vomiting, rash and fatigue." "" "" ""</seg>
<seg id="1919">2 / 3 Abosis may not be used in patients who may be hypersensitive (allergic) to amponavir or any of the other ingredients.</seg>
<seg id="1920">"" "" "" "Agenerase should also not be used in patients with currant (herbal supplement for the treatment of depression) or medicines, which are reduced equally to asgenerase and are harmful to health in high concentrations." "" "" ""</seg>
<seg id="1921">"" "" "" "as with other medicines for HIV, the risk of a lipodystrophy (changes in the distribution of body fat), osteoarthritis (loss of bone tissue) or an immune reactivation syndrome (symptoms of an infection caused by the regenerating immune system)." "" "" ""</seg>
<seg id="1922">The Committee for Medicinal Products (CHMP) concluded that the benefits of Agenerase in combination with other antiretroviral medicines used to treat HIV-1 infected adults and children over four years compared to the risks.</seg>
<seg id="1923">"" "" "" "Agenerase is usually taken together with the pharmacokinetic amplifier Ritonavir, but the committee noted that the use of Agenerase in combination with knight avir in patients previously did not have protease inhibitors is not proven." "" "" ""</seg>
<seg id="1924">"" "" "" "Agenerase was originally authorised under" exceptional circumstances, "since only limited information was available for scientific reasons." "" "" ""</seg>
<seg id="1925">"" "" "" "in October 2000, the European Commission granted the company Glaxo Group Limited a permit for the placing of Agenerase throughout the European Union." "" "" ""</seg>
<seg id="1926">"" "" "" "Agenerase is indicated in combination with other antiretroviral medicines for treating HIV-1 infected, Protease inhibitors (PI) -pre-treated adults and children over 4 years." "" "" ""</seg>
<seg id="1927">"" "" "" "usually, amonase capsules are to be administered to amexploavir pharmacokinetic boosters along with low doses of Ritonavir (see Sections 4.2 and 4.5)." "" "" ""</seg>
<seg id="1928">"" "" "" "the use of Amexploavir should take place in consideration of the individual viral resistance pattern and the pretreatment of the patient (see section 5.1)." "" "" ""</seg>
<seg id="1929">The bioavailability of Amexploavir as a solution to intake is 14% lower than from Amexploavir as capsule; hence Agenerase capsules and solution to intake on a milligram per milligram are not interchangeable (see Section 5.2).</seg>
<seg id="1930">"" "" "" "the recommended dose for Agenerase capsules is 600 mg amexploavir twice a day, together with 100 mg of pinion twice a day in combination with other antiretroviral medicines." "" "" ""</seg>
<seg id="1931">"" "" "" "2 If asgenerase capsules are used without the added addition of pinion (booster), higher doses of asgenerase (1200 mg twice daily) must be applied." "" "" ""</seg>
<seg id="1932">The recommended dose for Agenerase capsules is 20 mg amexploavir / kg body weight twice daily in combination with other antiretroviral medicines up to a daily dose of 2400 mg amexploavir that should not be exceeded (see section 5.1).</seg>
<seg id="1933">"" "" "" "pharmacokinetics, efficacy and safety of asgenerase in combination with low doses of Ritonavir or other protease inhibitors were not investigated in children." "" "" ""</seg>
<seg id="1934">"" "" "" "Agenerase is not recommended for use in children under 4 years, due to the absence of data for unacceptability and efficacy (see Section 5.2)." "" "" ""</seg>
<seg id="1935">"" "" "" "based on pharmacokinetic data, the dose of Agenerase capsules in adults with moderate liver dysfunctions should be reduced to 300 mg twice daily and in patients with severe liver function disorders." "" "" ""</seg>
<seg id="1936">"" "" "" "the simultaneous application should be performed with caution in patients with mild or moderate liver dysfunction, in patients with severe liver dysfunction (see Section 4.3)." "" "" ""</seg>
<seg id="1937">"" "" "" "Agenera must not be given at the same time with medicines which have a low therapeutic width, and can also present mediums of the Cytochrom P450-Isoenzyme 3A4 (CYP3A4)." "" "" ""</seg>
<seg id="1938">Herbal preparations containing currants (Hypericum perforatum) may not be applied because of the risk of reduced plasma concentrations and a reduced therapeutic effect of amponavir while taking amponavir (see Section 4.5).</seg>
<seg id="1939">Patients should be advised that asgenerase or any other antiretroviral therapy does not lead to a cure of HIV infection and that they can continue to develop opportunistic infections or other complications of HIV infection.</seg>
<seg id="1940">"" "" "" "the present antiretroviral therapy, including treatment with asgenerase, does not prevent the risk of transferring HIV to others through sexual contact or contamination with blood." "" "" ""</seg>
<seg id="1941">"" "" "" "usually, Agenerase capsules should be used together with low doses of knights and in combination with other antiretroviral medicines (see Section 4.2)." "" "" ""</seg>
<seg id="1942">"" "" "" "patients suffering from chronic hepatitis B or C and treated with antiretroviral therapy, have an increased risk of severe liver damage with potentially fatal progression." "" "" ""</seg>
<seg id="1943">"" "" "" "for the case of simultaneous antiviral treatment of hepatitis B or C, please consult the specialist information of this medicine." "" "" ""</seg>
<seg id="1944">Patients with advanced liver function including chronic-active hepatitis show increased frequency of liver dysfunctions under antiretroviral therapy and should be monitored in accordance with clinical practice.</seg>
<seg id="1945">The simultaneous use of Agenerase and Ritonavir with fluticason or other glucocorticoides which are confused by CYP3A4 is not recommended unless the potential benefits of a treatment exceed the risk of systemic corticosteroid effects including Morbus Cushing and Suppression of the adrenal function (see Section 4.5).</seg>
<seg id="1946">As the metabolism of the HMG-CoA-reductase inhibitor Lovastatin and Simvastatin is strongly dependent on CYP3A4 it is not recommended to administer Agenerase with Lovastatin and Simvastatin because of the increased risk of myopathies including Rhabdomyolysis.</seg>
<seg id="1947">"" "" "" "4 For some medicines which can cause serious or life-threatening adverse events such as carbamazepine, phenobarbital, phenytoin, tricyclic antidepressants and warfarin (under supervision of the International Normised Ratio), methods are available to determine the agent concentration." "" "" ""</seg>
<seg id="1948">"" "" "" "in patients who take these drugs simultaneously, Agenerase can be less effective because of reduced plasma levels of Amexploavir (see Section 4.5)." "" "" ""</seg>
<seg id="1949">"" "" "" "due to the possibility of metabolic interactions with Amexploavir, the efficacy of hormonal contraceptives can be altered but the information is not sufficient to assess the type of interactions." "" "" ""</seg>
<seg id="1950">"" "" "" "if methadone is also given with amponavir at the same time, the patients should be monitored on breath removal symptoms, especially if also low doses of Ritonavir are administered." "" "" ""</seg>
<seg id="1951">"" "" "" "due to the potential risk of toxicity due to the high propylene glycol content, this formulation is contraindicated in children under an age of four years and should be applied with caution in certain other patient populations." "" "" ""</seg>
<seg id="1952">"" "" "" "asgenerase should be cancelled in duration 5, if a rash of systemic or allergic symptoms is accompanied or the mucous membranes are involved (see Section 4.8)." "" "" ""</seg>
<seg id="1953">"" "" "" "in patients receiving antiretroviral therapy including protease inhibitors, diabetes mellitus, hyperglycemia or an examaceration of an existing diabetes mellitus was reported." "" "" ""</seg>
<seg id="1954">"" "" "" "many of the patients had other illnesses associated with therapy medications, which are associated with the development of diabetes mellitus or hyperglycemia." "" "" ""</seg>
<seg id="1955">"" "" "" "B. higher age, and with drug-dependent factors, such as a longer lasting antiretroviral treatment and associated metabolic disorders." "" "" ""</seg>
<seg id="1956">"" "" "" "in hemophile patients (type A and B) treated with protease inhibitors, reports of an increase of bleeding including spontaneous cutaneous hematoma and hematoma occur." "" "" ""</seg>
<seg id="1957">In the event of an antiretroviral combination therapy (ART) infected patients with severe immune defect can develop an inflammatory reaction to asymptomatic or residual opportunistic infections leading to severe clinical conditions or worsening symptoms.</seg>
<seg id="1958">"" "" "" "although a multifactorial etiology is assumed (including corticosteroids, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteoarthritis were reported especially in patients with advanced HIV disease and / or long-term use of antiretroviral therapy (ART)." "" "" ""</seg>
<seg id="1959">CYP3A4 substrates with low therapeutic width Agenerase should not be given at the same time with medicines which have a low therapeutic width and can also display mediums of the Cytochrom P450-Isoenzyme 3A4 (CYP3A4).</seg>
<seg id="1960">CYP2D6 substrates with low therapeutic width Agenerase with pinion may not be used together with medicines whose active ingredients are mainly confused with CYP2D6 and are associated with severe and / or life-threatening side effects.</seg>
<seg id="1961">"" "" "" "it has been shown that Rifampicin causes a 82% reduction in the AUC of Amexploavir, which can lead to virological failure and resistance development." "" "" ""</seg>
<seg id="1962">"" "" "" "in trying to compensate the reduced plasma levels by a dose increase of other protease inhibitors in combination with knight avir, adverse effects on the liver were observed." "" "" ""</seg>
<seg id="1963">St. John's wort (Hypericum perforatum) The serum levels of Amexploavir can be reduced by the simultaneous use of herbal preparations with currant (Hypericum perforatum).</seg>
<seg id="1964">"" "" "" "if a patient already occupies Johanniskraut, the ampar mirrors and, if possible, check the virus load and suspend currant." "" "" ""</seg>
<seg id="1965">A dose adjustment for one of the medicines is not required when nelfinavir is administered together with Amexploavir (see also Efavirenz below).</seg>
<seg id="1966">"" "" "" "508% increase, for Cmax. decreases by 30% if Ritonavir (100 mg twice daily) was administered in combination with Amexploavir capsules (600 mg twice daily)." "" "" ""</seg>
<seg id="1967">"" "" "" "in clinical studies, doses of 600 mg amexploavir twice daily and Ritonavir 100 mg twice daily were used to demonstrate the efficacy and harmlessness of this treatment scheme." "" "" ""</seg>
<seg id="1968">52% lower when Amexploavir (750 mg twice a day) was administered twice a day in combination with Kaletra (400 mg Lopinavir + 100 mg Ritonavir twice a day).</seg>
<seg id="1969">The Cmin-values of Amexploavir (600 mg twice a day) with Kaletra (400 mg Lopinavir + 100 mg Ritonavir twice a day) are approximately 40 to 50% lower than when Amexploavir (600 mg twice daily) is administered twice a day in combination with 100 mg.</seg>
<seg id="1970">"" "" "" "a dosage recommendation for the simultaneous administration of Amexploavir and Kaletra cannot be given, however, it is recommended a closely meshed monitoring as the effectiveness and harmlessness of this combination is not known." "" "" ""</seg>
<seg id="1971">"" "" "" "no pharmacokinetic trial was carried out in combination with Didanosin, however, due to the imaginary component of Didanosin it is recommended that the revenues of Didanosin and Agenerase are at least one hour apart (see Antazida below)." "" "" ""</seg>
<seg id="1972">"" "" "" "therefore, in combination with Amexploavir (600 mg twice a day) and knight raviolr (100 mg twice daily), dosage adjustment is required." "" "" ""</seg>
<seg id="1973">"" "" "" "the treatment with Efavirenz in combination with Amexploavir and Saquinavir is not recommended, as the exposure of both protease inhibitors would reduce." "" "" ""</seg>
<seg id="1974">The effect of Nevirapin on other protease inhibitors and existing limited data suggests that Nevirapin may reduce the serum concentration of Amexploavir.</seg>
<seg id="1975">"" "" "" "should these drugs be used simultaneously, caution is advisable because Delavirdin might be less effective because of the reduced or possibly subtherapeutic plasma levels." "" "" ""</seg>
<seg id="1976">"" "" "" "when these drugs are applied together, caution is advisable; a thorough clinical and virological monitoring should be made, as a precise prediction of the effect of the combination of Amexploavir and Ritonavir is difficult." "" "" ""</seg>
<seg id="1977">"" "" "" "the simultaneous administration of amexploavir and fabutin resulted in an increase in plasma concentration (AUC) of fabutin by 193%, resulting in a rise in adverse events associated with fabutin." "" "" ""</seg>
<seg id="1978">"" "" "" "if it is necessary for clinical reasons to administer Rickutin together with asgenerase, at least half of the recommended dose is advised, although there are no clinical data available for this." "" "" ""</seg>
<seg id="1979">"" "" "" "pharmacokinetic studies with asgenerase in combination with erythromycin were not carried out, however the plasma levels of both drugs could be increased in case of simultaneous administration." "" "" ""</seg>
<seg id="1980">The simultaneous application of twice daily 700 mg of Fosamexploavir and 100 mg ketoconazole once daily led to an increase of the Cmax of ketoconazol in the plasma by 25% and the AUC (0 degree) once daily without the simultaneous use of Fosamexploavir with ketovir.</seg>
<seg id="1981">"" "" "" "other drugs that are listed below, including substrates, inhibitors or inductors from CYP3A4, can possibly result in interactions with Agenerase." "" "" ""</seg>
<seg id="1982">"" "" "" "therefore, patients should be monitored for toxic reactions associated with these medicines if they are used in combination with asgenera." "" "" ""</seg>
<seg id="1983">"" "" "" "based on the data of other Protease inhibitors, it is advisable that antacids are not taken at the same time as asgenerase because it may cause resorption dysfunction." "" "" ""</seg>
<seg id="1984">"" "" "" "the simultaneous use of anticonvulsants known as enzyme ductors (phenytoin, phenobarbital, carbamazepine), with amexploavir can lead to a degradation of the plasma levels of Amexploavir." "" "" ""</seg>
<seg id="1985">"" "" "" "serum levels of calcium channel blockers such as amlodipine, diltiazem, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine." "" "" ""</seg>
<seg id="1986">"" "" "" "simultaneous intake of Agenerase can considerably increase its plasma concentrations and increase with PDE5 inhibitors associated with side effects including hypotension, vision disorders and priapism (see Section 4.4)." "" "" ""</seg>
<seg id="1987">In a clinical trial in which Ritonavir 100 mg capsules were given twice daily together with 50 µg fluticasonpropionate intranasal (4 times daily) over 7 days of subjects increased the endogenous cortisol decreased by about 86% (90% confidence interval 82 to 89%).</seg>
<seg id="1988">"" "" "" "as a result, the simultaneous gift of adrenase with knight caviar together with these glucocorticoides is not recommended unless the potential benefits of a treatment exceed the risk of systemic corticosteroid effects (see Section 4.4)." "" "" ""</seg>
<seg id="1989">HMG-CoA-reductase inhibitors such as Lovastatin and Simvastatin whose metabolism is strongly dependent on CYP3A4 are distinct increases in the plasma level while conserving asgenerase.</seg>
<seg id="1990">"" "" "" "as plasma level increases in this HMG-CoA Reductase inhibitors may lead to myopathy, including a Rhabdomyolysis, the combined use of these drugs with Amexploavir is not recommended." "" "" ""</seg>
<seg id="1991">"" "" "" "it is recommended more frequent monitoring of the therapeutic concentrations to stabilizing the mirror, as the plasma concentrations can be increased by cyclosporine, rapamycin and tacrolimus, while simultaneously offering amponavir (see Section 4.4)." "" "" ""</seg>
<seg id="1992">"" "" "" "therefore, Agenerase cannot be used together with orally taken midazolam (see Section 4.3) while using asgenerase with parenteral Midazolam caution." "" "" ""</seg>
<seg id="1993">Data for simultaneous use of parenteral midazolam with other protease inhibitors point to a possible increase in the plasma level of Midazolam by 3 to 4 faeces.</seg>
<seg id="1994">"" "" "" "if methadone is administered together with Amexploavir, patients should therefore be monitored for emergency symptoms, especially if also low doses of Ritonavir are administered." "" "" ""</seg>
<seg id="1995">"" "" "" "because of the low reliability of historic comparisons, no recommendation can be given at the moment, as the ampar dose is adapted once amponavir is administered with methadone at the same time." "" "" ""</seg>
<seg id="1996">"" "" "" "with simultaneous gift of warfarin or other oral anticoagulants, an increased control of the INR (International Normised Ratio) is recommended because of the possibility of weakening or reinforcing the antithrombotic effect (see Section 4.4)." "" "" ""</seg>
<seg id="1997">"" "" "" "the effect of an additional administration of knight on hormonal contraceptives is not predictable, so alternative methods for contraception are also recommended." "" "" ""</seg>
<seg id="1998">Careful observation of the therapeutic effects and side effects of tricyclic antidepressants (for example Desipramine and Nortryptilin) is recommended at the same time with angenerase (see Section 4.4).</seg>
<seg id="1999">"" "" "" "during pregnancy, this drug may only be used after careful weighing of possible benefits for the mother compared to the possible risks for the fetus." "" "" ""</seg>
<seg id="2000">"" "" "" "in the milk lactate rats, amexploavir related substances were detected, but it is not known whether amexploavir is transferred to the mother's milk." "" "" ""</seg>
<seg id="2001">"" "" "" "during the lactation period, a decreased increase in 12 body weight during the lactation period showed a reduction in pregnant rats." "" "" ""</seg>
<seg id="2002">"" "" "" "the further development of descendants, including fertility and reproductive capacity, was not affected by the administration of Amexploavir to the dam." "" "" ""</seg>
<seg id="2003">"" "" "" "in adults and children over the age of 4, the safety of Agenerase was examined in controlled clinical trials in combination with various other antiretroviral medicines." "" "" ""</seg>
<seg id="2004">"" "" "" "most of the side effects associated with the asgenerase treatment were moderate to moderate, occurred early and rarely resulted in the treatment outbreak." "" "" ""</seg>
<seg id="2005">"" "" "" "in many of these events, it is not clear whether they are related to taking Agenerase or another at the same time for the treatment of HIV treatment or whether they are a consequence of the disease." "" "" ""</seg>
<seg id="2006">"" "" "" "most of the side effects listed below stem from two clinical trials (PROAB3001, PROAB3006), in which previously untreated patients receive 1200 mg of Agenerase twice daily." "" "" ""</seg>
<seg id="2007">Events (degree 2 to 4) which were evaluated by the investigators as related to the study medication and were performed with more than 1% of the patients as well as laboratory changes occurring during the treatment (Grade 3 to 4).</seg>
<seg id="2008">Antiretroviral combination therapy was associated with a redistribution of the body fat (lipodystrophy) in HIV patients including loss of peripheral and faal subcutaneous fat tissue. hypertrophy of the breasts and dorsocervical fat accumulation (bull crack).</seg>
<seg id="2009">"" "" "" "among 113 antiretroviral inhibitors treated with amnivudine in combination with lamivudin / Zidovudine over an average duration of 36 weeks, only one case (stitching) (&lt; 1%) was observed." "" "" ""</seg>
<seg id="2010">In the study PROAB 3006 patients with 245 NRTIs performed 7 cases (3%) compared to 27 cases (11%) in 241 patients under Indinavir in combination with different NRTIs over a mean duration of 56 weeks (p &lt; 0.001).</seg>
<seg id="2011">"" "" "" "skin rashes were generally mild to moderately pronounced, erythematous or makulopapilous nature, with or without itching and spontaneously disappeared during the second week of treatment and disappeared spontaneously within two weeks without the treatment with Amexploavir." "" "" ""</seg>
<seg id="2012">Cases of osteoarthritis were reported in particular in patients with generally known risk factors such as advanced HIV disease or long-term use of antiretroviral therapy (ART).</seg>
<seg id="2013">In the event of an antiretroviral combination therapy (ART) infected patients with severe immune defect can develop an inflammatory reaction to asymptomatic or residual opportunistic infections (see Section 4.4).</seg>
<seg id="2014">"" "" "" "patients receiving 600 mg of Agenerase twice a day with low dose levels (Grade 2 to 4) and laboratory changes (Grade 3 and 4) were observed, except for increased levels of triglycerid and CPK patients." "" "" ""</seg>
<seg id="2015">"" "" "" "in case of overdose, the patient is able to observe signs of an intoxication (see Section 4.8) if necessary are necessary supporting measures to be initiated." "" "" ""</seg>
<seg id="2016">"" "" "" "amexploavir binds to the active centre of HIV-1 protease, thereby preventing the process of viral gene and gag-polarity with the result of a formation of unprovoked, non-infectious viral particles." "" "" ""</seg>
<seg id="2017">"" "" "" "the anti-viral activity of Amexploavir in vitro against HIV-1 IIIB was examined both on acute and chronic lymphoblastic cell lines (MT-4, CEM-CCRF, H9) and peripheral blood lymphocytes." "" "" ""</seg>
<seg id="2018">The 50% inhibit concentration (IC50) of amexploavir lies in the range between 0,012 to 0.08 µM in acute infected cells and is 0.41 µM in case of chronic infected cells.</seg>
<seg id="2019">The connection between the activity of Amexploavir against HIV-1 in vitro and the inhibition of HIV-1 replication in humans is not yet defined.</seg>
<seg id="2020">"" "" "" "in the treatment of antiretroviral treated patients with the currently approved Fosamexploavir / Ritonavir dosages, the described mutations were rarely observed." "" "" ""</seg>
<seg id="2021">"" "" "" "in the age of sixteen of 434 antiretroviral patients who received 700mg of Fosamexploavir twice a day in the trial ESS100732, a virological failure occurred by week 48, whereby 14 isolates could be examined genotypically." "" "" ""</seg>
<seg id="2022">"" "" "" "a genotypic analysis of 13 out of 14 children, in which a virological failure occurred within the 59 patients, showed resistance patterns, similar to those in adults." "" "" ""</seg>
<seg id="2023">"" "" "" "L10F / I / V, V11I, V32I, I50V, I50V, I50V, I54V, I82A / I, I84V, I82A / M / V, I84V, I82A / M / V, I84V, I82A / M." "" "" ""</seg>
<seg id="2024">"" "" "" "in the APV30003 study and its extension APV30005 (700 mg of Fosamexploavir twice daily: n = 107) in patients with virological failure over 96 weeks, the following protease inhibitors appeared:" "" "" ""</seg>
<seg id="2025">Genotypic interpretation systems based on genotypic resistance testing can be used to estimate the activity of amponavir / Ritonavir or Fosamexploavir / Ritonavir in patients with protease inhibitor isolates.</seg>
<seg id="2026">The current (July 2006) ANRS-AC-11 algorithm for Fosamexploavir / Ritonavir defines resistance as the presence of mutations V32I + 147a / V / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / F / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M / M</seg>
<seg id="2027">"" "" "" "the conclusions regarding the relevance of certain mutations or mutations may be subject to additional data, and it is recommended to always draw up the current interpretation systems for analysing the results of resistance tests." "" "" ""</seg>
<seg id="2028">Phenotypic interpretation systems based on phenotypic resistance testing can be used in conjunction with genotypic data to estimate the activity of amponavir / Ritonavir or Fosamexploavir / Ritonavir in patients with protease inhibitor isolates.</seg>
<seg id="2029">Companies that distribute diagnostic resistance tests have developed clinical-phenotypical cut-offs (separation points) for FPV / RTV which can be used for the interpretation of results of a resistance test.</seg>
<seg id="2030">"" "" "" "each four with a reduced sensitivity to Amexploavir associated genetic patterns produces a certain cross resistance to knight avir, but the sensitivity to indinavir, nelfinavir and Saquinavir is generally preserved." "" "" ""</seg>
<seg id="2031">"" "" "" "there are currently data for cross resistance between Amexploavir and other protease inhibitors for all 4 Fosamexploavir resistances, either alone or in combination with other mutations." "" "" ""</seg>
<seg id="2032">"" "" "" "on the basis of twenty-five antiretroviral and not pre-treated patients (one of 25 isolates), Darunavir / Ritonavir (three out of 24 isolates), Darunavir / Ritonavir (three out of 24 isolates), renounavir / Ritonavir (four out of 24 isolates)." "" "" ""</seg>
<seg id="2033">"" "" "" "vice versa, Amexploavir reserves its activity against some other protease inhibitor resistant isolates; maintaining this activity seems to depend on the number and type of resistance mutations in the isolates." "" "" ""</seg>
<seg id="2034">Early demolition of a failing therapy is recommended to limit the accumulation of a variety of mutations that can affect subsequent treatment.</seg>
<seg id="2035">The evidence of the efficacy of Agenerase in combination with rite avir 100 mg twice a day is based on the study PRO30017 (600 mg twice daily) and nucleoavir (100 mg twice daily) and nucleoavir (100 mg twice daily) and a standard therapy (standard of care, SOC) with a PI.</seg>
<seg id="2036">"" "" "" "one hundred threescore (n = 163) patients with proven virus sensitivity compared to Agenerase, at least another PI and at least one NRTI were included in the study A of PRO30017." "" "" ""</seg>
<seg id="2037">The primary analysis showed the non-superiority of APV / Ritonavir compared to the SOC-PI group in the viral load (HIV-1 RNA) in the viral load (HIV-1 RNA) in the plasma after 16 weeks in a non-slip threshold of 0.4 to 10 copies / ml.</seg>
<seg id="2038">"" "" "" "evidence of the efficacy of unbiased asgenerase is based on two uncontrolled trials involving 288 HIV-infected children aged 2 to 18, of which 152 were pre-treated with PI." "" "" ""</seg>
<seg id="2039">"" "" "" "in the studies, asgenerase solution for intake and capsules in dosages of 15 mg / kg three times daily, 20 mg / kg twice daily and 22.5 mg / kg twice daily, with the majority of patients received 20 mg / kg twice daily." "" "" ""</seg>
<seg id="2040">No low dose ritonavir was given at the same time; the majority of patients treated with PI previously had at least one (78%) or two (42%) of the NRTIs administered together with Agenerase.</seg>
<seg id="2041">After 48 weeks approximately 25% of patients included a plasma-HIV-1 RNA concentration of &lt; 10.000 copies / ml and 9% &lt; 400 copies / ml in a median increase of CD4 cell count of 26 cells / mm ³ (n = 74).</seg>
<seg id="2042">"" "" "" "19 In order to optimize treatment with PI preset children, 19 Basically on these data should be considered to be the expected benefits of" unbiased "asgenera." "" "" ""</seg>
<seg id="2043">"" "" "" "after oral administration, the average duration (Tmax) to the maximum serum concentration of Amexploavir takes about 1 to 2 hours for the capsule and about 0.5 to 1 hour for the solution." "" "" ""</seg>
<seg id="2044">"" "" "" "508% increase, for Cmax, by 30%, when Ritonavir (100 mg twice daily) was administered together with Amexploavir (600 mg twice daily)." "" "" ""</seg>
<seg id="2045">"" "" "" "the administration of Amexploavir with a meal results in a 25% decline in AUC, but has no effect on the concentration of Amexploavir 12 hours after dosage (C12)." "" "" ""</seg>
<seg id="2046">"" "" "" "therefore the minimum concentration in the Steady State (Cmin, ss) was impacted by the intake of food although the simultaneous eating intake affects the extent and rate of resorption." "" "" ""</seg>
<seg id="2047">"" "" "" "the apparent distribution volume amounts to about 430 litres (6 l / kg at a weight of 70 kg) and can be closed to a large distribution volume, as well as an unobstructed penetration of the blood stream into the tissue." "" "" ""</seg>
<seg id="2048">"" "" "" "this change leads to a decrease in the total concentration of the active ingredient in the plasma, with the amount of unbound amexploavir that represents the active part, probably remains unchanged." "" "" ""</seg>
<seg id="2049">"" "" "" "while absolute concentration remains constant, the percentage of free active components fluctuates depending on the total dose concentration in the Steady State over the range of Cmax, ss to Cmin, ss." "" "" ""</seg>
<seg id="2050">"" "" "" "therefore, drugs that induce or inhibit CYP3A4 or a substrate of CYP3A4 must be given with care if they are given at the same time with asgenerase (see Sections 4.3, 4.4 and 4.5)." "" "" ""</seg>
<seg id="2051">"" "" "" "the gift of Agenerase capsules, either 20 mg / kg twice or 15 mg / kg three times a day, leads to a similar daily ampar exposure as in adults with a dosage of 1200 mg twice daily." "" "" ""</seg>
<seg id="2052">"" "" "" "Amexploavir is from the solution 14% less bioavailability than from the capsules, hence, Agenerase solution and Agenerase capsules are not interchangeable on a milligram basis." "" "" ""</seg>
<seg id="2053">"" "" "" "the renal Clearance of Ritonavir is also negligible, so the effect of a renal dysfunction on the elimination of Amexploavir and Ritonavir is likely to be low." "" "" ""</seg>
<seg id="2054">"" "" "" "these treatment schemes lead to Amexploavir plasma levels, comparable to those obtained at healthy subjects after a dose of 1200 mg amexploavir twice a day without the simultaneous administration of knight cavir." "" "" ""</seg>
<seg id="2055">"" "" "" "in long-term studies on carcinogenicity in mice and rats, genigne hepatocellular adenomas (rats) or 3,8- times (rat) of exposure to humans, after twice daily application of 1200 mg amexploavir." "" "" ""</seg>
<seg id="2056">The 21 underlying mechanism for the formation of hepatocellular adenomas and carcinomas has not yet been clarified and the relevance of these observed effects is unclear.</seg>
<seg id="2057">"" "" "" "however, little evidence of the clinical relevance of these findings resulted from the exposure data of the human being from clinical studies as well as from the therapeutic application." "" "" ""</seg>
<seg id="2058">"" "" "" "in a standard battery of in-vivo- and in-vitro genotoxicity tests, the bacterial reverse mutation tests (Ames test), microkernel test in rats and chromosomenaberrations in human peripheral lymphocytes, was neither mutagen, nor genotoxic." "" "" ""</seg>
<seg id="2059">"" "" "" "this liver toxicity can be monitored and proven in clinical everyday life by measuring AST, ALT and the activity of alkaline phosphatase." "" "" ""</seg>
<seg id="2060">"" "" "" "previously, no significant liver toxicity was observed in patients in clinical studies, neither during the administration of asgenerase after the end of the treatment." "" "" ""</seg>
<seg id="2061">"" "" "" "studies on toxicity in young animals treated at the age of 4 showed a high mortality, both in the control animals and in the animals treated with amponavir." "" "" ""</seg>
<seg id="2062">"" "" "" "however, a number of minor changes including thyme elongation and minor skeletal changes were observed, which indicate a delayed development." "" "" ""</seg>
<seg id="2063">"" "" "" "24 If asgenerase capsules are used without the added addition of pinion (booster), higher doses should be applied to asgenerase (1200 mg twice daily)." "" "" ""</seg>
<seg id="2064">The recommended dose for Agenerase capsules is 20 mg amexploavir / kg body weight twice daily in combination with other antiretroviral medicines up to a daily dose of 2400 mg amexploavir that should not be exceeded (see section 5.1).</seg>
<seg id="2065">"" "" "" "the simultaneous application should be performed with caution in patients with weak or slight liver dysfunction, in patients with severe liver dysfunction (see Section 4.3)." "" "" ""</seg>
<seg id="2066">"" "" "" "26 For some medicines which can cause serious or life-threatening adverse events such as carbamazepine, phenobarbital, phenytoin, tricyclic antidepressants and warfarin (under supervision of the International Normised Ratio), methods are available to determine the concentration of active substances." "" "" ""</seg>
<seg id="2067">"" "" "" "Agenerase should be reduced to 27 if a rash is accompanied by systemic or allergic symptoms, or the mucous membranes are involved (see Section 4.8)." "" "" ""</seg>
<seg id="2068">"" "" "" "an increased risk of a lipodystrophy was associated with individual factors such as higher age, and with drug-dependent factors such as a longer-lasting antiretroviral treatment and associated metabolic disorders." "" "" ""</seg>
<seg id="2069">"" "" "" "it has been shown that Rifampicin causes a 82% reduction in the AUC of Amexploavir, which can lead to virological failure and resistance development." "" "" ""</seg>
<seg id="2070">"" "" "" "508% increase, for Cmax. decreases by 30% if Ritonavir (100 mg twice daily) was administered in combination with Amexploavir capsules (600 mg twice daily)." "" "" ""</seg>
<seg id="2071">The Cmin-values of Amexploavir (600 mg twice a day) with Kaletra (400 mg Lopinavir + 100 mg Ritonavir twice a day) are approximately 40 to 50% lower than when Amexploavir (600 mg twice daily) is administered twice a day in combination with 100 mg.</seg>
<seg id="2072">"" "" "" "a dosage recommendation for the simultaneous administration of Amexploavir and Kaletra cannot be given, however, it is recommended a closely meshed monitoring as the effectiveness and harmlessness of this combination is not known." "" "" ""</seg>
<seg id="2073">"" "" "" "the treatment with Efavirenz in combination with Amexploavir and Saquinavir is not recommended, as the exposure of both protease inhibitors would reduce." "" "" ""</seg>
<seg id="2074">"" "" "" "when these drugs are applied together, caution is advisable; a thorough clinical and virological monitoring should be made, as a precise prediction of the effect of the combination of Amexploavir and Ritonavir is difficult." "" "" ""</seg>
<seg id="2075">"" "" "" "if it is necessary for clinical reasons to administer Rickutin together with Agenerase, at least half of the recommended dose is 31, although there are no clinical data available for this." "" "" ""</seg>
<seg id="2076">"" "" "" "serum levels of calcium channel blockers such as amlodipine, diltiazem, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine, nifedipine." "" "" ""</seg>
<seg id="2077">In a clinical trial in which Ritonavir 100 mg capsules were given twice daily together with 50 µg fluticasonpropionate intranasal (4 times daily) over 7 days of subjects increased the endogenous cortisol decreased by about 86% (90% confidence interval 82 to 89%).</seg>
<seg id="2078">"" "" "" "with simultaneous gift of warfarin or other oral anticoagulants, an increased control of the INR (International Normised Ratio) is recommended because of the possibility of weakening or reinforcing the antithrombotic effect (see Section 4.4)." "" "" ""</seg>
<seg id="2079">Simultaneous administration of ortho-Novum 1 / 35 (0.035 mg ethinylestradiol plus 1.0 mg Norethindron) resulted in a decrease in the AUC and Cmin by Amexploavir by 22% respectively.</seg>
<seg id="2080">"" "" "" "during pregnancy, this drug may only be applied after careful weighing of possible benefits for the mother compared to possible risks for the fetus." "" "" ""</seg>
<seg id="2081">"" "" "" "during the lactation period, a decreased increase in body weight during the lactation period showed a diminished increase in body weight during breastfeeding." "" "" ""</seg>
<seg id="2082">"" "" "" "in adults and children over the age of 4, the safety of Agenerase was examined in controlled clinical trials in combination with various other antiretroviral medicines." "" "" ""</seg>
<seg id="2083">"" "" "" "in case of overdose, the patient is able to observe signs of an intoxication (see Section 4.8) if necessary are necessary supporting measures to be initiated." "" "" ""</seg>
<seg id="2084">"" "" "" "the anti-viral activity of Amexploavir in vitro against HIV-1 IIIB was examined both on acute and chronic lymphoblastic cell lines (MT-4, CEM-CCRF, H9) and peripheral blood lymphocytes." "" "" ""</seg>
<seg id="2085">The 50% inhibit concentration (IC50) of amexploavir lies in the range between 0,012 to 0.08 µM in acute infected cells and is 0.41 µM in chronic infected cells (1 µM = 0.50 µg / ml).</seg>
<seg id="2086">"" "" "" "vice versa, Amexploavir reserves its activity against some other protease inhibitor resistant isolates; maintaining this activity seems to depend on the number and type of resistance mutations in the isolates." "" "" ""</seg>
<seg id="2087">"" "" "" "based on these data, the benefit of" unbiased "asgenerase should be considered in the treatment optimisation of patients treated with PI." "" "" ""</seg>
<seg id="2088">"" "" "" "while absolute concentration remains constant, the percentage of free active components fluctuates depending on the total dose concentration in the Steady State over the range of Cmax, ss to Cmin, ss." "" "" ""</seg>
<seg id="2089">"" "" "" "therefore, drugs that induce or inhibit CYP3A4 or a substrate of CYP3A4 must be given with care if they are given at the same time with asgenerase (see Sections 4.3, 4.4 and 4.5)." "" "" ""</seg>
<seg id="2090">"" "" "" "also, the renal Clearance of Ritonavir is negligible; hence the effect of a renal dysfunction on the elimination of Amexploavir and Ritonavir is likely to be low." "" "" ""</seg>
<seg id="2091">In long-term studies on carcinogenicity in mice and rats occurring in male animals benign hepatocellular adenomas observed in dosages of 2,0-times (rats) of exposure to humans after twice daily dosage of 1200 mg amexploavir.</seg>
<seg id="2092">The underlying mechanism for the formation of hepatocellular adenomas and carcinomas has not yet been clarified and the relevance of these observed effects is unclear.</seg>
<seg id="2093">"" "" "" "however, from the present exposure data to humans, both clinical trials and the therapeutic application, however, there were little evidence for the clinical relevance of these findings." "" "" ""</seg>
<seg id="2094">"" "" "" "in a standard battery of in-vivo- and in-vitro genotoxicity tests, the bacterial reverse mutation tests (Ames test), microkernel test in rats and chromosomenaberrations in human peripheral lymphocytes, was neither mutagen, nor genotoxic." "" "" ""</seg>
<seg id="2095">"" "" "" "studies on toxicity in young animals treated at the age of 4 showed a high mortality, both in the control animals and in the animals treated with amponavir." "" "" ""</seg>
<seg id="2096">"" "" "" "these results suggest that the metabolisation routes are not fully mature in young animals, causing amponavir or other critical components of the formulation (z." "" "" ""</seg>
<seg id="2097">"" "" "" "Agenerase solution for intake is indicated in combination with other antiretroviral medicines for the treatment of HIV-1 infected, Protease inhibitors (PI) -pre-treated adults and children over 4 years." "" "" ""</seg>
<seg id="2098">"" "" "" "the use of" "" "" "" "geboosterer" "" "" "" "Agenerase solution was not approved for patients with PI previously treated." "" "" ""</seg>
<seg id="2099">The bioavailability of Amexploavir as a solution to intake is 14% lower than from Amexploavir as capsule; hence Agenerase capsules and solution to intake on a milligram per milligram are not interchangeable (see Section 5.2).</seg>
<seg id="2100">"" "" "" "patients should, as soon as they are able to swallow the capsules, stop taking the solution to take up (see Section 4.4)." "" "" ""</seg>
<seg id="2101">The recommended dose for Agenerase solution amounts to 17 mg (1.1 ml) Amexploavir / kg body weight three times a day in combination with other antiretroviral medicines up to a daily dose of 2800 mg amexploavir that should not be exceeded (see section 5.1).</seg>
<seg id="2102">"" "" "" "in addition, there should be no dosage recommendation for simultaneous application of Agenerase solution to intake and low dosed knight caviar, this combination with these patient groups can be avoided." "" "" ""</seg>
<seg id="2103">"" "" "" "although a dose adjustment for Amexploavir is not considered necessary, an application of Agenerase solution is contraindicated in patients with kidney failure (see Section 4.3)." "" "" ""</seg>
<seg id="2104">"" "" "" "due to the potential risk of toxic reaction as a result of high Propylene glycol content, Agenerase is contraindicated in pregnant women, patients with impaired liver function or liver failure, and in patients with kidney failure." "" "" ""</seg>
<seg id="2105">"" "" "" "simultaneous administration may lead to a competitive inhibition of the metabolisation of these drugs, and may cause serious and / or life-threatening adverse events such as cardiac arrhythmia (z)." "" "" ""</seg>
<seg id="2106">Patients should be advised that asgenerase or any other antiretroviral therapy does not lead to a cure of HIV infection and that they continue to develop opportunistic infections or other complications of HIV infection.</seg>
<seg id="2107">"" "" "" "the present antiretroviral therapy, including treatment with asgenerase, does not prevent the risk of transmission from HIV to others through sexual contact or contamination with blood." "" "" ""</seg>
<seg id="2108">"" "" "" "for some medicines which can cause serious or life-threatening adverse events such as carbamazepine, phenobarbital, phenytoin, tricyclic antidepressants and warfarin (under supervision of the International Normised Ratio), methods are available to determine the concentration of active substances." "" "" ""</seg>
<seg id="2109">"" "" "" "if a rash is accompanied by systemic or allergic symptoms or the mucous membranes are involved (see Section 4.8)." "" "" ""</seg>
<seg id="2110">"" "" "" "an increased risk of a lipodystrophy was associated with individual factors such as higher age, and with drug-49 dependent factors, such as a prolonged antiretroviral treatment and associated metabolic disorders." "" "" ""</seg>
<seg id="2111">"" "" "" "in hemophile patients (type A and B) treated with protease inhibitors, reports of an increase of bleeding including spontaneous cutaneous hematoma and hematoma occur." "" "" ""</seg>
<seg id="2112">"" "" "" "it has been shown that Rifampicin causes a 82% reduction in the AUC of Amexploavir, which can lead to virological failure and resistance development." "" "" ""</seg>
<seg id="2113">"" "" "" "508% increase, for Cmax. decreases by 30% if Ritonavir (100 mg twice daily) was administered in combination with Amexploavir capsules (600 mg twice daily)." "" "" ""</seg>
<seg id="2114">"" "" "" "simultaneous intake of Agenerase can considerably increase its plasma concentrations and increase with PDE5 inhibitors associated with side effects including hypotension, vision disorders and priapism (see Section 4.4)." "" "" ""</seg>
<seg id="2115">"" "" "" "based on the data on 54 other CYP3A4 inhibitors, Midazolam significantly higher plasma concentrations of Midazolam." "" "" ""</seg>
<seg id="2116">"" "" "" "the potential risk for humans is unknown. due to possible toxic reactions, the fetus should not be used during pregnancy (see Section 4.3)." "" "" ""</seg>
<seg id="2117">"" "" "" "in the milk lactate rats, amexploavir related substances were detected, but it is not known whether amexploavir is transferred to the mother's milk." "" "" ""</seg>
<seg id="2118">"" "" "" "during the lactation period, a decreased increase in 55 body weight was shown during the lactation period." "" "" ""</seg>
<seg id="2119">"" "" "" "in adults and children over the age of 4, the safety of Agenerase was examined in controlled clinical trials in combination with various other antiretroviral medicines." "" "" ""</seg>
<seg id="2120">"" "" "" "in many of these events, it is not clear whether they are related to taking Agenerase or another at the same time for the treatment of HIV treatment or whether they are a consequence of the disease." "" "" ""</seg>
<seg id="2121">"" "" "" "in the treatment of antiretroviral treated patients with the currently approved Fosamexploavir / Ritonavir dosages, the described mutations were rarely observed." "" "" ""</seg>
<seg id="2122">"" "" "" "early departure of a failing 60 therapy is recommended to limit the accumulation of a variety of mutations, which can have a detrimental effect on subsequent treatment." "" "" ""</seg>
<seg id="2123">"" "" "" "based on these data, 62% of this data should be considered to be the benefit of" unbiased "asgenera." "" "" ""</seg>
<seg id="2124">The apparent distribution volume amounts to about 430 litres (6 l / kg at a weight of 70 kg) and can be close to a large cousin volume and an unhindered penetration of amexploavir from the bloodstream into the tissue.</seg>
<seg id="2125">The underlying mechanism for the genesis of hepatocellular adenomas and carcinomas has not yet been clarified and the relevance of these observed effects is unclear.</seg>
<seg id="2126">"" "" "" "however, a number of minor changes including thyme elongation and minor skeletal changes were observed, which indicate a delayed development." "" "" ""</seg>
<seg id="2127">"" "" "" "if you have any further questions, please contact your doctor or pharmacist. - This medicine was personally prescribed to you." "" "" ""</seg>
<seg id="2128">"" "" "" "it can harm other people even if they have the same ailments as you. − If any of the listed side effects you have significantly impaired or you notice side effects that are not stated in this manual information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="2129">"" "" "" "your doctor will usually instruct you to use Agenerase capsules, along with low doses of Ritonavir to increase the effect of asgenerase." "" "" ""</seg>
<seg id="2130">"" "" "" "the use of asgenerase is based on the individual viral resistance test carried out by your doctor, and your treatment history." "" "" ""</seg>
<seg id="2131">"" "" "" "tell your doctor if you are suffering from any of the above-mentioned conditions, or take any of the drugs above." "" "" ""</seg>
<seg id="2132">"" "" "" "if your doctor has recommended that you take Agenerase capsules along with low doses of knight avir to enhance the effect (boosters), make sure you have read the utility information about Ritonavir carefully before the treatment begins." "" "" ""</seg>
<seg id="2133">"" "" "" "there is also no adequate information to recommend the application of Agenerase capsules together with knight avir for the impact amplification of children aged 4 to 12, or in general in patients under 50 kg of body weight." "" "" ""</seg>
<seg id="2134">"" "" "" "therefore, it is important that you read the section" When taking Agenerase with other medicines, "before you start taking Agenerase." "" "" ""</seg>
<seg id="2135">"" "" "" "you may need additional factor VIII to control bleeding. − In patients receiving an antiretroviral combination therapy, a redistribution, collection or loss of body fat can occur." "" "" ""</seg>
<seg id="2136">"" "" "" "if you have certain medicines which may lead to serious side effects such as carbamazepine, phenytoin, lidocaine, rapamycin, tricyclic antidepressants, lidocaine, rapamycin, tricyclic antidepressants, lidocaine, rapamycin, rapamycin, rapamycin, rapamycin, lidocaine, lidocaine, rapamycin, rapamycin, lidocaine, rapamycin, rapamycin, lidocaine, rapamycin, lidocaine, rapamycin, rapamycin, lidocaine, rapamycin, lidocaine, rapamycin, rapamycin, lidocaine, rapamycin, rapamycin, lidocaine, rapamycin, lidocaine." "" "" ""</seg>
<seg id="2137">"" "" "" "" "" "" "" "it is recommended that HIV positive women should not breastfeed their children under no circumstances to prevent HIV transmission." "" "" ""</seg>
<seg id="2138">"" "" "" "traffic tightness and operation of machines There were no studies on the influence of asgenera on the driving ability, or the ability to operate machines." "" "" ""</seg>
<seg id="2139">"" "" "" "please take this medicine after consultation with your doctor, if you know that you suffer from an intolerance to certain sugars." "" "" ""</seg>
<seg id="2140">"" "" "" "taking Didanosin), it is advisable that you take this more than one hour before or after agenerase, otherwise the effects of atherase can be reduced." "" "" ""</seg>
<seg id="2141">"" "" "" "dose of Agenerase capsules is 600 mg twice a day, together with 100 mg of pinion twice a day in combination with other antiretroviral medicines." "" "" ""</seg>
<seg id="2142">"" "" "" "if your doctor decides that taking Ritonavir is not suitable for you, you will need to take higher doses (1200 mg amexploavir twice daily)." "" "" ""</seg>
<seg id="2143">"" "" "" "85 With it Agenerase brings as much benefit as possible, it is very important that you take the entire daily dose that your doctor has prescribed." "" "" ""</seg>
<seg id="2144">"" "" "" "if you have taken a larger amount of asgenerase than you should have taken more than the prescribed dose of asgenerase, you should contact your doctor or pharmacist immediately." "" "" ""</seg>
<seg id="2145">"" "" "" "if you have forgotten taking asterase if you have forgotten taking asterase, take it as soon as you think about it and then continue taking the intake as before." "" "" ""</seg>
<seg id="2146">"" "" "" "in the treatment of an HIV infection, it is not always possible to say whether any side effects caused by asgenerase are caused by other medicines which are taken at the same time, or caused by the HIV disease itself." "" "" ""</seg>
<seg id="2147">"" "" "" "headache, fatigue, diarrhoea, vomiting, vomiting, flatulence skin rash (redness, blisters or itching) - occasionally the rash may be of serious nature and you may force you to stop taking this medicine." "" "" ""</seg>
<seg id="2148">"" "" "" "mood disorders, depression, sleep disorders, loss of appetite Kribbles in the lips and in mouth, uncontrollable movements pain, discomfort or excessive stomach enzymes, which are called transamines, increase of an enzyme of the pancreas called Amylase" "" "" ""</seg>
<seg id="2149">"" "" "" "elevated blood levels for sugar or cholesterol (a particular blood fat) Increased blood values of a substance called bilirubin swelling of the face, lips and tongue (angioödem bzw)." "" "" ""</seg>
<seg id="2150">"" "" "" "this can include fat loss on legs, arms and face, fat increase in the abdomen and in other internal organs, breast augmentation and fat growths in the neck (" pins ")." "" "" ""</seg>
<seg id="2151">Please inform your doctor or pharmacist if any of the listed side effects do significantly affect you or notice side effects that are not stated in this information.</seg>
<seg id="2152">"" "" "" "therefore, it is important that you read the section" When taking Agenerase with other medicines, "before you start taking Agenerase." "" "" ""</seg>
<seg id="2153">"" "" "" "in some patients who receive antiretroviral therapy, osteoarthritis may develop (the death of bone tissue due to insufficient blood supply)." "" "" ""</seg>
<seg id="2154">"" "" "" "taking Didanosin), it is advisable that you take this more than one hour before or after agenerase, otherwise the effects of atherase can be reduced." "" "" ""</seg>
<seg id="2155">"" "" "" "94 With it Agenerase brings as much benefit as possible, it is very important that you take the entire daily dose that your doctor has prescribed." "" "" ""</seg>
<seg id="2156">"" "" "" "if you have forgotten taking astbladder if you have forgotten taking asterase, take it as soon as you think about it and then continue taking it as before." "" "" ""</seg>
<seg id="2157">"" "" "" "headache, fatigue, diarrhoea, vomiting, vomiting, flatulence skin rash (redness, blisters or itching) - occasionally the rash may be of serious nature and you may force you to stop taking this medicine." "" "" ""</seg>
<seg id="2158">Please inform your doctor or pharmacist if any of the listed side effects do significantly affect you or notice side effects that are not stated in this information.</seg>
<seg id="2159">"" "" "" "dose of Agenerase capsules is 600 mg twice a day, together with 100 mg of pinion twice a day in combination with other antiretroviral medicines." "" "" ""</seg>
<seg id="2160">"" "" "" "in order for Agenerase to benefit as much as possible, it is very important that you take the entire daily dose that your doctor has prescribed." "" "" ""</seg>
<seg id="2161">"" "" "" "if you have taken larger amounts of asgenerase than you should have taken more than the prescribed dose of asgenerase, you should contact your doctor or pharmacist immediately." "" "" ""</seg>
<seg id="2162">"" "" "" "the benefit of" "" "" "" "geboosterer" Agenerase "" "" "" "" was not proven in patients who were previously treated with Protease Inhibitors. "" "" "" "</seg>
<seg id="2163">"" "" "" "for the use of low doses of Ritonavir (usually used to amplify the effect [boosters] of Agenerase Capsules) along with Agenerase solution, no dosage recommendations can be given." "" "" ""</seg>
<seg id="2164">"" "" "" "take Ritonavir's solution, or take propylene glycol while taking Agenerase solution (see also Agenerase must not be taken)." "" "" ""</seg>
<seg id="2165">"" "" "" "your doctor may also observe side effects associated with the Propylene glycol content of the Aciase solution, especially if you have kidney or liver illness." "" "" ""</seg>
<seg id="2166">"" "" "" "111 If you can cause serious side effects such as carbamazepine, phenobarbital, lidocaine, lidocaine, rapamycin, tricyclic antidepressants, rapamycin, tricyclic antidepressants, lidocaine, rapamycin, rapamycin, rapamycin, rapamycin, lidocaine, rapamycin, rapamycin, lidocaine, rapamycin, rapamycin, lidocaine, rapamycin, rapamycin, lidocaine, rapamycin, rapamycin, lidocaine, rapamycin, rapamycin, lidocaine, rapamycin, rapamycin, lidocaine, rapamycin, rapamycin, lidocaine, rapamycin, lidocaine." "" "" ""</seg>
<seg id="2167">"" "" "" "rite raviolr solution for insertion) or additional Propylene glycol, while taking asgenerase (see asgenerase must not be taken)." "" "" ""</seg>
<seg id="2168">"" "" "" "important information about certain other components of asgenerase solution to include The solution to take-up contains propylene glycol, which can cause side effects in high doses." "" "" ""</seg>
<seg id="2169">"" "" "" "Propylene glycol may cause a number of side effects including varicose attacks, dizziness, palpitations and the reduction of red blood cells (see also Agenerase is necessary precautions)." "" "" ""</seg>
<seg id="2170">"" "" "" "if you have forgotten taking asterase if you have forgotten taking asterase, take it as soon as you think about it and then continue taking the intake as before." "" "" ""</seg>
<seg id="2171">"" "" "" "headache, fatigue, diarrhoea, vomiting, vomiting, flatulence skin rash (redness, blisters or itching) - occasionally the rash may be of serious nature and you may force you to stop taking this medicine." "" "" ""</seg>
<seg id="2172">"" "" "" "this can include fat loss on legs, arms and face, fat increase in the abdomen and in other internal organs, breast augmentation and fat growths in the neck (" pins ")." "" "" ""</seg>
<seg id="2173">"" "" "" "the other ingredients are Propylene glycol, Tocofersolan (TPGS), Acesulfam potassium, sodium chloride, artificial chewing gum, citric acid, sodium citrate dihydrat, purified water." "" "" ""</seg>
<seg id="2174">The frequency of application and duration of treatment with Aldara depend on the disease to be treated. • In case of small basal cell carcinomas the cream is to be added five times a week for six weeks. • In case of actinic keratoses it is to be applied three times a week during one or two weeks of treatment.</seg>
<seg id="2175">"" "" "" "before bedtime, the cream is thin-layered to the affected areas of the skin so that it remains sufficiently long (approximately eight hours) on the skin before it is washed away." "" "" ""</seg>
<seg id="2176">"" "" "" "in all studies Aldara was compared with a placebo (the same cream, but without the drug)." "" "" ""</seg>
<seg id="2177">"" "" "" "• Aldara was also studied at 724 patients with small basal cell carcinomas in two studies, in which patients were treated for six weeks and took Aldara or placebo either daily or five times a week." "" "" ""</seg>
<seg id="2178">"" "" "" "the main indicator for efficacy was the number of patients with complete healing of the tumors after twelve weeks. • Aldara, in addition, has been tested in two studies to a total of 505 patients with actinic keratoses." "" "" ""</seg>
<seg id="2179">"" "" "" "• In all studies Aldara was more effective than placebo. in all four main studies, the total treatment rate was 15% to 52% in patients treated with placebo." "" "" ""</seg>
<seg id="2180">The most common side effects of Aldara (observed in more than 1 out of 10 patients) are reactions to the application point of the cream (pain or itching).</seg>
<seg id="2181">"" "" "" "clinically typical, non-hyperkeratotic, non-hypertrophic actinic keratoses (AKs) in the face or on the scalp in immunocompetent adults, if the size or number of lesions limit the efficacy and / or the acceptance of cryotherapy and other topical treatment options are contraindicated or less suitable." "" "" ""</seg>
<seg id="2182">"" "" "" "apply Monday, Wednesday and Friday or Tuesday, Thursday and Saturday before bedtime and leave for 6 to 10 hours on the skin." "" "" ""</seg>
<seg id="2183">"" "" "" "treatment with Imiquimod cream is so long to continue until all visible clinches have disappeared in the genital or peripheral area, or up to 16 weeks per treatment period." "" "" ""</seg>
<seg id="2184">"" "" "" "an interruption of the treatment procedure described above should be considered when intensive local inflammatory reactions occur (see Section 4.4), or if an infection is observed in the treatment area." "" "" ""</seg>
<seg id="2185">"" "" "" "if after the follow-up examination 4 to 8 weeks after the second treatment period the treated lesions are only incomplete, another therapy should be started (see Section 4.4)." "" "" ""</seg>
<seg id="2186">"" "" "" "when a dose is omitted, the patient should apply the cream as soon as he / she notices it and then continue with the usual therapy plan." "" "" ""</seg>
<seg id="2187">"" "" "" "Imiquimod cream is to be applied in a thin layer and rub in the cleaned, moistened skin area until the cream is completely absorbed." "" "" ""</seg>
<seg id="2188">"" "" "" "in these patients, weighing is carried out between the benefit of treatment with Imiquimod and the risk associated with a possible worsening of their autoimmune disease." "" "" ""</seg>
<seg id="2189">"" "" "" "in these patients, weighing is carried out between the benefit of a treatment with Imiquimod and the risk associated with possible organ rejection or graft vs. host reaction." "" "" ""</seg>
<seg id="2190">"" "" "" "in other studies, in which no daily Vorhauthygiene was carried out, two cases of severe phimosis and one case were observed with a strikscore that is becoming a circumcision." "" "" ""</seg>
<seg id="2191">At an application of Imiquimod cream in higher than the recommended doses there is an increased risk of severe local skin irritation (see Section 4.2.) In rare cases severe local skin irritation were observed also under proper application which necessitated a treatment and / or led to a temporary physical impairment.</seg>
<seg id="2192">"" "" "" "in cases where such reactions occurred at the output of the urethra, some women had difficulty passing urine which necessitated emergency catheterisation and treatment of the affected area." "" "" ""</seg>
<seg id="2193">"" "" "" "until now, no clinical experience exists for the use of Imiquimod cream after treatment with other cutaneous applied means for the treatment of external inclinations in the genital and peripheral areas." "" "" ""</seg>
<seg id="2194">"" "" "" "limited data suggest an increased rate of infanticide reductions in HIV positive patients, Imiquimod cream has shown less effectiveness in this group of patients with regard to the elimination of inclinations." "" "" ""</seg>
<seg id="2195">"" "" "" "the treatment of basal cell carcinoma with Imiquimod within 1 cm around the eyelids, the nose, the lips, or the hair approach was not investigated." "" "" ""</seg>
<seg id="2196">"" "" "" "local skin reactions are common, but the intensity of these reactions generally decreases during therapy or the reactions form after completion of treatment with Imiquimod cream." "" "" ""</seg>
<seg id="2197">"" "" "" "if it is necessary due to patient complaints or due to the severity of local skin reactions, a treatment period of several days may be made." "" "" ""</seg>
<seg id="2198">"" "" "" "after the regeneration of the treated skin, the clinical outcome of the treatment can be assessed about 12 weeks after the treatment." "" "" ""</seg>
<seg id="2199">"" "" "" "since there is currently no data on long-term recovery rates of more than 36 months after the treatment, other appropriate forms of treatment should be considered in the case of super-certified basal cell carcinomas." "" "" ""</seg>
<seg id="2200">"" "" "" "in patients with recurrent and pre-treated BCCs, no clinical experience is available, so the application is not recommended for pre-treated tumors." "" "" ""</seg>
<seg id="2201">Data from an open clinical study suggest that in large tumours (&gt; 7.25 cm2) there is less likelihood of response to Imiquimod therapy.</seg>
<seg id="2202">"" "" "" "Imiquimod was not examined for treatment of actinic keratoses on eyelids, inside the nose or ears or on the lip area within the lipstick." "" "" ""</seg>
<seg id="2203">"" "" "" "there are only very limited information about the application of Imiquimod for the treatment of actinic keratoses in anatomical places outside the face, and the scalp." "" "" ""</seg>
<seg id="2204">"" "" "" "the available data on the actinic keratosis on the underarm and hands do not support effectiveness in this application, therefore such application is not recommended." "" "" ""</seg>
<seg id="2205">"" "" "" "local skin reactions occur frequently, but these reactions usually decrease in intensity over the course of therapy or go back after the treatment with Imiquimod cream." "" "" ""</seg>
<seg id="2206">"" "" "" "if local skin reactions cause great discomfort or are very strong, the treatment may be exposed for a few days." "" "" ""</seg>
<seg id="2207">"" "" "" "from the data of an open clinical study, patients with more than 8 lesions showed a lower total healing rate than patients with fewer than 8 lesions." "" "" ""</seg>
<seg id="2208">"" "" "" "due to the immune-stimulating properties, Imiquimod cream should be applied with caution in patients receiving immunosuppressive treatment (see 4.4)." "" "" ""</seg>
<seg id="2209">"" "" "" "animal studies show no direct or indirect harmful effects on pregnancy, embryonic / fetal development, de-binding or postnatal development (see 5.3)." "" "" ""</seg>
<seg id="2210">"" "" "" "although neither the serum levels (&gt; 5ng / ml) were achieved neither after a one-time nor after several times, no recommendation can be given during breastfeeding." "" "" ""</seg>
<seg id="2211">The most frequently communicated and possibly with the application of Imiquimod cream in related side effects in the studies with three times weekly treatment were local reactions in the treatment of inclinations (33.7% of patients treated with Imiquimod).</seg>
<seg id="2212">Among the most frequently reported and as likely or possibly with the application of Imiquimod cream in related side effects include complaints at the application place with a frequency of 28.1%.</seg>
<seg id="2213">"" "" "" "from a placebo-controlled clinical study of Phase III reported side effects, the results reported by Imiquimod-creme are shown below." "" "" ""</seg>
<seg id="2214">"" "" "" "the most common, probably or possibly with the application of the Imiquimod cream in connection, were in these studies a response to the application location (22% of patients treated with Imiquimod)." "" "" ""</seg>
<seg id="2215">"" "" "" "the side effects, which were noted by 252 in placebo-controlled Phase III clinical trials with Imiquimod-creme patients with actinic keratosis, are listed below." "" "" ""</seg>
<seg id="2216">"" "" "" "this clinical evidence assessed according to the study plan shows that in these placebo-controlled clinical studies with Imiquimod cream frequently leads to local skin reactions including Erythema (61%), excreation / deformation (23%) and Ödem (14%) (see Section 4.4)." "" "" ""</seg>
<seg id="2217">"" "" "" "this clinical evidence assessed according to the study plan shows that in these studies five times weekly treatment with Imiquimod cream was very frequent (31%), heavy erosions (13%), and severe atrophy (19%)." "" "" ""</seg>
<seg id="2218">In clinical studies investigating the application of Imiquimod for the treatment of actinic keratosis Alopecia was diagnosed with a frequency of 0.4% (5 / 1214) at the treatment center or in the surrounding area.</seg>
<seg id="2219">"" "" "" "the accidental single oral recording of 200 mg Imiquimod, which corresponds to the contents of about 16 bags, could lead to nausea, vomiting, headache, myalgia and fever." "" "" ""</seg>
<seg id="2220">"" "" "" "the clinically serious side effect, which occurred after several oral doses of &gt; 200 mg, existed in hypotony, which normalized after oral or intravenous hydration." "" "" ""</seg>
<seg id="2221">"" "" "" "in a pharmacokinetic investigation, systemic concentrations of alpha interferons and other cytokines were detected after the topical application of Imiquimod." "" "" ""</seg>
<seg id="2222">In 3 pivotal Phase 3 efficacy studies it was possible to show that the efficacy in relation to a complete curing of the inclinations during an Imiquimod treatment was clearly superior over 16 weeks of a placebo treatment.</seg>
<seg id="2223">"" "" "" "in 60% of the patients treated with Imiquimod, the patients were treated completely; this was 20% of the 105 patients who had been treated with placebo (95% CI):" "" "" ""</seg>
<seg id="2224">"" "" "" "a complete healing could be achieved in 23% of 157 with Imiquimod treated male patients, compared to 5% of 161 with placebo treated male patients (95% CI):" "" "" ""</seg>
<seg id="2225">"" "" "" "the efficacy of Imiquimod with five-time application per week was examined in two double-blind, placebo-controlled clinical trials." "" "" ""</seg>
<seg id="2226">The target tumors were histologically confirmed single primary superficially confirmed basal cell carcinomas with a minimum size of 0.5 cm2 and a maximum diameter of 2 cm.</seg>
<seg id="2227">"" "" "" "data from an open, uncontrolled long-term study after four years show that approximately 79.3% [95% CI (73.7%, 84.9%) of all treated patients had been clinically cured and this remained for 48 months." "" "" ""</seg>
<seg id="2228">"" "" "" "the efficacy of Imiquimod with three weeks of treatment in one or two treatment periods of 4 weeks, interrupted by a four week treatment period, was investigated in two double-blind, placebo-controlled clinical trials." "" "" ""</seg>
<seg id="2229">"" "" "" "patients had clinically typical, visible, discrete, non-hypertrophic acuations within a connected 25 cm2 treatment area on the unhairy scalp or face." "" "" ""</seg>
<seg id="2230">The single-year data from two combined observation studies show a recurrence of 27% (35 / 128 patients) for patients with clinical healing after one or two treatment periods.</seg>
<seg id="2231">"" "" "" "the approved indications of external clinching, actin keratosis and superintentional basal cell carcinoma are usually not observed in paediatric patients and were therefore not investigated." "" "" ""</seg>
<seg id="2232">"" "" "" "Aldara Creme was examined in four randomised, double-blind placebo-controlled studies of children aged 2 to 15 with Molluscum contagiosum (Imiquimod n = 576, placebo n = 313)." "" "" ""</seg>
<seg id="2233">"" "" "" "the efficacy of Imiquimod could not be shown in these studies at the dosages studied there (3x / week, for a period of ≤ 16 weeks or more." "" "" ""</seg>
<seg id="2234">A minimal systemic absorption of 5% Imiquimod cream through the skin of 58 patients with actinic keratosis was observed during the three times weekly application during 16 weeks.</seg>
<seg id="2235">"" "" "" "the highest concentrations of drugs at the end of the week 16 were observed between 9 and 12 hours. in the face (12.5 mg, 1 disposable bag), on the scalp (25 mg, 2 pouches) and on the hands / arms (75 mg, 6 bags)." "" "" ""</seg>
<seg id="2236">The estimated half-life time was about 10 times higher than the 2hourly half-life after the subcutaneous application in an earlier study; this indicates an extended retention of the medicine in the skin.</seg>
<seg id="2237">The data on systemic exposure showed that the resorption of Imiquimod after topical application on MC-diseased skin was low from 6 to 12 years and comparable to that of healthy adults and adults with actinic keratosis or superficially portable basal cell carcinoma.</seg>
<seg id="2238">"" "" "" "in a four-month study on the dermal toxicity of the rat, doses of 0.5 and 2.5 mg / kg KG resulted in significantly reduced body weight and increased milz weight; a study for the dermal application showed no similar effects for the mouse." "" "" ""</seg>
<seg id="2239">"" "" "" "a two-year study of carcinogenicity in mice during one-time administration, on three days a week, did not induce tumours in the application area." "" "" ""</seg>
<seg id="2240">"" "" "" "the corresponding mechanism is not known, but since Imiquimod has only a small systemical absorption of the human skin and is not mutagen, a risk for human beings is considered to be very low due to systemic exposure." "" "" ""</seg>
<seg id="2241">"" "" "" "the tumors occurred in the group of mice treated with the effective free cream, earlier and in greater numbers than in the control group with low UVR." "" "" ""</seg>
<seg id="2242">"" "" "" "it can harm other people even if they have the same symptoms as you. − If any of the listed side effects you have significantly impaired or you notice side effects that are not stated in this utility information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="2243">● Feignices (condylomata acuminata) formed on the skin in the genitals of the genitals (genital organs) and the anus (after) have formed a frequently growing type of skin cancer with very low probability of spread to other parts of the body.</seg>
<seg id="2244">"" "" "" "if it remains untreated, it can lead to distortion, especially in the face - therefore a early detection and treatment is important." "" "" ""</seg>
<seg id="2245">"" "" "" "actinic keratoses are rough areas of the skin, which occur in humans that were exposed to sunlight during their life." "" "" ""</seg>
<seg id="2246">Aldara should only be used in case of flat actinic keratoses in the face and on the scalp in patients with a healthy immune system where your doctor has chosen that Aldara is the best suitable treatment.</seg>
<seg id="2247">"" "" "" "Aldara Cream supports your body's immune system in the production of natural substances that help your body to fight the superficial basal cell carcinoma, the actinic keratosis or the virus responsible for the infection." "" "" ""</seg>
<seg id="2248">"" "" "" "O If you already used Aldara cream or other medicines, please inform your doctor about this before treating any problems with your immune system. o Avoid contact with eyes, lips and nasal mucosa." "" "" ""</seg>
<seg id="2249">"" "" "" "if allergic reactions occur in the treated area after applying Aldara cream, do not apply cream with a bandage or patch. o If allergic reactions occur in the treated area, wash the cream with a mild soap and water." "" "" ""</seg>
<seg id="2250">"" "" "" "once the reactions are cleared, you can continue the treatment. o inform your doctor if they do not have a normal blood pattern" "" "" ""</seg>
<seg id="2251">"" "" "" "if this daily cleansing is not performed under the foreskin, swelling of the skin or difficulty can be expected to retract the foreskin." "" "" ""</seg>
<seg id="2252">"" "" "" "do not use Aldara cream in the urethra, in the vagina (vagina), the cervix (cervix) or within the anus (anus)." "" "" ""</seg>
<seg id="2253">"" "" "" "if other medicines have serious problems with your immune system, you should not use this medication for more than one treatment cycle." "" "" ""</seg>
<seg id="2254">"" "" "" "if you have sexual intercourse during the infection with inclinations in the genital area, the treatment with Aldara Creme is after sexual intercourse (not before)." "" "" ""</seg>
<seg id="2255">"" "" "" "please inform your doctor or pharmacist if you use other medicines or have recently applied, even if it is not prescription." "" "" ""</seg>
<seg id="2256">"" "" "" "do not satisfy your infant during treatment with Aldara Creme, because it is not known whether imiquimod surpasses into breast milk." "" "" ""</seg>
<seg id="2257">"" "" "" "the frequency and duration of the treatment are different in case of inclinations, basal cell carcinoma and actinic keratosis (see specific instructions for each application)." "" "" ""</seg>
<seg id="2258">"" "" "" "apply a thin layer of Aldara cream to the clean, dry skin with the feet and rub gently on the skin until the cream is completely absorbed." "" "" ""</seg>
<seg id="2259">Men with inclinations under the foreskin must withdraw the foreskin each day and wash the skin area underneath (see Section 2 "What do you have to consider before using Aldara Creme?").</seg>
<seg id="2260">Please talk to your doctor or pharmacist if you have the impression that the effect of Aldara is too strong or too weak.</seg>
<seg id="2261">"" "" "" "for 6 weeks, apply a sufficient amount of Aldara cream per week to cover the affected area and 1 cm around this area." "" "" ""</seg>
<seg id="2262">"" "" "" "common side effects (in less than 1 out of 10 patients expected) Have common side effects (in less than 1 out of 1,000 patients expected) Very rare adverse events (in less than 1 out of 10,000 patients expected)" "" "" ""</seg>
<seg id="2263">Inform your doctor or pharmacist immediately if you do not feel comfortable during the application of Aldara Creme.</seg>
<seg id="2264">"" "" "" "if your skin reacts too strongly to the treatment with Aldara Creme, you should not use the cream to wash the affected area with water and mild soap and communicate your doctor or pharmacist." "" "" ""</seg>
<seg id="2265">"" "" "" "a lower number of blood cells can cause you more susceptible to infections; it can cause you to produce a blue stain sooner or later, or it can cause abutment." "" "" ""</seg>
<seg id="2266">Tell your doctor or pharmacist if any of the listed side effects do significantly affect you or notice side effects that are not stated in this information.</seg>
<seg id="2267">"" "" "" "in addition, you can feel itching (32% of patients), burning (26% of patients) or pain in the areas that you applied Aldara Creme (8% of patients)." "" "" ""</seg>
<seg id="2268">"" "" "" "most of the time, it is about easier skin reactions which may sound once again within 2 weeks after the treatment has been removed." "" "" ""</seg>
<seg id="2269">"" "" "" "occasionally some patients notice changes at the application location (wound secretion, inflammation, swelling, blisters, dermatitis) or irritability, nausea, dry mouth, flu-like symptoms and fatigue." "" "" ""</seg>
<seg id="2270">"" "" "" "occasionally, some patients suffer from alterations to the application location (bleeding, inflammation, wound secretion, swelling, heat sensation or discomfort), inflammation of the eye lids, sore throat, diarrhoea, fever, weakness, or chills." "" "" ""</seg>
<seg id="2271">Aldurazyme is used for enzymatic treatment in patients with a secure diagnosis of a Mucopolysaccharidosis I (MPS I; α-L-Iduronidase deficiency) to treat the neurological manifestations of the disease (the symptoms that are not related to brain or nerves).</seg>
<seg id="2272">"" "" "" "this means that certain substances (glycosaminoglycans, gags) are not broken down and thus accumulate in most organs in the body and damage them." "" "" ""</seg>
<seg id="2273">"" "" "" "the following non neurological symptoms of the MPS I can occur: increased liver, stiff joints, the movements complicate, reduced lung volume, heart and eye disease." "" "" ""</seg>
<seg id="2274">"" "" "" "the treatment with Aldurazyme should be monitored by a doctor, who possesses experience in treating patients with MPS I or other hereditary metabolic diseases." "" "" ""</seg>
<seg id="2275">"" "" "" "the administration of Alendurazyme should take place in a hospital or a clinic with revitalization equipment, and patients may require appropriate medicines prior to the administration to prevent allergic reactions." "" "" ""</seg>
<seg id="2276">(44-20) 74 18 84 00 Fax (44-20) 74 18 86 68 E-mail: mail @ emea.eu http: / / www.emea.europa.eu ww.EMEA 2007 Reproduction and / or distribution of this document is Authorised for non commercial purposes How does Aldurazyme work?</seg>
<seg id="2277">"" "" "" "the study focused mainly on the safety of the drug, but its effectiveness was measured in terms of reducing GAG concentrations in urine and in relation to the size of the liver." "" "" ""</seg>
<seg id="2278">"" "" "" "in children under five years of age, Aldurazyme decreased the GAG concentrations in the urine by approximately 60%, and half of the treated children showed a normal large liver at the end of the study." "" "" ""</seg>
<seg id="2279">"" "" "" "the most common side effects of Aldurazyme in patients at the age of more than five years (observed in more than 1 of 10 patients) are headaches, nausea, abdominal pain, arthralgia, pain in limbs (in hands and feet), heat, fever and reactions at the infusion site." "" "" ""</seg>
<seg id="2280">"" "" "" "very common side effects in patients under five years are elevated blood pressure, reduced oxygen saturation (a measurement size of lung function), tachycardia (accelerated heart rate), fever and chills." "" "" ""</seg>
<seg id="2281">Aldurazyme may not be used in patients who may be hypersensitive (allergic) to laronidase or any of the other components (anaphylactic reaction).</seg>
<seg id="2282">"" "" "" "each year, the European Medicines Agency (EMEA) will review all new information that may be known, where necessary update and update this summary." "" "" ""</seg>
<seg id="2283">"" "" "" "the Aldurazyme manufactures patients receiving aldurazyms, observing the reactions to the infusion and the development of antibodies." "" "" ""</seg>
<seg id="2284">"" "" "" "in June 2003, the European Commission granted Genzyme Europe B.V. to approve Alendurazyms in the entire European Union." "" "" ""</seg>
<seg id="2285">Laronidase is a recombinant form of human α-L-Iduronidase and is produced using recombinant DNA technology using CHO mammal cell cultures (Chinese hamster Ovary (Chinese hamster ovaries).</seg>
<seg id="2286">Aldurazyme is indicated for long-term enzyme treatment in patients with secure diagnosis of a Mucopolysaccharidosis I (MPS I, α-L-Iduronidase deficiency) in order to treat the non-neurological manifestations of the disease (see section 5.1).</seg>
<seg id="2287">"" "" "" "the treatment with Aldurazyme should be done by a doctor, who possesses experience in the treatment of patients with MPS I or other hereditary metabolic diseases." "" "" ""</seg>
<seg id="2288">The initial infusion rate of 2 E / kg / h can be increased every 15 minutes in single steps to a maximum dose of 43 E / kg / h.</seg>
<seg id="2289">"" "" "" "the safety and efficacy of Aldurazyme in adults over 65 years has not been determined, and no dosage schedule can be recommended for these patients." "" "" ""</seg>
<seg id="2290">"" "" "" "the safety and efficacy of Aldurazyme in patients with kidney or liver failure was not determined, and no dosage schedule can be recommended for these patients." "" "" ""</seg>
<seg id="2291">Patients treated with Aldurazyme can develop infusion-related reactions which are defined as any side effect that occurs during infusion or until the end of the infusion-day (see Section 4.8).</seg>
<seg id="2292">"" "" "" "for this reason, these patients should also continue to be closely monitored and the infusion of Aldurazyme should only be carried out in an appropriate clinical setting, in which recovery facilities for medical emergencies are immediately available." "" "" ""</seg>
<seg id="2293">"" "" "" "due to the clinical Phase 3 study, nearly all IgG antibodies against laronidase are expected, usually within 3 months from the beginning of the treatment." "" "" ""</seg>
<seg id="2294">"" "" "" "patients who develop antibodies or symptoms of infusion-induced reaction must be treated with caution when using Aldurazyme (see Sections 4.3 and 4.8)." "" "" ""</seg>
<seg id="2295">"" "" "" "since there is little experience regarding the resumption of treatment after a longer break, the risk of a hypersensitivity reaction has to be cautious after an interruption of the treatment." "" "" ""</seg>
<seg id="2296">"" "" "" "60 minutes before beginning the infusion with medication (antihistaminika and / or antipyretika), to minimize the potential occurrence of infusion-related reactions." "" "" ""</seg>
<seg id="2297">In case of an easy or medium-severe infusion-related reaction the treatment with antihistamines and paracetamol / ibuprofen should be weighed and / or a reduction in the infusion rate to half of the infusion rate in which the reaction has occurred.</seg>
<seg id="2298">"" "" "" "in case of a severe infusion-induced reaction, the infusion must be stopped until the symptoms are reduced, a treatment with antihistamines and paracetamol / ibuprofen is to be considered." "" "" ""</seg>
<seg id="2299">The infusion can be resumed with a reduction in the infusion rate to 1 / 2 - 1 / 4 of the infusion rate in which the reaction occurred.</seg>
<seg id="2300">3 (antihistamines and paracetamol / ibuprofen and / or corticosteroids) and a reduction of the infusion rate to 1 / 2 - 1 / 4 of the infusion rate in which the previous reaction has occurred.</seg>
<seg id="2301">"" "" "" "Aldurazyme should not be applied simultaneously with chloroquin or Procain, because there is a potential risk of interference with the intracellular absorption of laronidase." "" "" ""</seg>
<seg id="2302">"" "" "" "animal experimental studies do not affect direct or indirect harmful effects on pregnancy, embryonic / fetal development, birth and postnatal development (see Section 5.3)." "" "" ""</seg>
<seg id="2303">"" "" "" "since there are no data on newborns exposed to laridase over the breast milk, it is recommended to not meet with Aldurazyms." "" "" ""</seg>
<seg id="2304">Side effects in clinical trials were mainly classified as infusion-related reactions which were observed in 53% of patients in the Phase 3 study (treatment duration up to 4 years) and 35% of patients in the study with participants under 5 years (treatment duration up to 1 year).</seg>
<seg id="2305">"" "" "" "adverse drug reactions related to Aldurazyme, which have been observed in 45 patients at the age of 5 or older during a treatment period of up to 4 years, are frequently (≥ 1 / 100); frequently (≥ 1 / 100 to &lt; 1 / 10)." "" "" ""</seg>
<seg id="2306">"" "" "" "in some patients with severe MPS-I-unconditional involvement of upper respiratory tract and lungs in prehistory, severe reactions, including bronchospasm, crest and facial oils (see Section 4.4)." "" "" ""</seg>
<seg id="2307">"" "" "" "children Undesired drug interactions related to Aldurazyme, which have been reported during a phase 2 study with a total of 20 patients at the age of 5, with predominantly severe follow-up form and a treatment duration of up to 12 months, are listed in the table." "" "" ""</seg>
<seg id="2308">"" "" "" "100 E / kg intravenous once a week (recommended dose), 200 E / kg intravenous once weekly, 200 E / kg intravenously every 2 weeks or 300 E / kg intravenously every 2 weeks." "" "" ""</seg>
<seg id="2309">"" "" "" "in most patients it occurred within 3 months after the beginning of the treatment for a seroconversion, with a more severe sieve form usually within a month to a seroconversion (average after 26 days versus 45 days in patients aged 5 years and older)." "" "" ""</seg>
<seg id="2310">"" "" "" "up to the end of the phase 3 trial (or up to a premature departure from the study) no antibodies were detected in 13 / 45 patients (RIP) assay, including 3 patients with whom it never came to Serokonversion." "" "" ""</seg>
<seg id="2311">Patients with missing or low antibody levels showed a robust reduction of the GAG mirror in urine while in patients with high antibody titers a variable reduction of GAG in urine was determined.</seg>
<seg id="2312">Four patients (three in phase 3 study and one in phase 2 study) showed a marginal to low neutralizing inhibitory effect on enzymatic larvae activity in vitro that seemed to not impair clinical efficacy and / or reduction of GAG in urine.</seg>
<seg id="2313">"" "" "" "the presence of antibodies did not seem to be associated with the incidence of adverse drug reactions, even if the occurrence of adverse drug reactions typically coincided with the formation of IgG antibodies." "" "" ""</seg>
<seg id="2314">"" "" "" "for the hydrolysis of the accumulated substrate and the prevention of further accumulation, the enzymes are sufficient to restore the enzyme activity." "" "" ""</seg>
<seg id="2315">"" "" "" "after IV infusion, laronidase is quickly removed from the circulation and absorbed by cells into the lysosomes, most likely via Mannose-6 phosphate receptors." "" "" ""</seg>
<seg id="2316">"" "" "" "the safety and efficacy of Aldurazyme were examined in a randomised double-blind, placebo-controlled phase 3 study to 45 patients aged 6 to 43." "" "" ""</seg>
<seg id="2317">"" "" "" "although patients were recruited for the study, the majority of patients were affected by the mean phenotype and only one patient showed the severe phenotype." "" "" ""</seg>
<seg id="2318">Patients were recruited if they had a forced expiratory volume (FEV) of less than 80% of the expected value and they had to be able to stand 6 minutes and walk 5 meters.</seg>
<seg id="2319">"" "" "" "the primary endpoints for efficacy were the percentage change of the expected FEV, and the absolute path in the 6-minute walking test." "" "" ""</seg>
<seg id="2320">"" "" "" "all patients were subsequently recruited for an open-label extension study, where they received 100 E / kg Aldurazyms each week for 3.5 years (182 weeks)." "" "" ""</seg>
<seg id="2321">"" "" "" "after 26 weeks of therapy, the patients treated with Aldurazyme showed an improvement in lung function and capacity in the following table." "" "" ""</seg>
<seg id="2322">The open extension study showed an improvement and / or maintenance of these effects of up to 208 weeks in the Aldurazyme / Aldurazyme group and from 182 weeks in the placebo / Aldurazyme group as shown in the following table.</seg>
<seg id="2323">"" "" "" "over this period, the decrease in the expected percentage of FEV is clinically not significant and the total lung volumes increased further proportionally to the size of growing children." "" "" ""</seg>
<seg id="2324">"" "" "" "from 26 patients with a hepatomaceous before treatment, 22 (85%) had a normal liver size until the end of the study." "" "" ""</seg>
<seg id="2325">"" "" "" "within the first four weeks, a significant drop in the GAG mirror was found in the urine (µg / mg of Kreatinin), which remained constant until the end of the university." "" "" ""</seg>
<seg id="2326">"" "" "" "in general, 26 patients (58%), no change in 10 patients (22%), and a deterioration in 9 patients (20%) were observed." "" "" ""</seg>
<seg id="2327">A one-year open phase 2 study was carried out in which the safety and pharmacokinetics of Aldurazyms were examined in 20 patients at the time of their inclusion in the study under 5 years old (16 patients with severe form and 4 with the average follow-up form).</seg>
<seg id="2328">"" "" "" "in four patients, the dosage was increased to 200 E / kg due to increased Gag- Mirror in the urine in week 22." "" "" ""</seg>
<seg id="2329">A normal mental development speed was observed in several patients (n = 7) and a weight gain (n = 3) after the Z-Score for this age group. the younger patients with severe freewheel form showed a normal mental development speed whereas older patients with severe freewheel form were limited or no progress in cognitive development.</seg>
<seg id="2330">"" "" "" "in a phase 4 trial, investigations on pharmacodynamic effects of various aldurazyms dosage regimens were carried out on the GAG mirror in the urine, liver volume and the 6-minute hearing test." "" "" ""</seg>
<seg id="2331">"" "" "" "100 E / kg intravenous once a week (recommended dose), 200 E / kg intravenous once weekly, 200 E / kg intravenously every 2 weeks or 300 E / kg intravenously every 2 weeks." "" "" ""</seg>
<seg id="2332">"" "" "" "the dosage schedule with 200 E / kg intravenously every 2 weeks can be an acceptable alternative for patients who have difficulties with weekly infusions; however, it is not proven that the long-term clinical efficacy of these two dosing schemes is equivalent." "" "" ""</seg>
<seg id="2333">"" "" "" "the European Medicines Agency (EMEA) will evaluate any new information that is available annually, and if necessary, the summary of the characteristics of the medicine will be updated." "" "" ""</seg>
<seg id="2334">The pharmacokinetic profile in patients aged under 5 years was similar to older and less severely affected patients.</seg>
<seg id="2335">"" "" "" "based on conventional safety resharmacology studies, toxicity in a unique gift, toxicity in repeated application and reproductive toxicity, the preclinical data do not reveal any particular danger to humans." "" "" ""</seg>
<seg id="2336">"" "" "" "since there are no compatibility studies carried out, this medicine may not be mixed with other medicines unless listed under 6.6.." "" "" ""</seg>
<seg id="2337">"" "" "" "if the ready-to-use preparation is not used immediately, it is no longer than 24 hours at 2 ° C - 8º C if the dilution is performed under controlled and validated aseptic conditions." "" "" ""</seg>
<seg id="2338">5 ml concentrate for manufacturing a solution in a glass bottle (type I-glass) with stoppers (silicone-chlorbutyl rubber) and sealing (aluminum) with tear cap (polypropylene).</seg>
<seg id="2339">10 Preparation of the Aldurazyme infusion (using aseptic technique) • first determine the number of dilution bottles to be diluted.</seg>
<seg id="2340">"" "" "" "within the given period, the holder of approval for the transport has to complete the following study program, whose results form the basis for the annual evaluation report on the benefit-risk ratio." "" "" ""</seg>
<seg id="2341">"" "" "" "this register becomes longer-term security and efficacy information on patients treated with Aldurazyme, as well as data about the natural progression of the disease in patients without this treatment." "" "" ""</seg>
<seg id="2342">"" "" "" "in patients suffering from MPS I, an enzyme called α-L-Iduronidase is split up, which contains certain substances in the body (glycosaminoglycans), either in low amounts before or this enzyme is completely absent." "" "" ""</seg>
<seg id="2343">If you are allergic (hypersensitive) to one of the ingredients of Aldurazyme or if a severe allergic reaction has occurred on laronidase.</seg>
<seg id="2344">Infusion-conditional reaction is any side effect occurring during infusion or until the end of the infusion day (see Section 4 "Which side effects are possible").</seg>
<seg id="2345">If you use Aldurazyme with other medicines Please tell your doctor if you take drugs that contain chloroquin or Procain because there is a possible risk of diminished efficacy of Aldurazyme.</seg>
<seg id="2346">"" "" "" "please inform your doctor or pharmacist if you take other medicines or have recently taken, including non-prescription medicines." "" "" ""</seg>
<seg id="2347">Instructions for handling - thinning and application The concentrate for producing an infusion solution must be diluted prior to the application and is intended for IV use (see information for physicians or medical professionals).</seg>
<seg id="2348">The initial infusion rate of 2 E / kg / h can be increased every 15 minutes to a maximum dose of 43 E / kg / h.</seg>
<seg id="2349">"" "" "" "in some patients with severe MPS-I- unconditional involvement of upper respiratory tract and lungs in prehistory, however severe reactions to, including bronchospasm, breathing stops and facial oils." "" "" ""</seg>
<seg id="2350">"" "" "" "very common (occurrence in more than 1 out of 10 patients): • headache • nausea • rash disease, joint pain, back pain, pain in arms and legs • Increased pulse • hypertension" "" "" ""</seg>
<seg id="2351">"" "" "" "the European Medicines Agency (EMEA) will evaluate any new information that is available annually, and if necessary, the packing unit will be updated." "" "" ""</seg>
<seg id="2352">"" "" "" "if the ready-to-use preparation is not used immediately, it is no longer than 24 hours at 2 ° C - 8º C if the dilution is performed under controlled and validated aseptic conditions." "" "" ""</seg>
<seg id="2353">Preparation of the Aldurazyme infusion (using aseptic technique) • first determine the number of dilution bottles to be diluted.</seg>
<seg id="2354">Alimta is used together with Cisplatin (other medicines for cancer) in patients who have not yet received chemotherapy (cancer treatment) and "malign" (malignant - the cancer has already spread to other parts of the body) and is likely to spread slightly to other parts of the body.</seg>
<seg id="2355">"" "" "" "Alimta is used for patients previously untreated, in combination with cisplatin and in patients previously received other chemotherapies." "" "" ""</seg>
<seg id="2356">"" "" "" "to reduce side effects, patients should receive a corticosteroid and folic acid (a vitamin) during treatment with Alimta and receive injections of vitamin B12." "" "" ""</seg>
<seg id="2357">"" "" "" "if Alimta is administered together with cisplatin, before or after the administration of cisplatin, an" antiemetic "(drug against vomiting) and liquids should be given (to prevent fluid deficiency)." "" "" ""</seg>
<seg id="2358">"" "" "" "in patients whose blood-image changes or in which certain other side effects occur, the treatment should be postponed, canceled or reduced the dose." "" "" ""</seg>
<seg id="2359">The active form of Pemetrexed thus slows down the formation of DNA and RNA and prevents cells from sharing.</seg>
<seg id="2360">"" "" "" "the transformation of Pemetrexed into its active form is easier in cancer cells than in healthy cells, leading to higher concentrations of the active form of the drug and a longer duration of activity in cancer cells." "" "" ""</seg>
<seg id="2361">"" "" "" "for the treatment of the malignant pleuramesothelioma, Alimta was examined in a major study of 456 patients who had previously not received chemotherapy for their disease." "" "" ""</seg>
<seg id="2362">"" "" "" "in the treatment of non-small cell lung cancer, the effects of Alimta were compared to 571 people with local advanced or metastatic disease previously treated with chemotherapy, with the effects of docetaxel (another medicine against cancer)." "" "" ""</seg>
<seg id="2363">"" "" "" "Alimta was also compared with gemcitabine (another medicine against cancer), both in combination with Cisplatin in a study of 1 725 patients who had previously not received chemotherapy for lung cancer." "" "" ""</seg>
<seg id="2364">Patients treated with Alimta and Cisplatin survived an average of 12.1 months compared with 9.3 months in the sole administration of cisplatin.</seg>
<seg id="2365">"" "" "" "in patients who had previously received chemotherapy, the average survival time with Alimta was 8.3 months, compared with 7.9 months at docetaxel." "" "" ""</seg>
<seg id="2366">"" "" "" "in both studies, however, patients with whom cancer did not attack the squamous cell cells, when administration of Alimta continued survival compared to the drug therapy." "" "" ""</seg>
<seg id="2367">"" "" "" "in September 2004, the European Commission issued a permit for the deployment of Alimta in the entire European Union to Eli Lilly Nederland B.V." "" "" ""</seg>
<seg id="2368">"" "" "" "each glass bottle must be dissolved with 4.2 ml 0.9% sodium chloride injection solution (9 mg / ml), which results in a solution of 25 mg / ml." "" "" ""</seg>
<seg id="2369">The corresponding volume of the necessary dosage is extracted from the glass bottle and diluted with 0.9% sodium chloride injection solution (9 mg / ml) to 100 ml (see Section 6.6).</seg>
<seg id="2370">ALIMTA is indicated in combination with Cisplatin for first-line treatment of patients with locally advanced or metastatic non-small-celled bronchial carcinoma (see section 5.1).</seg>
<seg id="2371">ALIMTA in Monotherapy is indicated for treatment in second-line treatment of patients with Lo- Kal advanced or metastatic non-small cell carcinoma (see section 5.1).</seg>
<seg id="2372">The recommended dose of ALIMTA 500 mg / m ² of body surface (KOF) is administered as an intravenous infusion over a period of 10 minutes on the first day of each 21 day treatment cycle.</seg>
<seg id="2373">The recommended dose of cisplatin is 75 mg / m ² KOF over a period of 2 hours approximately 30 minutes after completion of the pemetrexed- infusion on the first day of each 21 day treatment cycle.</seg>
<seg id="2374">For patients with non-small cell lung cancer following previous chemotherapy the recommended dose of ALIMTA 500 mg / m ² KOF is administered as an intravenous infusion over a period of 10 minutes on the first day of each 21 day treatment cycle.</seg>
<seg id="2375">"" "" "" "to reduce the frequency and severity of skin reactions on the day before and on the day of the pemetrexed gift, as well as on the day after treatment a corticosteroid is given." "" "" ""</seg>
<seg id="2376">"" "" "" "during the seven days before the first dose of Pemetrexed, at least 5 doses of folic acid must be taken and the dosage should be continued during the whole therapy period and for another 21 days after the final Pemetrexed- dose." "" "" ""</seg>
<seg id="2377">"" "" "" "patients also need to receive an intramuscular injection of vitamin B12 (1,000 micrograms) in the week before the first pemetrexed dose and after each third operating cycle." "" "" ""</seg>
<seg id="2378">"" "" "" "in patients receiving pemetrexed, a full blood pattern should be created before each gift, including a differentiation of the leukocytes and platelet counts." "" "" ""</seg>
<seg id="2379">"" "" "" "alkaline phosphatase (AP), aspartate transaminase (AST or SGOT) and Alanine transaminase (ALT or SGPT) should be ≤ 3 times the upper limit value." "" "" ""</seg>
<seg id="2380">"" "" "" "at the beginning of a new treatment cycle, a dose test must take place under the supervision of the Nadir of the hemorrhage or the maximum non-haematological toxicity of the previous therapy cycles." "" "" ""</seg>
<seg id="2381">"" "" "" "after recovery, the patients must be treated according to the indications in tables 1, 2 and 3, which are to be applied for ALIMTA as monotherapy or in combination with Cisplatin." "" "" ""</seg>
<seg id="2382">These criteria correspond to the definition of the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) ≥ CTC Grad 2 bleeding.</seg>
<seg id="2383">"" "" "" "should patients not develop hematological toxicity ≥ Grade 3 (except for neurotoxicity), the treatment with ALIMTA must be interrupted until the patient has the value before treatment." "" "" ""</seg>
<seg id="2384">Treatment with ALIMTA must be canceled if a hematological toxicity or non-haematological toxicity or non-haematological toxicity level 3 or 4 occurs or so- in case of Grade 3 or 4 neurotoxicity.</seg>
<seg id="2385">"" "" "" "clinical studies have no indication that in patients at the age of 65, or in comparison to patients aged 65, there is an increased side effect risk." "" "" ""</seg>
<seg id="2386">"" "" "" "ALIMTA is not recommended for use in children under 18 years of age, due to insufficient data for unacceptability and efficacy." "" "" ""</seg>
<seg id="2387">"" "" "" "in clinical trials, in patients with a creatinin-Clearance of ≥ 45 ml / min no dose adaptations were necessary, which go beyond the dose adaptations recommended for all patients." "" "" ""</seg>
<seg id="2388">"" "" "" "the data location in patients with a creatinin-Clearance of less than 45 ml / min was not sufficient; therefore, the application is not recommended (see Section 4.4)." "" "" ""</seg>
<seg id="2389">"" "" "" "however, patients with a liver function restriction of &gt; the 1.5-fold of the upper limit value and / or transaminase values of &gt; the upper limit value (in case of liver metastases) are not specifically investigated in the studies." "" "" ""</seg>
<seg id="2390">Patients need to be monitored with respect to bone marshalling and Pemetrexed must not be given to patients before their absolute neutrality rate has reached a value of ≥ 1500 cells / mm ³ and the thrombo- cyte count has reached a value of ≥ 100.000 cells / mm ³.</seg>
<seg id="2391">"" "" "" "a dose reduction for further cycles is based on the Nadir of absolute neutrality, thrombocyte count and maximum non-hairy toxicity as they were observed in previous treatment cycles (see Section 4.2)." "" "" ""</seg>
<seg id="2392">A lower toxicity and a reduction of grade 3 / 4 hematological and nicotic toxicity such as neutropenie, febrile neutropenia and infection with grade 3 / 4 neutropenia was considered to be treated when a pre-treatment with folic acid and vitamin B12 had taken place.</seg>
<seg id="2393">"" "" "" "therefore, all patients treated with Pemetrexed need to use folic acid and vitamin B12 as prophylactic measure to reduce treatment-related toxicity (see Section 4.2)." "" "" ""</seg>
<seg id="2394">Patients with mild to medium kidney failure (Creatinin-Clearance 45 to 79 ml / min) must avoid simultaneous consumption of non-steroidal anti-phlogistika (NSAIDs) like ibuprofen and acetylsali- cyllic acid (&gt; 1.3 g daily) for at least 2 days after therapy with Pemetrexed (see Section 4.5).</seg>
<seg id="2395">All patients for which a therapy with Pemetrexed are intended to avoid taking NSAIDs with long semi-life for at least 5 days before therapy and at least 2 days after therapy with Pemetrexed (see Section 4.5).</seg>
<seg id="2396">"" "" "" "many patients experienced these events had risk factors for the occurrence of renal events, including dehydration, high blood pressure or diabetes." "" "" ""</seg>
<seg id="2397">"" "" "" "therefore, in patients with clinically significant fluid accumulation in the transcellular space, drainage of the effusion before the pemetrexed treatment is to be weighed." "" "" ""</seg>
<seg id="2398">"" "" "" "five key cardiovascular events, including myocardial infarction, and cerebrovascular events were occasionally reported in clinical trials involving Pemetrexed if this drug was usually administered in combination with another cytotoxic substance." "" "" ""</seg>
<seg id="2399">"" "" "" "for this reason, the simultaneous application of attenuated live vaccine (except yellow fever, this vaccination is contraindicated) is not recommended (see Section 4.3 and 4.5)." "" "" ""</seg>
<seg id="2400">"" "" "" "since the possibility of an irreversible recovery of reproductive capacity is indicated by Pemetrexed, men should be cautioned in front of the treatment regimen to obtain advice regarding sperm preservation." "" "" ""</seg>
<seg id="2401">In patients with normal kidney function (Creatinin-Clearance ≥ 80 ml / min) high doses of nonsteroidal anti-phlogistica (NSAIDs as ibuprofen = 1600 mg / day) and acetylsalicylic acid can lead to reduced pemetrexed excretion with the result of increased incidence of side effects.</seg>
<seg id="2402">Therefore caution is advisable if high doses of NSAIDs or Ace- tylsalicylic acid can be used in high doses in patients with normal kidney function (Creatinin-Clearance ≥ 80 ml / min).</seg>
<seg id="2403">Ibuprofen) or acetylsalicylic acid in high doses for at least 2 days before therapy to be avoided on the day of therapy and at least 2 days after therapy with Pemetrexed (see Section 4.4).</seg>
<seg id="2404">As there is no data concerning the interaction potential with NSAIDs with long semi-life such as Piro- xicam or Rofecoxib the simultaneous application with Pemetrexed must be avoided for at least 5 days before therapy and at least 2 days after therapy with Pemetrexed.</seg>
<seg id="2405">The great intra-individual variability of the coagulation status during the disease and the possibility of interactions between oral anticoagulants and antineoplastic chemotherapy requires an increased monitoring frequency of INR (International Normised Ratio) if the decision was made to treat the patient with oral anticoagulants.</seg>
<seg id="2406">"" "" "" "there are no data for the use of pemetrexed in pregnant women, but as with anney- antimetabolites severe birth defects are expected during pregnancy." "" "" ""</seg>
<seg id="2407">"" "" "" "Pemetrexed must not be used during pregnancy, except if necessarily - demanding and after careful weighing of the benefit for the mother and the risk for the fetus (see Section 4.4)." "" "" ""</seg>
<seg id="2408">"" "" "" "since the possibility of an irreversible damage to reproductive capacity exists by Pemetrexed, men should be advised before the beginning of the treatment to get advice regarding the sperm-service." "" "" ""</seg>
<seg id="2409">"" "" "" "it is not known whether pemetrexed leaves in breast milk, and unwanted effects in the breastfed baby can not be excluded." "" "" ""</seg>
<seg id="2410">The following table shows the incidence and severity of adverse effects reported in &gt; 5% of 168 patients with Mesothelioma and the randomised Cisplatin and Pemetrexed - were randomized cisplatin as monotherapy.</seg>
<seg id="2411">"" "" "" "frequent (≥ 1 / 100 and &lt; 1 / 100), rare (≥ 1 / 1000 and &lt; 1 / 1000), very rare (≥ 1 / 10 and &lt; 1 / 1000), very rare (≥ 1 / 10) and not known (based on the available data of spontaneous reports not estimated)." "" "" ""</seg>
<seg id="2412">* Regarding the National Cancer Institute CTC Version 2 for each toxicity level excluded the event "Creatinin-Clearance" * * which was derived from the term "kidneys / genital tract Other." * * * Beackled on National Cancer Institute CTC (v2.0; NCI 1998) should be reported on taste disorder and hair loss only as grade 1 or 2.</seg>
<seg id="2413">"" "" "" "for this table, a threshold of 5% was set for inclusion of all events where the reporting physician held a connection with Pemetrexed and Cisplatin for possible." "" "" ""</seg>
<seg id="2414">"" "" "" "clinically relevant CTC toxicity, which were reported at &lt; 1% (occasionally) of patients, were randomised cisplatin and Pemetrexed, covered arrhythmia and motor neuropathy." "" "" ""</seg>
<seg id="2415">The following table shows the incidence and severity of adverse events reported in &gt; 5% of 265 patients who were randomised to receive phaetrexed as monotherapy with gifts of folic acid and vitamin B12 and 276 patients who were randomized docetaxel as monotherapy.</seg>
<seg id="2416">* Regarding National Cancer Institute CTC Version 2 for any toxicity level. * * Beackled at National Cancer Institute CTC (v2.0; NCI 1998) should be reported to hair loss only as grade 1 or 2.</seg>
<seg id="2417">"" "" "" "for this table, a threshold of 5% was set for the inclusion of all events in which the reporting physician held a connection with Pemetrexed for possible." "" "" ""</seg>
<seg id="2418">"" "" "" "clinically relevant CTC toxicity, which were reported at &lt; 1% (occasionally) of patients, were randomised pemetrexed, comprised supraventricular arrhythmias." "" "" ""</seg>
<seg id="2419">The clinically relevant laboratory toxicity grade 3 and 4 was similar to the phase 2 of three Pemetrexed monotherapies (12.8% compared to 5.3%) and an increase in the Alanine transaminase (15.2% compared to 1.9%).</seg>
<seg id="2420">These under- parties are likely to be traced back to differences in the patient population as the phasis 2 studies include both chemonaive and clearly pre-treated breast cancer patients with existing liver metastases and / or abnormal starting values of liver function tests.</seg>
<seg id="2421">The following table shows the incidence and severity of adverse effects that could be possible in connection with study medication; they were randomised to patients with NSCLC and 830 patients with NSCLC who were randomized cisplatin and gemcitabine.</seg>
<seg id="2422">11 * P values &lt; 0.05 Comparison of Pemetrexed / Cisplatin and Gemcitabine / Cisplatin for any toxicity level. * * * Move to National Cancer Institute CTC (v2.0; NCI 1998) should be reported at National Cancer Institute CTC (v2.0; NCI 1998).</seg>
<seg id="2423">"" "" "" "for this table, a threshold of 5% was specified for the inclusion of all events in which the reporting physician held a connection with Pemetrexed and Cisplatin for possible." "" "" ""</seg>
<seg id="2424">Clinically relevant toxicity that was reported in ≥ 1% and ≤ 5% (often) of patients who were randomised Cisplatin and Pemetrexed were:</seg>
<seg id="2425">"" "" "" "clinically relevant toxicity, which was reported at &lt; 1% (occasionally) of patients who were rancised cisplatin and Pemetrexed, included:" "" "" ""</seg>
<seg id="2426">"" "" "" "serious cardiovascular and cerebrovascular events, including myocardial infarction, angina pectoris, cerebrovascular insulin and transitory ischemic attacks were occasionally reported in combination with another cytotoxic substance." "" "" ""</seg>
<seg id="2427">"" "" "" "from clinical studies patients with Pemetrexed were occasionally reported cases of coli- tis (including intestinal and rectal bleeding, sometimes fatal perfo- ration, intestinal necrosis and typhlitis)." "" "" ""</seg>
<seg id="2428">"" "" "" "from clinical studies, cases of sometimes fatal interstitial pneumonitis with respiratory failure were reported in patients with Pemetrexed." "" "" ""</seg>
<seg id="2429">It was reported about cases of acute renal failure in pemetrexed monotherapy or in combination with other chemotherapy agents (see Section 4.4).</seg>
<seg id="2430">"" "" "" "cases of radionitis were reported in patients who were treated before, during or after their Pemetrexed therapy (see Section 4.4)." "" "" ""</seg>
<seg id="2431">ALIMTA (Pemetrexed) is a antineoplastic antifold that exerts its effect by interrupting important metabolic processes that are necessary for cell replication.</seg>
<seg id="2432">In vitro studies showed that Pemetrexed works as an antifold with multiple attack points by blocking the thymidylatsynthase (DHFR) and glycoamidribonucleotidfor- myltransferase (GARFT).</seg>
<seg id="2433">"" "" "" "EMPHACIS, a multi-centric, randomised, simple-blind Phase 3 study of ALIMTA and Cisplatin demonstrated a clinically meaningful benefit to patients who were treated with cisplatin only." "" "" ""</seg>
<seg id="2434">"" "" "" "the primary analysis of this study was made in the population of all patients, who received the examination medication in the treatment arm (randomised and treated)." "" "" ""</seg>
<seg id="2435">A statistically significant improvement of the clinically relevant symptoms (pain and dyspnoea) in connection with the malignant pleuramesothelioma was shown in the case of the Lun- genesis symptom scale in ALIMTA / Cisplatin-arm (212 patients) compared to the allucle- tin-arm (218 patients).</seg>
<seg id="2436">The differences between the two arms were improved by improving the lung function parameters in the ALIMTA / Cisplatin-arm and a worsening of lung function over time in the control arm.</seg>
<seg id="2437">A multi-centric, randomised, open phase III study with ALIMTA against docetaxel in patients with locally advanced or metastatic NSCLC after previous chemotherapy had a median survival time of 8.3 months in patients treated with docetaxel (ITT n = 288).</seg>
<seg id="2438">"" "" "" "an analysis of histology in patients with NSCLC in patients with squamous cell carcinoma (n = 172, 6.2 versus 7.4 months, matched HR = 0.61-2.26, p = 0.018)." "" "" ""</seg>
<seg id="2439">Limited data of a separately randomised controlled Phase 3 study showed that efficacy data (survival and progression-free survival) for pemetrexed between patients with (n = 41) and without (n = 540) pretreatment by docetaxel are similar.</seg>
<seg id="2440">The efficacy analyses of the PQ population are consistent with the analysis of the ITT population and support the non-superiority of the ALIMTA Cisplatin combination compared to gemcitabine cisplatin combination.</seg>
<seg id="2441">Mean PFS was 4.8 months for the combination ALIMTA Cisplatin versus 5.1 months for the combination of gemcitabine Cisplatin compared to 28.2% (95% CI = 0.94 - 31.4) for the combination gemcitabine cisplatin.</seg>
<seg id="2442">"" "" "" "the analysis of the impact of NSCLC histology on survival showed clinically relevant under- or histology, see table below." "" "" ""</seg>
<seg id="2443">CI = Concernation interval; ITT = Orientation interval; N = Size of the total population a statistically set for non-superiority with a total confidence interval for HR (= Hazard ratio) significantly below the non-negative limit of 1.17645 (p &lt; 0.001).</seg>
<seg id="2444">Patients treated with ALIMTA and Cisplatin required less transfusions (16.4% versus 28.9%, p &lt; 0.001) and thrombocyte transfusions (1.8% versus 4.5% vs. 4.5%; p = 0.002).</seg>
<seg id="2445">Patients also needed the administration of Erythropoetin / Darbopoetin (10.4% versus 18.1% versus 18.1% versus 18.1% vs. 6% versus 7.0% versus 7.0% versus 7.0% versus P = 0.021).</seg>
<seg id="2446">The pharmacokinetic properties of Pemetrexed according to administration as a monotherapist were examined in 426 cancer patients with different solid tumours in doses of 0.2 to 838 mg / m ² in infusi- ons over a period of 10 minutes.</seg>
<seg id="2447">"" "" "" "Pemetrexed is mainly excreted in the urine and 70% to 90% of the administered dose is found in the urine, unchanged within 24 hours after application." "" "" ""</seg>
<seg id="2448">Pemetrexed has a total of 91,8 ml / min and half-life in the plasma is 3.5 hours in patients with normal kidney function (Creatinin-Clearance 90 ml / min).</seg>
<seg id="2449">"" "" "" "in a study with Beagle dogs, who received intravenous bolus injections for 9 months, Testikulinary changes were observed (degeneration / necrosis of the seminier epithelial tissue)." "" "" ""</seg>
<seg id="2450">"" "" "" "unless otherwise applied, storage times and conditions after preparation are in the responsibility of the user and should normally not exceed 24 hours at 2 to 8 ° C unless the preparation / dilution has taken place under controlled and validated aseptic conditions." "" "" ""</seg>
<seg id="2451">Dissolve the contents of the 100 mg capsule with 4.2 ml 0.9% sodium chloride injection solution (9 mg / ml) without preservative. this results in a solution with a concentration of approximately 25 mg / ml Pemetrexed.</seg>
<seg id="2452">"" "" "" "the resulting solution is clear and the coloring ranges from colorless to yellow or greenish, without compromising product quality." "" "" ""</seg>
<seg id="2453">"" "" "" "each glass bottle must be dissolved with 20 ml 0.9% sodium chloride injection solution (9 mg / ml), which results in a solution of 25 mg / ml." "" "" ""</seg>
<seg id="2454">"" "" "" "23 key cardiovascular events, including myocardial infarction, and cerebrovascular events were occasionally reported in clinical trials involving Pemetrexed if this drug was usually administered in combination with another cytotoxic substance." "" "" ""</seg>
<seg id="2455">* Regarding the National Cancer Institute CTC Version 2 for each toxicity level excluded the event "Creatinin-Clearance" * * which was derived from the term "kidney / genital tract other." * * * Beackled on National Cancer Institute CTC (v2.0; NCI 1998) should only be reported as grade 1 or 2.</seg>
<seg id="2456">"" "" "" "for this table, a threshold of 5% was set for the inclusion of all events in which the reporting physician held a connection with Pemetrexed and Cisplatin for possible." "" "" ""</seg>
<seg id="2457">* Regarding National Cancer Institute CTC Version 2 for any toxicity level. * * Beackled at National Cancer Institute CTC (v2.0; NCI 1998) should be reported to hair loss only as grade 1 or 2.</seg>
<seg id="2458">29 * P values &lt; 0.05 Comparison of Pemetrexed / Cisplatin and Gemcitabine / Cisplatin for any toxicity level. * * * Move to National Cancer Institute CTC (v2.0; NCI 1998) should be reported at National Cancer Institute CTC (v2.0; NCI 1998).</seg>
<seg id="2459">"" "" "" "clinically relevant toxicity, which was reported at &lt; 1% (occasionally) of patients who were rancised cisplatin and Pemetrexed, included:" "" "" ""</seg>
<seg id="2460">"" "" "" "an analysis of histology in patients with NSCLC in patients with squamous cell carcinoma (n = 172, 6.2 versus 7.4 months, matched HR = 0.61-2.26, p = 0.018)." "" "" ""</seg>
<seg id="2461">Dissolve the contents of the 500 mg porphylactic tank with 20 ml 0.9% sodium chloride injection solution (9 mg / ml) without preservative. this results in a solution with a concentration of approximately 25 mg / ml Pemetrexed.</seg>
<seg id="2462">"" "" "" "the resulting solution is clear and the coloring ranges from colorless to yellow or greenish yellow, without compromising product quality." "" "" ""</seg>
<seg id="2463">"" "" "" "Pharmacovigilance System The holder of approval for marketing has to ensure that the pharmaceutical kovigilance system, as described in version 2.0, is ready and ready for use as soon as the product is brought into circulation and while the product is in the market." "" "" ""</seg>
<seg id="2464">Risk Management Plan The holder of approval for the transfer is obliged to carry out the studies and the additional pharmaceutical kovigilance activities according to the Pharmacovigilance Plan as agreed in modules 1.8.2. the approval for the placing and all the following updates of the RMP which were decided by the CHMP.</seg>
<seg id="2465">"" "" "" "according to" CHMP Guideline on Risk Management Systems for Product for Human Use, "an updated RMP must be submitted simultaneously with the next" Periodic Safety Update Report "(PSUR)." "" "" ""</seg>
<seg id="2466">"" "" "" "in addition, an updated RMP must be submitted • If new information is available that could affect the current safety specifications, the pharmaceutical vigilance plan or risk reduction) milestones • On request by EMEA" "" "" ""</seg>
<seg id="2467">ALIMTA 100 mg powder for the production of an infusion solution ALIMTA 500 mg powder for the production of an infusion solution</seg>
<seg id="2468">"" "" "" "ALIMTA is used in patients who have not received prior chemotherapy, in combination with Cisplatin, another medicine for treating cancer." "" "" ""</seg>
<seg id="2469">"" "" "" "if you have kidney disease or earlier, please discuss it with your doctor or hospital pharmacist since you may not be allowed to receive ALIMTA." "" "" ""</seg>
<seg id="2470">"" "" "" "you will be performed before any infusion of blood tests, checking whether your kidney and liver function is sufficient and whether you have enough blood cells to get ALIMTA to 49." "" "" ""</seg>
<seg id="2471">Your doctor may possibly change the dose or stop the treatment if your general condition requires and if your blood values are too low.</seg>
<seg id="2472">"" "" "" "if you also receive cisplatin, your doctor will ensure that your body contains sufficient water and you will get the necessary medicines to avoid vomiting before and after Cisplatin." "" "" ""</seg>
<seg id="2473">"" "" "" "if you have a fluid accumulation around the lungs, your doctor may decide to eliminate this liquid before you get ALIMTA." "" "" ""</seg>
<seg id="2474">"" "" "" "if you want to buy a child during the treatment or during the first 6 months of treatment, please contact your doctor or pharmacist." "" "" ""</seg>
<seg id="2475">"" "" "" "interactions with other medicines Please tell your doctor if you are taking drugs against pain or inflammation (swelling), including drugs that are non-prescription (like ibuprofen)." "" "" ""</seg>
<seg id="2476">"" "" "" "depending on the planned period of your ALIMTA infusion and / or the extent of your renal function, your doctor will tell you what other medicines you can use and when." "" "" ""</seg>
<seg id="2477">"" "" "" "please inform your doctor or pharmacist if you take other medicines, or have recently taken, even if it is not prescribed for prescription medicaments." "" "" ""</seg>
<seg id="2478">"" "" "" "a hospital doctor, nursing staff or a doctor will mix the ALIMTA powder with sterile 0.9% sodium chloride injection solution (9 mg / ml) before it is applied to you." "" "" ""</seg>
<seg id="2479">Your doctor will prescribe cortison tablets (according to 4 mg Dexameth- son twice a day) that you have to take on the day before and during the day following the application of ALIMTA.</seg>
<seg id="2480">Your doctor will prescribe folic acid (a vitamin) for intake or multivitamins which contain folic acid (350 to 1000 micrograms) to prescribe you during the application of ALIMTA once a day.</seg>
<seg id="2481">"" "" "" "in the week before the application of ALIMTA and approximately every 9 weeks (according to 3 cycles of treatment with ALIMTA), you will also receive an injection of Vi- tamin B12 (1000 microgram)." "" "" ""</seg>
<seg id="2482">"" "" "" "in this utility information, a side effect is described as" very common "means that it was reported by at least 1 out of 10 patients." "" "" ""</seg>
<seg id="2483">"" "" "" "if a side effect is described as" frequent, "this means that it was reported of at least 1 out of 100 patients but was reported less than 1 out of 10 patients." "" "" ""</seg>
<seg id="2484">"" "" "" "a side effect is described as" occasional "- indicates that they were reported by at least 1 out of 1,000 but less than 1 out of 100 patients." "" "" ""</seg>
<seg id="2485">"" "" "" "fever or infection (often): if you have a body temperature of 38 ° C or above, sweating or other signs of infection (because you may have less white blood cells than normal, which is very common)." "" "" ""</seg>
<seg id="2486">"" "" "" "if you feel tired or weak, quickly get into breath or look pale (because you may have fewer hemoglobin than normal, which is very common)." "" "" ""</seg>
<seg id="2487">"" "" "" "if you find a bleeding gums, nose or mouth or another bleeding that does not come to a halt, or have a reddish or pink urine or unexpected bruising (because you may have fewer blood platelets than normal, which is very common)." "" "" ""</seg>
<seg id="2488">"" "" "" "occasionally (occurs at least 1 out of 1,000 patients, but less than 1 of 100 patients) increased pulse rate Colitis (inflammation of the inner lining of the colon and endgut)" "" "" ""</seg>
<seg id="2489">"" "" "" "rare (occurs with more than 1 of 10,000 patients, but less than 1 out of 1,000 patients)" Radiation Recall "(a rash resembling a severe sunburn), appearance on the skin that was previously exposed (several days to years) of radiotherapy." "" "" ""</seg>
<seg id="2490">"" "" "" "occasionally, in patients with ALIMTA, usually in combination with other cancer patients received, stroke or stroke with minor damage." "" "" ""</seg>
<seg id="2491">"" "" "" "in patients who before, during or after their ALIMTA treatment also receive radiation treatment, a radiation caused by radiation can occur (scarring of the pulmonary blower that is related to radiation treatment)." "" "" ""</seg>
<seg id="2492">52 Inform your doctor or pharmacist if any of the listed side effects may be significant or if you notice any side effects that are not contained in this package.</seg>
<seg id="2493">"" "" "" "provided as required, the chemical and physical stability of the diluted and infusion solution for storage in the refrigerator or at 25 ° C was proven for a period of 24 hours." "" "" ""</seg>
<seg id="2494">Tél / Tel: + 32- (0) 2 548 84 84 Goldsmieská republika ELI LILLY ČR s.r.o.</seg>
<seg id="2495">Tel: + 420 234 664 111 Danmark Eli Lilly Danmark A / S Tlf: + 45 45 26 6100 Germany Lilly Holdings Limited Eesti filiaal</seg>
<seg id="2496">Ireland: + 34-91-623-1732 France Lilly France SAS Tél: + 33- (0) 1 55 49 34 34 Ireland Eli Lilly and Company (Ireland) Limited Tel: + 353- (0) 1 661 4377 Ísland Icepharma hf.</seg>
<seg id="2497">Tel: + 39- 055 42571 Reply: + 357 22715000 Latvija Eli Lilly Holdings Limited atstovybė Tel. + 371 67364000 Lietuva Eli Lilly Holdings Limited atstovybė Tel. + 370 (5) 2649600</seg>
<seg id="2498">Tel.: + 48 (0) 22 440 33 00 Portugal Lilly Portugal - produtos Farmacêuticos and Lda Tel: + 351-21-4126600 România S.R.L.</seg>
<seg id="2499">Tel: + 421 220 663 111 Suomi / Finland Oy Eli Lilly Finland Ab Puh / Tel: + 358- (0) 8 7378800 United Kingdom Eli Lilly and Company Limited Tel: + 44- (0) 1256 315999</seg>
<seg id="2500">Dissolve the contents of the 100 mg capsule bottle with 4.2 ml 0.9% sodium chloride injection solution (9 mg / ml) without preservative which results in a solution with a concentration of approximately 25 mg / ml Pemetrexed.</seg>
<seg id="2501">Dissolve the contents of the 500 mg porphylactic bottles with 20 ml 0.9% sodium chloride injection solution (9 mg / ml) without preservative which results in a solution with a concentration of approximately 25 mg / ml Pemetrexed.</seg>
<seg id="2502">"" "" "" "the resulting solution is clear and the coloring ranges from colorless to yellow or greenish, without compromising the quality." "" "" ""</seg>
<seg id="2503">"" "" "" "it is used in obese adults with a body mass index (BMI) of ≥ 28 kg per square meter in combination with low-calorie, fat-reduced nutrition." "" "" ""</seg>
<seg id="2504">"" "" "" "patients who take Alli and do not have weight loss after 12 weeks, should contact their doctor or pharmacist." "" "" ""</seg>
<seg id="2505">"" "" "" "if these enzymes are inhibited, they can't break down some fats in food, causing about a quarter of the fats that have been added to food ingested the intestines." "" "" ""</seg>
<seg id="2506">"" "" "" "in a third study, Alli was compared to patients with BMI between 25 and 28 kg / m2 with placebo." "" "" ""</seg>
<seg id="2507">"" "" "" "in both studies of patients with a BMI of ≥ 28 kg / m2 patients, the Alli 60 mg, had an average weight loss of 4.8 kg, compared to 2.3 kg in the intake of placebo." "" "" ""</seg>
<seg id="2508">"" "" "" "in the study with Alli in patients with BMI between 25 and 28 kg / m2, no weight loss could be observed for patients." "" "" ""</seg>
<seg id="2509">"" "" "" "the most common side effects of Alli (observed in more than 1 out of 10 patients) are oily stains at after, flatus (winds) with stuhula, oily / oily chair, drains (winds), flatulence (winds) and soft chairs." "" "" ""</seg>
<seg id="2510">It may not be used in patients treated with Ciclosporin (to prevent organ rejection in patients) or with medicines such as warfarin to prevent blood clots.</seg>
<seg id="2511">It may not be used in patients suffering from long-term malabsorption syndrome (where not enough nutrients are absorbed from the digestive tract) or to cholestase (liver disease) and in pregnant or nursing mothers.</seg>
<seg id="2512">"" "" "" "July 2007, the European Commission granted the company Glaxo Group Limited a permit for placing orlistat GSK in the entire European Union." "" "" ""</seg>
<seg id="2513">"" "" "" "ualli is indicated for weight reduction of adults with overweight (Body Mass Index BMI ≥ 28 kg / m2) and should be used in conjunction with a slightly hypokaloric, fat-reduced diet." "" "" ""</seg>
<seg id="2514">"" "" "" "alli may not be used by children and adolescents under 18, since there are not enough data for efficacy and safety." "" "" ""</seg>
<seg id="2515">"" "" "" "however, since orlistat is only minimally absorbed, no adjustment of the dosage is necessary for older people and patients with reduced liver and / or kidney function." "" "" ""</seg>
<seg id="2516">• hypersensitivity to the active ingredient or other ingredients • Simultaneous treatment with Ciclosporin (see section 4.6) • Premature treatment with Warfarin or other oral anticoagulants (see Sections 4.5 and 4.8)</seg>
<seg id="2517">"" "" "" "the probability of occurrence of gastrointestinal symptoms (see Section 4.8) may increase if alli is taken together with a fat-rich diet or low-fat diet." "" "" ""</seg>
<seg id="2518">"" "" "" "as the weight reduction in diabetes can be accompanied with improved metabolic control, patients who take a medicine against diabetes should consult a doctor or pharmacist before starting a therapy with alli because the dosage of the antidiabetic must be adapted if necessary." "" "" ""</seg>
<seg id="2519">"" "" "" "patients receiving alli as well as medicines for high blood pressure or increased cholesterol, should consult their doctor or pharmacist if the dosage of these medicines must be adjusted." "" "" ""</seg>
<seg id="2520">"" "" "" "it is recommended to take additional pregnancies-prevention measures, in order to prevent the failure of oral contraception in case of severe diarrhoea (see Section 4.5)." "" "" ""</seg>
<seg id="2521">"" "" "" "in a study on drug interactions as well as in several cases with simultaneous application of orlistat and Ciclosporin, a lowering of the Ciclosporin plasma level was observed." "" "" ""</seg>
<seg id="2522">"" "" "" "in the use of warfarin or other oral anticoagulants in combination with orlistat, the Quick values (internationally normal ratio, INR) could be influenced (see Section 4.8)." "" "" ""</seg>
<seg id="2523">"" "" "" "in most patients who have been treated with orlistat in clinical trials up to 4 full years, the concentrations of vitamins A, D, E and K and beta carotene remained in the normal range." "" "" ""</seg>
<seg id="2524">"" "" "" "however, the patient should be recommended to take a supplementary multivitamin supplement before bedtime to ensure adequate intake of vitamins (see Section 4.4)." "" "" ""</seg>
<seg id="2525">"" "" "" "after the administration of the Amiodaron one-off dose, a marginal amount of healthy volunteers was observed at the same time." "" "" ""</seg>
<seg id="2526">"" "" "" "animal experimental studies showed no direct or indirect harmful effects on pregnancy, embryonic / fetal development, birth or postnatal development (see Section 5.3)." "" "" ""</seg>
<seg id="2527">"" "" "" "the side effects of orlistat are mainly gastrointestinal nature and are related to pharmacological effects of the drug, because absorption of captured fat is prevented." "" "" ""</seg>
<seg id="2528">The gastrointestinal side effects were determined from clinical studies with Orlistat 60 mg over a period of 18 months to 2 years and were generally light and temporary.</seg>
<seg id="2529">"" "" "" "the frequencies are defined as follows: very common (≥ 1 / 100, &lt; 1 / 10), rare (≥ 1 / 1000, &lt; 1 / 1000), not known (frequency based on available data is not estimated)." "" "" ""</seg>
<seg id="2530">"" "" "" "the incidence of known side-effects reported after the introduction of orlistat has not been known, since these events were voluntarily reported by a population of uncertain size." "" "" ""</seg>
<seg id="2531">"" "" "" "† It is plausible that the treatment with alli may lead to trimming with regard to possible, or actual gastrointestinal side effects." "" "" ""</seg>
<seg id="2532">"" "" "" "single doses of 800 mg orlistat and multiple doses of up to 400 mg three times a day were administered over a period of 15 days in normal and obese subjects, without significant clinical findings." "" "" ""</seg>
<seg id="2533">"" "" "" "in the majority of cases reported after the launch of orlistat overdose, no side effects or similar side effects were reported as at the recommended dose of orlistat." "" "" ""</seg>
<seg id="2534">"" "" "" "based on studies on humans and animals, a rapid return formation of possible systemic effects can be assumed to be attributed to the assimilating properties of orlistat." "" "" ""</seg>
<seg id="2535">"" "" "" "the therapeutic effect is based on the lumen of the stomach and the upper small intestine, by covalent bonding to the active Serin-rest of the gastrian and pankreatic elevators." "" "" ""</seg>
<seg id="2536">"" "" "" "from clinical studies, 60 mg orlistat, taken three times a day, blocks absorption of about 25% of the food fat." "" "" ""</seg>
<seg id="2537">"" "" "" "two double-blind, randomised, placebo-controlled studies in adults with a BMI ≥ 28 kg / m2 demonstrate the efficacy of 60 mg orlistat which was taken three times a day in combination with a hypokaloric, fat-reduced diet." "" "" ""</seg>
<seg id="2538">The primary parameter that changes the body weight compared to the initial value (at the time of randomisation) has been evaluated as follows: as a variation of the body weight in the course of study (Table 1) and as part of the study participants who have lost more than 5% or more than 10% of their starting weight (table 2).</seg>
<seg id="2539">"" "" "" "although the weight reduction was observed over 12 months in both studies, the greatest loss of weight in the first 6 months occurred." "" "" ""</seg>
<seg id="2540">The average change in the total cholestess was 60 mg -2.4% (initial value: 5.20 mmol / l) and placebo + 2.8% (initial value: 5.26 mmol / l).</seg>
<seg id="2541">The average change in LDL cholesterol was 60 mg -3.5% (starting value: 3.30 mmol / l) and placebo + 3.8% (starting value: 3.41 mmol / l).</seg>
<seg id="2542">At waist circumference the average change was -4.5 cm with orlistat 60 mg (initial value 103.7 cm) and with placebo -3.6 cm (starting value 103.5 cm).</seg>
<seg id="2543">Plasma concentrations of non-metabolised orlistat were not measurable 8 hours after oral administration of 360 mg orlistat (&lt; 5 ng / ml).</seg>
<seg id="2544">"" "" "" "7 In general, therapeutic doses not metabolized in plasma could only be sporadically and in extremely low concentrations (&lt; 10 ng / ml or 0.02 µmol) and without signs of accumulation." "" "" ""</seg>
<seg id="2545">"" "" "" "in a study of obese patients with minimal systemic absorbed dose, M1 (in position 4 hydrolysed Lactonring) and M3 (M1 after splitting the N-Formyl-Leucine group) could be identified, which represented approximately 42% of the total plasma concentration." "" "" ""</seg>
<seg id="2546">"" "" "" "based on the conventional studies on safety resharmacology, toxicity in repeated application, genotoxicity, carcinogenic potential and reproductive toxicity, the preclinical data do not reveal any particular danger to humans." "" "" ""</seg>
<seg id="2547">"" "" "" "pharmaceutical vigilance system The holder of approval for the transport must ensure that the pharmaceutical vigilance system, as described in module 1.8.1. of the authorisation application, must ensure that the product is available on the market before and while the product is available." "" "" ""</seg>
<seg id="2548">"" "" "" "risk management planning The holder of approval for the application is obliged to carry out the studies and additional pharmaceutical vigilance activities as described in the pharmaceutical vigilance plan as well as all other updates of the RMPs, which are agreed with the Committee for Medicinal Products (CHMP)." "" "" ""</seg>
<seg id="2549">"" "" "" "according to the CHMP guidelines on risk management systems for human medicines, the updated RMP must be submitted simultaneously with the next PSUR (Periodic Safety Update Report)." "" "" ""</seg>
<seg id="2550">"" "" "" "furthermore, an updated RMP should be submitted: • If new information is available, the current security policies, the pharmaceutical vigilance plan or risk inimitation affected within 60 days of submission to the European Medicines Agency (EMEA)" "" "" ""</seg>
<seg id="2551">"" "" "" "12 PSURs The holder of approval for the placing of approval will take place in the first year after the Commission's decision to expand the alli 60 mg hard capsules of PSURs every 6 months, then for two years annually and then every three years." "" "" ""</seg>
<seg id="2552">Do not use if you are under 18 if you are pregnant or breastfeeding if you are hypersensitive to orlistat or any of the other ingredients if you are hypersensitive to orlistat or any of the other ingredients if you have problems with eating (chronic malabsorption syndrome).</seg>
<seg id="2553">"" "" "" "• Take a capsule with water three times a day. • Do not take more than three capsules per day. • You should take one capsule daily, before bedtime, a multivitamin tablet (with vitamins A, D, E and K). • You should not use alli for more than 6 months." "" "" ""</seg>
<seg id="2554">"" "" "" "use: take one capsule with water three times a day with each main meal. • Do not take more than three capsules per day. • You should take a multivitamin tablet daily, before bedtime (with vitamins A, D, E and K)." "" "" ""</seg>
<seg id="2555">"" "" "" "if you need further information or advice, ask a doctor or pharmacist for advice if you need more information or advice." "" "" ""</seg>
<seg id="2556">"" "" "" "you may need to end the intake of alli. • If any of the side effects listed you are significantly impaired or you notice side effects, which are not stated in this manual information, please inform your doctor or pharmacist." "" "" ""</seg>
<seg id="2557">What do you need to consider before taking alli? • Special caution when taking alli with other medicines • When taking alli with food and drinks • Pregnancy and feeding time • Transport and operation of machines 3.</seg>
<seg id="2558">How to take alli? • How can you prepare your weight loss o Sset your goal for your weight loss o Sset yourself goals for your calorie and fat intake • How long should I take alli? O If you have alli in too large quantities o If you have forgotten the intake of alli 4.</seg>
<seg id="2559">What side effects are possible? • Grade side effects • Very frequent side effects • Frequent side effects • Frequent side effects • How can you control nutritional supplements?</seg>
<seg id="2560">"" "" "" "further information • What alli contains • How alli looks and content of pack • Pharmaceutical entrepreneur and manufacturer, Additional information" "" "" ""</seg>
<seg id="2561">The weight reduction is used alli and is used for overweight adults over 18 years with a Body Mass Index (BMI) of 28 or above. alli should be used in conjunction with a low-fat and low-calorie diet.</seg>
<seg id="2562">BMI helps you determine whether you have a normal weight in relation to your body size or are overweight.</seg>
<seg id="2563">"" "" "" "even if these conditions do not cause you to feel uncomfortable, you should still ask your doctor for a control examination." "" "" ""</seg>
<seg id="2564">"" "" "" "for each 2 kg body weight you lose during a diet, you can lose an additional kilogram with the help of alli." "" "" ""</seg>
<seg id="2565">"" "" "" "please inform your doctor or pharmacist if you take other medicines or have recently taken, even if it is not prescription." "" "" ""</seg>
<seg id="2566">"" "" "" "Ciclosporin is used after transplants, in severe rheumatoid arthritis and certain severe skin diseases." "" "" ""</seg>
<seg id="2567">Oral contraception and alli • The effect of oral contraception methods (pill) may be weakened or canceled if you have strong diarrhoea (diarrhea).</seg>
<seg id="2568">"" "" "" "before taking alli to your doctor or pharmacist, please contact your doctor or pharmacist if you are using: • Amiodarone for treating cardiac arrhythmia." "" "" ""</seg>
<seg id="2569">Ask your doctor or pharmacist if you take alli and take medication against high blood pressure as you may need to adjust the dosage. • If you take drugs against too high cholesterol because you may need to adjust the dosage.</seg>
<seg id="2570">"" "" "" "for more useful information on the blue pages, see Section 6 for more information." "" "" ""</seg>
<seg id="2571">"" "" "" "if you omit a meal or contains a meal no fat, take no capsule. alli can only work if the food contains fat." "" "" ""</seg>
<seg id="2572">"" "" "" "if you take the capsule in combination with a meal containing too much fat, you risk nutritional deficiency symptoms (see Section 4)." "" "" ""</seg>
<seg id="2573">"" "" "" "in order to get used to your body's new eating habits, start early on with a calorie and fat reduction diet." "" "" ""</seg>
<seg id="2574">"" "" "" "food diaries are effective as you can understand at any time, what you eat, how much you eat and it will likely be easier to change your dietary habits." "" "" ""</seg>
<seg id="2575">"" "" "" "in order to safely reach your target weight, you should define two daily goals in advance: one for the calories and one for fat." "" "" ""</seg>
<seg id="2576">"" "" "" "• Have reduced fat, to reduce the likelihood of nutritional deficiency symptoms (see Section 4). • Try to move more before you begin taking the capsules." "" "" ""</seg>
<seg id="2577">"" "" "" "remember to consult your doctor in advance, if you are not used to physical activity. • Stay physically active during intake and after the intake of alli." "" "" ""</seg>
<seg id="2578">"" "" "" "• alli may not be taken for longer than 6 months. • If you can not find any reduction in weight after twelve weeks of application by alli, ask your doctor or pharmacist for advice." "" "" ""</seg>
<seg id="2579">"" "" "" "in certain circumstances, you need to finish the intake of alli. • In case of successful weight loss, it is not about changing nutrition at short notice and returning to the old habits." "" "" ""</seg>
<seg id="2580">"" "" "" "• If less than an hour has passed since the last meal, take the capsule after. • If more than one hour has passed since the last meal, take no capsule." "" "" ""</seg>
<seg id="2581">"" "" "" "flatulence with and without an oily outlet, sudden or increased stool / soft chair) can be attributed to the mechanism of action (see Section 1)." "" "" ""</seg>
<seg id="2582">"" "" "" "severe allergic reactions • Serious allergic reactions occur in the following changes: severe breathing difficulties, sweats, skin rashes, itching, swelling in the face, palpitations, vascular collapse." "" "" ""</seg>
<seg id="2583">29 Very frequent side effects These can occur in more than 1 out of 10 people who take alli. • Fluence (flatulence) with and without oily outlet • A fatter or oily chair • Weicher chair Inform your doctor or pharmacist if one of these side effects intensifies or significantly affects you.</seg>
<seg id="2584">Frequent side effects These can occur at 1 out of 10 people who are alli taking occur. • stomach (abdominal) pain, • Incontinence (chair) • Increased stuhldst • convert your doctor or pharmacist if one of these side effects intensifies or significantly affects you.</seg>
<seg id="2585">Effects on blood tests It is not known how frequently these effects occur. • Increase certain liver enzymes • affect blood clotting in patients who use warfarin or other blood thinner (anticoagulation) medicines.</seg>
<seg id="2586">Please inform your doctor or pharmacist if any of the listed side effects do significantly affect you or notice side effects that are not stated in this information.</seg>
<seg id="2587">"" "" "" "the most common side effects are related to the mode of action of the capsules, resulting in increased fat from the body." "" "" ""</seg>
<seg id="2588">"" "" "" "these side effects usually occur within the first weeks of the treatment, as you may not have reduced the fat content of your diet at this time." "" "" ""</seg>
<seg id="2589">With the following basic rules you can learn to minimize the nutritional effects: • Begin a few days or better a week before the first intake of capsules with a fat-reduced diet. • Learn more about the usual fat content of your favorite foods and about the size of portions that you normally take.</seg>
<seg id="2590">"" "" "" "if you know exactly how much you eat, the likelihood that you may exceed your fat limit decreases. • Share your recommended amount of fat evenly on your daily meals." "" "" ""</seg>
<seg id="2591">"" "" "" "save the amount of calories and fat you may take per meal, not to take them in the form of a fat-rich main court or a substantial dessert, learn to control them with time by adjusting their diet." "" "" ""</seg>
<seg id="2592">• Keep out of the reach of children. • Do not use any unused medicine after the expiry date specified on the carton. • Keep container tightly closed to protect the contents from moisture. • The bottle contains two white sealed containers with silicagel that serve to keep the capsules dry.</seg>
<seg id="2593">"" "" "" "do not swallow this in any case. • You can carry your daily dose of alli in the blue transport box (shuttle), which is included in this pack." "" "" ""</seg>
<seg id="2594">"" "" "" "FAMAR, 190 11 Avlona, Greece Catalent UK Packaging Limited, Sedge Close, Headway, Great Oakley, Corby, Northamptonshire NN18 8HS, United Kingdom" "" "" ""</seg>
<seg id="2595">"" "" "" "overweight has an impact on your health and increases the risk of developing various serious diseases such as: • hypertension, diabetes, heart disease • stroke • Certain cancers • osteoarthritis talk to your doctor about your risk of these diseases." "" "" ""</seg>
<seg id="2596">"" "" "" "permanent weight loss, for example by improving diet and more exercise, can prevent serious diseases and has a positive impact on your health." "" "" ""</seg>
<seg id="2597">"" "" "" "choose meals containing a wide range of nutrients, and gradually learn to feed permanently healthy." "" "" ""</seg>
<seg id="2598">"" "" "" "energy is also measured in kilojoules, which you can also find as an indication of food packaging. • The recommended calorie intake indicates how many calories you should take maximum per day." "" "" ""</seg>
<seg id="2599">"" "" "" "the recommended fat intake in grams is the maximum amount of fat, which you should take with each meal." "" "" ""</seg>
<seg id="2600">"" "" "" "which amount is appropriate for you, check out the information below which indicates the number of calories that is appropriate for you." "" "" ""</seg>
<seg id="2601">"" "" "" "if you take the same amount of fat as before, this can mean that your body cannot process this amount of fat." "" "" ""</seg>
<seg id="2602">"" "" "" "by complying with the recommended fat intake, you can maximize the weight loss and at the same time reduce the probability of nutrition-related side effects. • You should try to gradually increase your weight." "" "" ""</seg>
<seg id="2603">"" "" "" "34 This reduced caloric intake should allow you to gradually lose weight about 0.5 kg per week, without developing frustrations and disappointments." "" "" ""</seg>
<seg id="2604">"" "" "" "the more active you are, the higher your recommended calorie intake." "" "" ""</seg>
<seg id="2605">"" "" "" "• For permanent weight loss, it is necessary to set up realistic calorie and fat targets and adhere to them. • Sense is a nutrition journal with information on calorie and fat content of your meals. • Try to move more before you start taking alli." "" "" ""</seg>
<seg id="2606">The alli program for weight loss combines the capsules with a diet plan and a large number of other information materials that can help you feed calorie and fat reduction and give guidelines to become physically active.</seg>
<seg id="2607">"" "" "" "in conjunction with a program tailored to your type, this information can help you develop a healthier lifestyle and achieve your target weight." "" "" ""</seg>
<seg id="2608">"" "" "" "Alois is used for chemotherapies, the strong trigger for nausea and vomiting (like Cisplatin), as well as chemotherapy, the moderate trigger for nausea and vomiting (such as cyclophosphamide, doxorubicin or carboplatin)." "" "" ""</seg>
<seg id="2609">The effectiveness of Aloxi may be increased by the additional gift of a corticosteroids (a medicine used as an antiemetic drug).</seg>
<seg id="2610">"" "" "" "the application for patients under 18 years of age is not recommended, since the effects in this age group are not enough information." "" "" ""</seg>
<seg id="2611">"" "" "" "this means that the agent prevents the binding of a chemical substance in the body, 5-hydroxytryptamin (5HT, also known as serotonin), to the receptors in the intestine." "" "" ""</seg>
<seg id="2612">"" "" "" "Aloxi has been studied in three main studies of 1 842 adults who received chemotherapy, which are strong and moderate triggers for nausea and vomiting." "" "" ""</seg>
<seg id="2613">"" "" "" "for chemotherapies, the strong trigger for nausea and vomiting, 59% of patients treated with Alois showed no vomiting (132 of 223) compared to 57% of patients treated with Ondansetron (126 of 221)." "" "" ""</seg>
<seg id="2614">"" "" "" "81% of patients treated with Alois showed no vomiting (153 of 189), 69% of patients treated with Ondansetron (127 of 189)." "" "" ""</seg>
<seg id="2615">In comparison with Dolasetron these values were 63% for Aloxi (119 of 189 patients) and 53% for Dolasetron (101 of 191 patients).</seg>
<seg id="2616">"" "" "" "in March 2005, the European Commission issued its approval to the company Helsinki Birex Pharmaceuticals Ltd. it was approved by Aloxi throughout the European Union." "" "" ""</seg>
<seg id="2617">"" "" "" "Aloxi is indicated: for prevention of acute nausea and vomiting in highly emetogenic chemotherapy, due to cancer and for prevention of nausea and vomiting in moderately emetogenic chemotherapy due to cancer." "" "" ""</seg>
<seg id="2618">"" "" "" "the efficacy of Alois for the prevention of nausea and vomiting, induced by a highly emetogenic chemotherapy may be amplified by adding a corticosteroids." "" "" ""</seg>
<seg id="2619">"" "" "" "since Palonosetron can prolong the colon, patients with amnesty or signs of a subacute ileus should be closely monitored after injection." "" "" ""</seg>
<seg id="2620">"" "" "" "however, as with other 5HT3 antagonists, caution is advisable with simultaneous offering of Palonosetron with medicines that extend the QT interval or in patients with whom the Qt interval is extended or which tend to such an extension." "" "" ""</seg>
<seg id="2621">"" "" "" "in addition to chemotherapy, Aloxi may not be used for prevention or treatment of nausea and vomiting in the days following chemotherapy." "" "" ""</seg>
<seg id="2622">"" "" "" "in preclinical studies, Palonosetron inhibited the activity of the five chemotherapeutic agents investigated by tumours, cyclophosphamide, cyclophosphamide, doxorubicin and mitomycin C)." "" "" ""</seg>
<seg id="2623">A clinical study showed no significant pharmacokinetic interaction between a single intravenous dose of Palonosetron and a Steady State- concentration of oral metocloprams and a CYP2D6 inhibitor.</seg>
<seg id="2624">"" "" "" "in a pharmacokinetic analysis based on a population, CYP2D6 Inhibitors (Dexamethasone and Rifampicin) and CYP2D6 inhibitors have no significant effect on Palonosetron's clearing." "" "" ""</seg>
<seg id="2625">Experience of the use of palonosetron in human pregnancies is not present; therefore palonosetron should not be used in pregnant women unless it is considered necessary by the treating physician.</seg>
<seg id="2626">"" "" "" "in clinical trials, the most common side effects were observed in a dose of 250 micrograms (a total of 633 patients), at least possibly with alarms, headache (9%) and obsession (5%)." "" "" ""</seg>
<seg id="2627">"" "" "" "very rare cases (&lt; 1 / 10,000) of hypersensitivity reactions and reactions to the delivery place (burning, hardening, discomfort and pain) were indicated in post marketing experience reports." "" "" ""</seg>
<seg id="2628">"" "" "" "in the group with the highest dosage, similar frequencies of adverse events were shown as in the other dosage groups; no dose of activity had to be observed." "" "" ""</seg>
<seg id="2629">"" "" "" "no dialysis studies were carried out, however, due to the large distribution volume, dialysis is probably not effective therapy with an alligation." "" "" ""</seg>
<seg id="2630">In two randomised double-blind studies a total of 1.132 patients receiving a moderately emetogenic chemotherapy with ≤ 50 mg / m2 cyclophosphamide and 250 micrograms / m2 cyclophosphorubicin and 250 microgram / m2 cyclophosphamide and 250 microgram / m2 cyclophosphamide (half-life: 7.3 hours) received intravenously in day 1 without Dexamethasone.</seg>
<seg id="2631">In a randomised double-blind study a total of 667 patients receiving chemotherapy with ≥ 60 mg / m2 cyclophosphamide and Dacarbazine as well as 250 or 750 micrograms of Palonosetron have been compared to patients receiving 32 mg of ondansetron.</seg>
<seg id="2632">"" "" "" "results of the studies with medically emetogenic chemotherapy, and the study of chemotherapy-based chemotherapy are summarized in the following tables." "" "" ""</seg>
<seg id="2633">"" "" "" "in clinical trials for the indication of chemotherapy-induced nausea and vomiting (CINV), the effects of palonosetron on blood pressure, heart rate and ECG parameters were comparable with the corresponding effects of ondansetron and Dolasetron." "" "" ""</seg>
<seg id="2634">"" "" "" "according to clinical studies, Palonosetron has the ability to block the ion channels involved in ventricular de- and repolarization and extend the duration of the action potential." "" "" ""</seg>
<seg id="2635">"" "" "" "the aim of the study carried out in 221 healthy volunteers was to evaluate the ECG effects of intravenous palonosetron in individual doses of 0,25, 0.75 and 2,25 mg." "" "" ""</seg>
<seg id="2636">Resorption After IV administration follows an initial decrease in the plasma concentrations a slow elimination of the body with an average terminal half-life of about 40 hours.</seg>
<seg id="2637">The average maximum plasma concentration (Cmax) and the surface under the concentration time curve (AUC0- ∞) are generally dose-proportional in the entire dose range of 0.3 90 μ / kg in healthy and cancer patients.</seg>
<seg id="2638">After intravenous administration of Palonosetron 0.25 mg every second day for a total of 3 doses the mean (± SD) increase of the palonosetron plasma concentration was 42 ± 34%.</seg>
<seg id="2639">"" "" "" "pharmacokinetic simulations indicate that once daily intravenous intravenous administration of 0,25 mg Palonosetron was comparable to an intravenous administration of 0.75 mg." "" "" ""</seg>
<seg id="2640">About 40% are eliminated through the kidneys and about another 50% are converted into two primary metabolites that have less than 1% of the antagonistic effect on the 5HT3 receptor in comparison to palonosetron.</seg>
<seg id="2641">"" "" "" "in vitro studies for the metabolism have shown that CYP2D6 and, to a lesser extent, the Isoenzyme CYP3A4 and CYP1A2 are involved in the metabolism of Palonosetron." "" "" ""</seg>
<seg id="2642">Elimination After an intravenous single dose of 10 micrograms / kg [14C] -Palonosetron approximately 80% of the dose was found within 144 hours in the urine. palonosetron made about 40% of the given dose.</seg>
<seg id="2643">"" "" "" "after a unique IV bolted injection, the total body was 173 ± 73 ml / min and the renal Clearance 53 ± 29 ml / min." "" "" ""</seg>
<seg id="2644">"" "" "" "while patients with severe liver dysfunctions increase the terminal elimination time and the average systemic exposure to palonosetron, however, a reduction in the dose is not justified." "" "" ""</seg>
<seg id="2645">"" "" "" "in pre-clinical studies, effects were observed only after exposures which are considered adequate over the maximum human therapeutic exposure, suggesting a low relevance for clinical use." "" "" ""</seg>
<seg id="2646">"" "" "" "10 Out of preclinical studies, evidence suggests that palonosetron can only block ions in very high concentrations, which are involved in ventricular de- and repolarization." "" "" ""</seg>
<seg id="2647">"" "" "" "high doses of Palonosetron (each dose corresponding to the 30x of therapeutic exposure to humans), which were given daily over two years, led to increased frequency of liver tumours, endocrine neoplasma (in thyroid, pituitary, pancreas, adrenal disease) and skin tumors in rats." "" "" ""</seg>
<seg id="2648">"" "" "" "the underlying mechanisms are not fully known, but because of the high dosages and since alxi is intended for a unique application, the relevance of these results is considered low for humans." "" "" ""</seg>
<seg id="2649">"" "" "" "" "" "" "" "the holder of this permit for the transport must inform the European Commission on the plans for the placing of the medicine approved within this decision." "" "" ""</seg>
<seg id="2650">"" "" "" "• If any of the side effects listed are significantly impaired or you notice side effects that are not indicated in this information, please inform your doctor." "" "" ""</seg>
<seg id="2651">• Aloxi is a clear, colorless injection solution for injecting into a vein. • This medication (palonosetron) belongs to a group of drugs called serotonin (5HT3-) antagonists.</seg>
<seg id="2652">"" "" "" "21 If using alxi with other medicines Please tell your doctor if you use other medicines, or use it recently, even if it is not prescription." "" "" ""</seg>
<seg id="2653">"" "" "" "pregnancy If you are pregnant or believe to be pregnant, your doctor will not give you aloo unless it is clearly required." "" "" ""</seg>
<seg id="2654">Ask your doctor or pharmacist for advice before taking medication if you are pregnant or believe to be pregnant.</seg>
<seg id="2655">"" "" "" "in some very rare cases, allergic reactions to aloxi or burning or pain occurred at the insertion point." "" "" ""</seg>
<seg id="2656">"" "" "" "like aloxi looks and content of the pack Aloxi injection solution is a clear, colourless solution and is available in a package with 1 glass bottle made of glass that contains 5 ml of the solution." "" "" ""</seg>
<seg id="2657">Arteriosus of the arteries of the arteries and arteries.: + 359 2 975 13 95 (6)</seg>
<seg id="2658">LV-1011 Tel: + 37167502185 Lietuva UAB pharmaceuticals Swiss syndicate kicks in Latvija Pharma Swiss Latvia SIA 54-5</seg>
<seg id="2659">United Kingdom IS Pharmaceuticals Ltd Office Village Chester Business Park Chester CH4 9QZ - UK Tel: + 44 1244 625 152</seg>
<seg id="2660">June 2006 the Committee for Medicinal Products (CHMP) adopted a negative report in which the approval of the approval of the treatment of hepatitis C for the treatment of hepatitis C was recommended by Alpheon 6 million IE / ml injection solution.</seg>
<seg id="2661">"" "" "" "this means that Alpheon is similar to a biological medicine called Roferon-A, which is already approved in the EU (also called" reference drug ")." "" "" ""</seg>
<seg id="2662">Alpheon should be used to treat adult patients with chronic (long-lasting) hepatitis C (a liver disease called by viral infection).</seg>
<seg id="2663">"" "" "" "in the case of a microscopic investigation, the liver tissue damage is damaged, also the values of the liver enzyme Alanine Aminotransferase (ALT) in the blood abnormally." "" "" ""</seg>
<seg id="2664">"" "" "" "it is produced by a yeast produced by a gene (DNA), which stimulates them to form the active ingredient." "" "" ""</seg>
<seg id="2665">"" "" "" "Alpheon manufactures data that demonstrate the comparison of Alpheon with Roferon-A (drug structure, composition and purity of the medicine, mode of action, safety and efficacy in hepatitis C)." "" "" ""</seg>
<seg id="2666">"" "" "" "in the study of patients with hepatitis C, the efficacy of Alpheon was compared with the efficacy of the reference drug to 455 patients." "" "" ""</seg>
<seg id="2667">"" "" "" "the study measured how many patients after 12 of a total of 48 treatment weeks, and 6 months after the treatment was applied to the medicine (i.e. no signs of the virus in the blood)." "" "" ""</seg>
<seg id="2668">(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 e-mail: mail @ emea.eu.int © EMEA 2006 Reproduction and / or distribution of this document is Authorised for non commercial purposes only.</seg>
<seg id="2669">"" "" "" "furthermore, concerns were expressed that the data on the stability of the drug and the drug to be marketed do not suffice." "" "" ""</seg>
<seg id="2670">"" "" "" "the number of patients with hepatitis C, which responded to the treatment with Alpheon and Roferon-A, was similar in the clinical trial." "" "" ""</seg>
<seg id="2671">"" "" "" "after adjusting the treatment with Alpheon, the disease persisted in more patients than with the reference drug; furthermore, Alpheon had more side effects." "" "" ""</seg>
<seg id="2672">"" "" "" "apart from this, the test used in the study to investigate the extent to which the medicine produces an immune response (i.e. the body produces antibodies - special proteins - against the drug), not adequately validated." "" "" ""</seg>
<seg id="2673">"" "" "" "it can be used to treat Impetigo (skin infection associated with crusts) and small infected ladies (tears or cuts), abrasions and sewn wounds." "" "" ""</seg>
<seg id="2674">Altargo should not be used to treat infections that have been proven or probably caused by methicillinresistant Staphylococcus aureus (MRSA) because Alargo against this type of infection may not work.</seg>
<seg id="2675">"" "" "" "Altargo can be used in patients from the age of nine months, but patients under the age of 18 may not exceed 2% of the body surface." "" "" ""</seg>
<seg id="2676">"" "" "" "if the patient does not respond to treatment after two or three days, the doctor should examine the patient again and consider alternative treatments." "" "" ""</seg>
<seg id="2677">It works by blocking bacterial ribosomes (the parts of the bacterial cell in which proteins are produced) and inhibits the growth of the bacteria.</seg>
<seg id="2678">"" "" "" "the main indicator of efficacy was in all five studies of the proportion of patients, whose infection was cleared after the end of the treatment." "" "" ""</seg>
<seg id="2679">"" "" "" "119 (85,6%) of the 139 patients at Altargo and 37 (52.1%) of 71 patients under placebo pronounced the treatment." "" "" ""</seg>
<seg id="2680">"" "" "" "in the treatment of infected skin-dogs, Altargo and Cefalexin showed similar response rates: when the results of both studies were taken together at home-hours, about 90% of patients from both groups discussed the treatment." "" "" ""</seg>
<seg id="2681">"" "" "" "however, in these two studies Altargo was not effective enough for the treatment of abscesses (uterine cavities in the body tissue) or of infections that have been proven or probably caused by MRSA." "" "" ""</seg>
<seg id="2682">The most common side effect with altargo (which was observed in 1 to 10 of 100 patients) is a irritation to the job.</seg>
<seg id="2683">The Committee for Medicinal Products (CHMP) concluded that the advantages of Altargo in short-term treatment of the following superficial skin infections outweigh the risks: • Impetigo - infected small Ladisations and abrasions or sewn wounds.</seg>
<seg id="2684">"" "" "" "may 2007, the European Commission issued a permit for the company Glaxo Group Ltd. to transport Altargo across the European Union." "" "" ""</seg>
<seg id="2685">"" "" "" "patients with no improvement within two to three days should be examined once more, and an alternative therapy should be considered (see Section 4.4)." "" "" ""</seg>
<seg id="2686">"" "" "" "in case of sensitization or severe local irritation through the use of Retapamulin ointment, the treatment should be canceled, the ointment carefully wiped and an appropriate alternative therapy of the infection is started." "" "" ""</seg>
<seg id="2687">"" "" "" "retapamulin should not be used to treat infections, in which MRSA is known as pathogen or suspected (see section 5.1)." "" "" ""</seg>
<seg id="2688">"" "" "" "in clinical trials in infected open wounds, the efficacy of Retapamulin was insufficient in patients with infection caused by a methicillin resistant Staphylococcus aureus (MRSA)." "" "" ""</seg>
<seg id="2689">"" "" "" "an alternative therapy should be taken into consideration, if there is no improvement or deterioration of the infected area after a 2 to 3 day treatment." "" "" ""</seg>
<seg id="2690">The effect of simultaneous use of reapamulin and other topical remedies on the same skin surface is not examined and the simultaneous use of other topical drugs is not recommended.</seg>
<seg id="2691">"" "" "" "due to the low plasma concentrations, which have been achieved in humans following topical application on scratched skin or infected superficial wounds, a clinically relevant inhibition can not be expected in vivo (see Section 5.2)." "" "" ""</seg>
<seg id="2692">3 Accurally oral administration of 2 times a day 200 mg of ketoconazol increased the mean Retapamulin AUC (0-24) and Cmax according to topical application of 1% retapamulin ointment on sprayed skin of healthy adult men by 81%.</seg>
<seg id="2693">"" "" "" "due to the low systemic exposure to topical application in patients, dosage adjustments are not considered necessary if topical Retapamulin is applied during systemic treatment with CYP3A4 inhibitors." "" "" ""</seg>
<seg id="2694">Animal studies have shown a reproductive toxicity following oral consumption and are insufficient with regard to a statement on the birth and the fetal / postnatal development (see Section 5.3).</seg>
<seg id="2695">"" "" "" "during pregnancy, Retapamulin should be used only if topical antibacterial therapy is clearly indicated and the use of retapamulin is preferable to a systemic antibiotic." "" "" ""</seg>
<seg id="2696">"" "" "" "when deciding whether the breastfeeding continues or ended or the therapy with Altargo should be continued / terminated, the benefits of breastfeeding for the infant and the benefit of the Altargo therapy for women." "" "" ""</seg>
<seg id="2697">"" "" "" "in clinical trials involving 2150 patients with superficial skin infections, the Altargo was the most frequently reported side effect irritation at the delivery place, which concerned about 1% of the patients." "" "" ""</seg>
<seg id="2698">Mode Retapamulin is a semi-synthetic derivative of Pleuromutilin containing a substance that is isolated from Clitopilus passeckerianus (formerly pleurotus passeckerianus).</seg>
<seg id="2699">The mode of action of Retapamulin is based on selective inhibition of bacterial protein synthesis by interaction at a specific binding site of the bacterial ribosome that differs from the binding sites of other ribosomal interacting antibacterial substances.</seg>
<seg id="2700">Data point out that the binding site ribosomal protein L3 is involved and is located in the region of the ribosomal P-Binding Centre and the Peptidyltransferase Center.</seg>
<seg id="2701">"" "" "" "by binding at this binding site, glandromutiline inhibits peptide transfer, block partial P-binding interactions and prevent normal formation of active 50 ribosome subunits." "" "" ""</seg>
<seg id="2702">"" "" "" "due to the local prevalence of resistance, the application of Retapamulin at least some infection forms should appear questionable, advice should be sought by experts." "" "" ""</seg>
<seg id="2703">There were no differences in the in vitro activity of Retapamulin compared to S.aureus regardless of whether the isolates were sensitive or resistant to methicillin.</seg>
<seg id="2704">"" "" "" "in case of non-response to the treatment at S.aureus, the presence of strains with additional virulence factors (such as PVL = Panton-Valentine Leucocidin) should be considered." "" "" ""</seg>
<seg id="2705">"" "" "" "resorption In a study involving healthy adults, 1% reapamulin ointment was applied daily under occlusion on intact and on lactated skin for up to 7 days." "" "" ""</seg>
<seg id="2706">"" "" "" "of 516 patients (adults and children) who received 1% retapamulin ointment twice daily for 5 days for topical treatment of secondary traumatic wounds, single plasma samples were obtained." "" "" ""</seg>
<seg id="2707">"" "" "" "sampling was performed on days 3 or 4 in the adults, each before medication and in children between 0-12 hours after the last application." "" "" ""</seg>
<seg id="2708">However the maximum individual systemic inclusion in humans after topical application of 1% ointment to 200 cm2 of skunk skin (Cmax = 22 ng / ml; AUC (0-24) = 238 ng · h / ml) 660 times lower than the Retapamulin IC50 for the PGP escapement.</seg>
<seg id="2709">Metabolism The in vitro oxidative metabolism of Retapamulin in human liver microsomes was primarily mediated by CYP3A4 and lower participation of CYP2C8 and CYP2D6 (see Section 4.5).</seg>
<seg id="2710">"" "" "" "in studies of oral toxicity of rats (50, 150 or 450 mg / kg) conducted over 14 days, there were signs of adaptive liver and thyroid gland changes." "" "" ""</seg>
<seg id="2711">In vitro screening of gene mutation and / or chromosomal effects in mouse-lymphoma test or in cultures of human peripheral blood lymphocytes as well as in rats microkernel test for in-vivo investigation of chromosomal effects.</seg>
<seg id="2712">"" "" "" "there was neither male nor female rats at oral dosages of 50, 150 or 450 mg / kg / day, which has been achieved by up to 5 times higher exposure to the highest estimated exposure to humans (topical application to 200 cm2)." "" "" ""</seg>
<seg id="2713">"" "" "" "in an embryotoxicity study of rats at oral dosages of ≥ 150 mg / kg / day (corresponding to the estimated human exposure (see above)), development stoxicity (reduced body weight of fetus and delayed Ossification) and maternal toxicity." "" "" ""</seg>
<seg id="2714">"" "" "" "the holder of approval for the transport must ensure that a pharmaceutical vigilance system, as presented in the module 1.8.1 of the authorisation application (version 6.2) and works before the product is marketed and used as long as the product marketed." "" "" ""</seg>
<seg id="2715">"" "" "" "the holder of approval for the application is obliged to carry out detailed studies and additional pharmaceutical co-vigilance activities, as described in version 1 of Risk Management Plan (RMP), as well as all additional updates of the RMP agreement with the CHMP." "" "" ""</seg>
<seg id="2716">"" "" "" "as described in the CHMP Guideline on Risk Management Systems for Product for Human Use, the updated RMP is to be submitted simultaneously with the next Periodic Safety Update Report." "" "" ""</seg>
<seg id="2717">"" "" "" "show irritation or other signs and symptoms in the treated area, you should quit the application of Altargo and talk to your doctor." "" "" ""</seg>
<seg id="2718">"" "" "" "do not apply any other ointments, creams or lotions on the surface treated with altargo if it has not been prescribed to you by your doctor." "" "" ""</seg>
<seg id="2719">"" "" "" "it may not be applied in sight, mouth or lips, in the nose or in the female genital area." "" "" ""</seg>
<seg id="2720">"" "" "" "if the ointment appears on one of these surfaces, wash the place with water and ask your doctor for advice if complaints occur." "" "" ""</seg>
<seg id="2721">"" "" "" "after applying the ointment, you can cover the affected area with a sterile association or a gazebo unless your doctor has advised you to not cover the surface." "" "" ""</seg>
<seg id="2722">"" "" "" "it is offered in an aluminum tube with a plastic closure that contains 5, 10 or 15 grams of ointment, or in an aluminium bag containing 0,5 g ointment." "" "" ""</seg>
<seg id="2723">"" "" "" "Ambirix is used to protect against hepatitis A and hepatitis B (diseases affecting the liver) in children aged between 1 and 15 years, which are not immune to these two diseases." "" "" ""</seg>
<seg id="2724">"" "" "" "Ambirix is used as part of a vaccination plan consisting of two doses, and a protection against hepatitis B may be achieved only after administration of the second dose." "" "" ""</seg>
<seg id="2725">"" "" "" "for this reason, Ambiani must only be used if there is a low risk of hepatitis B infection during the immunisation process and it is ensured that the inoculation plan can be run out of two doses." "" "" ""</seg>
<seg id="2726">"" "" "" "if a refresher dose is desirable against hepatitis A or B, the Ambirix or other hepatitis A or B vaccine may be given." "" "" ""</seg>
<seg id="2727">"" "" "" "vaccines act by contributing to the immune system (the natural defense of the body)," as it can fight against a disease. "" "" "" "</seg>
<seg id="2728">"" "" "" "after a child has received the vaccine, the immune system detects viruses and surface antigens as" foreign "and produces antibodies against it." "" "" ""</seg>
<seg id="2729">"" "" "" "Ambirix contains the same components as the vaccines authorized since 1996, and the vaccines authorized since 1997." "" "" ""</seg>
<seg id="2730">"" "" "" "the three vaccines are used to protect against the same disease, but Twinrix adults and Twinrix children are administered as part of one vaccination system consisting of three doses." "" "" ""</seg>
<seg id="2731">"" "" "" "because Ambirix and Twinrix adults contain identical ingredients, some of the data that support the application of Twinrix adults were also used as evidence for the application of Ambirix." "" "" ""</seg>
<seg id="2732">"" "" "" "the main indicator for efficacy was the share of vaccinated children, who had developed a protective antibody concentration one month after the last injection." "" "" ""</seg>
<seg id="2733">"" "" "" "in an additional study of 208 children, the efficacy of the vaccine was compared with a six month and a 12 month intervals between the two injections." "" "" ""</seg>
<seg id="2734">"" "" "" "at between 98 and 100% of vaccinated children, Ambirix introduced a month after the last injection to develop protective antibodies against hepatitis A and B." "" "" ""</seg>
<seg id="2735">"" "" "" "the additional study showed that Ambiani's degree of protection was similar to a six-month interval between the injections, which was 12 months." "" "" ""</seg>
<seg id="2736">"" "" "" "the most common side effects of Ambiani (observed in more than 1 of 10 vaccines) are headache, loss of appetite, pain at the injection point, redness, mating, and irritability." "" "" ""</seg>
<seg id="2737">"" "" "" "Ambirix may not be used in patients who may be hypersensitive (allergic) to the active ingredients, one of the other ingredients or Neomycin (an antibiotic)." "" "" ""</seg>
<seg id="2738">"" "" "" "August 2002, the European Commission issued a permit for the company GlaxoSmithKline Biologicals s.a." "" "" ""</seg>
<seg id="2739">"" "" "" "the first dose is given at the appointment of the choice, and the second dose is administered between six and twelve months after the first dose." "" "" ""</seg>
<seg id="2740">"" "" "" "if a refresher vaccination is required for both hepatitis A and hepatitis B, vaccines or combination vaccines can be vaccinated." "" "" ""</seg>
<seg id="2741">The anti-HBsAg (anti-HBsAg) and anti-hepatitis A virus (anti-HBsAg) and anti-hepatitis A virus (anti-HBsAg) and anti-hepatitis A virus (anti-HBsAg) and anti-hepatitis A virus (anti-HBsAg).</seg>
<seg id="2742">"" "" "" "it is not yet fully assured whether immunocompetent persons, who have approached a Hepatitis B vaccination, need a refresher vaccination as protection, since they may also be protected by immunological memory." "" "" ""</seg>
<seg id="2743">3 As for all vaccination vaccines should be immediately available for the rare case of an anaphylactic response after the application of the vaccine appropriate possibilities of medical treatment and monitoring.</seg>
<seg id="2744">"" "" "" "if a rapid protection against hepatitis B is required, the standardisation scheme is recommended with the combination drug, which contains 360 ELISA units formalininininininininactivated hepatitis B virus and 10 µg recombinant hepatitis B surface antigen." "" "" ""</seg>
<seg id="2745">"" "" "" "in case of hemodialysis patients and persons with disorders of the immune system, no adequate anti-HAV- and anti-HBs-antibody level is reached, so that in these cases the gift of other vaccines may be necessary." "" "" ""</seg>
<seg id="2746">"" "" "" "since intraocular injection or intramuscular administration could lead to a suboptimal impact success in the gluteal muscles, these injection systems should be avoided." "" "" ""</seg>
<seg id="2747">"" "" "" "however, for thrombocytopenia or blood clots, Ambiani can be injected in a subcutaneous way, since it can occur in these cases after intramuscular administration." "" "" ""</seg>
<seg id="2748">"" "" "" "when Ambirix was administered in the second year in form of a separate injection with a combined diphtherie-, tetanus, acellulus pertussis-, inactivated poliomyelitis and Haemophilus influenza vaccine, the immune response to all antigens was sufficient (see section 5.1)." "" "" ""</seg>
<seg id="2749">"" "" "" "in patients with immunosuppressive therapy or in patients with immune defects, it may be assumed that insufficient immune response may be achieved." "" "" ""</seg>
<seg id="2750">"" "" "" "in a clinical study conducted with 3 vaccines of this formulation in adults, the incidence of pain, redness, swelling, matology, gastroenteritis, headaches and fever was comparable to the frequency observed in the earlier Thiomerang and preservative formulation." "" "" ""</seg>
<seg id="2751">"" "" "" "in clinical trials, 2029 vaccines were administered to a total of 1027 vaccinations at the age of 1 to 15 years." "" "" ""</seg>
<seg id="2752">"" "" "" "in a study involving 300 participants at the age of 12 to including 15 years, the compatibility of Ambirix was compared to that of the 3-doses combined vaccine." "" "" ""</seg>
<seg id="2753">"" "" "" "only exceptions were the higher frequencies of pain and intensity on a basis of calculation per vaccination dose Ambirix, but not based on a basis for calculation per person." "" "" ""</seg>
<seg id="2754">"" "" "" "pain was observed after the inclusion of Ambiani at 50.7% of the subjects, compared with 39,1% in the subjects following the administration of a dose of the 3-doses combination drug." "" "" ""</seg>
<seg id="2755">"" "" "" "after the complete inoculation cycle reported 66.4% of the subjects that had been administered to the Ambiani, compared to 63.8% in the subjects who had been vaccinated with the 3-dose vaccine." "" "" ""</seg>
<seg id="2756">"" "" "" "however, the frequency of matchiness was comparable to per subject (i.e. over the entire inoculation cycle at 39.6% of the subjects who were Ambirix received, compared with 36.2% of the subjects who received the 3-doses combination drug)." "" "" ""</seg>
<seg id="2757">"" "" "" "the frequency of pronounced pain and thickness was low and comparable to those observed after administration of the vaccine, with the 3-doses vaccine." "" "" ""</seg>
<seg id="2758">In a comparative study at 1 to 11 year-old vaccines the occurrence of local reactions and general reactions in the Ambirixgruppe was comparable to that which was observed in conjunction with the 3-doses combination drug with the alpha-A virus and 10 µg recombinant hepatitis B surface antigen.</seg>
<seg id="2759">"" "" "" "for the 6- to 11-year-olds, after vaccination with Ambirix a frequent occurrence of pain (at the injection point) per dose, not per proband, was reported." "" "" ""</seg>
<seg id="2760">The share of vaccines reported on severe side effects during the 2-doses vaccine with Ambirix or during the 3-doses vaccine with the combination of hepatitis A virus and 10 µg recombinant Hepatitis B surface antigen was not statistically different.</seg>
<seg id="2761">"" "" "" "in clinical studies carried out at vaccines at the age of 1 and including 15 years, the serum convergence rates for anti-HAV 99.1% a month after the second dose and 100% a month after the second dose (i.e. in month 7)." "" "" ""</seg>
<seg id="2762">"" "" "" "serum conversions for anti-HBs were 74.2% a month after the first dose and 100% a month after the second dose, in month 7." "" "" ""</seg>
<seg id="2763">"" "" "" "7 In a comparative study conducted at 12- to including 15-year olds, 142 two doses of Ambirix and 147 received the standard recombinant vaccine with three doses." "" "" ""</seg>
<seg id="2764">"" "" "" "in the 289 persons whose immunogenicity was evaluated, the seroprotection rates (SP in the table below) were significantly higher against hepatitis B in month 2 and 6 after the administration of the 3-dose vaccine significantly higher than with Ambirix." "" "" ""</seg>
<seg id="2765">"" "" "" "the immune responses received in a clinical comparative study at 1 to 11 year-olds after the completion of the full vaccine series (i.e. in month 7), are listed in the following table." "" "" ""</seg>
<seg id="2766">"" "" "" "in both studies, the vaccinations received either a 2-doses vaccine with Ambirix or a 3-doses vaccine with a combination of 360 ELISA units with alpha-A virus and 10µg recombinant Hepatitis B surface antigen." "" "" ""</seg>
<seg id="2767">The persistence of anti-HAV- and anti-HBs-antibodies could be proven at least 24 months after immunization with Ambirix in the 0-6 month vaccination scheme.</seg>
<seg id="2768">The immune response observed in this study was comparable to that observed after vaccination of 3 doses with a combination sim- A virus and 10 µg recombinant hepatitis B surface antigen in a dose volume of 0.5 ml.</seg>
<seg id="2769">In a clinical study at 12- to including 15-year-olds the persistence of anti-HAV- and anti-HBs-antibodies could be compared 24 months after immunization in the 0-6 months vaccination scheme.</seg>
<seg id="2770">"" "" "" "if the first dose of Ambirix in the second year of life was given at the same time using a combined diphtherie-, tetanus, acellulus pertussis-, inactivated poliomyelitis and 8 Haemophilus influenza vaccine, the immune response was sufficient to all antigens." "" "" ""</seg>
<seg id="2771">"" "" "" "a clinical study conducted with 3 doses of the present formulation in adults, showed similar seroprotection and serum rates similar to previous formulation." "" "" ""</seg>
<seg id="2772">"" "" "" "the vaccine is examined both before and after the respiration, to examine any foreign particles and / or physically visible changes." "" "" ""</seg>
<seg id="2773">"" "" "" "according to article 114 of Directive 2001 / 83 / EC, the state-of-the-art batch release is carried out by a state laboratory or a laboratory accredited to this purpose." "" "" ""</seg>
<seg id="2774">14 ANGABEN AUF DER outer casing 1 finished syringe WITHOUT needle. 10 finished syringes WITHOUT needles 10 finished syringes WITH needles 50 finished syringes WITHOUT needles</seg>
<seg id="2775">"" "" "" "suspension for injection 1 ready-to-use syringe with needle, 10 finished syringes without needles 10 finished syringes with needles 50 finished syringes without needles 1 dose (1 ml)" "" "" ""</seg>
<seg id="2776">EU / 1 / 02 / 224 / 001 1 ready-to-fill syringe with needle EU / 1 / 02 / 224 / 003 10 pre-filled syringes with needles EU / 1 / 02 / 224 / 005 10 pre-filled syringes with needles EU / 1 / 02 / 224 / 005 50 finished syringes without needles</seg>
<seg id="2777">"" "" "" "the hepatitis A virus is usually transmitted through viral food and beverages, but can also be transferred through other ways, such as bathing in water contaminated by waste water." "" "" ""</seg>
<seg id="2778">"" "" "" "you can feel very tired, have a dark urine, pale face, yellow skin and / or eyes (jaundice) and other symptoms that may make a stationary treatment necessary." "" "" ""</seg>
<seg id="2779">"" "" "" "as with all vaccines, Ambiis cannot fully protect against infection with Hepatitis B or Hepatitis B virus even if the complete vaccine series has been completed with 2 doses." "" "" ""</seg>
<seg id="2780">If you / your child are infected with hepatitis B or hepatitis B virus prior to the administration of both vaccinations (even though you / your child feel uncomfortable or sick) a vaccination may not prevent a disease.</seg>
<seg id="2781">"" "" "" "protection against other infections, which damage the liver or cause symptoms, which are similar to those following a hepatitis B or hepatitis B infection can not be mediated." "" "" ""</seg>
<seg id="2782">"" "" "" "• If you / your child has already shown an allergic reaction to ambient rix or any part of this vaccine, including Neomycin (an antibiotic)." "" "" ""</seg>
<seg id="2783">"" "" "" "an allergic reaction may be caused by itching skin rash, shortbreath or swelling of the face or tongue. • If you / your child has already occurred an allergic reaction to an earlier vaccination against hepatitis A or hepatitis B." "" "" ""</seg>
<seg id="2784">"" "" "" "• If you want to quickly have a protection against hepatitis B (i.e., within 6 months and before the usually scheduled dosage of the second vaccination dose)." "" "" ""</seg>
<seg id="2785">"" "" "" "at a possible risk of infection with hepatitis B between the first and second vaccination, the doctor will advise you / her child from vaccination with Ambirix." "" "" ""</seg>
<seg id="2786">"" "" "" "instead, it will recommend you / your child 3 injections of a combined hepatitis A / hepatitis B vaccine with a reduced content of active hepatitis A virus and 10 micrograms of a recombinant hepatitis B surface." "" "" ""</seg>
<seg id="2787">"" "" "" "the second vaccination dose of this vaccine with reduced content of effective ingredients is usually administered one month after the first dose, and is likely to give you a vaccination protection before completion of the vaccination series." "" "" ""</seg>
<seg id="2788">"" "" "" "sometimes, Ambiani is injected under the skin and not injected into the muscle. if you / your child is weakened by a disease or treatment in your / her body's defense, or if you / your child undergo a hemodialysis." "" "" ""</seg>
<seg id="2789">"" "" "" "Ambirix can be given in these cases, but the immune response of these persons to vaccination may not be sufficient so that a blood test may be necessary to see how strongly the response to vaccination is." "" "" ""</seg>
<seg id="2790">21 Say to your doctor if you / your child may take additional medicine / take it (including those that you can get without prescription) or if you / your child has been vaccinated / has been given / or has been planned in the near future.</seg>
<seg id="2791">"" "" "" "however, it may be that in this case the immune response is not sufficient and the person is not protected against one or both hepatitis A and B viruses." "" "" ""</seg>
<seg id="2792">"" "" "" "if another vaccine has to be given at the same time with ambirix, it should be vaccinated in separate places and as different extremities." "" "" ""</seg>
<seg id="2793">"" "" "" "if ambirix is to be given at the same time or shortly before or after an injection of immunoglobulins, it is likely that the reaction to the vaccine will still be sufficient." "" "" ""</seg>
<seg id="2794">"" "" "" "usually, Ambiani's pregnant or lactating women are not given, unless it is urgent that they are vaccinated against hepatitis A and hepatitis B." "" "" ""</seg>
<seg id="2795">Important information about certain other components of Ambiani Please tell your doctor if your child has already shown an allergic reaction to Neomycin (antibiotic).</seg>
<seg id="2796">"" "" "" "if you miss the agreed appointment for the second vaccination, talk to your doctor and arrange a new appointment as soon as possible." "" "" ""</seg>
<seg id="2797">"" "" "" "♦ very common (more than 1 case per 10 decimated doses): • Pain, or discomfort at the puncture or redness • Matching • irritability • headache • appetite deficit" "" "" ""</seg>
<seg id="2798">"" "" "" "♦ frequently (up to 1 case per 10 dosed doses): • swelling at the injection point • fever (over 38 ° C) • Well-being, gastrointestinal symptoms" "" "" ""</seg>
<seg id="2799">"" "" "" "other side effects, which were reported days or weeks after vaccination with comparable combination or single vaccines against hepatitis A and hepatitis B (less than 1 case per 10,000 displaced doses) are:" "" "" ""</seg>
<seg id="2800">"" "" "" "these include locally restricted or extended surges that can be itchy or blower, swelling of the eyes and face, frightened breathing or swallowing, sudden blood pressure drop and consciousness." "" "" ""</seg>
<seg id="2801">"" "" "" "flu-like ailments, including chills, muscle and joint pain seizures, dizziness, abnormalities such as tingling, loss of sensation or mobility of some body parts, severe headache and stiffness of the neck, interruption of normal brain functions" "" "" ""</seg>
<seg id="2802">"" "" "" "impotence inflammations of some blood vessels may be discomfort or illness, loss of appetite, diarrhoea, stomach pain, or increases bleeding or bruising (blue spots), caused by the decrease of blood platelet." "" "" ""</seg>
<seg id="2803">23 Inform your doctor or pharmacist if any of the side effects you / your child significantly affects you / your child or you notice side effects that are not indicated in this package.</seg>
<seg id="2804">"" "" "" "Ambirix is available in packs of 1 and 10 with or without needles, and in packs of 50 without needles." "" "" ""</seg>
<seg id="2805">"" "" "" "on the basis of the data, which has become known since the first approval for the market launch, the CHMP withdrew the view that the benefit-risk relationship for Ambirix remained positive." "" "" ""</seg>
<seg id="2806">"" "" "" "however, since Ambiani was only brought into circulation in a Member State (in the Netherlands since May 2003), the available safety data for this drug is limited due to the low patient exposure." "" "" ""</seg>
<seg id="2807">Ammonwealth can also be used in patients at the age of over a month with ineffectual encephalopathy or hyperammonia encephalopathy (brain damage due to high ammonia concentrations) in prehistory.</seg>
<seg id="2808">Ammonia - split to several individual doses to the meals - swallowed and mixed under food or administered via a gastrostomieslauch (through the abdominal wall into the stomach leading tube) or a nasal probe (through the nose into the stomach leading tube).</seg>
<seg id="2809">"" "" "" "it was not a comparative study, since ammonia could not be compared with another treatment or placebo (a headlight drug, i.e. without substance)." "" "" ""</seg>
<seg id="2810">"" "" "" "ammonia can also lead to loss of appetite, a abnormal acidity in the blood, depression, irritability, headache, impotence, vomiting, nausea, constipation, skin rash, unpleasant body odor or weight gain." "" "" ""</seg>
<seg id="2811">"" "" "" "the Committee for Medicinal Products (CHMP) concluded that ammonia in patients with disorders of the urea cycle, effectively prevented ammonia levels." "" "" ""</seg>
<seg id="2812">"" "" "" "ammonwealth was approved under" exceptional circumstances, "because the rarity of the disease has only limited information to this drug at the time of approval." "" "" ""</seg>
<seg id="2813">"" "" "" "the application is indicated in all patients, where a complete lack of enzyme has already manifested in newborns (within the first 28 days of life)." "" "" ""</seg>
<seg id="2814">"" "" "" "in patients with a late manium form (incomplete enzyme defect, which manifests after the first life month), there is an indication of the use if a hyperammonia encephalopathy is present in the anamnesis." "" "" ""</seg>
<seg id="2815">"" "" "" "for infants, for children who are not able to swallow tablets or for patients with swallowing disorders AMMONAPS is also available in granular form." "" "" ""</seg>
<seg id="2816">"" "" "" "the daily dose is calculated individually, taking account of the protein tolerance and the necessary daily protein intake of the patient." "" "" ""</seg>
<seg id="2817">According to previous clinical experience the normal daily dose sodium methylbutyrat: • 450 - 600 mg / kg / day in children with a weight of less than 20 kg • 9.9 - 13.0 g / m ² / day in children with a body weight of 20 kg and with adolescents and adults.</seg>
<seg id="2818">The substitution of citrulline or arginine in a dose of 0.17 g / kg / day or 3.8 g / m ² / day is required for patients suffering from an early-manifested lack of carbamylphosphate synthetase or ornithintranscarylase.</seg>
<seg id="2819">Arginine can be obtained in a dose of 0.4 - 0.7 g / kg / day or 8.8 - 15.4 g / m ² / day.</seg>
<seg id="2820">AMMONAPS tablets may not be administered patients with swallowing disorders as there is a risk for the emergence of oesophagusulcera if the tablets do not immediately get into the stomach.</seg>
<seg id="2821">"" "" "" "each tablet AMMONAPS contains 62 mg (2,7 mmol) sodium, equivalent to 2.5 g (108 mmol) sodium per 20 g sodium phenylbutyrat, which corresponds to the maximum daily dose." "" "" ""</seg>
<seg id="2822">"" "" "" "therefore, AMMONAPS should only be applied with caution in patients with congestive heart failure or severe kidney failure as well as with sodium retention and odeformation." "" "" ""</seg>
<seg id="2823">"" "" "" "due to the metabolism and excretion of sodium methylbutyrat through the liver and kidneys, AMMONAPS should only be applied with extreme caution in patients with liver or kidney failure." "" "" ""</seg>
<seg id="2824">The importance of these results regarding pregnant women is not known; the use of AMMONAPS during pregnancy is therefore contraindicated (see 4.3).</seg>
<seg id="2825">"" "" "" "in the case of subcutaneous injection of phenylacetate to young rats in high doses (190 - 474 mg / kg), there was a slowing of neuronal reproduction and increased loss of neurons." "" "" ""</seg>
<seg id="2826">"" "" "" "there was also a delayed maturation of cerebral synapses, and a reduced number of functioning nerve endings in the brain and thereby a disability of brain growth." "" "" ""</seg>
<seg id="2827">"" "" "" "it could not be determined whether phenylacetate is excreted in the mother's milk, and for this reason the use of AMMONAPS is contraindicated during breastfeeding (see 4.3)." "" "" ""</seg>
<seg id="2828">In clinical trials involving AMMONAPS at least an undesirable event (AE) was observed in 56% of patients and 78% of these adverse events were assumed that they were not associated with AMMONAPS.</seg>
<seg id="2829">"" "" "" "the frequency is defined as follows: very common (≥ 1 / 10), frequently (≥ 1 / 100, &lt; 1 / 10) and occasionally (≥ 1 / 1000, &lt; 1 / 100)." "" "" ""</seg>
<seg id="2830">"" "" "" "a likely toxic reaction to AMMONAPS (450 mg / kg / day) was reported by an 18 year old anorectic patient, who developed a metabolic Encephalopathy in conjunction with lactacidosis, severe hypokalemia, peripheral neuropathy and pancreatitis." "" "" ""</seg>
<seg id="2831">"" "" "" "in a 5 month old infant, a case of overdose came with an unintentional single dose of 10 g (1370 mg / kg)." "" "" ""</seg>
<seg id="2832">These symptoms are associated with the accumulation of phenylacetate in an intravenous administration of doses of up to 400 mg / kg / day a dose-limiting neurotoxicity.</seg>
<seg id="2833">"" "" "" "phenylacetate is a metabolically active compound, conjugated with glutamine to phenylacetylglutamine, which is excreted through the kidneys." "" "" ""</seg>
<seg id="2834">"" "" "" "phenylacetylglutamine is comparable with urea (both compounds contain 2 nitrogen atoms), and phenylacetylglutamine is therefore suitable as an alternative carrier for elimination of excess nitrogen." "" "" ""</seg>
<seg id="2835">5 patients with disorders of the urea cycle may be assumed that sodium methylacetylacetylacetylacetylacetylacetylglutamine-nitrogen can be taken for each gram.</seg>
<seg id="2836">"" "" "" "it is important that diagnosis is early, and treatment is immediately started to improve survival and clinical results." "" "" ""</seg>
<seg id="2837">The prognosis of the early-manifested form of the disease with the occurrence of the first symptoms in newborns was almost always infaust and the disease did lead to death even in the treatment of peritoneal dialysis and essential amino acids or with their nitrogen-free analogs.</seg>
<seg id="2838">"" "" "" "it was possible to increase the survival rate of newborn babies at postpartal (however, within the first month of life) to 80%." "" "" ""</seg>
<seg id="2839">"" "" "" "in patients whose disease was diagnosed during the course of pregnancy, survival rates were 100%, but even in these patients it was time for many mental disabilities or other neurological deficits." "" "" ""</seg>
<seg id="2840">Patients with a late maniacs form of the disease (including female patients with the heterozygotic form of the ornithintranscarbamylase deficiency) which were treated permanently with sodium phenylbutyrat and a protein reduced diet was 98% survival.</seg>
<seg id="2841">"" "" "" "existing neurological deficits are hardly reversible, and in some patients a further deterioration of the neurological condition can occur." "" "" ""</seg>
<seg id="2842">"" "" "" "it is known that phenylacetate is oxidized to phenylacetate, which is conjugated with glutamine in liver and kidneys, with phenylacetylglutamine." "" "" ""</seg>
<seg id="2843">The concentrations of phenylbutyrat and its metabolites in plasma and urine were determined according to the administration of a single dose of 5 g sodium phenylbutyrat in patients with disorders of the urea cycle and hemoglobin metabolism and with repeated gifts of oral dosages of up to 20 g / day (not controlled studies).</seg>
<seg id="2844">The behavior of phenylbutyrat and its metabolites was also examined for cancer patients following intravenous administration of sodium phenylbutyrat (up to 2 g / m ²) or phenylacetate.</seg>
<seg id="2845">"" "" "" "after an oral single dose of 5 g sodium phenylbutyrat in tablet form, 15 minutes after taking measurable plasma concentrations of phenylbutyrat." "" "" ""</seg>
<seg id="2846">"" "" "" "according to different doses, phenylbutyrat (300-650 mg / kg / day up to 20 g / day) in the next morning, no phenylacetate in plasma was detected." "" "" ""</seg>
<seg id="2847">In three of six patients with cirrhosis treated with sodium polyphenylbutyrat (20 g / day oral in three individual doses) the average phenylacetate concentrations in the plasma level were five times higher than after the first gifts.</seg>
<seg id="2848">"" "" "" "excretion The medication is excreted from the kidneys within 24 hours, about 80 - 100% in the form of the conjugated product phenylacetylglutamine." "" "" ""</seg>
<seg id="2849">"" "" "" "according to Micronucleus tests, rats no toxic effects (examination 24 and 48 h after oral administration of a single dose of 878 to 2800 mg / kg)." "" "" ""</seg>
<seg id="2850">"" "" "" "AMMONAPS granulate is taken orally (infants and children, who still cannot swallow a tablet or treat patients with swallowing disorders) or via a gastrostomiesleither or a nasal probe." "" "" ""</seg>
<seg id="2851">"" "" "" "according to previous clinical experience, the normal daily dose sodium methylbutyrat: • 450 - 600 mg / kg / day in infants, infants and children with a body weight of 20 kg and in adolescents and adults." "" "" ""</seg>
<seg id="2852">"" "" "" "the concentration of ammonia, arginine, essential amino acids (especially branched chain amino acids), carnitine and serum proteins in the plasma should be kept within the normal range." "" "" ""</seg>
<seg id="2853">The substitution of citrulline or arginine in a dose of 0.17 g / kg / day or 3.8 g / m ² / day is required for patients suffering from an early-manifested lack of carbamylphosphate synthetase or ornithintranscarylase.</seg>
<seg id="2854">AMMONAPS granulate contains 124 mg (5.4 mmol) sodium per gram sodium phenylbutyrat according to 2.5 g (108 mmol) sodium per 20 g sodium phenylbutyrat which corresponds to the maximum daily dose.</seg>
<seg id="2855">"" "" "" "when rats were exposed to phenylacetate (active metabolics of phenylbutyrat) before birth, it occurred to lesions in the pyramid cells of the cerebral cortex." "" "" ""</seg>
<seg id="2856">"" "" "" "a likely toxic reaction to AMMONAPS (450 mg / kg / day) was reported by an 18 year old anorectic patient, who developed a metabolic Encephalopathy in conjunction with lactacidosis, severe hypokalemia, peripheral neuropathy and pancreatitis." "" "" ""</seg>
<seg id="2857">Phenylacetylglutamine is comparable with urea (both compounds contain 2 nitrogen atoms); phenylacetylglutamine is therefore suitable as an alternative carrier for elimination of excess</seg>
<seg id="2858">On the basis of investigations on the excretion of phenylacetylglutamine in patients with disorders of the urea cycle can be assumed that for each gram-taken sodium polyphenylbutyrat can be produced between 0.12 and 0.15 g phenylacetylacetylglutamine nitrogen.</seg>
<seg id="2859">"" "" "" "existing neurological deficits are hardly reversible, and in some patients a further deterioration of the neurological condition can occur." "" "" ""</seg>
<seg id="2860">"" "" "" "after an oral single dose of 5 g sodium phenylbutyrat in granular form, measured plasma concentrations of phenylbutyrat were detected in 15 minutes." "" "" ""</seg>
<seg id="2861">"" "" "" "during the duration of durability, the patient can store the finished product once for a period of 3 months at a temperature of not exceeding 25 ° C." "" "" ""</seg>
<seg id="2862">"" "" "" "in this procedure, the small measuring spoon contains 0.95 g, the average measuring spoon of 2.9 g and the large measuring spoon 8.6 g sodium phenylbutyrat." "" "" ""</seg>
<seg id="2863">If a patient has to receive the medication via a probe AMMONAPS can also be dissolved in water before use (the solubility of sodium phenylbutyrat is up to 5 g in 10 ml of water).</seg>
<seg id="2864">"" "" "" "in patients with these rare diseases, certain liver enzymes are missing so that they can not excrete the nitrogen-containing waste products that accumulate in the body after eating proteins." "" "" ""</seg>
<seg id="2865">"" "" "" "if your lab tests are carried out, you need to tell the doctor that you are taking AMMONAPS, as sodium phenylbutyrat can affect the results of certain laboratory tests." "" "" ""</seg>
<seg id="2866">"" "" "" "when taking AMMONAPS with other medicines, please tell your doctor or pharmacist if you take other medicines or have recently taken, even if it is not prescription." "" "" ""</seg>
<seg id="2867">"" "" "" "during breastfeeding, you may not take AMMONAPS, as the medicine may pass to breast milk and harm your baby." "" "" ""</seg>
<seg id="2868">"" "" "" "in rare cases confusion, headaches, taste disturbances, retaining the ear, disorientation, memory problems and a deterioration of existing neurological conditions were observed." "" "" ""</seg>
<seg id="2869">"" "" "" "if you notice any of these symptoms, contact your doctor immediately or with the emergency uptake of your hospital in order to initiate appropriate treatment." "" "" ""</seg>
<seg id="2870">"" "" "" "if you forget taking AMMONAPS, take the appropriate dose as soon as possible with the next meal." "" "" ""</seg>
<seg id="2871">"" "" "" "changes in the blood pattern (red blood cells, white blood cells, thrombocytes), reduced appetite, stomach pain, vomiting, nausea, constipation, loss of skin, weight gain and anomalous laboratory values." "" "" ""</seg>
<seg id="2872">Please inform your doctor or pharmacist if any of the listed side effects do significantly affect you or notice side effects that are not stated in this information.</seg>
<seg id="2873">"" "" "" "after the expiration date, you may no longer use AMMONAPS according to the expiration date and the container." "" "" ""</seg>
<seg id="2874">"" "" "" "like AMMONAPS, and content of the pack AMMONAPS tablets are of whitish colour and oval shape, and they are provided with the embossing" UCY 500. "" "" "" ""</seg>
<seg id="2875">"" "" "" "30 If your lab tests are carried out, you need to tell the doctor that you are taking AMMONAPS, as sodium phenylbutyrat can affect the results of certain laboratory tests." "" "" ""</seg>
<seg id="2876">"" "" "" "when taking AMMONAPS with other medicines, please tell your doctor or pharmacist if you take other medicines or have recently taken, even if it is not prescription." "" "" ""</seg>
<seg id="2877">You should take AMMONAPS to same single doses orally or via a gastric fistle (tube that runs through the abdominal wall directly into the stomach) or a nasal probe (tube that is run through the nose into the stomach).</seg>
<seg id="2878">31 • Remove from the container a heaped measuring spoon granulate. • Strange a straight edge such as a knife back over the upper edge of the measuring spoon to remove excess granules. • Discover the recommended number of measuring spoon granules from the container.</seg>
<seg id="2879">Angiox is used to treat adult patients with acute coronary syndromes (ACS, reduced blood supply to the heart) for example in unstable Angina (a form of pain in the chest of different thickness) or myocardial infarction (an anomaly measured value in the electrocardiogram or ECG).</seg>
<seg id="2880">"" "" "" "if angiox is used to prevent blood clots in patients undergoing a PCI, a higher dose is administered and the infusion can be continued up to four hours after the procedure." "" "" ""</seg>
<seg id="2881">"" "" "" "in patients with angina or heart attack, this can contribute to the maintenance of blood flow to the heart and increase the effectiveness of a PCI." "" "" ""</seg>
<seg id="2882">Nearly 14 000 patients participated in the main study on the treatment of ACS in which the effect of angiox at allsome gift or in combination with a glycoprotein IIb / IIIa inhibitor (GPI) was compared to conventional combination treatment with Heparin (another anticoagulant) and a GPI.</seg>
<seg id="2883">"" "" "" "during the PCI, patients often used a stent (a short tube that remains in the artery to prevent closure), and they also received other medicines to prevent blood clots such as abciximab and aspirin." "" "" ""</seg>
<seg id="2884">"" "" "" "in the treatment of ACS, angiox - with or without the gift of GPI - was as effective in the prevention of new events (deaths, heart attacks or revascularization) after 30 days or a year as well as conventional treatment." "" "" ""</seg>
<seg id="2885">"" "" "" "in patients undergoing a PCI, angiox related to all indicators was as effective as heparin except for severe bleeding, in which it was much more effective than heparin." "" "" ""</seg>
<seg id="2886">"" "" "" "angiox must not be used in patients who may be hypersensitive (allergic) to bivalirudine, other hirudine or other ingredients." "" "" ""</seg>
<seg id="2887">"" "" "" "it may not be used in patients who recently had bleeding, as well as in people with high blood pressure or severe kidney problems or a heart infection." "" "" ""</seg>
<seg id="2888">The Committee for Medicinal Products (CHMP) concluded that angiox in the treatment of ACS and during a PCI is an acceptable substitute for Heparin.</seg>
<seg id="2889">"" "" "" "in September 2004, the European Commission granted the Medicines Company UK Ltd approval for the placing of Angiox in the entire European Union." "" "" ""</seg>
<seg id="2890">For the treatment of adult patients with acute coronary syndrome (unstable Angina / non-ST leverage infarction (IA / NSTEMI)) in case of emergency intervention or if an early intervention is provided.</seg>
<seg id="2891">The recommended initial dose of angiox in patients with ACS is an intravenous placement of 0.1 mg / kg followed by an infusion of 0.25 mg / kg / h.</seg>
<seg id="2892">"" "" "" "if a PCI is carried out further, an additional bolus of 0.5 mg / kg should be given and the infusion should be increased to 1.75 mg / kg / h." "" "" ""</seg>
<seg id="2893">"" "" "" "according to the PCI, the reduced infusion dose of 0.25 mg / kg / h can be recorded for 4 to 12 hours after clinical needs." "" "" ""</seg>
<seg id="2894">"" "" "" "just before the procedure, a stud rate of 0.5 mg / kg shall be given, followed by an infusion of 1.75 mg / kg / h for the duration of the intervention." "" "" ""</seg>
<seg id="2895">The recommended dosage of angiox in patients with a PCI consists of an initial intravenous bushing of 0.75 mg / kg body weight and an intravenous IV infusion with a dose of 1.75 mg / kg body weight / h at least for the duration of the surgery.</seg>
<seg id="2896">"" "" "" "the safety and efficacy of an allusive Bolus-Gift of Angiox has not been studied, and is not recommended even if a short PCI interference is planned." "" "" ""</seg>
<seg id="2897">"" "" "" "if this value (ACT after 5 minutes) is reduced to less than 225 seconds, a second bolt of 0,3 mg / kg / bodyweight should be done." "" "" ""</seg>
<seg id="2898">"" "" "" "in order to reduce the occurrence of lower ACT values, the reconstituted and diluted medicine should be carefully mixed before the application and the bolted dose should be administered intravenously." "" "" ""</seg>
<seg id="2899">"" "" "" "once the ACT value is more than 225 seconds, another monitoring is no longer required, provided that the 1.75 mg / kg infusion dose is administered correctly." "" "" ""</seg>
<seg id="2900">A lower infusion rate of 1.4 mg / kg / h should be used in patients with moderate kidney function restriction (GFR 30-59 ml / min).</seg>
<seg id="2901">"" "" "" "if the ACT-value lies below 225 seconds, a second dose of 0,3 mg / kg is to be administered and the ACT 5 minutes after the second ultrasound dose to be checked again." "" "" ""</seg>
<seg id="2902">In patients with moderate renal damage included in phase III- PCI-study (REPLACE-2) the ACT value was 5 minutes after administration of the bivalirudin Bolus without dose adjustment with an average of 366 ± 89 seconds.</seg>
<seg id="2903">"" "" "" "3 For patients with severe kidney damage (GFR &lt; 30 ml / min), angiox is contraindicated in patients with severe kidney damage (see section 4.3)." "" "" ""</seg>
<seg id="2904">The treatment with Angiox can be initiated 30 minutes after the intravenous administration of unquestionable heparin or 8 hours after completion of the subcutaneous administration of low molecular heparin.</seg>
<seg id="2905">• Well-known hypersensitivity to the active ingredient or other ingredients or against Hirudine • active bleeding or increased bleeding risk due to a disturbance of hemostasis and / or irreversible bacterial endocarditis. • severe kidney damage (GFR &lt; 30 ml / min) and in dialysis patients</seg>
<seg id="2906">"" "" "" "patients are carefully supervised during treatment with regard to symptoms and signs of bleeding, especially if bivaliant is given in combination with another anticoagulant (see Section 4.5)." "" "" ""</seg>
<seg id="2907">"" "" "" "even if the majority of bleeding at arterial points occur in patients under Bivalirudin, patients who undergo a percutaneous coronary intervention (PCI) can generally occur throughout the treatment." "" "" ""</seg>
<seg id="2908">"" "" "" "in patients receiving warfarin and treated with bivalirudine, monitoring of the INR-Werts (International Normised Ratio) should be considered to ensure that the value after settling the treatment with bivaliant once again reaches the level before the treatment." "" "" ""</seg>
<seg id="2909">"" "" "" "starting from the knowledge of the mode of action of anticoagulants (heparin, warfarin, thrombolytics or thrombocyte aggregates), these substances can increase the risk of bleeding." "" "" ""</seg>
<seg id="2910">"" "" "" "in combination with bivalirudine with thrombocyte aggregates or anticoagulants, the clinical and biological hemostatic parameters are checked regularly in each case." "" "" ""</seg>
<seg id="2911">"" "" "" "the animal experimental studies are inadequate in relation to pregnancy, embryonic / fetal development, the connection or postnatal development (see section 5.3)." "" "" ""</seg>
<seg id="2912">4612 were randomised to bivalirudin alone, 4604 were randomised to bivalirudin plus GPIIb / IIIa inhibitor and 4603 were randomised to either unquestionable heparin or Enoxaparin plus GPIIb / IIIa inhibitor.</seg>
<seg id="2913">"" "" "" "in both the bivaliant group as well as in the comparison groups treated with Heparin, it was more common in women as well as in patients over 65 years more frequently than in male or younger patients." "" "" ""</seg>
<seg id="2914">"" "" "" "severe bleeding was defined according to ACUITY and Timi standards for severe bleeding, as in table 2." "" "" ""</seg>
<seg id="2915">Both light and heavy bleedings did not significantly lower than in groups with Heparin plus GPIIb / IIIa inhibitor and bivalidrudin plus GPIIb / III- inhibitor (see table 2).</seg>
<seg id="2916">"" "" "" "an ACUITY severe bleeding was defined as one of the following events: contracranial, retroperitoneal, intraocular hematoma of ≥ 3 g / dl with known bleeding point, reoperation due to bleeding, application of blood products for transfusion." "" "" ""</seg>
<seg id="2917">"" "" "" "further, less frequently observed blood-localizations that occurred at more than 0.1% (occasionally) were" other "spot points, retroperitoneal, gastrointestinal, ear, nose or throat." "" "" ""</seg>
<seg id="2918">The following information on side effects is based on data from a clinical trial with bivalirudin in 6000 patients undergoing a PCI.</seg>
<seg id="2919">"" "" "" "in both the bivaliant group as well as in the comparison groups treated with Heparin, it was more common in women as well as in patients over 65 years more frequently than in male or younger patients." "" "" ""</seg>
<seg id="2920">"" "" "" "under bivaliant, both light and heavy bleeding occurred significantly less frequently than in the comparison group under Heparin plus GPIIb / IIIa inhibitor." "" "" ""</seg>
<seg id="2921">"" "" "" "the following side effects, which are not listed above, have been reported after comprehensive application in practice and are grouped according to system organclasses in table 6." "" "" ""</seg>
<seg id="2922">"" "" "" "in case of overdose, the treatment with bivaliant is immediately abrupt and the patient is closely meshed with regard to signs of bleeding." "" "" ""</seg>
<seg id="2923">"" "" "" "Angiox contains bivaliant, a direct and specific thromboinhibitor, which binds both at the catalytic center and in the anion-bond region of Thrombin, irrespective of whether Thrombin is bound in the liquid phase or on tinns." "" "" ""</seg>
<seg id="2924">"" "" "" "the binding of bivalirudin to thromboin, and hence its effect, is reversible because Thrombin regenerates the binding of bivalirudin-ARG3-Pro4 slowly, thereby regenerating the function of the active center of Thrombin." "" "" ""</seg>
<seg id="2925">"" "" "" "in addition, Bivalirudin was able to induce serotonin-induced thrombocytopenie / heparininduced thrombocytopenie / heparininduced thrombocytopenia (HIT / HITTS)." "" "" ""</seg>
<seg id="2926">"" "" "" "in healthy volunteers and in patients bivaliant shows a dose-dependent anticoagulatory effect, which is proven by the extension of ACT, aPTT, PT, INR and TT." "" "" ""</seg>
<seg id="2927">"" "" "" "if a PCI was carried out below, an additional bolus of 0,5mg / kg bivalirudin should be given and the infusion should be increased to 1.75mg / kg / h." "" "" ""</seg>
<seg id="2928">In the arm A of the ACUITY study unquestionable heparin or anodisaparin was administered in accordance with the relevant guidelines for the treatment of acute coronary syndrome (ACS) in patients with unstable Angina / non-ST leverage infarction (IA / NSTEMI).</seg>
<seg id="2929">Patients in arm A and B were also randomised to obtain a GPIIb / IIIa inhibitor either before the start of angiography (at the time of randomisation) or with the PCI.</seg>
<seg id="2930">"" "" "" "in the ACUITY study the characteristics of high-risk patients, which required angiography within 72 hours, were evenly distributed across the 3 treatment arms." "" "" ""</seg>
<seg id="2931">"" "" "" "about 77% of patients had recurrent ischemia, 70% had dynamic EKG- changes or increased cardiac biomarkers, 28% had diabetes and about 99% of all patients undergoing 72 hours of angiography." "" "" ""</seg>
<seg id="2932">The primary analysis and results from the ACUITY study for the 30-day and 1 year endpoint for the overall population (ITT) and for the patients who received aspirin and clopidogrel according to the protocol (before angiography or before the PCI) are presented in tables 7 and 8.</seg>
<seg id="2933">ACUITY study; 30-day and 1 year risk difference for the combined ischemic endpoint and its components for patients who received aspirin and Clopidogrel according to protocol *</seg>
<seg id="2934">Patients who aspirin and Clopidogrel received arm A arm B arm C UFH / Enox Bival B- A C- A Bival + GPIIb / IIIa Risk Diff.</seg>
<seg id="2935">The frequency of bleeding both in ACUITY- and timing-scale up to day 30 for the overall population (ITT) and for patients receiving aspirin and Clopidogrel according to protocol is presented in table 9.</seg>
<seg id="2936">Patients who were Aspirin and Clopidogrel overall population (ITT) according to protocol received UFH / Enox Bival Bival Bival + + GPIIb / IIIa alone GPIIb / IIIa GPIIb / IIIa (N = 4604) (N = 4604)%%%</seg>
<seg id="2937">"" "" "" "* Clopidogrel before angiography or before PCI 1 An ACUITY severe bleeding was defined as one of the following occurrences: intracranial, retroperito-neal, intraocular hemoglobin levels of ≥ 3 g / dl with known bleeding point, reoperation due to bleeding, use of blood products for transfusion." "" "" ""</seg>
<seg id="2938">"" "" "" "the 30-day results, based on four triple and triple endpoints of a randomized double blind study with more than 6,000 patients undergoing a PCI (REPLACE-2), are presented in table 10." "" "" ""</seg>
<seg id="2939">Clinical studies with a small number of patients provided limited information on the application of angiox in patients with HIT / HITTS.</seg>
<seg id="2940">The pharmacokinetic properties of bivalirudine were evaluated in patients who underwent a percutaneous coronary intervention (PCI) and in patients with ACS.</seg>
<seg id="2941">"" "" "" "it is expected that bivalirudine as peptide has a catabolism in its amino acid constituents with subsequent revaluation of amino acids in the body pool." "" "" ""</seg>
<seg id="2942">"" "" "" "due to the loss of its affinity to the catalytic center of Thrombin, the primary metabolite that results from splitting the ARG3-Pro4 binding of the N-terminal sequence is not effective." "" "" ""</seg>
<seg id="2943">The elimination occurs in patients with normal renal function after a first order process with a terminally half-life of 25 ± 12 minutes.</seg>
<seg id="2944">"" "" "" "based on conventional safety resharmacology studies, toxicity in repeated application, genotoxicity or reproductive toxicity, the preclinical data do not reveal any particular danger to humans." "" "" ""</seg>
<seg id="2945">The toxicity of animals with repeated or continuous exposure (1 day to 4 weeks with exposure to 10-fold of the clinical steady state plasma concentration) was limited to excessive pharmacological effects.</seg>
<seg id="2946">Side effects caused by long-term physiological strain as reaction to non-homeopathic coagulation were not observed after short-term exposure to those in clinical use even at very much higher dosage.</seg>
<seg id="2947">"" "" "" "if the ready-to-use solution is not under controlled and validated aseptic conditions, it is no longer than 24 hours at 2 ° C to 8 ° C." "" "" ""</seg>
<seg id="2948">Angiox is a freeze-dried powder in single dose bursting bottles of type 1 glass to 10 ml which are sealed with a butyl rubber stopper and sealed with a cap made of pressed aluminium.</seg>
<seg id="2949">"" "" "" "5 ml sterile water for injection purposes are given in a glass bottle of Angiox and easily swung until everything has dissolved, and the solution is clear." "" "" ""</seg>
<seg id="2950">5 ml are taken from the glass bottle and diluted with 5% glucose solution for injection or with 9 mg / ml (0.9%) sodium chloride solution for injection in a total volume of 50 ml to obtain a final concentration of 5mg / ml bivalirudin.</seg>
<seg id="2951">"" "" "" "the owner of the approval for the transport agrees to carry out the studies and pharmacological activities outlined in the Pharmacovigilance Plan, as outlined in version 4 of the Risk Management Plan (RMP), as well as any subsequent changes in the RMP agreed by the CHMP." "" "" ""</seg>
<seg id="2952">"" "" "" "according to the CHMP Guideline at risk management systems for human medicines, the revised RMP is to be submitted simultaneously with the next Periodic Safety Update Report (PSUR)." "" "" ""</seg>
<seg id="2953">• Patients with chest pain due to a heart disease (acute coronary syndromes - ACS) • Patients that are operated for the treatment of closures in the blood vessels (angioplasty and / or percutaneous coronary angioplasty - PCI).</seg>
<seg id="2954">"" "" "" "• You are pregnant or suspect that you might be pregnant, you intend to become pregnant while breastfeeding." "" "" ""</seg>
<seg id="2955">"" "" "" "there have been no investigations of the impact on traffic and the ability to operate machines, but it is known that the effects of this drug are only short-term." "" "" ""</seg>
<seg id="2956">"" "" "" "should a bleeding occur, the treatment with angiox is aborted. before the beginning of the injection or infusion, you will inform your doctor about the possible signs of allergic reaction." "" "" ""</seg>
<seg id="2957">Such reactions are rare (they occur in less than 1 out of 1000 treated patients). • A particularly careful observation is carried out if you have a radiation therapy for the vessels that supply the heart with blood (this treatment is referred to as beta or gamma-brachytherapy).</seg>
<seg id="2958">• 0.1 mg / kg body weight as an injection followed by an infusion (tropical solution) with 0.25 mg / kg body weight per hour (0.25 mg / kg body weight per hour) means a quarter of a milligram of the medicine for each kilogram of body weight per hour).</seg>
<seg id="2959">"" "" "" "more likely, if Angiox is administered in combination with other antimicrobial drugs (see Section 2" for the use of angiox with other medicines ")." "" "" ""</seg>
<seg id="2960">"" "" "" "these are occasional side effects (in less than 1 out of 100 patients). • Thrombose (blood clots), which could lead to serious complications such as a heart attack." "" "" ""</seg>
<seg id="2961">"" "" "" "this is an occasional side effect (in less than 1 out of 100 patients). • Pain, bleeding and bleeding at the puncture site (after a PCI treatment)." "" "" ""</seg>
<seg id="2962">"" "" "" "please inform your doctor if any of the side effects listed are significantly impaired or you notice side effects, which are not indicated in this information." "" "" ""</seg>
<seg id="2963">"" "" "" "after the expiration date, the angiox can no longer be applied after the expiration date specified on the label and carton." "" "" ""</seg>
<seg id="2964">Polska The Medicines Company UK Ltd.: + 800 843 633 26 lub + 41 61 528700 E-mail:</seg>
<seg id="2965">"" "" "" "Apidra is used to treat adults, adolescents and children six years with diabetes that require treatment with insulin." "" "" ""</seg>
<seg id="2966">"" "" "" "Apidra is subcutaneous (under the skin) injected into the abdominal wall, thigh or upper arm or administered as a permanent infusion with an insulin pump." "" "" ""</seg>
<seg id="2967">"" "" "" "diabetes is a disease in which the body does not produce enough insulin to regulate the glucose level (sugar) in the blood, or insulin cannot be processed effectively." "" "" ""</seg>
<seg id="2968">"" "" "" "insulin lulisine differs very slightly from human insulin, and the change means that it acts faster and has a shorter duration than a short-effective human insulin." "" "" ""</seg>
<seg id="2969">Apidra was used in combination with a long-effective insulin in patients with type 1 diabetes in which the body can not produce insulin in two studies with a total of 1 549 adults and in a study of 572 children aged between 4 and 17 years.</seg>
<seg id="2970">"" "" "" "in type 2 diabetes, where insulin is not effectively processed, Apidra has been examined in a study involving 878 adults." "" "" ""</seg>
<seg id="2971">The main indicator for efficacy was the change in the concentration of the substance glycosylated hemoglobin (HbA1c) in the blood that indicates how well the blood sugar is set.</seg>
<seg id="2972">In the first study of adults with type 1 diabetes a reduction of 0.14% (from 7.60% to 7.46%) was determined in comparison to a reduction of 0.14% in insulin liseconds.</seg>
<seg id="2973">In adults with type 2 diabetes the reduction of HbA1c concentration was 0.46% after six months with Apidra versus 0.30% in human normal insulin.</seg>
<seg id="2974">"" "" "" "Apidra can not be used in patients who may be hypersensitive (allergic) to insulin lulisin or any of the other ingredients, or in patients who are already suffering from hypoglycemia." "" "" ""</seg>
<seg id="2975">The doses of Apidra may be adjusted if it is administered together with a number of other medicines that may affect blood glucose levels.</seg>
<seg id="2976">"" "" "" "in September 2004, the European Commission granted Sanofi-Aventis Deutschland GmbH a permit for the transport of Apidra throughout the European Union." "" "" ""</seg>
<seg id="2977">"" "" "" "Apidra can be applied as subcutaneous injection either in the abdominal wall, thigh or delta muscle or subcutaneous by continuous infusion in the abdominal wall." "" "" ""</seg>
<seg id="2978">"" "" "" "due to reduced glucose capacity and reduced insulin delivery, insulin demand in patients with reduced liver function can be reduced." "" "" ""</seg>
<seg id="2979">"" "" "" "any change of the effect, the brand (manufacturer), the insulin type (normal, NPH, zinc-delayed etc.), the type of insulin (animal insulin) and / or the production method can result in a change in insulin demand." "" "" ""</seg>
<seg id="2980">"" "" "" "3 A insufficient dose or interruption of treatment, especially in patients with insulin-based insulin, may lead to hyperglycemia and diabetic ketoacidosis. these states are potentially life-threatening." "" "" ""</seg>
<seg id="2981">"" "" "" "the conversion of a patient to another insulin type or an insulin of another manufacturer should take place under strict medical supervision, and may make a change in dosage necessary." "" "" ""</seg>
<seg id="2982">"" "" "" "the time of occurrence of hypoglycaemia depends on the active profile of the insulin used, and can therefore change during the conversion of the treatment scheme." "" "" ""</seg>
<seg id="2983">"" "" "" "to the substances that increase blood sugar lowering activity and increase the propensity to hypoglycemia, include oral antidiabetic, angiotensin-converting enzymes, pentoxifylline, propoxyphene, Salizylates and sulfonamide-antibiotics." "" "" ""</seg>
<seg id="2984">"" "" "" "in addition, under the effect of Sympatholytics such as beta-blockers, Clonidin, Guanethidin, and reserve the symptoms of adrenaline counter-regulation can be weakened or absent." "" "" ""</seg>
<seg id="2985">"" "" "" "animal experiments on reproductive toxicity showed no differences between insu- linglulisin and human insulin in relation to pregnancy, embryonic / fetal development, birth or postnatal development (see Section 5.3)." "" "" ""</seg>
<seg id="2986">"" "" "" "it is not known whether insulin is transferred into human breast milk, but generally insulin does not occur in breast milk nor is it resorbed to oral application." "" "" ""</seg>
<seg id="2987">"" "" "" "≥ 1 / 10; frequently: ≥ 1 / 1000, &lt; 1 / 10; rare: ≥ 1 / 1000; rarely known (frequency based on the available data is not estimated)." "" "" ""</seg>
<seg id="2988">"" "" "" "cold sweat, cool and pale skin, fatigue, nervousness or tremor, anxiety, unusual creation or weakness, confusion, lack of concentration, nausea, headache, nausea and palpitations." "" "" ""</seg>
<seg id="2989">"" "" "" "lipodystrophy is neglected to continuously change the injection unit within the injection area, as a result, a lipodystrophy can occur at the injection point." "" "" ""</seg>
<seg id="2990">Severe hypoglycemia cells with unconsciousness can be treated by an intramuscular or subcutaneous injection of glucagon (0.5 to 1 mg) which is given by an appropriately trained person or by intravenous administration of glucose by a doctor.</seg>
<seg id="2991">"" "" "" "after a glucose injection, the patient should be monitored in a hospital to determine the cause of severe hypoglycemia and to avoid similar episodes." "" "" ""</seg>
<seg id="2992">"" "" "" "insulin reduces blood sugar levels by stimulating the peripheral glucose intake (in particular by skeletal muscles and fat), as well as by inhibiting glucose production in the liver." "" "" ""</seg>
<seg id="2993">Studies with healthy volunteers and patients with diabetes have shown that the effect occurs faster with subcutaneous GA- be of insulin-ulisine and the duration of the operation is shorter than in whey-manem normal insulin.</seg>
<seg id="2994">"" "" "" "in a study involving 18 male people aged 21 to 50 years with type 1 diabetes, insulin-relevant dosing range from 0,075 to 0.15 E / kg showed a disproportionate increase in the intake effect, just like human insulin." "" "" ""</seg>
<seg id="2995">"" "" "" "insulin lulisin has a twice as fast effect as normal human insulin, and achieves total glucosm effect approximately 2 hours earlier than human insulin." "" "" ""</seg>
<seg id="2996">"" "" "" "from the data, a similar post-densitemic glycaemic control is achieved during an application of insulin therapy in 2 minutes before the meal." "" "" ""</seg>
<seg id="2997">"" "" "" "in 2 minutes before the meal, a better postdensital control was achieved than with human normal insulin, which was given 2 minutes before meal." "" "" ""</seg>
<seg id="2998">"" "" "" "if insulin is applied 15 minutes after the start of the meal, a comparable glycaemic control as in human normal insulin is achieved (see Figure 1)." "" "" ""</seg>
<seg id="2999">Insulin lulisine in administration 2 minutes (GLULISIN - before) before the start of the meal was given in comparison to human normal insulin (Figure 1A) as well as compared to human normal insulin for 2 minutes (NORMAL - before) before a meal (Figure 1B).</seg>
<seg id="3000">Insulin lulisine in administration 15 minutes (GLULISIN - afterwards) after the start of the meal compared to human Nor- maline that was given 2 minutes (NORMAL - before) before the start of the meal (Figure 1C).</seg>
</doc>
</tstset>
